<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24470789</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1537-744X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2013</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>TheScientificWorldJournal</Title>
          <ISOAbbreviation>ScientificWorldJournal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Effects of Two Lactobacillus plantarum Strains on Rat Lipid Metabolism Receiving a High Fat Diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>135142</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/135142</ELocationID>
        <Abstract>
          <AbstractText>The aim of our study was to evaluate the effects of the different probiotic strains, Lactobacillus plantarum LS/07 and Lactobacillus plantarum Biocenol LP96, on lipid metabolism and body weight in rats fed a high fat diet. Compared with the high fat diet group, the results showed that Lactobacillus plantarum LS/07 reduced serum cholesterol and LDL cholesterol, but Lactobacillus plantarum Biocenol LP96 decreased triglycerides and VLDL, while there was no change in the serum HDL level and liver lipids. Both probiotic strains lowered total bile acids in serum. Our strains have no significant change in body weight, gain weight, and body fat. These findings indicate that the effect of lactobacilli on lipid metabolism may differ among strains and that the Lactobacillus plantarum LS/07 and Lactobacillus plantarum Biocenol LP96 can be used to improve lipid profile and can contribute to a healthier bowel microbial balance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Salaj</LastName>
            <ForeName>Rastislav</ForeName>
            <Initials>R</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stofilov&#xE1;</LastName>
            <ForeName>Jana</ForeName>
            <Initials>J</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soltesov&#xE1;</LastName>
            <ForeName>Alena</ForeName>
            <Initials>A</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hertelyov&#xE1;</LastName>
            <ForeName>Zdenka</ForeName>
            <Initials>Z</Initials>
            <Affiliation>Department of Medical and Clinical Biochemistry, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hijov&#xE1;</LastName>
            <ForeName>Em&#xED;lia</ForeName>
            <Initials>E</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bertkov&#xE1;</LastName>
            <ForeName>Izabela</ForeName>
            <Initials>I</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strojn&#xFD;</LastName>
            <ForeName>Ladislav</ForeName>
            <Initials>L</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kru&#x17E;liak</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Affiliation>Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's Faculty Hospital, Masaryk University, Pekarsk&#xE1; 53, 656 91 Brno, Czech Republic.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bomba</LastName>
            <ForeName>Alojz</ForeName>
            <Initials>A</Initials>
            <Affiliation>Institute of Experimental Medicine, Faculty of Medicine, P. J. &#x160;af&#xE1;rik University, Trieda SNP 1, 040 01 Ko&#x161;ice, Slovakia.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>ScientificWorldJournal</MedlineTA>
        <NlmUniqueID>101131163</NlmUniqueID>
        <ISSNLinking>1537-744X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1155/2013/135142</ArticleId>
        <ArticleId IdType="pubmed">24470789</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24469991</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>28</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-6860</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
          <ISOAbbreviation>FASEB J.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Does reversible cysteine oxidation link the Western diet to cardiac dysfunction?</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Using a novel cysteine thiol labeling strategy coupled with mass spectrometric analysis, we identified and quantified the changes in global reversible cysteine oxidation of proteins in the left ventricle of hearts from mice with metabolic syndrome-associated diastolic dysfunction. This phenotype was induced by feeding a high-fat, high-sucrose, type-2 diabetogenic diet to C57BL/6J mice for 8 mo. The extent of reversible thiol oxidation in relationship to the total available (free and reducible) level of each cysteine could be confidently determined for 173 proteins, of which 98 contained cysteines differentially modified =1.5-fold by the diet. Our findings suggest that the metabolic syndrome leads to potentially deleterious changes in the oxidative modification of metabolically active proteins. These alterations may adversely regulate energy substrate flux through glycolysis, &#xDF;-oxidation, citric acid (TCA) cycle, and oxidative phosphorylation (oxphos), thereby contributing to maladaptive tissue remodeling that is associated with, and possibly contributing to, diastolic left ventricular dysfunction.-Behring, J. B., Kumar, V., Whelan, S. A., Chauhan, P., Siwik, D. A., Costello, C. E., Colucci, W. S., Cohen, R. A., McComb M. E., Bachschmid, M. M. Does reversible cysteine oxidation link the Western diet to cardiac dysfunction?</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Behring</LastName>
            <ForeName>Jessica B</ForeName>
            <Initials>JB</Initials>
            <Affiliation>*Vascular Biology Section and &#x2020;Myocardial Unit, Whitaker Cardiovascular Institute, and &#x2021;Cardiovascular Proteomics Center, Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts, USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Kumar</LastName>
            <ForeName>Vikas</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author>
            <LastName>Whelan</LastName>
            <ForeName>Stephen A</ForeName>
            <Initials>SA</Initials>
          </Author>
          <Author>
            <LastName>Chauhan</LastName>
            <ForeName>Pratibha</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author>
            <LastName>Siwik</LastName>
            <ForeName>Deborah A</ForeName>
            <Initials>DA</Initials>
          </Author>
          <Author>
            <LastName>Costello</LastName>
            <ForeName>Catherine E</ForeName>
            <Initials>CE</Initials>
          </Author>
          <Author>
            <LastName>Colucci</LastName>
            <ForeName>Wilson S</ForeName>
            <Initials>WS</Initials>
          </Author>
          <Author>
            <LastName>Cohen</LastName>
            <ForeName>Richard A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author>
            <LastName>McComb</LastName>
            <ForeName>Mark E</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author>
            <LastName>Bachschmid</LastName>
            <ForeName>Markus M</ForeName>
            <Initials>MM</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>FASEB J</MedlineTA>
        <NlmUniqueID>8804484</NlmUniqueID>
        <ISSNLinking>0892-6638</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">metabolic heart disease</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">oxidative post-translational modifications</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen and nitrogen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">fj.13-233445</ArticleId>
        <ArticleId IdType="doi">10.1096/fj.13-233445</ArticleId>
        <ArticleId IdType="pubmed">24469991</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24468157</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-1484</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>232</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Atherosclerosis</Title>
          <ISOAbbreviation>Atherosclerosis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Corticosterone accelerates atherosclerosis in the apolipoprotein E-deficient mouse.</ArticleTitle>
        <Pagination>
          <MedlinePgn>414-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.atherosclerosis.2013.11.076</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0021-9150(13)00735-1</ELocationID>
        <Abstract>
          <AbstractText>Chronic stress is an important risk factor for atherosclerosis, which is a chief process in the development of cardiovascular disease. Increased circulating levels of corticosterone have been documented in several animal models of chronic stress. However, it remains to be established whether corticosterone is sufficient to exacerbate atherosclerosis. To test this hypothesis, apolipoprotein E (ApoE)-deficient mice were fed a high-fat diet for 13 weeks with exposure to either corticosterone or vehicle in the drinking water (CORT and Con). Corticosterone treatment significantly increased atherosclerotic plaque area at the aortic root. Such exacerbation of atherosclerosis was accompanied by significantly lower levels of circulating white blood cells and serum interleukin-1&#xDF; (IL-1&#xDF;), and significantly elevated serum concentrations of total cholesterol, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and small dense low-density lipoprotein (sd-LDL) in CORT mice when compared to Con mice. These findings demonstrate that corticosterone is sufficient to exacerbate atherosclerosis in&#xA0;vivo despite its anti-inflammatory properties and that this marked pro-atherogenic phenotype is primarily associated with increased dyslipidaemia.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Okutsu</LastName>
            <ForeName>Mitsuharu</ForeName>
            <Initials>M</Initials>
            <Affiliation>Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan; Institute for Biomedical Engineering, Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, Tokyo, Japan. Electronic address: mitsu.okutsu@aoni.waseda.jp.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lira</LastName>
            <ForeName>Vitor A</ForeName>
            <Initials>VA</Initials>
            <Affiliation>Department of Health and Human Physiology, University of Iowa, Iowa City, IA, USA; Obesity Research and Education Initiative, University of Iowa, Iowa City, IA, USA; Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higashida</LastName>
            <ForeName>Kazuhiko</ForeName>
            <Initials>K</Initials>
            <Affiliation>Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peake</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <Affiliation>School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higuchi</LastName>
            <ForeName>Mitsuru</ForeName>
            <Initials>M</Initials>
            <Affiliation>Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan; Institute for Biomedical Engineering, Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, Tokyo, Japan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Katsuhiko</ForeName>
            <Initials>K</Initials>
            <Affiliation>Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama, Japan; Institute for Biomedical Engineering, Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, Tokyo, Japan.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Atherosclerosis</MedlineTA>
        <NlmUniqueID>0242543</NlmUniqueID>
        <ISSNLinking>0021-9150</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ApoE-deficient mice</Keyword>
        <Keyword MajorTopicYN="N">Cholesterol</Keyword>
        <Keyword MajorTopicYN="N">Dyslipidaemia</Keyword>
        <Keyword MajorTopicYN="N">Hypothalamic&#x2013;pituitary&#x2013;adrenal axis</Keyword>
        <Keyword MajorTopicYN="N">Stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0021-9150(13)00735-1</ArticleId>
        <ArticleId IdType="doi">10.1016/j.atherosclerosis.2013.11.076</ArticleId>
        <ArticleId IdType="pubmed">24468157</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24463729</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-1953</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology</Title>
          <ISOAbbreviation>Eur J Cardiovasc Nurs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effects of a counselling intervention on lifestyle change in people at risk of cardiovascular disease.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Background:The study assessed the effects of a counselling intervention on lifestyle changes in certain-aged people at risk of cardiovascular disease.Design and methods:This was an intervention study at baseline and six- and 12-month follow-ups. The participants were 40 years old (n= 53 at baseline, n=33 at six months and n=34 at 12 months). The main outcomes were cardiovascular health parameters, such as weight, BMI, waist circumference, blood pressure, cholesterol (total, high density lipoprotein, low density lipoprotein), blood glucose, and self-assessed and reported lifestyle and adherence to lifestyle changes. The counselling intervention was Internet-based and carried out via Skype or face-to-face in small groups (on average, six participants).Results:There were statistically significant differences between the baseline and the 12-month follow-up with respect to the consumption of fat and snacks. Some positive cardiovascular health improvements were detected between baseline and six months, but not as clearly between baseline and 12 months. The participants reported having a healthier diet at 12 months than at baseline. At 12 months, BMI measurements indicated that all participants were overweight (mean BMI 29.8), but according to the self-assessed data, only 25% considered themselves to be so.Conclusions:Changes in lifestyle were detected as a result of the intervention. These lifestyle changes may improve cardiovascular health in the long term. Discrepancies were found between the measured indicators of cardiovascular health and information obtained from questionnaires and diary records. In order to achieve sustainable lifestyle changes, long-term support is required.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Ylim&#xE4;ki</LastName>
            <ForeName>Eeva-Leena</ForeName>
            <Initials>EL</Initials>
            <Affiliation>1University of Oulu, Finland.</Affiliation>
          </Author>
          <Author>
            <LastName>Kanste</LastName>
            <ForeName>Outi</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author>
            <LastName>Heikkinen</LastName>
            <ForeName>Hanna</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author>
            <LastName>Bloigu</LastName>
            <ForeName>Risto</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Kyng&#xE4;s</LastName>
            <ForeName>Helvi</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eur J Cardiovasc Nurs</MedlineTA>
        <NlmUniqueID>101128793</NlmUniqueID>
        <ISSNLinking>1474-5151</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular health</Keyword>
        <Keyword MajorTopicYN="N">adherence</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular risk</Keyword>
        <Keyword MajorTopicYN="N">counselling intervention</Keyword>
        <Keyword MajorTopicYN="N">lifestyle</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1474515114521725</ArticleId>
        <ArticleId IdType="doi">10.1177/1474515114521725</ArticleId>
        <ArticleId IdType="pubmed">24463729</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24462788</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-6216</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Mechanisms of ageing and development</Title>
          <ISOAbbreviation>Mech. Ageing Dev.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>"Healthy aging diets other than the Mediterranean: A Focus on the Okinawan Diet"</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0047-6374(14)00003-7</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.mad.2014.01.002</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">The traditional diet in Okinawa is anchored by root vegetables (principally sweet potatoes), green and yellow vegetables, soybean-based foods, and medicinal plants. Marine foods, lean meats, fruit, medicinal garnishes and spices, tea, alcohol are also moderately consumed. Many characteristics of the traditional Okinawan diet are shared with other healthy dietary patterns, including the traditional Mediterranean diet, DASH diet, and Portfolio diet. All these dietary patterns are associated with reduced risk for cardiovascular disease, among other age-associated diseases. Overall, the important shared features of these healthy dietary patterns include: high intake of unrefined carbohydrates, moderate protein intake with emphasis on vegetables/legumes, fish, and lean meats as sources, and a healthy fat profile (higher in mono/polyunsaturated fats, lower in saturated fat; rich in omega-3). The healthy fat intake is likely one mechanism for reducing inflammation, optimizing cholesterol, and other risk factors. Additionally, the lower caloric density of plant-rich diets results in lower caloric intake with concomitant high intake of phytonutrients and antioxidants. Other shared features include low glycemic load, less inflammation and oxidative stress, and potential modulation of aging-related biological pathways. This may reduce risk for chronic age-associated diseases and promote healthy aging and longevity.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014. Published by Elsevier Ireland Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Willcox</LastName>
            <ForeName>Donald Craig</ForeName>
            <Initials>DC</Initials>
            <Affiliation>Okinawa International University, Department of Human Welfare, 2-6-1 Ginowan, Okinawa, Japan 901-2701; Department of Geriatric Medicine, University of Hawaii, HPM-9, 347N. Kuakini Street, Honolulu HI. 96817; Department of Research, Kuakini Medical Center, 347N. Kuakini Street, Honolulu HI. 96817.</Affiliation>
          </Author>
          <Author>
            <LastName>Scapagnini</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Medicine and Health Science, Via de Sanctis 86100, University of Molise, Campobasso, Italy.</Affiliation>
          </Author>
          <Author>
            <LastName>Willcox</LastName>
            <ForeName>Bradley J</ForeName>
            <Initials>BJ</Initials>
            <Affiliation>Department of Geriatric Medicine, University of Hawaii, HPM-9, 347N. Kuakini Street, Honolulu HI. 96817; Department of Research, Kuakini Medical Center, 347N. Kuakini Street, Honolulu HI. 96817.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mech Ageing Dev</MedlineTA>
        <NlmUniqueID>0347227</NlmUniqueID>
        <ISSNLinking>0047-6374</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DASH</Keyword>
        <Keyword MajorTopicYN="N">Diet</Keyword>
        <Keyword MajorTopicYN="N">Healthy aging</Keyword>
        <Keyword MajorTopicYN="N">Longevity</Keyword>
        <Keyword MajorTopicYN="N">Okinawa</Keyword>
        <Keyword MajorTopicYN="N">Portfolio</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0047-6374(14)00003-7</ArticleId>
        <ArticleId IdType="doi">10.1016/j.mad.2014.01.002</ArticleId>
        <ArticleId IdType="pubmed">24462788</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24462051</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition, metabolism, and cardiovascular diseases : NMCD</Title>
          <ISOAbbreviation>Nutr Metab Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Back to the future: The Mediterranean diet paradigm.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0939-4753(13)00302-5</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.numecd.2013.11.007</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">The Mediterranean diet was introduced to the scientific community by the classic Seven Countries study. Since then data on the association between this diet and cardiovascular disease, cancer and other chronic diseases have been accumulating. The Mediterranean diet is characterized by a high intake of olive oil, plant products, fish and seafood; a low intake of dairies, meat and meat products; and a moderate ethanol intake. The Mediterranean diet has been operationalized through various computational scores (e.g. the Mediterranean diet score for adults and the KIDMED index for children) which are all based on the dietary components that capture its essence. Next to evidence generated through both observational studies and intervention trials on the inverse association between Mediterranean diet and several risk factors, inflammatory markers and mortality or incidence of disease, there is increasing evidence that Mediterranean populations are abandoning their traditional eating habits. Publications presenting changes over time in the diet of populations participating in the Seven Countries Study point towards an increase in the intake of processed foods and saturated fat and a decrease in the intake of plant foods and monounsaturated fatty acids. Findings are alarming, particularly in relation to younger generations. Studies among children and adolescents in the Mediterranean region clearly indicate that the largest proportions of these populations poorly adhere to their traditional diet. Mediterraneans have clearly not been the major benefactors in the research on the effects of the Mediterranean lifestyle and younger populations in the regions are already following the wrong path.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Naska</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Athens 11527, Greece. Electronic address: anaska@nut.uoa.gr.</Affiliation>
          </Author>
          <Author>
            <LastName>Trichopoulou</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Affiliation>Hellenic Health Foundation, Athens, Greece.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nutr Metab Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>9111474</NlmUniqueID>
        <ISSNLinking>0939-4753</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Coronary heart disease</Keyword>
        <Keyword MajorTopicYN="N">Life style</Keyword>
        <Keyword MajorTopicYN="N">Mediterranean diet</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0939-4753(13)00302-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.numecd.2013.11.007</ArticleId>
        <ArticleId IdType="pubmed">24462051</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24458711</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4636</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
          <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interleukin 1 Receptor 1 and Interleukin 1&#xDF; Regulate Megakaryocyte Maturation, Platelet Activation, and Transcript Profile During Inflammation in Mice and Humans.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Interleukin 1 Receptor 1 (IL1R1) and its ligand, IL1&#xDF;, are upregulated in cardiovascular disease, obesity, and infection. Previously, we reported a higher level of IL1R1 transcripts in platelets from obese individuals of the Framingham Heart Study (FHS) but its functional effect in platelets has never been described. Additionally, IL1&#xDF; levels are increased in atherosclerotic plaques and in bacterial infections. The aim of this work is to determine whether IL1&#xDF;, through IL1R1, can activate platelets and megakaryocytes to promote atherothrombosis.</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="UNASSIGNED">We found that IL1&#xDF;-related genes from platelets, as measured in 1819 FHS participants, were associated with increased body mass index, and a direct relationship was shown in wild-type mice fed a high-fat diet. Mechanistically, IL1&#xDF; activated NF?B and MAPK signaling pathways in megakaryocytes. IL1&#xDF;, through IL1R1, increased ploidy of megakaryocytes to 64 N or more by 2-fold over control. IL1&#xDF; increased agonist-induced platelet aggregation by 1.2-fold with thrombin and 4.2-fold with collagen. IL1&#xDF; increased adhesion to both collagen and fibrinogen, and heterotypic aggregation by 1.9-fold over resting. High-fat diet-enhanced platelet adhesion was absent in IL1R1(-/-) mice. Wild-type mice infected with Porphyromonas gingivalis had circulating heterotypic aggregates (1.5-fold more than control at 24 hours and 6.2-fold more at 6 weeks) that were absent in infected IL1R1(-/-) and IL1&#xDF;(-/-) mice.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In summary, IL1R1- and IL1&#xDF;-related transcripts are elevated in the setting of obesity. IL1R1/IL1&#xDF; augment both megakaryocyte and platelet functions, thereby promoting a prothrombotic environment during infection and obesity; potentially contributing to the development of atherothrombotic disease.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Beaulieu</LastName>
            <ForeName>Lea M</ForeName>
            <Initials>LM</Initials>
            <Affiliation>From the Department of Medicine (L.M.B., M.K., K.T., J.E.F.) and Quantitative Health Sciences (E.M.), University of Massachusetts Medical School, Worcester, MA; Department of Medicine (E.L., M.K., E.O.W., C.D.K., C.A.G., E.J.B.), Infectious Disease, Department of Medicine (C.A.G.), and Department of Microbiology (C.A.G.), Boston University School of Medicine, MA; NHLBI and Boston University's Framingham Heart Institute, Framingham, MA (M.G.L., E.J.B., J.E.F.); and Department of Mathematics and Statistics, Boston University, MA (M.G.L.).</Affiliation>
          </Author>
          <Author>
            <LastName>Lin</LastName>
            <ForeName>Elaine</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author>
            <LastName>Mick</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author>
            <LastName>Koupenova</LastName>
            <ForeName>Milka</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author>
            <LastName>Weinberg</LastName>
            <ForeName>Ellen O</ForeName>
            <Initials>EO</Initials>
          </Author>
          <Author>
            <LastName>Kramer</LastName>
            <ForeName>Carolyn D</ForeName>
            <Initials>CD</Initials>
          </Author>
          <Author>
            <LastName>Genco</LastName>
            <ForeName>Caroline A</ForeName>
            <Initials>CA</Initials>
          </Author>
          <Author>
            <LastName>Tanriverdi</LastName>
            <ForeName>Kahraman</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author>
            <LastName>Larson</LastName>
            <ForeName>Martin G</ForeName>
            <Initials>MG</Initials>
          </Author>
          <Author>
            <LastName>Benjamin</LastName>
            <ForeName>Emelia J</ForeName>
            <Initials>EJ</Initials>
          </Author>
          <Author>
            <LastName>Freedman</LastName>
            <ForeName>Jane E</ForeName>
            <Initials>JE</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
        <NlmUniqueID>9505803</NlmUniqueID>
        <ISSNLinking>1079-5642</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IL1R1 protein, human</Keyword>
        <Keyword MajorTopicYN="N">blood platelets</Keyword>
        <Keyword MajorTopicYN="N">diet, high-fat</Keyword>
        <Keyword MajorTopicYN="N">infection</Keyword>
        <Keyword MajorTopicYN="N">megakaryocytes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ATVBAHA.113.302700</ArticleId>
        <ArticleId IdType="doi">10.1161/ATVBAHA.113.302700</ArticleId>
        <ArticleId IdType="pubmed">24458711</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24454330</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>23</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1671-5411</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of geriatric cardiology : JGC</Title>
          <ISOAbbreviation>J Geriatr Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.</ArticleTitle>
        <Pagination>
          <MedlinePgn>361-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3969/j.issn.1671-5411.2013.04.007</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity is associated with unfavorable alternations in plasma lipid profile and a broad spectrum of cardio-metabolic disorders. Proprotein convestase subtilisin kexin type 9 (PCSK9) is a novel circulating protein that promotes hypercholesterolemia by decreasing hepatic low lipoprotein density receptor (LDLR) protein. However, the relationship between PCSK9 concentration and lipid profile in an obesity condition has less been investigated.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the changes of plasma PCSK9 concentration in a rat model fed with high fat diet (HFD) and its correlation to lipid profile, body weight and ageing.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty male Sprague Dawley (SD) rats were divided into two groups, control group (fed with normal pellet for 4 weeks), and high-fat diet group (fed with 3% cholesterol enrich diet for 4 weeks). Blood samples of rats were obtained before and at days 14, 21, and 28 in both groups. The body weight, plasma metabolic parameters (glucose, lipid profile) and PCSK9 were determined at indicated time points.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The body weights were significantly increased in rats fed with HFD compared to that in rats with normal pellets at day 28. Additionally, total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) levels in rat fed with HFD were also higher than that in rats fed with control diet while decreased high density lipoprotein cholesterol (HDL-C) levels were found in rats with HFD at day 28. More interesting, there were no differences of plasma PCSK9 concentrations as well as hepatic expression of LDLR between the two groups at day 28.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the body weight and LDL-C were significantly increased in rats fed with HFD at 4 weeks, there were no differences of changes in plasma PCSK9 concentration and LDLR expression of liver tissue in both groups at baseline and day 28, suggesting that dyslipidemia in the rat model with HFD appears not to be associated with PCSK9-LDLR pathway but ageing.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Yan-Jun</ForeName>
            <Initials>YJ</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Yuan-Lin</ForeName>
            <Initials>YL</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Rui-Xia</ForeName>
            <Initials>RX</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Jiang</ForeName>
            <Initials>J</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian-Jun</ForeName>
            <Initials>JJ</Initials>
            <Affiliation>Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>J Geriatr Cardiol</MedlineTA>
        <NlmUniqueID>101237881</NlmUniqueID>
        <ISSNLinking>1671-5411</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3888919</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ageing</Keyword>
        <Keyword MajorTopicYN="N">Dyslipidemia</Keyword>
        <Keyword MajorTopicYN="N">High fat diet</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.3969/j.issn.1671-5411.2013.04.007</ArticleId>
        <ArticleId IdType="pii">jgc-10-04-361</ArticleId>
        <ArticleId IdType="pubmed">24454330</ArticleId>
        <ArticleId IdType="pmc">PMC3888919</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24445216</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-0641</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of hepatology</Title>
          <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Spondin 2 Inhibits Hepatic Steatosis, Insulin Resistance and Obesity via Interaction with Peroxisome Proliferator-Activated Receptor a in Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0168-8278(14)00057-9</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.jhep.2014.01.011</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Obesity and its related pathologies, such as hepatic steatosis, are associated with chronic inflammation and insulin resistance (IR), which contribute to cardiovascular disease. Our previous studies indicated that Spondin 2 has a protective role in the context of cardiovascular and cerebrovascular diseases. Whether Spondin 2 is also associated with the development of hepatic steatosis and IR remains unclear.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Wild-type mice, Spondin 2-knockout (KO) mice, hepatic-specific Spondin 2 transgenic (Spondin 2-TG) mice, high fat diet (HFD)-induced obese mice injected with an adenovirus expressing Spondin 2-specific shRNA or a Spondin 2 mutant and genetically obese (ob/ob) mice injected with an adenovirus expressing Spondin 2 were fed normal chow (NC) or HFD for indicated time to induce obesity, hepatic steatosis, inflammation and IR. Biomedical, histological and metabolic analyses were conducted to identify pathologic alterations in these mice. The molecular mechanisms of Spondin 2's functions were explored in mice and in hepatocytes or cell lines.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistent with Spondin 2 repression in the livers of HFD-induced and ob/ob mice, the Spondin 2-KO or hepatic-specific Spondin 2 knockdown mice exhibited more severe obesity, hepatic steatosis, inflammation and IR upon HFD. Conversely, these pathological conditions were significantly improved in the Spondin 2-TG mice or Spondin 2-overexpressing ob/ob mice. Spondin 2 interacts with PPARa to regulate PPARa-target genes, thereby improving the pathological phenotypes. In contrast, the hepatic overexpression of mutant Spondin 2 without the PPARa-interacting domain failed to improve the aggravated phenotypes observed in the Spondin 2-KO mice.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Spondin 2 regulates hepatic lipid metabolism and alleviates hepatic steatosis, obesity, inflammation and IR in mice via its interaction with PPARa.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Zhu</LastName>
            <ForeName>Li-Hua</ForeName>
            <Initials>LH</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Aibing</ForeName>
            <Initials>A</Initials>
            <Affiliation>College of Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Luo</LastName>
            <ForeName>Pengcheng</ForeName>
            <Initials>P</Initials>
            <Affiliation>Department of Urology, Renmin Hospital of Wuhan University, 99, Ziyang Rd, Wuhan, Hubei Province, 430060, China; Huangshi Central Hospital, Hubei Polytechnic University, Huangshi, Hubei Province, 435000, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Xinan</ForeName>
            <Initials>X</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Jiang</LastName>
            <ForeName>Ding-Sheng</ForeName>
            <Initials>DS</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Deng</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Xiaofei</ForeName>
            <Initials>X</Initials>
            <Affiliation>College of Life Sciences, Wuhan University, Wuhan 430072, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Liu</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <Affiliation>College of Life Sciences, Wuhan University, Wuhan 430072, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Gao</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <Affiliation>Department of Cardiology, Institute of Cardiovascular Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Shumin</ForeName>
            <Initials>S</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Xiaodong</ForeName>
            <Initials>X</Initials>
            <Affiliation>College of Life Sciences, Wuhan University, Wuhan 430072, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Affiliation>Department of Urology, Renmin Hospital of Wuhan University, 99, Ziyang Rd, Wuhan, Hubei Province, 430060, China; Huangshi Central Hospital, Hubei Polytechnic University, Huangshi, Hubei Province, 435000, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Hongliang</ForeName>
            <Initials>H</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China. Electronic address: lihl@whu.edu.cn.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Hepatol</MedlineTA>
        <NlmUniqueID>8503886</NlmUniqueID>
        <ISSNLinking>0168-8278</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">, non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">3-hydroxy-3-methyl-glutaryl-CoA reductase</Keyword>
        <Keyword MajorTopicYN="N">ABCA</Keyword>
        <Keyword MajorTopicYN="N">ABCG</Keyword>
        <Keyword MajorTopicYN="N">ACC</Keyword>
        <Keyword MajorTopicYN="N">ACOX</Keyword>
        <Keyword MajorTopicYN="N">ALP</Keyword>
        <Keyword MajorTopicYN="N">ALT</Keyword>
        <Keyword MajorTopicYN="N">AMP-activated protein kinase</Keyword>
        <Keyword MajorTopicYN="N">AMPK</Keyword>
        <Keyword MajorTopicYN="N">ARG-1</Keyword>
        <Keyword MajorTopicYN="N">AST</Keyword>
        <Keyword MajorTopicYN="N">ATGL</Keyword>
        <Keyword MajorTopicYN="N">ATP-binding cassette transporter A</Keyword>
        <Keyword MajorTopicYN="N">ATP-binding cassette transporter G</Keyword>
        <Keyword MajorTopicYN="N">AUC</Keyword>
        <Keyword MajorTopicYN="N">Akt</Keyword>
        <Keyword MajorTopicYN="N">CPT-1a</Keyword>
        <Keyword MajorTopicYN="N">CYP7A1</Keyword>
        <Keyword MajorTopicYN="N">DGAT</Keyword>
        <Keyword MajorTopicYN="N">ECM</Keyword>
        <Keyword MajorTopicYN="N">FAS</Keyword>
        <Keyword MajorTopicYN="N">FBG</Keyword>
        <Keyword MajorTopicYN="N">FFA</Keyword>
        <Keyword MajorTopicYN="N">FGF21</Keyword>
        <Keyword MajorTopicYN="N">Fatty liver</Keyword>
        <Keyword MajorTopicYN="N">Fins</Keyword>
        <Keyword MajorTopicYN="N">GFP</Keyword>
        <Keyword MajorTopicYN="N">GPAT</Keyword>
        <Keyword MajorTopicYN="N">GTT</Keyword>
        <Keyword MajorTopicYN="N">H&amp;E</Keyword>
        <Keyword MajorTopicYN="N">HDL</Keyword>
        <Keyword MajorTopicYN="N">HFD</Keyword>
        <Keyword MajorTopicYN="N">HMGCR</Keyword>
        <Keyword MajorTopicYN="N">HOMA-IR</Keyword>
        <Keyword MajorTopicYN="N">HSL</Keyword>
        <Keyword MajorTopicYN="N">IKK&#xDF;</Keyword>
        <Keyword MajorTopicYN="N">IL</Keyword>
        <Keyword MajorTopicYN="N">IR</Keyword>
        <Keyword MajorTopicYN="N">IRS</Keyword>
        <Keyword MajorTopicYN="N">ITT</Keyword>
        <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">JNK</Keyword>
        <Keyword MajorTopicYN="N">Jun N-terminal kinase</Keyword>
        <Keyword MajorTopicYN="N">KO</Keyword>
        <Keyword MajorTopicYN="N">LCAD</Keyword>
        <Keyword MajorTopicYN="N">LDL</Keyword>
        <Keyword MajorTopicYN="N">LDLR</Keyword>
        <Keyword MajorTopicYN="N">LXR-a</Keyword>
        <Keyword MajorTopicYN="N">MCAD</Keyword>
        <Keyword MajorTopicYN="N">MCP-1</Keyword>
        <Keyword MajorTopicYN="N">MGL</Keyword>
        <Keyword MajorTopicYN="N">MRC1</Keyword>
        <Keyword MajorTopicYN="N">NAFLD</Keyword>
        <Keyword MajorTopicYN="N">NC</Keyword>
        <Keyword MajorTopicYN="N">NL</Keyword>
        <Keyword MajorTopicYN="N">NTG</Keyword>
        <Keyword MajorTopicYN="N">PPARa</Keyword>
        <Keyword MajorTopicYN="N">PPRE</Keyword>
        <Keyword MajorTopicYN="N">SCD</Keyword>
        <Keyword MajorTopicYN="N">SREBP1c</Keyword>
        <Keyword MajorTopicYN="N">Spondin 2</Keyword>
        <Keyword MajorTopicYN="N">TG</Keyword>
        <Keyword MajorTopicYN="N">TNF-a</Keyword>
        <Keyword MajorTopicYN="N">UCP</Keyword>
        <Keyword MajorTopicYN="N">WT</Keyword>
        <Keyword MajorTopicYN="N">acetyl-CoA carboxylase</Keyword>
        <Keyword MajorTopicYN="N">acyl-coenzyme A oxidase</Keyword>
        <Keyword MajorTopicYN="N">adipose triacylglycerol lipase</Keyword>
        <Keyword MajorTopicYN="N">alanine transaminase</Keyword>
        <Keyword MajorTopicYN="N">alkaline phosphatase</Keyword>
        <Keyword MajorTopicYN="N">area under the curve</Keyword>
        <Keyword MajorTopicYN="N">arginase-1</Keyword>
        <Keyword MajorTopicYN="N">aspartate transaminase</Keyword>
        <Keyword MajorTopicYN="N">carnitine palmitoyltransferase-1-a</Keyword>
        <Keyword MajorTopicYN="N">cytochrome P450, family 7, subfamily A, polypeptide 1</Keyword>
        <Keyword MajorTopicYN="N">diglyceride acyltransferase</Keyword>
        <Keyword MajorTopicYN="N">extracellular matrix</Keyword>
        <Keyword MajorTopicYN="N">fasting glucose</Keyword>
        <Keyword MajorTopicYN="N">fasting insulin</Keyword>
        <Keyword MajorTopicYN="N">fatty acid synthase</Keyword>
        <Keyword MajorTopicYN="N">fibroblast growth factor</Keyword>
        <Keyword MajorTopicYN="N">free fatty acid</Keyword>
        <Keyword MajorTopicYN="N">glucose tolerance test</Keyword>
        <Keyword MajorTopicYN="N">glycerol-3-phosphate acyltransferase</Keyword>
        <Keyword MajorTopicYN="N">green fluorescent protein</Keyword>
        <Keyword MajorTopicYN="N">hematoxylin and eosin</Keyword>
        <Keyword MajorTopicYN="N">high density lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">homeostasis model assessment of insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">hormone sensitive lipase</Keyword>
        <Keyword MajorTopicYN="N">inhibitor of nuclear factor kappa B kinase beta subunit</Keyword>
        <Keyword MajorTopicYN="N">insulin receptor substrate</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">interleukin</Keyword>
        <Keyword MajorTopicYN="N">intraperitoneal insulin tolerance test</Keyword>
        <Keyword MajorTopicYN="N">knockout</Keyword>
        <Keyword MajorTopicYN="N">liver X receptor-a</Keyword>
        <Keyword MajorTopicYN="N">long-chain acyl-CoA dehydrogenase</Keyword>
        <Keyword MajorTopicYN="N">low density lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoprotein receptor</Keyword>
        <Keyword MajorTopicYN="N">macrophage galactose-type C-type lectin</Keyword>
        <Keyword MajorTopicYN="N">mannose receptor, C type 1</Keyword>
        <Keyword MajorTopicYN="N">medium-chain acyl-CoA dehydrogenase</Keyword>
        <Keyword MajorTopicYN="N">monocyte chemoattractant protein 1</Keyword>
        <Keyword MajorTopicYN="N">nontransgenic</Keyword>
        <Keyword MajorTopicYN="N">normal chow</Keyword>
        <Keyword MajorTopicYN="N">normal liver</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator-activated receptor alpha</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferators response element</Keyword>
        <Keyword MajorTopicYN="N">protein kinase B</Keyword>
        <Keyword MajorTopicYN="N">shRNA</Keyword>
        <Keyword MajorTopicYN="N">short hairpin RNA</Keyword>
        <Keyword MajorTopicYN="N">stearoyl-CoA desaturase</Keyword>
        <Keyword MajorTopicYN="N">sterol response element binding protein 1c</Keyword>
        <Keyword MajorTopicYN="N">transgenic</Keyword>
        <Keyword MajorTopicYN="N">tumor necrosis factor alpha</Keyword>
        <Keyword MajorTopicYN="N">uncoupling protein</Keyword>
        <Keyword MajorTopicYN="N">wild type</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0168-8278(14)00057-9</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jhep.2014.01.011</ArticleId>
        <ArticleId IdType="pubmed">24445216</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24445045</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4847</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of nutritional biochemistry</Title>
          <ISOAbbreviation>J. Nutr. Biochem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>201-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jnutbio.2013.10.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0955-2863(13)00232-5</ELocationID>
        <Abstract>
          <AbstractText>Obesity is associated with metabolic disorders. Sulforaphane, an isothiocyanate, inhibits adipogenesis and the occurrence of cardiovascular disease. In this study, we investigated whether sulforaphane could prevent high-fat diet (HFD)-induced obesity in C57BL/6N mice. Mice were fed a normal diet (ND), HFD or HFD plus 0.1% sulforaphane (SFN) for 6 weeks. Food efficiency ratios and body weight were lower in HFD-SFN-fed mice than in HFD-fed mice. SFN attenuated HFD-induced visceral adiposity, adipocyte hypertrophy and fat accumulation in the liver. Serum total cholesterol and leptin, and liver triglyceride levels were lower in HFD-SFN-fed mice than in HFD-fed mice. SFN decreased the expression of peroxisome proliferator-activated receptor ? (PPAR?), CCAAT/enhancer-binding protein a (C/EBPa) and leptin in the adipose tissue of HFD-SFN mice and increased adiponectin expression. Phosphorylation of AMP-activated protein kinase a (AMPKa) and acetyl-CoA carboxylase in the adipose tissue of HFD-SFN-fed mice was elevated, and HMG-CoA reductase expression was decreased compared with HFD-fed mice. Thus, these results suggest that SFN may induce antiobesity activity by inhibiting adipogenesis through down-regulation of PPAR? and C/EBPa and by suppressing lipogenesis through activation of the AMPK pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Kyeong-Mi</ForeName>
            <Initials>KM</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Youn-Sun</ForeName>
            <Initials>YS</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Wonkyun</ForeName>
            <Initials>W</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Seung Jung</ForeName>
            <Initials>SJ</Initials>
            <Affiliation>Department of Medicine, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shin</LastName>
            <ForeName>Kyong-Oh</ForeName>
            <Initials>KO</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Ji-Yeon</ForeName>
            <Initials>JY</Initials>
            <Affiliation>Laboratory of Chemical Genomics, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Mi Kyeong</ForeName>
            <Initials>MK</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Yong-Moon</ForeName>
            <Initials>YM</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Jin Tae</ForeName>
            <Initials>JT</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yun</LastName>
            <ForeName>Yeo-Pyo</ForeName>
            <Initials>YP</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoo</LastName>
            <ForeName>Hwan-Soo</ForeName>
            <Initials>HS</Initials>
            <Affiliation>College of Pharmacy and Center for Innovative Cancer Therapeutics, Chungbuk National University, 52 Naesudong-ro, Heungduk-gu, Cheongju 361-763, Republic of Korea. Electronic address: yoohs@chungbuk.ac.kr.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nutr Biochem</MedlineTA>
        <NlmUniqueID>9010081</NlmUniqueID>
        <ISSNLinking>0955-2863</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AMPK</Keyword>
        <Keyword MajorTopicYN="N">Adipogenesis</Keyword>
        <Keyword MajorTopicYN="N">Leptin</Keyword>
        <Keyword MajorTopicYN="N">Lipogenesis</Keyword>
        <Keyword MajorTopicYN="N">Obesity</Keyword>
        <Keyword MajorTopicYN="N">Sulforaphane</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0955-2863(13)00232-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jnutbio.2013.10.007</ArticleId>
        <ArticleId IdType="pubmed">24445045</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24445044</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4847</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of nutritional biochemistry</Title>
          <ISOAbbreviation>J. Nutr. Biochem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The inflammatory profile and liver damage of a sucrose-rich diet in mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>193-200</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jnutbio.2013.10.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0955-2863(13)00231-3</ELocationID>
        <Abstract>
          <AbstractText Label="UNLABELLED">It is still unclear if an isoenergetic, sucrose-rich diet leads to health consequences.</AbstractText>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To investigate the effects of excessive sucrose within an isoenergetic diet on metabolic parameters in male C57BL/6 mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Animals were fed a control diet (10% fat, 8% sucrose - SC group), a high-sucrose diet (10% fat, 32% sucrose - HSu group), a high-fat diet (42% fat, 8% sucrose - HF group) or a high-fat/high-sucrose diet (42% fat, 32% sucrose - HF/HSu group) for 8 weeks.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mice fed HF and HF/HSu diets gained more body mass (BM) and more body adiposity than SC- or Hsu-fed mice. Despite the unchanged BM and adiposity indices, HSu mice presented adipocyte hypertrophy, which was also observed in the HF and HF/HSu groups (P&lt;.0001). The HF, HSu and HF/HSu mice were glucose intolerant and had elevated serum insulin levels (P&lt;.05). The levels of leptin, resistin and monocyte chemotactic protein-1 increased, while the serum adiponectin decreased in the HF, HSu and HF/HSu groups (P&lt;.05). In the adipose tissue, the HF, HSu and HF/HSu groups showed higher levels of leptin expression and lower levels of adiponectin expression in comparison with the SC group (P&lt;.05). Liver steatosis was higher in the HF, HSu and HF/HSu groups than in the SC group (P&lt;.0001). Hepatic cholesterol was higher in the HF and HF/HSu groups, while hepatic TG was higher in the HSu and HF/HSu groups (P&lt;.05). In hepatic tissue, the sterol receptor element-binding protein-1c expression was increased in the HF, HSu and HF/HSu groups, unlike the peroxisome proliferator-activated receptor-alpha expression that decreased in the HF, HSu and HF/HSu groups in comparison with the SC group (P&lt;.05).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A sucrose-rich diet does not lead to a state of obesity but has the potential to cause changes in the adipocytes (hypertrophy) as well as glucose intolerance, hyperinsulinemia, hyperlipidemia, hepatic steatosis and increases in the number of inflammatory cytokines. The deleterious effects of a sucrose-rich diet in an animal model, even when the sucrose replaces starch isocalorically in the feed, can have far-reaching consequences for health.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Oliveira</LastName>
            <ForeName>Liliane Soares C</ForeName>
            <Initials>LS</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santos</LastName>
            <ForeName>Daiane A</ForeName>
            <Initials>DA</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbosa-da-Silva</LastName>
            <ForeName>Sandra</ForeName>
            <Initials>S</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandarim-de-Lacerda</LastName>
            <ForeName>Carlos A</ForeName>
            <Initials>CA</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aguila</LastName>
            <ForeName>Marcia B</ForeName>
            <Initials>MB</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: marciaguila@gmail.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nutr Biochem</MedlineTA>
        <NlmUniqueID>9010081</NlmUniqueID>
        <ISSNLinking>0955-2863</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adipokines</Keyword>
        <Keyword MajorTopicYN="N">Adipose tissue</Keyword>
        <Keyword MajorTopicYN="N">High-fat diet</Keyword>
        <Keyword MajorTopicYN="N">High-sucrose diet</Keyword>
        <Keyword MajorTopicYN="N">Liver</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0955-2863(13)00231-3</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jnutbio.2013.10.006</ArticleId>
        <ArticleId IdType="pubmed">24445044</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24444538</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1607-551X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Kaohsiung journal of medical sciences</Title>
          <ISOAbbreviation>Kaohsiung J. Med. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Maternal diabetes or hypertension and lifestyle factors may be associated with metabolic syndrome: A population-based study in Taiwan.</ArticleTitle>
        <Pagination>
          <MedlinePgn>86-93</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.kjms.2013.09.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1607-551X(13)00222-2</ELocationID>
        <Abstract>
          <AbstractText>Early detection and interventions for metabolic syndrome (MetS) are the most cost-effective methods for preventing many chronic diseases. There have been discordant findings in various countries due to different genetics and lifestyles. The goal of this study was to investigate the association of MetS with parental diseases, a Chinese-style diet, and rural-urban regional differences with a large-scale epidemiological survey in Taiwan. Data were obtained from the Taiwanese Survey on Hypertension, Hyperglycemia, and Hyperlipidemia (TwSHHH), a cross-sectional population-based study with multistage stratified random sampling conducted by the Taiwan Bureau of Health Promotion in 2002. Public health nurses visited homes to conduct the survey, including blood drawing and an interview. Multiple logistic regression analysis was used for exploring the factors associated with MetS. A total of 6591 people completed data for analysis. Our results revealed that older age, male sex, and maternal diabetes or hypertension, were significantly associated with MetS. Eating poultry with skin and fat and eating a bean-free diet may be associated with a higher risk of MetS. People who exercised regularly and the residents of the Taipei metropolitan area had a lower prevalence of MetS. As a result, people with maternal diabetes or hypertension should pay attention to their cardiovascular health and prevention of MetS. We suggest that eating skinless and low-fat poultry, eating more beans, and exercising regularly, may decrease the risk of MetS. We should make an effort to advocate for health promotion, including lifestyle modification, especially among the high-risk population and among residents in rural areas with limited medical resources.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tzu-Hua</ForeName>
            <Initials>TH</Initials>
            <Affiliation>Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsiao</LastName>
            <ForeName>Hui-Pin</ForeName>
            <Initials>HP</Initials>
            <Affiliation>Division of Pediatric Genetics, Endocrinology and Metabolism, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiu</LastName>
            <ForeName>Yu-Wen</ForeName>
            <Initials>YW</Initials>
            <Affiliation>School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan; Department of Family Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shih</LastName>
            <ForeName>Nai-Hua</ForeName>
            <Initials>NH</Initials>
            <Affiliation>Department of Laboratory, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chuang</LastName>
            <ForeName>Hung-Yi</ForeName>
            <Initials>HY</Initials>
            <Affiliation>Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, no.100 Shih-Chuan 1(st) Road, Kaohsiung City 807, Taiwan. Electronic address: ericch@kmu.edu.tw.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Chia-Tsuan</ForeName>
            <Initials>CT</Initials>
            <Affiliation>Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>China (Republic : 1949- )</Country>
        <MedlineTA>Kaohsiung J Med Sci</MedlineTA>
        <NlmUniqueID>100960562</NlmUniqueID>
        <ISSNLinking>1607-551X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Diet</Keyword>
        <Keyword MajorTopicYN="N">Maternal diabetes</Keyword>
        <Keyword MajorTopicYN="N">Maternal hypertension</Keyword>
        <Keyword MajorTopicYN="N">Metabolic syndrome</Keyword>
        <Keyword MajorTopicYN="N">Metropolitan</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S1607-551X(13)00222-2</ArticleId>
        <ArticleId IdType="doi">10.1016/j.kjms.2013.09.001</ArticleId>
        <ArticleId IdType="pubmed">24444538</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24438079</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1475-2840</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular diabetology</Title>
          <ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An accelerated mouse model for atherosclerosis and adipose tissue inflammation.</ArticleTitle>
        <Pagination>
          <MedlinePgn>23</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1475-2840-13-23</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity and particularly the metabolic syndrome, which is often associated with obesity, combine a major risk for type 2 diabetes and cardiovascular disease. Emerging evidence indicate obesity-associated subclinical inflammation primarily originating from adipose tissue as a common cause for type 2 diabetes and cardiovascular disease. However, a suitable and well-characterized mouse model to simultaneously study obesity-associated metabolic disorders and atherosclerosis is not available yet. Here we established and characterized a murine model combining diet-induced obesity and associated adipose tissue inflammation and metabolic deteriorations as well as atherosclerosis, hence reflecting the human situation of cardio-metabolic disease.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We compared a common high-fat diet with 0.15% cholesterol (HFC), and a high-fat, high-sucrose diet with 0.15% cholesterol (HFSC) fed to LDL receptor-deficient (LDLR-/-) mice. Insulin resistance, glucose tolerance, atherosclerotic lesion formation, hepatic lipid accumulation, and inflammatory gene expression in adipose tissue and liver were assessed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After 12-16&#xA0;weeks, LDLR-/- mice fed HFSC or HFC developed significant diet-induced obesity, adipose tissue inflammation, insulin resistance, and impaired glucose tolerance compared to lean controls. Notably, HFSC-fed mice developed significantly higher adipose tissue inflammation in parallel with significantly elevated atherosclerotic lesion area compared to those on HFC. Moreover, LDLR-/- mice on HFSC showed increased insulin resistance and impaired glucose tolerance relative to those on HFC. After prolonged feeding (20&#xA0;weeks), however, no significant differences in inflammatory and metabolic parameters as well as atherosclerotic lesion formation were detectable any more between LDLR-/- mice fed HFSC or HFC.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of high sucrose rather than more complex carbohydrates in high-fat diets significantly accelerates development of obesity-driven metabolic complications and atherosclerotic plaque formation parallel to obesity-induced adipose tissue inflammation in LDLR-/- mice. Hence LDLR-/- mice fed high-fat high-sucrose cholesterol-enriched diet appear to be a suitable and time-saving animal model for cardio-metabolic disease. Moreover our results support the suggested interrelation between adipose tissue inflammation and atherosclerotic plaque formation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Neuhofer</LastName>
            <ForeName>Angelika</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wernly</LastName>
            <ForeName>Bernhard</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leitner</LastName>
            <ForeName>Lukas</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarabi</LastName>
            <ForeName>Alisina</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sommer</LastName>
            <ForeName>Nicole G</ForeName>
            <Initials>NG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Staffler</LastName>
            <ForeName>G&#xFC;nther</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeyda</LastName>
            <ForeName>Maximilian</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stulnig</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
            <Affiliation>Christian Doppler Laboratory for Cardio-Metabolic Immunotherapy and Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria. thomas.stulnig@meduniwien.ac.at.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>01</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cardiovasc Diabetol</MedlineTA>
        <NlmUniqueID>101147637</NlmUniqueID>
        <ISSNLinking>1475-2840</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):624-8</RefSource>
          <PMID Version="1">10712383</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E207-14</RefSource>
          <PMID Version="1">11739102</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2002 Mar;75(3):492-8</RefSource>
          <PMID Version="1">11864854</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2002 May 8;287(18):2414-23</RefSource>
          <PMID Version="1">11988062</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2002 Apr;87(4):337-42</RefSource>
          <PMID Version="1">12064343</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1029-34</RefSource>
          <PMID Version="1">12730087</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2003 Nov;112(9):1318-31</RefSource>
          <PMID Version="1">14597759</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2003 Dec;112(12):1796-808</RefSource>
          <PMID Version="1">14679176</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G264-73</RefSource>
          <PMID Version="1">15044174</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2004 Aug;80(2):348-56</RefSource>
          <PMID Version="1">15277155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2004 Aug 25;292(8):927-34</RefSource>
          <PMID Version="1">15328324</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 1987 Apr 24;257(16):2176-80</RefSource>
          <PMID Version="1">3560398</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 1992 Oct 16;258(5081):468-71</RefSource>
          <PMID Version="1">1411543</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 1993 Nov;42(11):1405-9</RefSource>
          <PMID Version="1">8231834</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 1994 May;43(5):554-8</RefSource>
          <PMID Version="1">8177043</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1995 Aug;125(8):2156-64</RefSource>
          <PMID Version="1">7643250</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 1996 Feb 16;271(5251):994-6</RefSource>
          <PMID Version="1">8584938</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hypertens. 1998 Jul;16(7):895-906</RefSource>
          <PMID Version="1">9794728</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1999 May;19(5):1223-30</RefSource>
          <PMID Version="1">10323773</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1938-44</RefSource>
          <PMID Version="1">10446074</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2005 Mar;179(1):43-9</RefSource>
          <PMID Version="1">15721008</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2005 May 13;96(9):939-49</RefSource>
          <PMID Version="1">15890981</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2006 Dec 14;444(7121):860-7</RefSource>
          <PMID Version="1">17167474</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2007 Mar;45(3):778-88</RefSource>
          <PMID Version="1">17326204</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):878-85</RefSource>
          <PMID Version="1">17255537</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2007 Oct;117(10):2877-88</RefSource>
          <PMID Version="1">17823662</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2007 Oct;86(4):899-906</RefSource>
          <PMID Version="1">17921363</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2008 Jan;57(1):5-12</RefSource>
          <PMID Version="1">17914034</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2008 Feb 12;117(6):798-805</RefSource>
          <PMID Version="1">18212290</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2008 Mar;149(3):1350-7</RefSource>
          <PMID Version="1">18048491</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2008 Mar;87(3):627-37</RefSource>
          <PMID Version="1">18326601</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Surgery. 2009 Mar;145(3):255-9</RefSource>
          <PMID Version="1">19231576</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2009 Apr;89(4):1037-42</RefSource>
          <PMID Version="1">19211821</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2009 Apr 4;373(9670):1175-82</RefSource>
          <PMID Version="1">19329177</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2009 May;119(5):1322-34</RefSource>
          <PMID Version="1">19381015</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gerontology. 2009;55(4):379-86</RefSource>
          <PMID Version="1">19365105</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2009 Oct 20;120(16):1640-5</RefSource>
          <PMID Version="1">19805654</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):218-24</RefSource>
          <PMID Version="1">19965778</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):612-9</RefSource>
          <PMID Version="1">20018935</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2010 Apr;59(4):935-46</RefSource>
          <PMID Version="1">20107108</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):366-70</RefSource>
          <PMID Version="1">20473150</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2010 Sep;21(9):1543-9</RefSource>
          <PMID Version="1">20595676</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2010 Nov;33(11):2477-83</RefSource>
          <PMID Version="1">20693348</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Diabetol. 2010;9:70</RefSource>
          <PMID Version="1">21034455</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2010 Dec;213(2):369-76</RefSource>
          <PMID Version="1">20732681</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2011 Aug;54(8):2132-42</RefSource>
          <PMID Version="1">21562757</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2011 Nov;54(11):2900-10</RefSource>
          <PMID Version="1">21847582</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2011 Nov 2;14(5):575-85</RefSource>
          <PMID Version="1">22055501</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2011 Dec;219(2):402-8</RefSource>
          <PMID Version="1">21703625</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Mol Med. 2012 Mar;29(3):331-7</RefSource>
          <PMID Version="1">22160183</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Diabetol. 2011;10:117</RefSource>
          <PMID Version="1">22204493</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2012 Mar;18(3):363-74</RefSource>
          <PMID Version="1">22395709</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(8):e43127</RefSource>
          <PMID Version="1">22927948</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Diabetol. 2012;11:71</RefSource>
          <PMID Version="1">22709409</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2012 Oct 4;367(14):1310-20</RefSource>
          <PMID Version="1">23034020</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2013 Jun;62(6):1945-56</RefSource>
          <PMID Version="1">23349501</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2007 Jan;56(1):24-33</RefSource>
          <PMID Version="1">17192461</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3902066</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1475-2840-13-23</ArticleId>
        <ArticleId IdType="doi">10.1186/1475-2840-13-23</ArticleId>
        <ArticleId IdType="pubmed">24438079</ArticleId>
        <ArticleId IdType="pmc">PMC3902066</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24429541</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-3207</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of clinical nutrition</Title>
          <ISOAbbreviation>Am. J. Clin. Nutr.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dietary intake of palmitate and oleate has broad impact on systemic and tissue lipid profiles in humans.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Epidemiologic evidence has suggested that diets with a high ratio of palmitic acid (PA) to oleic acid (OA) increase risk of cardiovascular disease (CVD).</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To gain additional insights into the relative effect of dietary fatty acids and their metabolism on CVD risk, we sought to identify a metabolomic signature that tracks with diet-induced changes in blood lipid concentrations and whole-body fat oxidation.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">We applied comprehensive metabolomic profiling tools to biological specimens collected from 18 healthy adults enrolled in a crossover trial that compared a 3-wk high-palmitic acid (HPA) with a low-palmitic acid and high-oleic acid (HOA) diet.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A principal components analysis of the data set including 329 variables measured in 15 subjects in the fasted state identified one factor, the principal components analysis factor in the fasted state (PCF1-Fasted), which was heavily weighted by the PA:OA ratio of serum and muscle lipids, that was affected by diet (P &lt; 0.0001; HPA greater than HOA). One other factor, the additional principal components analysis factor in the fasted state (PCF2-Fasted), reflected a wide range of acylcarnitines and was affected by diet in women only (P = 0.0198; HPA greater than HOA). HOA lowered the ratio of serum low-density lipoprotein to high-density lipoprotein (LDL:HDL) in men and women, and adjustment for the PCF1-Fasted abolished the effect. In women only, adjustment for the PCF2-Fasted eliminated the HOA-diet effect on serum total- and LDL-cholesterol concentrations. The respiratory exchange ratio in the fasted state was lower with the HPA diet (P = 0.04), and the diet effect was eliminated after adjustment for the PCF1-Fasted. The messenger RNA expression of the cholesterol regulatory gene insulin-induced gene-1 was higher with the HOA diet (P = 0.008).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that replacing dietary PA with OA reduces the blood LDL concentration and whole-body fat oxidation by modifying the saturation index of circulating and tissue lipids. In women, these effects are also associated with a higher production and accumulation of acylcarnitines, possibly reflecting a shift in fat catabolism.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Kien</LastName>
            <ForeName>C Lawrence</ForeName>
            <Initials>CL</Initials>
            <Affiliation>Departments of Pediatrics (CLK), Medicine (CLK and KC), and Medical Biostatistics (JYB), University of Vermont, Burlington, VT, and the Stedman Nutrition and Metabolism Center (RS, JB, OI, TRK, and DMM) and Departments of Medicine (TRK and DMM) and Pharmacology and Cancer Biology (DMM), Duke University, Durham, NC.</Affiliation>
          </Author>
          <Author>
            <LastName>Bunn</LastName>
            <ForeName>Janice Y</ForeName>
            <Initials>JY</Initials>
          </Author>
          <Author>
            <LastName>Stevens</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Bain</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Ikayeva</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author>
            <LastName>Crain</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author>
            <LastName>Koves</LastName>
            <ForeName>Timothy R</ForeName>
            <Initials>TR</Initials>
          </Author>
          <Author>
            <LastName>Muoio</LastName>
            <ForeName>Deborah M</ForeName>
            <Initials>DM</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Clin Nutr</MedlineTA>
        <NlmUniqueID>0376027</NlmUniqueID>
        <ISSNLinking>0002-9165</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ajcn.113.070557</ArticleId>
        <ArticleId IdType="doi">10.3945/ajcn.113.070557</ArticleId>
        <ArticleId IdType="pubmed">24429541</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24424058</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1945-7170</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Endocrinology</Title>
          <ISOAbbreviation>Endocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>en20131795</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Smoking is a major risk factor for diabetes, cardiovascular disease and non-alcoholic fatty liver disease (NAFLD). The health risk associated with smoking can be exaggerated by obesity. We hypothesize that nicotine, when combined with a high-fat diet (HFD) can also cause ectopic lipid accumulation in skeletal muscle, similar to recently observed hepatic steatosis. Adult C57BL6 male mice were fed a normal chow diet (NCD) or HFD and received twice daily intraperitoneal (IP) injections of nicotine (0.75 mg/kg BW) or saline for 10 weeks. Transmission electron microscopy of the gastrocnemius muscle revealed substantial intramyocellular lipid (IMCL) accumulation in close association with intramyofibrillar (IMF) mitochondria along with IMF mitochondrial swelling and vacuolization in nicotine-treated mice on a HFD compared to mice on a HFD and saline. These abnormalities were reversed by acipimox, an inhibitor of lipolysis. Mechanistically, the detrimental effect of nicotine plus HFD on skeletal muscle was associated with significantly increased oxidative stress, plasma free fatty acid and muscle triglyceride levels coupled with inactivation of adenosine-5-monophosphate (AMP)-activated protein kinase (AMPK) and activation of its downstream target, acetyl-CoA-carboxylase (ACC). We conclude that: 1) greater oxidative stress together with inactivation of AMPK mediates the effect of nicotine on skeletal muscle abnormalities in diet-induced obesity and 2) adipose tissue lipolysis is an important contributor of muscle steatosis and mitochondrial abnormalities.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Sinha-Hikim</LastName>
            <ForeName>Indrani</ForeName>
            <Initials>I</Initials>
            <Affiliation>Division of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine (I. S.-H., T. C. F, C.-S. S., D. L., R. I., A. P. S.-H.), Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059 and David Geffen School of Medicine at University of California (I. S.-H., T.C. F.), Los Angeles, Los Angeles, CA 90095.</Affiliation>
          </Author>
          <Author>
            <LastName>Friedman</LastName>
            <ForeName>Theodore C</ForeName>
            <Initials>TC</Initials>
          </Author>
          <Author>
            <LastName>Shin</LastName>
            <ForeName>Chang-Sung</ForeName>
            <Initials>CS</Initials>
          </Author>
          <Author>
            <LastName>Lee</LastName>
            <ForeName>Desean</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author>
            <LastName>Ivey</LastName>
            <ForeName>Rashid</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Sinha-Hikim</LastName>
            <ForeName>Amiya P</ForeName>
            <Initials>AP</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Endocrinology</MedlineTA>
        <NlmUniqueID>0375040</NlmUniqueID>
        <ISSNLinking>0013-7227</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1210/en.2013-1795</ArticleId>
        <ArticleId IdType="pubmed">24424058</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedBookArticle>
    <BookDocument>
      <PMID Version="1">24404629</PMID>
      <ArticleIdList>
        <ArticleId IdType="bookaccession">NBK174884</ArticleId>
      </ArticleIdList>
      <Book>
        <Publisher>
          <PublisherName>University of Washington, Seattle</PublisherName>
          <PublisherLocation>Seattle (WA)</PublisherLocation>
        </Publisher>
        <BookTitle book="gene">GeneReviews&#x2122;</BookTitle>
        <PubDate>
          <Year>1993</Year>
        </PubDate>
        <BeginningDate>
          <Year>1993</Year>
        </BeginningDate>
        <EndingDate>
          <Year>2014</Year>
        </EndingDate>
        <AuthorList Type="editors">
          <Author>
            <LastName>Pagon</LastName>
            <ForeName>Roberta A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author>
            <LastName>Adam</LastName>
            <ForeName>Margaret P</ForeName>
            <Initials>MP</Initials>
          </Author>
          <Author>
            <LastName>Bird</LastName>
            <ForeName>Thomas D</ForeName>
            <Initials>TD</Initials>
          </Author>
          <Author>
            <LastName>Dolan</LastName>
            <ForeName>Cynthia R</ForeName>
            <Initials>CR</Initials>
          </Author>
          <Author>
            <LastName>Fong</LastName>
            <ForeName>Chin-To</ForeName>
            <Initials>CT</Initials>
          </Author>
          <Author>
            <LastName>Smith</LastName>
            <ForeName>Richard JH</ForeName>
            <Initials>RJH</Initials>
          </Author>
          <Author>
            <LastName>Stephens</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Medium>Internet</Medium>
      </Book>
      <ArticleTitle book="gene" part="hyperchol">Familial Hypercholesterolemia</ArticleTitle>
      <Language>eng</Language>
      <AuthorList Type="authors">
        <Author>
          <LastName>Youngblom</LastName>
          <ForeName>Emily</ForeName>
          <Initials>E</Initials>
        </Author>
        <Author>
          <LastName>Knowles</LastName>
          <ForeName>Joshua W</ForeName>
          <Initials>JW</Initials>
        </Author>
      </AuthorList>
      <Abstract>
        <AbstractText Label="DISEASE CHARACTERISTICS">Familial hypercholesterolemia (FH) is characterized by severely elevated LDL cholesterol (LDL-C) levels that cause atherosclerotic plaque deposition in arteries and a markedly increased risk of coronary artery disease at an early age. Cholesterol deposits are also sometimes found in the tendons (xanthomas) and/or around the eyes (xanthelasmas). In FH, the more common cardiovascular disease is coronary heart disease (CHD), which may manifest as angina and myocardial infarction; stroke occurs more rarely. Heterozygous FH (HeFH) can often be directly attributed to a heterozygous pathogenic variant in one of three genes (LDLR, APOB, PCSK9) known to account for 60%-80% of FH. FH is relatively common (prevalence 1:200-500). Persons with untreated FH are at an approximately 20-fold increased risk for CHD. Untreated men are at a 50% risk for a fatal or non-fatal coronary event by age 50 years; untreated women are at a 30% risk by age 60 years. In contrast, homozygous FH (HoFH) results from either biallelic (i.e., 2) mutations in one of these known genes or one mutation in each of two different genes. HoFH is much rarer (prevalence 1:160,000 to 1:1,000,000). Most individuals with HoFH experience severe CHD by their mid-20s. The rate of either death or coronary bypass surgery by the teenage years is high. Severe aortic stenosis is also common.</AbstractText>
        <AbstractText Label="DIAGNOSIS/TESTING">Several formal diagnostic criteria exist for FH. The likelihood of FH is increased in individuals with high levels of low density lipoprotein cholesterol (LDL-C) (in untreated adults: &gt;190 mg/dL [&gt;4.9 mmol/L] or total cholesterol levels &gt;310 mg/dL [&gt;8 mmol/L]; in untreated children or adolescents: LDL-C levels &gt;160 mg/dL [4.1 mmol/L] or total cholesterol levels &gt;230 mg/dL [&gt;6 mmol/L]); history of premature coronary heart disease (CHD); xanthomas, xanthelasmas, and/or corneal arcus; and a family history of FH. The diagnosis of HeFH can be confirmed by the presence of a pathogenic variant in one of the three genes (LDLR, APOB, and PCSK9) in which mutation is known to account for 60%-80% of FH.</AbstractText>
        <AbstractText Label="MANAGEMENT">Treatment of manifestations: Guidelines for the management of adults and children with HeFH and HoFH have been published by multiple national/international organizations. All individuals with HeFH are at high risk for CVD and should be treated actively with diet/lifestyle changes and pharmacotherapy to lower their lipid levels. Pharmacotherapy should initially be statin-based, followed by addition of other drugs if the targeted LDL-C level is not achieved. Children and adults with HoFH usually require LDL apheresis. Liver transplantation is also being used in rare circumstances at some centers. Prevention of primary manifestations: Statin therapy in combination with a heart-healthy diet (including reduced intake of saturated fat and increased intake of soluble fiber to 10-20 g/day), and increased physical activity Surveillance: Guidelines have been published by multiple national and international organizations. A child who has a family history of FH, who is heterozygous for the FH pathogenic variant in his or her family, who has a family history of premature CVD, or who has an elevated serum cholesterol concentration should have lipid levels checked before age ten years; some guidelines advise checking cholesterol as early as age two to five years. During treatment, individuals of any age diagnosed with: HeFH should have lipid levels monitored as recommended; HoFH should be monitored with various imaging modalities (including echocardiograms, CT angiograms and cardiac catheterization) as recommended. Agents/circumstances to avoid: Smoking, high intake of saturated and transunsaturated fat, excessive intake of cholesterol, sedentary lifestyle, obesity, hypertension, and diabetes mellitus. Evaluation of relatives at risk: Early diagnosis and treatment of first-degree and second-degree relatives at risk for FH can reduce morbidity and mortality. The genetic status of at-risk family members can be clarified by either: (1) molecular genetic testing if the pathogenic variant has been identified in an affected family member; or (2) measurement of LDL-C concentration. Pregnancy management: Pregnant women should incorporate all the recommended lifestyle changes including low-saturated fat intake, no smoking, and high dietary soluble fiber. Statins are contraindicated in pregnancy due to concerns for teratogenicity and should be discontinued prior to conception. Bile acid binding resins (colesevelam) are generally considered safe (Class B for pregnancy), and LDL apheresis is also occasionally used if there is evidence of established CHD.</AbstractText>
        <AbstractText Label="GENETIC COUNSELING">HeFH and HoFH are inherited in an autosomal co-dominant manner. Almost all individuals diagnosed with HeFH have an affected parent; the proportion of HeFH caused by de novo mutation is unknown but appears to be extremely low. Each child of an individual with HeFH has a 50% chance of inheriting the pathogenic variant. If both parents have HeFH, each child has a 75% chance of having FH (i.e., 50% chance of having HeFH and 25% chance of having HoFH). If the pathogenic variant has been identified in a family member with HeFH (or if both pathogenic variants have been identified in a family member with HoFH), prenatal testing for pregnancies at increased risk is possible. Requests for prenatal testing for conditions which (like FH) do not affect intellect and have some treatment available are not common.</AbstractText>
        <CopyrightInformation>Copyright &#xA9; 1993-2014, University of Washington, Seattle. All rights reserved.</CopyrightInformation>
      </Abstract>
      <Sections>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Summary">Summary</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Diagnosis">Diagnosis</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Clinical_Description">Clinical Description</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Differential_Diagnosis">Differential Diagnosis</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Management">Management</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Genetic_Counseling">Genetic Counseling</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Resources">Resources</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Molecular_Genetics">Molecular Genetics</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.References">References</SectionTitle>
        </Section>
        <Section>
          <SectionTitle book="gene" part="hyperchol" sec="hyperchol.Chapter_Notes">Chapter Notes</SectionTitle>
        </Section>
      </Sections>
      <ContributionDate>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>02</Day>
      </ContributionDate>
      <ItemList ListType="Synonyms">
        <Item>Hypercholesterolemia, Autosomal Dominant</Item>
        <Item>Hyperlipoproteinemia, Type IIA</Item>
        <Item>Familial Hypercholesterolaemia</Item>
      </ItemList>
      <ItemList ListType="Includes">
        <Item>APOB-Related Familial Hypercholesterolemia, Autosomal Dominant</Item>
        <Item>LDLR-Related Familial Hypercholesterolemia, Autosomal Dominant</Item>
        <Item>PCSK9-Related Familial Hypercholesterolemia, Autosomal Dominant</Item>
      </ItemList>
    </BookDocument>
    <PubmedBookData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24404629</ArticleId>
      </ArticleIdList>
    </PubmedBookData>
  </PubmedBookArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24397951</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-7544</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>4</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neuroscience</Title>
          <ISOAbbreviation>Neuroscience</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Blunted GABA-mediated inhibition within the dorsomedial hypothalamus potentiates the cardiovascular response to emotional stress in rats fed a high-fat diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0306-4522(13)01086-5</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.neuroscience.2013.12.053</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Rats fed a high-fat diet (HFD) present an exaggerated endocrine response to stress conditions, which, like obesity, show a high correlation with cardiovascular diseases. Meanwhile the GABAergic neurotransmission within the dorsomedial hypothalamus (DMH) is involved in the regulation of the physiological responses during emotional stress. Here we evaluated the influence of obesity, induced by a HFD, on the cardiovascular responses induced by air jet stress in rats, and the role of the GABAergic tonus within the DMH in these changes. Our results showed that consumption of a HFD (45% w/w fat) for 9weeks induced obesity and increases in baseline mean arterial pressure (MAP) and heart rate (HR). Moreover, obesity potentiated stress responsiveness, evidenced by the greater changes in MAP and HR induced by stress in obese rats. The injection of muscimol into the DMH reduced the maximal increases in HR and MAP induced by stress in both groups; however, the reduction in the maximal increases in MAP in the HFD group was less pronounced. Moreover, the injection of muscimol into the DMH of obese rats was less effective in reducing the stress-induced tachycardia, since the HR attained the same levels at the end of the stress paradigm as after the vehicle injection. Injection of bicuculline into DMH induced increases in MAP and HR in both groups. Nevertheless, obesity shortened the tachycardic response to bicuculline injection. These data show that obesity potentiates the cardiovascular response to stress in rats due to an inefficient GABAA-mediated inhibition within the DMH.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Abreu</LastName>
            <ForeName>A R</ForeName>
            <Initials>AR</Initials>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: alirriba@yahoo.com.br.</Affiliation>
          </Author>
          <Author>
            <LastName>de Abreu</LastName>
            <ForeName>A R</ForeName>
            <Initials>AR</Initials>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: arrabreu@gmail.com.</Affiliation>
          </Author>
          <Author>
            <LastName>Santos</LastName>
            <ForeName>L T</ForeName>
            <Initials>LT</Initials>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: laugbatista@yahoo.com.br.</Affiliation>
          </Author>
          <Author>
            <LastName>de Souza</LastName>
            <ForeName>A A</ForeName>
            <Initials>AA</Initials>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: alinearlindo.nut@gmail.com.</Affiliation>
          </Author>
          <Author>
            <LastName>da Silva</LastName>
            <ForeName>L G</ForeName>
            <Initials>LG</Initials>
            <Suffix>Jr</Suffix>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: gonzagaufmg@gmail.com.</Affiliation>
          </Author>
          <Author>
            <LastName>Chianca</LastName>
            <ForeName>D A</ForeName>
            <Initials>DA</Initials>
            <Suffix>Jr</Suffix>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: deochianca@gmail.com.</Affiliation>
          </Author>
          <Author>
            <LastName>de Menezes</LastName>
            <ForeName>R C</ForeName>
            <Initials>RC</Initials>
            <Affiliation>Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: rodrigo.menezes@iceb.ufop.br.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>4</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neuroscience</MedlineTA>
        <NlmUniqueID>7605074</NlmUniqueID>
        <ISSNLinking>0306-4522</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ANOVA</Keyword>
        <Keyword MajorTopicYN="N">BMI</Keyword>
        <Keyword MajorTopicYN="N">DMH</Keyword>
        <Keyword MajorTopicYN="N">GABA</Keyword>
        <Keyword MajorTopicYN="N">HFD</Keyword>
        <Keyword MajorTopicYN="N">HR</Keyword>
        <Keyword MajorTopicYN="N">MAP</Keyword>
        <Keyword MajorTopicYN="N">NPY</Keyword>
        <Keyword MajorTopicYN="N">PVN</Keyword>
        <Keyword MajorTopicYN="N">SEM</Keyword>
        <Keyword MajorTopicYN="N">analysis of variance</Keyword>
        <Keyword MajorTopicYN="N">bicuculline methiodide</Keyword>
        <Keyword MajorTopicYN="N">dorsomedial hypothalamus</Keyword>
        <Keyword MajorTopicYN="N">emotional stress</Keyword>
        <Keyword MajorTopicYN="N">heart rate</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">hypothalamic paraventricular nucleus</Keyword>
        <Keyword MajorTopicYN="N">mean arterial pressure</Keyword>
        <Keyword MajorTopicYN="N">neuropeptide Y</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">standard error of the mean</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24397951</ArticleId>
        <ArticleId IdType="pii">S0306-4522(13)01086-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neuroscience.2013.12.053</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24394536</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2072-6643</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>Nutrients</Title>
          <ISOAbbreviation>Nutrients</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The mediterranean diet and nutritional adequacy: a review.</ArticleTitle>
        <Pagination>
          <MedlinePgn>231-48</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/nu6010231</ELocationID>
        <Abstract>
          <AbstractText>The Mediterranean dietary pattern, through a healthy profile of fat intake, low proportion of carbohydrate, low glycemic index, high content of dietary fiber, antioxidant compounds, and anti-inflammatory effects, reduces the risk of certain pathologies, such as cancer or Cardiovascular Disease (CVD). Nutritional adequacy is the comparison between the nutrient requirement and the intake of a certain individual or population. In population groups, the prevalence of nutrient inadequacy can be assessed by the probability approach or using the Estimated Average Requirement (EAR) cut-point method. However, dietary patterns can also be used as they have moderate to good validity to assess adequate intakes of some nutrients. The objective of this study was to review the available evidence on the Nutritional Adequacy of the Mediterranean Diet. The inclusion of foods typical of the Mediterranean diet and greater adherence to this healthy pattern was related to a better nutrient profile, both in children and adults, with a lower prevalence of individuals showing inadequate intakes of micronutrients. Therefore, the Mediterranean diet could be used in public health nutrition policies in order to prevent micronutrient deficiencies in the most vulnerable population groups.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Castro-Quezada</LastName>
            <ForeName>Itandehui</ForeName>
            <Initials>I</Initials>
            <Affiliation>Department of Clinical Sciences, Health Sciences Faculty, University of Las Palmas de Gran Canaria, Luis Pasteur s/n, Las Palmas de Gran Canaria 35016, Spain. itandehuicastro@correo.ugr.es.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rom&#xE1;n-Vi&#xF1;as</LastName>
            <ForeName>Blanca</ForeName>
            <Initials>B</Initials>
            <Affiliation>Department of Clinical Sciences, Health Sciences Faculty, University of Las Palmas de Gran Canaria, Luis Pasteur s/n, Las Palmas de Gran Canaria 35016, Spain. blancaRV@blanquerna.url.edu.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serra-Majem</LastName>
            <ForeName>Llu&#xED;s</ForeName>
            <Initials>L</Initials>
            <Affiliation>Department of Clinical Sciences, Health Sciences Faculty, University of Las Palmas de Gran Canaria, Luis Pasteur s/n, Las Palmas de Gran Canaria 35016, Spain. lserra@dcc.ulpgc.es.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>01</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Nutrients</MedlineTA>
        <NlmUniqueID>101521595</NlmUniqueID>
        <ISSNLinking>2072-6643</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">nu6010231</ArticleId>
        <ArticleId IdType="doi">10.3390/nu6010231</ArticleId>
        <ArticleId IdType="pubmed">24394536</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24388434</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>6</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition, metabolism, and cardiovascular diseases : NMCD</Title>
          <ISOAbbreviation>Nutr Metab Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The results of Look AHEAD do not row against the implementation of lifestyle changes in patients with type 2 diabetes.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0939-4753(13)00303-7</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.numecd.2013.12.001</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">The Look AHEAD trial, evaluating the effects of weight loss on cardiovascular (CV) morbidity and mortality in overweight/obese people with type 2 diabetes (T2D), was interrupted after a median 9.5-year follow-up because the incidence of CV events was not different between the Intensive Lifestyle Intervention (ILI) and the control groups, and unlikely to statistically change thereafter. This made health providers and patients wondering about clinical value of diet and physical exercise in diabetic patients. Many factors may have made difficult to ascertain benefits of lifestyle intervention, besides the lower than predicted CV event rates. Among others, LDL-cholesterol was lowered more, with a higher use of statins, in the control group. Anyhow, ILI significantly improved numerous health conditions, including quality of life, CV risk factors and blood glucose control, with more diabetes remissions and less use of insulin. The intervention aimed at weight loss by reducing fat calories, and using meal replacements and, eventually, orlistat, likely underemphasizing dietary composition. There is suggestive evidence, in fact, that qualitative changes in dietary composition aiming at higher consumption of foods rich in fiber and with a high vegetable/animal fat ratio favorably influence CV risk in T2D patients. In conclusion, the Look AHEAD showed substantial health benefits of lifestyle modifications. Prevention of CV events may need higher attention to dietary composition, contributing to stricter control of CV risk factors. As a better health-related quality of life in people with diabetes is an important driver of our clinical decisions, efforts on early implementation of behavioral changes through a multifactorial approach are strongly justified.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Annuzzi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Clinical Medicine and Surgery, Federico II University, Via Pansini 5, Naples 80131, Italy. Electronic address: annuzzi@unina.it.</Affiliation>
          </Author>
          <Author>
            <LastName>Rivellese</LastName>
            <ForeName>A A</ForeName>
            <Initials>AA</Initials>
            <Affiliation>Department of Clinical Medicine and Surgery, Federico II University, Via Pansini 5, Naples 80131, Italy.</Affiliation>
          </Author>
          <Author>
            <LastName>Bozzetto</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <Affiliation>Department of Clinical Medicine and Surgery, Federico II University, Via Pansini 5, Naples 80131, Italy.</Affiliation>
          </Author>
          <Author>
            <LastName>Riccardi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Clinical Medicine and Surgery, Federico II University, Via Pansini 5, Naples 80131, Italy.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nutr Metab Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>9111474</NlmUniqueID>
        <ISSNLinking>0939-4753</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">Diet</Keyword>
        <Keyword MajorTopicYN="N">Lifestyle</Keyword>
        <Keyword MajorTopicYN="N">Look AHEAD trial</Keyword>
        <Keyword MajorTopicYN="N">Physical activity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0939-4753(13)00303-7</ArticleId>
        <ArticleId IdType="doi">10.1016/j.numecd.2013.12.001</ArticleId>
        <ArticleId IdType="pubmed">24388434</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24387274</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>6</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-277X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>6</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of human nutrition and dietetics : the official journal of the British Dietetic Association</Title>
          <ISOAbbreviation>J Hum Nutr Diet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Different measurements of waist circumference and sagittal abdominal diameter and their relationship with cardiometabolic risk factors in elderly men.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="doi">10.1111/jhn.12201</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Measures of central adiposity such as waist circumference (PC) and sagittal abdominal diameter (SAD) are better predictors of metabolic complications than measures of total body fat. Thus, this study aimed to assess the relationship of different measures of WC and SAD with cardiometabolic risk factors in elderly men.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This is a cross-sectional study that included 69 men (aged 60-92&#xA0;years old) enrolled in the Family Health Program of Vi&#xE7;osa, Minas Gerais, Brazil. The evaluations comprised anthropometric, biochemical and haemodynamic measurements. The WC (i.e. umbilical level; the narrowest waist; immediately above the iliac crests; and the midpoint between the last rib and iliac crest) and SAD (i.e. the narrowest point between the last rib and the iliac crest; higher abdominal diameter; umbilical level; and the midpoint between the iliac crests) were measured at different anatomical sites. Statistical analysis consisted of correlation coefficients between measures of abdominal adiposity and cardiometabolic risk factors.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The strongest correlations were between the WC measured at the narrowest waist and triglycerides (TG), fasting blood glucose (FBG) and high-density lipoprotein cholesterol (HDL-C) levels, and between the SAD measured at the midpoint between the iliac crests and TG, FBG and HDL-C.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SAD measured at the midpoint between the iliac crests and WC measured at the narrowest waist showed the best relationships with cardiometabolic risk factors in elderly men.</AbstractText>
          <CopyrightInformation>&#xA9; 2014 The British Dietetic Association Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Anuncia&#xE7;&#xE3;o</LastName>
            <ForeName>P C</ForeName>
            <Initials>PC</Initials>
            <Affiliation>Department of Nutrition and Health, Federal University of Vi&#xE7;osa, Vi&#xE7;osa, Brazil.</Affiliation>
          </Author>
          <Author>
            <LastName>Ribeiro</LastName>
            <ForeName>R C L</ForeName>
            <Initials>RC</Initials>
          </Author>
          <Author>
            <LastName>Pereira</LastName>
            <ForeName>M Q</ForeName>
            <Initials>MQ</Initials>
          </Author>
          <Author>
            <LastName>Comunian</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>6</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Hum Nutr Diet</MedlineTA>
        <NlmUniqueID>8904840</NlmUniqueID>
        <ISSNLinking>0952-3871</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">adiposity</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">elderly</Keyword>
        <Keyword MajorTopicYN="N">risk factors</Keyword>
        <Keyword MajorTopicYN="N">sagittal abdominal diameter</Keyword>
        <Keyword MajorTopicYN="N">waist circumference</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1111/jhn.12201</ArticleId>
        <ArticleId IdType="pubmed">24387274</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24385344</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>3</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1755-3245</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>2</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular research</Title>
          <ISOAbbreviation>Cardiovasc. Res.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fatty Acid Nitroalkenes Ameliorate Glucose Intolerance and Pulmonary Hypertension in High Fat Diet-Induced Obesity.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Obesity is a risk factor for diabetes and cardiovascular disease, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue dysfunction that promotes bioactive mediator secretion from visceral adipose tissue and the initiation of pro-inflammatory events that induce oxidative stress and tissue dysfunction. Current understanding supports that suppressing pro-inflammatory and oxidative events promotes improved metabolic and cardiovascular function. In this regard, electrophilic nitro-fatty acids display pleiotropic anti-inflammatory signaling actions.Methods and ResultsIt was hypothesized that high fat diet (HFD)-induced inflammatory and metabolic responses, manifested by loss of glucose tolerance and vascular dysfunction, would be attenuated by systemic administration of nitrooctadecenoic acid (OA-NO2). Male C57BL/6j mice subjected to a HFD for 20 weeks displayed increased adiposity, fasting glucose and insulin levels, which led to glucose intolerance and pulmonary hypertension (PH), characterized by increased right ventricular (RV) end systolic pressure (RVESP) and pulmonary vascular resistance (PVR). This was associated with increased lung xanthine oxidoreductase (XO) activity, macrophage infiltration and enhanced expression of pro-inflammatory cytokines. Left ventricular (LV) end diastolic pressure remained unaltered, indicating that the HFD produces pulmonary vascular remodeling, rather than LV dysfunction and pulmonary venous hypertension. Administration of OA-NO2 for the final 6.5 weeks of HFD improved glucose tolerance and significantly attenuated HFD-induced RVESP, PVR, RV hypertrophy, lung XO activity, oxidative stress and pro-inflammatory pulmonary cytokinelevels.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These observations support that the pleiotropic signaling actions of electrophilic fatty acids represent a therapeutic strategy for limiting the complex pathogenic responses instigated by obesity.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Kelley</LastName>
            <ForeName>Eric E</ForeName>
            <Initials>EE</Initials>
            <Affiliation>Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213.</Affiliation>
          </Author>
          <Author>
            <LastName>Baust</LastName>
            <ForeName>Jeff</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Bonacci</LastName>
            <ForeName>Gustavo</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author>
            <LastName>Golin-Bisello</LastName>
            <ForeName>Franca</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author>
            <LastName>Devlin</LastName>
            <ForeName>Jason E</ForeName>
            <Initials>JE</Initials>
          </Author>
          <Author>
            <LastName>St Croix</LastName>
            <ForeName>Claudette M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author>
            <LastName>Watkins</LastName>
            <ForeName>Simon C</ForeName>
            <Initials>SC</Initials>
          </Author>
          <Author>
            <LastName>Gor</LastName>
            <ForeName>Sonia</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Cantu-Medellin</LastName>
            <ForeName>Nadiezhda</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author>
            <LastName>Weidert</LastName>
            <ForeName>Eric R</ForeName>
            <Initials>ER</Initials>
          </Author>
          <Author>
            <LastName>Frisbee</LastName>
            <ForeName>Jefferson C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author>
            <LastName>Gladwin</LastName>
            <ForeName>Mark T</ForeName>
            <Initials>MT</Initials>
          </Author>
          <Author>
            <LastName>Champion</LastName>
            <ForeName>Hunter C</ForeName>
            <Initials>HC</Initials>
          </Author>
          <Author>
            <LastName>Freeman</LastName>
            <ForeName>Bruce A</ForeName>
            <Initials>BA</Initials>
          </Author>
          <Author>
            <LastName>Khoo</LastName>
            <ForeName>Nicholas K H</ForeName>
            <Initials>NK</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>2</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cardiovasc Res</MedlineTA>
        <NlmUniqueID>0077427</NlmUniqueID>
        <ISSNLinking>0008-6363</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">cvt341</ArticleId>
        <ArticleId IdType="doi">10.1093/cvr/cvt341</ArticleId>
        <ArticleId IdType="pubmed">24385344</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24380833</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>1</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-3061</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Trends in endocrinology and metabolism: TEM</Title>
          <ISOAbbreviation>Trends Endocrinol. Metab.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>New insights into IGF-1 signaling in the heart.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S1043-2760(13)00207-5</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.tem.2013.12.002</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Insulin-like growth factor 1 (IGF-1) signaling regulates contractility, metabolism, hypertrophy, autophagy, senescence, and apoptosis in the heart. IGF-1 deficiency is associated with an increased risk of cardiovascular disease, whereas cardiac activation of IGF-1 receptor (IGF-1R) protects from the detrimental effects of a high-fat diet and myocardial infarction. IGF-1R activates multiple pathways through its intrinsic tyrosine kinase activity and through coupling to heterotrimeric G protein. These pathways involve classic second messengers, phosphorylation cascades, lipid signaling, Ca(2+) transients, and gene expression. In addition, IGF-1R triggers signaling in different subcellular locations including the plasma membrane, perinuclear T tubules, and also in internalized vesicles. In this review, we provide a fresh and updated view of the complex IGF-1 scenario in the heart, including a critical focus on therapeutic strategies.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Troncoso</LastName>
            <ForeName>Rodrigo</ForeName>
            <Initials>R</Initials>
            <Affiliation>Facultad de Ciencias Quimicas y Farmaceuticas &amp; Facultad Medicina, Universidad de Chile, Santiago 838049, Chile; Centro de Estudios Moleculares de la C&#xE9;lula, Facultad de Ciencias Quimicas y Farmaceuticas &amp; Facultad de Medicina, Universidad de Chile, Santiago 838049, Chile.</Affiliation>
          </Author>
          <Author>
            <LastName>Ibarra</LastName>
            <ForeName>Cristi&#xE1;n</ForeName>
            <Initials>C</Initials>
            <Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17177, Sweden.</Affiliation>
          </Author>
          <Author>
            <LastName>Vicencio</LastName>
            <ForeName>Jose Miguel</ForeName>
            <Initials>JM</Initials>
            <Affiliation>Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK.</Affiliation>
          </Author>
          <Author>
            <LastName>Jaimovich</LastName>
            <ForeName>Enrique</ForeName>
            <Initials>E</Initials>
            <Affiliation>Centro de Estudios Moleculares de la C&#xE9;lula, Facultad de Ciencias Quimicas y Farmaceuticas &amp; Facultad de Medicina, Universidad de Chile, Santiago 838049, Chile.</Affiliation>
          </Author>
          <Author>
            <LastName>Lavandero</LastName>
            <ForeName>Sergio</ForeName>
            <Initials>S</Initials>
            <Affiliation>Facultad de Ciencias Quimicas y Farmaceuticas &amp; Facultad Medicina, Universidad de Chile, Santiago 838049, Chile; Centro de Estudios Moleculares de la C&#xE9;lula, Facultad de Ciencias Quimicas y Farmaceuticas &amp; Facultad de Medicina, Universidad de Chile, Santiago 838049, Chile; Department of Internal Medicine (Cardiology Division), University of Texas Southwestern Medical Center, Dallas, TX, 75390-8573, USA. Electronic address: slavander@uchile.cl.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Trends Endocrinol Metab</MedlineTA>
        <NlmUniqueID>9001516</NlmUniqueID>
        <ISSNLinking>1043-2760</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IGF-1R</Keyword>
        <Keyword MajorTopicYN="N">calcium</Keyword>
        <Keyword MajorTopicYN="N">cardiac progenitor stem cells</Keyword>
        <Keyword MajorTopicYN="N">inter-organelle communication</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S1043-2760(13)00207-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.tem.2013.12.002</ArticleId>
        <ArticleId IdType="pubmed">24380833</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24379686</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1178-7007</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>7</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes, metabolic syndrome and obesity : targets and therapy</Title>
          <ISOAbbreviation>Diabetes Metab Syndr Obes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1-14</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DMSO.S50209</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with diabesity have a significantly increased risk of developing cardiovascular disease. Therefore, therapy addressing the multiple metabolic abnormalities linked with diabesity and leading to further reduction of cardiovascular risk is highly desirable. Activation of the TGR5 receptor holds therapeutic potential for diabesity. In the present study, we evaluated the efficacy of TRC210258, a novel TGR5 agonist, in clinically relevant animal models of diabesity.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A novel small molecule, TRC210258 (N-(4-chlorophenyl)-2-(4-fluorophenoxy)-N-methylimidazo (1, 2-a) pyrimidine-3-carboxamide), was synthesized. The in vitro TGR5 receptor activation potential of TRC210258 was assessed by cyclic adenosine monophosphate (cAMP) assay and cAMP-responsive element reporter assay using cells overexpressing the human TGR5 receptor. The effect of TRC210258 on glucagon-like peptide-1 release was evaluated in vitro using a human enteroendocrine cell line. The effect of TRC210258 on energy expenditure and glycemic control was evaluated in high-fat diet-induced obese mice. Additionally, the effect of TRC210258 on dyslipidemic parameters was determined in high fat-fed hamsters.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">TRC210258 demonstrated potent TGR5 agonist activity, with enhanced glucagon-like peptide-1 release and energy expenditure. Treatment with TRC210258 resulted in better glycemic control and improved parameters of dyslipidemia such as plasma triglyceride, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol levels. Treatment with TRC210258 also improved emerging dyslipidemic cardiovascular risk parameters, including remnant cholesterol and triglyceride clearance.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study highlights the potential of TRC210258, a novel TGR5 agonist, to improve dyslipidemic cardiovascular risk beyond glycemic control in patients with type 2 diabetes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zambad</LastName>
            <ForeName>Shitalkumar P</ForeName>
            <Initials>SP</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuli</LastName>
            <ForeName>Davinder</ForeName>
            <Initials>D</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathur</LastName>
            <ForeName>Anoop</ForeName>
            <Initials>A</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghalsasi</LastName>
            <ForeName>Sameer A</ForeName>
            <Initials>SA</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chaudhary</LastName>
            <ForeName>Anita R</ForeName>
            <Initials>AR</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deshpande</LastName>
            <ForeName>Shailesh</ForeName>
            <Initials>S</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Ramesh C</ForeName>
            <Initials>RC</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chauthaiwale</LastName>
            <ForeName>Vijay</ForeName>
            <Initials>V</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dutt</LastName>
            <ForeName>Chaitanya</ForeName>
            <Initials>C</Initials>
            <Affiliation>Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, India.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Diabetes Metab Syndr Obes</MedlineTA>
        <NlmUniqueID>101515585</NlmUniqueID>
        <ISSNLinking>1178-7007</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3873233</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">TGR5</Keyword>
        <Keyword MajorTopicYN="N">atherogenic dyslipidemia</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular risks</Keyword>
        <Keyword MajorTopicYN="N">diabesity</Keyword>
        <Keyword MajorTopicYN="N">remnant cholesterol</Keyword>
        <Keyword MajorTopicYN="N">triglyceride clearance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2014</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.2147/DMSO.S50209</ArticleId>
        <ArticleId IdType="pii">dmso-7-001</ArticleId>
        <ArticleId IdType="pubmed">24379686</ArticleId>
        <ArticleId IdType="pmc">PMC3873233</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24377894</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0253-3758</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>41</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Zhonghua xin xue guan bing za zhi</Title>
          <ISOAbbreviation>Zhonghua Xin Xue Guan Bing Za Zhi</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Resveratrol reduces inflammatory cytokines via inhibiting nuclear factor-?B and mitogen-activated protein kinase signal pathway in a rabbit atherosclerosis model].</ArticleTitle>
        <Pagination>
          <MedlinePgn>866-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Inflammation serves as the initial pathologic step of cardiovascular diseases including atherosclerosis. Resveratrol possesses many pharmacological properties including antioxidant, cardioprotective and anti-cancer effects. In this study, we investigate the anti-inflammatory effect and mechanisms of resveratrol in an atherosclerotic rabbit model.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Rabbit were assigned to six groups (n = 10 each): control, high fat diet group, resveratrol low, medium and high dose groups, resveratrol pretreatment group. The serum tumor necrosis factor-a (TNF- a), interleukin-6 (IL-6) and interleukin-1&#xDF; (IL-1&#xDF;) were analyzed by Enzyme-linked immuno sorbent assay(ELISA). Phosphorylation levels of mitogen-activated protein kinases (MAPKs) cascades and NF-?B were determined by Western blot.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the control group, the expression of serum inflammatory factors IL-1&#xDF;, IL-6, TNF-a were increased in high-fat group (all P &lt; 0.05). Compared with high-fat group, the expressions of IL-6, IL-1&#xDF;, TNF-a were significantly reduced in resveratrol low, medium, high dose groups and resveratrol pretreatment group (all P &lt; 0.01), and this effect is dose-dependent. In addition, the NF-?B, p38MAPK, JNK, ERK1/2 protein phosphorylation in high-fat group were significantly upregulated compared with control group (P &lt; 0.05), which (except ERK1/2 phosphorylation level) were significantly downregulated in resveratrol treatment group and resveratrol pretreatment group.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study indicates that resveratrol reduces serum inflammatory cytokines in this atherosclerotic rabbit model via down-regulation phosphorylation of NF-?B, and MAPKs signaling, which might serve as the anti-inflammatory molecular basis of resveratrol.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital of Preclinical Medicine College of Kunming Medical University, Kunming 650000, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wan-Qiu</ForeName>
            <Initials>WQ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dou</LastName>
            <ForeName>Jian-Lin</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yan-Jie</ForeName>
            <Initials>YJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Jia-Zhi</ForeName>
            <Initials>JZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Di</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ge</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <Affiliation>Email: sunlinkm@sina.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>chi</Language>
        <PublicationTypeList>
          <PublicationType>English Abstract</PublicationType>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>Zhonghua Xin Xue Guan Bing Za Zhi</MedlineTA>
        <NlmUniqueID>7910682</NlmUniqueID>
        <ISSNLinking>0253-3758</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24377894</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24374005</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition, metabolism, and cardiovascular diseases : NMCD</Title>
          <ISOAbbreviation>Nutr Metab Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The association between carotid intima media thickness and individual dietary components and patterns.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0939-4753(13)00269-X</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.numecd.2013.10.024</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To review: 1) the correlation between individual dietary components and carotid intima media thickness (cIMT); 2) the relationship between dietary patterns and cIMT; 3) the effect of dietary interventions on cIMT progression.</AbstractText>
          <AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">An electronic search for epidemiological and intervention trials investigating the association between dietary components or patterns of intake and cIMT was performed in PUBMED, EMBASE and the Cochrane Library. Epidemiological data shows that a higher intake of fruit, wholegrains and soluble fibre and lower consumption of saturated fat in favour of polyunsaturated fat is associated with lower cIMT. In people at high risk of cardiovascular disease &gt;93&#xA0;g/day of fruit is associated with lower cIMT. Lower cIMT has also been observed when &gt;0.79&#xA0;serves/day of wholegrains and &gt;25&#xA0;g/day of fibre, predominately in the soluble form is consumed. Saturated fat is positively associated with cIMT, for every 10&#xA0;g/day increase in saturated fat cIMT is 0.03&#xA0;mm greater. Olive oil is inversely associated with cIMT, with a benefit seen when &gt;34&#xA0;g/day is consumed. While there are many epidemiological studies exploring the association between dietary intake and cIMT there are few intervention studies. Intervention studies show that a Mediterranean diet may reduce cIMT progression, especially in those with a higher cIMT.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A Mediterranean style dietary pattern, which is high in fruits, wholegrains, fibre and olive oil and low in saturated fat, may reduce carotid atherosclerosis development and progression. However further research from randomised controlled trials is required to understand the association between diet and cIMT and the underlying mechanisms.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Petersen</LastName>
            <ForeName>K S</ForeName>
            <Initials>KS</Initials>
            <Affiliation>School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5000, Australia.</Affiliation>
          </Author>
          <Author>
            <LastName>Clifton</LastName>
            <ForeName>P M</ForeName>
            <Initials>PM</Initials>
            <Affiliation>School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5000, Australia.</Affiliation>
          </Author>
          <Author>
            <LastName>Keogh</LastName>
            <ForeName>J B</ForeName>
            <Initials>JB</Initials>
            <Affiliation>School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5000, Australia. Electronic address: Jennifer.Keogh@unisa.edu.au.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>1</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nutr Metab Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>9111474</NlmUniqueID>
        <ISSNLinking>0939-4753</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">Carotid intima media thickness</Keyword>
        <Keyword MajorTopicYN="N">Dietary intake</Keyword>
        <Keyword MajorTopicYN="N">Mediterranean diet</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0939-4753(13)00269-X</ArticleId>
        <ArticleId IdType="doi">10.1016/j.numecd.2013.10.024</ArticleId>
        <ArticleId IdType="pubmed">24374005</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24370063</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1472-6882</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>BMC complementary and alternative medicine</Title>
          <ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Studies on two polyherbal formulations (ZPTO and ZTO) for comparison of their antidyslipidemic, antihypertensive and endothelial modulating activities.</ArticleTitle>
        <Pagination>
          <MedlinePgn>371</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1472-6882-13-371</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular disorders (CVDs) are the leading cause of disease burden worldwide. Apart from available synthetic drugs used in CVDs, there are many herbal formulations including POL-10 (containing 10 herbs), which have been shown to be effective in animal studies but POL-10 was found to cause tachycardia in rodents as its side effect. This study was designed to modify the composition of POL-10 for better efficacy and/or safety profile in CVDs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">To assess the antidyslipidemic, antihypertensive and endothelial modulatory properties of two herbal formulations, (ZPTO and ZTO) containing Z: Zingiber officinalis, P: Piper nigrum, T: Terminalia belerica and O: Orchis mascula, different animal models including, tyloxapol and high fat diet-induced dyslipidemia and spontaneously hypertensive rats (SHR) were used. Effect on endothelial function was studied using isolated tissue bath set up coupled with PowerLab data acquisition system. The antioxidant activity was carried out using DPPH radical-scavenging assay.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Based on preliminary screening of the ingredients of POL-10 in tyloxapol-induced hyperlipidemic rats, ZPTO and ZTO containing four active ingredients namely; Z, P, T and O were identified for further studies and comparison. In tyloxapol-induced hyperlipidemic rats, both ZPTO and ZTO caused significant reduction in serum triglyceride (TG) and total cholesterol (TC). In high fat diet-fed rats, ZPTO decreased TC, low-density lipoproteins cholesterol (LDL-C) and atherogenic index (AI). ZTO also showed similar effects to those of ZPTO with additional merits being more effective in reducing AI, body weight and more importantly raising high-density lipoproteins. In SHR, both formulations markedly reduced systolic blood pressure, AI and TG levels, ZTO being more potent in reversing endothelial dysfunction while was devoid of cardiac stimulatory effect. In addition, ZTO also reduced LDL-C and improved glucose levels in SHR. In DPPH radical-scavenging activity test, ZTO was also more potent than ZPTO.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The modified formulation, ZTO was not only found more effective in correcting cardiovascular abnormalities than ZPTO or POL-10 but also it was free from tachycardiac side-effect, which might be observed because of the presence of Piper nigrum in ZPTO.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Aziz</LastName>
            <ForeName>Nauman</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehmood</LastName>
            <ForeName>Malik Hassan</ForeName>
            <Initials>MH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gilani</LastName>
            <ForeName>Anwarul-Hassan</ForeName>
            <Initials>AH</Initials>
            <Affiliation>Natural Product Research Division, Department of Biological and Biomedical Sciences, The Aga Khan University Medical College, Karachi 74800, Pakistan. anwarhgilani@yahoo.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Complement Altern Med</MedlineTA>
        <NlmUniqueID>101088661</NlmUniqueID>
        <ISSNLinking>1472-6882</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1472-6882-13-371</ArticleId>
        <ArticleId IdType="doi">10.1186/1472-6882-13-371</ArticleId>
        <ArticleId IdType="pubmed">24370063</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24369828</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-2472</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Thrombosis research</Title>
          <ISOAbbreviation>Thromb. Res.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Postprandial coagulation activation in overweight individuals after weight loss: Acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0049-3848(13)00596-3</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.thromres.2013.12.010</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Diet is important in the prevention of cardiovascular disease, and it has been suggested that a high-MUFA diet is more cardioprotective than a low-fat diet. We hypothesised that the postprandial thrombotic risk profile is improved most favourably by a high-MUFA diet compared with a low-fat diet. This was tested in a parallel intervention trial on overweight individuals (aged 28.4 (SD 4.7) years) randomly assigned to a MUFA-diet (35-45% of energy as fat; &gt;20% as MUFA, n=21) or a low-fat (LF) diet (20-30% of energy as fat, n=22) for 6months after a weight loss of ~10%. All foods were provided free of charge from a purpose-built supermarket. Meal tests designed after the same principles were performed before and after the dietary intervention, and blood samples were collected at 8.00h (fasting), 12.00h, and 18.00h and analysed for factor VII coagulant activity (FVII:C), activated FVII, fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, plasminogen activator inhibitor (PAI:Ag), and thrombin activatable fibrinolysis inhibitor. There were significant postprandial increases in F1+2 and D-dimer before and after dietary intervention, with significantly lower values after 6months. No significant differences were observed between the postprandial changes induced by the two diets. The postprandial decrease in FVII:C and PAI:Ag did not differ before and after intervention, irrespective of the diets. Our findings suggest postprandial coagulation activation in overweight subjects with more pronounced acute than long-term effects. We observed similar effects of the MUFA diet and the LF diet on the postprandial prothrombotic risk profile.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013. Published by Elsevier Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Bladbjerg</LastName>
            <ForeName>Else-Marie</ForeName>
            <Initials>EM</Initials>
            <Affiliation>Unit for Thrombosis Research, Institute of Public Health, the University of Southern Denmark and Dept. of Clinical Biochemistry, Hospital of South West Denmark, Esbjerg, Denmark. Electronic address: ebladbjerg@health.sdu.dk.</Affiliation>
          </Author>
          <Author>
            <LastName>Larsen</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
            <Affiliation>Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark.</Affiliation>
          </Author>
          <Author>
            <LastName>Due</LastName>
            <ForeName>Anette</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark.</Affiliation>
          </Author>
          <Author>
            <LastName>Jespersen</LastName>
            <ForeName>J&#xF8;rgen</ForeName>
            <Initials>J</Initials>
            <Affiliation>Unit for Thrombosis Research, Institute of Public Health, the University of Southern Denmark and Dept. of Clinical Biochemistry, Hospital of South West Denmark, Esbjerg, Denmark.</Affiliation>
          </Author>
          <Author>
            <LastName>Stender</LastName>
            <ForeName>Steen</ForeName>
            <Initials>S</Initials>
            <Affiliation>Department of Clinical Biochemistry, Copenhagen University Hospital, Gentofte, Denmark.</Affiliation>
          </Author>
          <Author>
            <LastName>Astrup</LastName>
            <ForeName>Arne</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark; Department of Clinical Nutrition, Copenhagen University Hospital, Gentofte, Denmark.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Thromb Res</MedlineTA>
        <NlmUniqueID>0326377</NlmUniqueID>
        <ISSNLinking>0049-3848</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ANOVA</Keyword>
        <Keyword MajorTopicYN="N">BMI</Keyword>
        <Keyword MajorTopicYN="N">C-reactive protein</Keyword>
        <Keyword MajorTopicYN="N">CRP</Keyword>
        <Keyword MajorTopicYN="N">CVD</Keyword>
        <Keyword MajorTopicYN="N">Coagulation activation</Keyword>
        <Keyword MajorTopicYN="N">Diet interventions</Keyword>
        <Keyword MajorTopicYN="N">ELISA</Keyword>
        <Keyword MajorTopicYN="N">F1+2</Keyword>
        <Keyword MajorTopicYN="N">FVII</Keyword>
        <Keyword MajorTopicYN="N">GI</Keyword>
        <Keyword MajorTopicYN="N">Haemostasis</Keyword>
        <Keyword MajorTopicYN="N">ICAM</Keyword>
        <Keyword MajorTopicYN="N">LF</Keyword>
        <Keyword MajorTopicYN="N">MUFA</Keyword>
        <Keyword MajorTopicYN="N">MUFObes</Keyword>
        <Keyword MajorTopicYN="N">Mono Unsaturated Fatty acids in Obesity</Keyword>
        <Keyword MajorTopicYN="N">PAI</Keyword>
        <Keyword MajorTopicYN="N">Postprandial</Keyword>
        <Keyword MajorTopicYN="N">TAFI</Keyword>
        <Keyword MajorTopicYN="N">USDA</Keyword>
        <Keyword MajorTopicYN="N">United States Department of Agriculture</Keyword>
        <Keyword MajorTopicYN="N">VLDL</Keyword>
        <Keyword MajorTopicYN="N">analysis of variance</Keyword>
        <Keyword MajorTopicYN="N">body mass index</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">enzyme-linked immunosorbent assay</Keyword>
        <Keyword MajorTopicYN="N">factor VII</Keyword>
        <Keyword MajorTopicYN="N">glycaemic index</Keyword>
        <Keyword MajorTopicYN="N">intracellular adhesion molecule</Keyword>
        <Keyword MajorTopicYN="N">low-fat</Keyword>
        <Keyword MajorTopicYN="N">monounsaturated fatty acids</Keyword>
        <Keyword MajorTopicYN="N">plasminogen activator inhibitor type 1</Keyword>
        <Keyword MajorTopicYN="N">prothrombin fragment 1+2</Keyword>
        <Keyword MajorTopicYN="N">thrombin activatable fibrinolysis inhibitor</Keyword>
        <Keyword MajorTopicYN="N">very low density lipoprotein</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0049-3848(13)00596-3</ArticleId>
        <ArticleId IdType="doi">10.1016/j.thromres.2013.12.010</ArticleId>
        <ArticleId IdType="pubmed">24369828</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24368111</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0945</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>96</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Experimental and molecular pathology</Title>
          <ISOAbbreviation>Exp. Mol. Pathol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Protection from renal fibrosis, putative role of TRIB3 gene silencing.</ArticleTitle>
        <Pagination>
          <MedlinePgn>80-84</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii">S0014-4800(13)00149-4</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.yexmp.2013.12.003</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Renal fibrosis is thought to be the common pathway in most cases of chronic kidney disease. Recently, TRIB3 was found to play an important role in progression of cardiac fibrosis in an insulin-resistant state. We investigated whether TRIB3 might participate in the pathogenesis of renal fibrosis in insulin-resistant rats.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We randomly separated 40 male Sprague-Dawley into 4 groups for treatment (n=10 each): control and high-fat diet (HFD) with TRIB3 siRNA adenovirus transfection, vehicle transfection or HFD alone. Insulin resistance markers were measured. Renal tissues were stained with hematoxylin and eosin, Masson's trichrome and periodic acid-Schiff.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Rats with HFD showed insulin resistance and TRIB3 overexpression. Upregulated TRIB3 expression could induce renal fibrosis accompanied by increased phosphorylation of extracellular signal-regulated kinase (ERK). Also, TRIB3 siRNA knockdown could ameliorate renal fibrosis, which was accompanied by decreased phosphorylation of ERK.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TRIB3 gene silencing can attenuate renal fibrosis for beneficial effect on the development of renal fibrosis in chronic kidney disease in rat.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Ding</LastName>
            <ForeName>Wen-Yuan</ForeName>
            <Initials>WY</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Wen-Bo</ForeName>
            <Initials>WB</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Ti</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Bi</LastName>
            <ForeName>Xiu-Ping</ForeName>
            <Initials>XP</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Sun</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Zhi-Hao</ForeName>
            <Initials>ZH</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Geriatrics, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China. Electronic address: zhangweisdu@gmail.com.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhong</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, PR China. Electronic address: zhongmingzm@gmail.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Exp Mol Pathol</MedlineTA>
        <NlmUniqueID>0370711</NlmUniqueID>
        <ISSNLinking>0014-4800</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MAPK</Keyword>
        <Keyword MajorTopicYN="N">Renal fibrosis</Keyword>
        <Keyword MajorTopicYN="N">TRIB3</Keyword>
        <Keyword MajorTopicYN="N">siRNA</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24368111</ArticleId>
        <ArticleId IdType="pii">S0014-4800(13)00149-4</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yexmp.2013.12.003</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24367585</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e83174</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0083174</ELocationID>
        <Abstract>
          <AbstractText>Preclinical studies of animals with risk factors, and how those risk factors contribute to the development of cardiovascular disease and cardiac dysfunction, are clearly needed. One such approach is to feed mice a diet rich in fat (i.e. 60%). Here, we determined whether a high fat diet was sufficient to induce cardiac dysfunction in mice. We subjected mice to two different high fat diets (lard or milk as fat source) and followed them for over six months and found no significant decrement in cardiac function (via echocardiography), despite robust adiposity and impaired glucose disposal. We next determined whether antecedent and concomitant exposure to high fat diet (lard) altered the murine heart's response to infarct-induced heart failure; high fat feeding during, or before and during, heart failure did not significantly exacerbate cardiac dysfunction. Given the lack of a robust effect on cardiac dysfunction with high fat feeding, we then examined a commonly used mouse model of overt diabetes, hyperglycemia, and obesity (db/db mice). db/db mice (or STZ treated wild-type mice) subjected to pressure overload exhibited no significant exacerbation of cardiac dysfunction; however, ischemia-reperfusion injury significantly depressed cardiac function in db/db mice compared to their non-diabetic littermates. Thus, we were able to document a negative influence of a risk factor in a relevant cardiovascular disease model; however, this did not involve exposure to a high fat diet. High fat diet, obesity, or hyperglycemia does not necessarily induce cardiac dysfunction in mice. Although many investigators use such diabetes/obesity models to understand cardiac defects related to risk factors, this study, along with those from several other groups, serves as a cautionary note regarding the use of murine models of diabetes and obesity in the context of heart failure.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brainard</LastName>
            <ForeName>Robert E</ForeName>
            <Initials>RE</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watson</LastName>
            <ForeName>Lewis J</ForeName>
            <Initials>LJ</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demartino</LastName>
            <ForeName>Angelica M</ForeName>
            <Initials>AM</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brittian</LastName>
            <ForeName>Kenneth R</ForeName>
            <Initials>KR</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Readnower</LastName>
            <ForeName>Ryan D</ForeName>
            <Initials>RD</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boakye</LastName>
            <ForeName>Adjoa Agyemang</ForeName>
            <Initials>AA</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Deqing</ForeName>
            <Initials>D</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoetker</LastName>
            <ForeName>Joseph David</ForeName>
            <Initials>JD</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhatnagar</LastName>
            <ForeName>Aruni</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baba</LastName>
            <ForeName>Shahid Pervez</ForeName>
            <Initials>SP</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Steven P</ForeName>
            <Initials>SP</Initials>
            <Affiliation>Department of Physiology and Biophysics, Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2196-201</RefSource>
          <PMID Version="1">11045953</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Neurosci Methods. 2011 May 15;198(1):36-43</RefSource>
          <PMID Version="1">21402103</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Coron Artery Dis. 2001 Feb;12(1):37-44</RefSource>
          <PMID Version="1">11211164</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Acta Physiol Scand. 2001 Sep;173(1):139-43</RefSource>
          <PMID Version="1">11678736</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H277-82</RefSource>
          <PMID Version="1">12485820</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4891-6</RefSource>
          <PMID Version="1">12676984</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H276-82</RefSource>
          <PMID Version="1">12969888</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann N Y Acad Sci. 2004 May;1015:202-13</RefSource>
          <PMID Version="1">15201161</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Probl Cardiol. 1994 Feb;19(2):59-113</RefSource>
          <PMID Version="1">8174388</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabet Med. 1996 Jan;13(1):30-9</RefSource>
          <PMID Version="1">8741810</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1999 May;276(5 Pt 2):H1567-73</RefSource>
          <PMID Version="1">10330240</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1999 Aug;277(2 Pt 2):H763-9</RefSource>
          <PMID Version="1">10444504</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H365-70</RefSource>
          <PMID Version="1">15319210</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H146-53</RefSource>
          <PMID Version="1">16113078</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10086-91</RefSource>
          <PMID Version="1">16775082</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Heart Fail. 2006 Nov;8(7):687-93</RefSource>
          <PMID Version="1">16513421</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2743-51</RefSource>
          <PMID Version="1">16844920</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1498-506</RefSource>
          <PMID Version="1">17114240</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Hypertens. 2007 Apr;20(4):403-9</RefSource>
          <PMID Version="1">17386347</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1853-60</RefSource>
          <PMID Version="1">17616744</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Card Fail. 2008 Feb;14(1):82-8</RefSource>
          <PMID Version="1">18226777</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hypertens. 2008 Jul;26(7):1402-10</RefSource>
          <PMID Version="1">18551017</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2008 Jul 15;79(2):205-7</RefSource>
          <PMID Version="1">18515845</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Mol Cell Cardiol. 2008 Aug;45(2):313-25</RefSource>
          <PMID Version="1">18539296</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2009 Jan 2;104(1):41-9</RefSource>
          <PMID Version="1">19023128</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(3):e34402</RefSource>
          <PMID Version="1">22479624</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2012 May 15;302(10):H2122-30</RefSource>
          <PMID Version="1">22408028</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2012 Nov 1;122(11):3919-30</RefSource>
          <PMID Version="1">23023704</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Mol Cell Cardiol. 2009 Jun;46(6):883-90</RefSource>
          <PMID Version="1">19265702</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1585-93</RefSource>
          <PMID Version="1">19767529</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Cell Physiol. 2009 Dec;297(6):C1490-500</RefSource>
          <PMID Version="1">19625611</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17797-802</RefSource>
          <PMID Version="1">20876116</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2010 Dec;299(6):H1917-27</RefSource>
          <PMID Version="1">20852054</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Amino Acids. 2011 Mar;40(3):895-911</RefSource>
          <PMID Version="1">20798965</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2011 May 1;90(2):202-9</RefSource>
          <PMID Version="1">21289012</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Coron Artery Dis. 2000 Dec;11(8):593-7</RefSource>
          <PMID Version="1">11107506</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3867436</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0083174</ArticleId>
        <ArticleId IdType="pii">PONE-D-12-24951</ArticleId>
        <ArticleId IdType="pubmed">24367585</ArticleId>
        <ArticleId IdType="pmc">PMC3867436</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24366220</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1538-2990</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>347</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of the medical sciences</Title>
          <ISOAbbreviation>Am. J. Med. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aortomesenteric fat thickness with ultrasound predicts metabolic diseases in obese patients.</ArticleTitle>
        <Pagination>
          <MedlinePgn>8-13</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MAJ.0b013e318288f795</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relation between visceral fat accumulation and development of cardiovascular and metabolic disorders has been demonstrated. The aim of this study was to determine the relationship between a new ultrasound visceral fat thickness (VFT) measurement and clinical and anthropometric data in a consecutive series of obese patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-five consecutive male obese patients underwent ultrasound evaluation and metabolic and anthropometric parameters determination at baseline and after 3 weeks of a very low-calorie diet (VLCD) therapy. The new ultrasound measurement, the thickness of the fat between the aorta and the superior mesenteric artery (AMFT), was determined along with the maximum thickness of preperitoneal fat and the global VFT.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">AMFT showed a better correlation than VFT and preperitoneal fat with all anthropometric and metabolic parameters, both at baseline and after VLCD regimen. At baseline, patients in the middle and high AMFT and VFT tertiles had a significantly higher prevalence of metabolic diseases with respect to AMFT and VFT low tertile patients, whereas after VLCD period, AMFT only showed significant difference within tertiles. The odds ratios for the various metabolic diseases were higher in the middle and high AMFT tertiles than those in the middle and high VFT tertiles, remaining significant after adjustment for age, body mass index and VLCD regimen only in the middle and high AMFT tertiles.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ultrasonographic AMFT evaluation is strongly correlated to the presence of metabolic syndrome and could be a valuable tool to predict metabolic diseases and associated cardiovascular risks in men.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Monaco</LastName>
            <ForeName>Luigi</ForeName>
            <Initials>L</Initials>
            <Affiliation>Ultrasonography and Clinical Nutrition Units (LM, LC, GC), AORN G.Moscati, Avellino, Italy; Department of Cardiovascular Surgery (MM), Istituto Clinico Pineta Grande, Castelvolturno (CE), Italy; and Department of Cardiac Surgery (LDT, PS), University "Federico II," Medical School, Naples, Italy.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monaco</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Tommaso</LastName>
            <ForeName>Luigi</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stassano</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castaldo</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castaldo</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Sci</MedlineTA>
        <NlmUniqueID>0370506</NlmUniqueID>
        <ISSNLinking>0002-9629</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1097/MAJ.0b013e318288f795</ArticleId>
        <ArticleId IdType="pii">00000441-201401000-00002</ArticleId>
        <ArticleId IdType="pubmed">24366220</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24364133</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0391-5387</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>34</Volume>
            <Issue>6</Issue>
            <PubDate>
              <MedlineDate>2012 Nov-Dec</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>La Pediatria medica e chirurgica : Medical and surgical pediatrics</Title>
          <ISOAbbreviation>Pediatr Med Chir</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Milk and butter. From the Neolithic to the current nutritional aspects].</ArticleTitle>
        <Pagination>
          <MedlinePgn>266-82</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The evolution in the history of nutrition knowledge towards dairy products, is strictly related to the socio-cultural development of humans. In fact, milk and butter have accompanied humans since ancient times, which traces of the consumption of such products are dated back about the earliest times after the last (glaciation) ice age, while the application for extra nutritional uses, such as cosmetics and ceremonial rites, are reported in the writings of the Old Testament. Even in Italy, before the Roman Empire, were known rudimentary techniques of production and storage of dairy products. But only with the advent of the Etruscans, and the Romans later, that the use of milk and dairy products reach a wide diffusion in several applications. Since the advent of Christ until today, milk and its derivatives have maintained a privileged place in the human diet, but it is only with the advent of modern medicine and new findings in lipidic chemistry that emerged multiple biological and nutritional properties, very important for human health. After a short summary of the ancient history of the milk and butter, the role of dairy products in cancer, in hypercholesterolemia, and cardiovascular disease are reported. Moreover, the current opinions on saturated fatty acids, the role of polyunsaturated fatty acids and their lipid mediators obtained by the action of cyclooxygenase, lipoxygenase and the cytochrome P450 enzymes, are treated. Even if sometimes mistreated, the milk, but most of all its high fat content derivatives such as butter, is a rich source of biologically active compounds that foster a controversial action against neolplastic and cardiovascular disease. These compounds, mainly contained in the lipid fraction, for the more obvious relationships that exist between nutrition and health status, have been the subject in the last decades of intense scientific investigation in which there were expressed lights and shadows, but recognizing that not all fats are harmful and further thorough studies are necessary, in particular, on the derived lipid mediators. This will allow a significant progress based on new scientific evidences, further orienting researchers and clinicians on evidence-based nutritional science.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Caramia</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>Primario Emerito di Pediatria e Neonatologia Azienda Ospedaliera Specializzata Materno Infantile G. Salesi, Ancona. caramiagm@libero.it</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Losi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>Dipartimento di Scienze degli Alimenti, Alma Mater Studiorum, Universit&#xE0; di Bologna.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frega</LastName>
            <ForeName>N</ForeName>
            <Initials>N</Initials>
            <Affiliation>Dipartimento di Scienze Agrarie Alimenti ed Ambientali, Universit&#xE0; Politecnica delle Marche.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lercker</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>Dipartimento di Scienze degli Alimenti, Alma Mater Studiorum, Universit&#xE0; di Bologna.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cocchi</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <Affiliation>Paolo Sotgiu Institute for research in Quantitative &amp; Quantum Psychiatry &amp; Cardiology.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gori</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Affiliation>Dipartimento di Scienze degli Alimenti, Alma Mater Studiorum, Universit&#xE0; di Bologna.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cerretani</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <Affiliation>Dipartimento di Economia e Ingegneria Agrarie, Alma Mater Studiorum, Universit&#xE0; di Bologna.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ita</Language>
        <PublicationTypeList>
          <PublicationType>English Abstract</PublicationType>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Il latte e il burro. Dal Neolitico agli attuali aspetti nutrizionali.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Pediatr Med Chir</MedlineTA>
        <NlmUniqueID>8100625</NlmUniqueID>
        <ISSNLinking>0391-5387</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24364133</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24362355</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>08</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-6535</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in lipidology</Title>
          <ISOAbbreviation>Curr. Opin. Lipidol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metaorganismal nutrient metabolism as a basis of cardiovascular disease.</ArticleTitle>
        <Pagination>
          <MedlinePgn>48-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MOL.0000000000000036</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Atherosclerosis and associated cardiovascular disease (CVD) remains the leading cause of mortality in Western societies. It is well accepted that the consumption of foods abundant in saturated fats and cholesterol, like meats, egg yolk and high-fat dairy products, are associated with increased CVD risk. New evidence suggests that trimethylamine (TMA)-containing nutrients within these foods, including phosphatidylcholine, choline, and L-carnitine, can enter into a microbial metabolic pathway that promotes CVD. In this review, we highlight the role of gut microbiota-driven nutrient metabolism as a novel pathway promoting CVD.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent studies demonstrate a link between ingestion of dietary phosphatidylcholine, choline, and L-carnitine and CVD risk. At the center of this pathway is gut microbiota-dependent synthesis of a metabolic intermediate called TMA, and subsequent host-driven conversion of TMA to trimethylamine-N-oxide (TMAO). Microbiota-dependent generation of TMAO is associated with increased risk of incident major adverse cardiovascular events in humans, and provision of TMAO promotes atherosclerosis in mice.</AbstractText>
          <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Microbial metabolism of TMA containing nutrients can lead to formation of the proatherogenic compound TMAO. Recent insights into this diet-microbe-host interaction provide new clues surrounding the pathogenesis of atherosclerosis, and may serve as a framework for new CVD therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>J Mark</ForeName>
            <Initials>JM</Initials>
            <Affiliation>Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hazen</LastName>
            <ForeName>Stanley L</ForeName>
            <Initials>SL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 HL076491</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 HL098055</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P20 HL113452</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 HL096166</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL103866</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 RR024989</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Curr Opin Lipidol</MedlineTA>
        <NlmUniqueID>9010000</NlmUniqueID>
        <ISSNLinking>0957-9672</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1097/MOL.0000000000000036</ArticleId>
        <ArticleId IdType="pubmed">24362355</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24358329</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Momordica charantia (Bitter Melon) Reduces Obesity-Associated Macrophage and Mast Cell Infiltration as well as Inflammatory Cytokine Expression in Adipose Tissues.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e84075</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0084075</ELocationID>
        <Abstract>
          <AbstractText>Obesity is a world-wide epidemic disease that correlates closely with type 2 diabetes and cardiovascular diseases. Obesity-induced chronic adipose tissue inflammation is now considered as a critical contributor to the above complications. Momordica charantia (bitter melon, BM) is a traditional Chinese food and well known for its function of reducing body weight gain and insulin resistance. However, it is unclear whether BM could alleviate adipose tissue inflammation caused by obesity. In this study, C57BL/6 mice were fed high fat diet (HFD) with or without BM for 12 weeks. BM-contained diets ameliorated HFD-induced obesity and insulin resistance. Histological and real-time PCR analysis demonstrated BM not only reduced macrophage infiltration into epididymal adipose tissues (EAT) and brown adipose tissues (BAT). Flow cytometry show that BM could modify the M1/M2 phenotype ratio of macrophages in EAT. Further study showed that BM lowered mast cell recruitments in EAT, and depressed pro-inflammatory cytokine monocyte chemotactic protein-1 (MCP-1) expression in EAT and BAT as well as interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) expression in EAT. Finally, ELISA analysis showed BM-contained diets also normalized serum levels of the cytokines. In summary, in concert with ameliorated insulin resistance and fat deposition, BM reduced adipose tissue inflammation in diet-induced obese (DIO) mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bao</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yan-Guang</ForeName>
            <Initials>YG</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Na Xu</LastName>
            <ForeName>Yan Lin</ForeName>
            <Initials>YL</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qu</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Affiliation>School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, China.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2008 Apr;99(4):806-12</RefSource>
          <PMID Version="1">17942003</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2008 Feb;99(2):230-9</RefSource>
          <PMID Version="1">17651527</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Res Clin Pract. 2008 Aug;81(2):134-43</RefSource>
          <PMID Version="1">18550200</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2008 Oct;100(4):751-9</RefSource>
          <PMID Version="1">18321395</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2009 Aug;15(8):940-5</RefSource>
          <PMID Version="1">19633655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2009 Dec;102(12):1703-8</RefSource>
          <PMID Version="1">19825210</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2010 Feb 11;362(6):485-93</RefSource>
          <PMID Version="1">20147714</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Annu Rev Physiol. 2010;72:219-46</RefSource>
          <PMID Version="1">20148674</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Genomics. 2010 Jun;42(1):55-66</RefSource>
          <PMID Version="1">20215417</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMC Complement Altern Med. 2010;10:34</RefSource>
          <PMID Version="1">20587058</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2010;5(11):e13973</RefSource>
          <PMID Version="1">21085595</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2010 Dec;104(11):1613-20</RefSource>
          <PMID Version="1">20615270</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Med Food. 2011 Jan-Feb;14(1-2):86-93</RefSource>
          <PMID Version="1">21128828</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Immunol. 2011 Feb;11(2):85-97</RefSource>
          <PMID Version="1">21252989</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2011 Mar;52(3):480-8</RefSource>
          <PMID Version="1">21148461</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Ethnopharmacol. 2011 Apr 26;135(1):156-61</RefSource>
          <PMID Version="1">21392566</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Mol Med. 2011 Jul;11(5):417-36</RefSource>
          <PMID Version="1">21568930</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Immunol. 2011 Jul;32(7):307-14</RefSource>
          <PMID Version="1">21616718</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Neuroinflammation. 2011;8:64</RefSource>
          <PMID Version="1">21639917</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2011 Aug 27;378(9793):815-25</RefSource>
          <PMID Version="1">21872750</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Obes (Lond). 2011 Sep;35(9):1165-72</RefSource>
          <PMID Version="1">21224828</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Biochem. 2011 Nov;22(11):1064-73</RefSource>
          <PMID Version="1">21277185</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Metab Res Rev. 2011 Nov;27(8):919-24</RefSource>
          <PMID Version="1">22069285</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Phytomedicine. 2011 Dec 15;19(1):32-7</RefSource>
          <PMID Version="1">22133295</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2012 Mar;18(3):363-74</RefSource>
          <PMID Version="1">22395709</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Pharm Des. 2012;18(16):2261-77</RefSource>
          <PMID Version="1">22390690</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2012 Jul;142(7):1197-204</RefSource>
          <PMID Version="1">22623391</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Pharmacol. 2012 Aug 15;689(1-3):241-8</RefSource>
          <PMID Version="1">22683870</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2012 Oct;55(10):2583-92</RefSource>
          <PMID Version="1">22733483</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2013;8(4):e62309</RefSource>
          <PMID Version="1">23638033</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Phytother Res. 2000 Dec;14(8):592-5</RefSource>
          <PMID Version="1">11113993</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Jun 11;105(23):2696-8</RefSource>
          <PMID Version="1">12057978</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2003 Apr;133(4):1088-93</RefSource>
          <PMID Version="1">12672924</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2003 Dec;112(12):1796-808</RefSource>
          <PMID Version="1">14679176</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Ethnopharmacol. 2004 Jul;93(1):123-32</RefSource>
          <PMID Version="1">15182917</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2005 May;93(5):747-54</RefSource>
          <PMID Version="1">15975176</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2005 Nov;135(11):2517-23</RefSource>
          <PMID Version="1">16251604</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Chem Pharm Bull (Tokyo). 2006 Jul;54(7):1017-21</RefSource>
          <PMID Version="1">16819222</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2006 Dec 14;444(7121):847-53</RefSource>
          <PMID Version="1">17167472</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2007 Jan;117(1):175-84</RefSource>
          <PMID Version="1">17200717</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2007 Feb 27;115(8):1029-38</RefSource>
          <PMID Version="1">17296858</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2007 Jun;13(6):719-24</RefSource>
          <PMID Version="1">17546038</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Chem Biol. 2008 Mar;15(3):263-73</RefSource>
          <PMID Version="1">18355726</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3866167</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0084075</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-19203</ArticleId>
        <ArticleId IdType="pubmed">24358329</ArticleId>
        <ArticleId IdType="pmc">PMC3866167</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24346072</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">0717-6287</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Biological research</Title>
          <ISOAbbreviation>Biol. Res.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy.</ArticleTitle>
        <Pagination>
          <MedlinePgn>251-5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4067/S0716-97602013000300005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0716-97602013000300005</ELocationID>
        <Abstract>
          <AbstractText>Obesity is a major global health issue. Obese patients develop metabolic syndrome, which is a cluster of clinical features characterized by insulin resistance and dyslipidemia. Its cardiac manifestation, diabetic cardiomyopathy, leads to heart failure. Bone marrow-derived multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSC) are envisioned as a therapeutic tool not only for cardiovascular diseases but also for other degenerative conditions. Our aim was to evaluate whether the intravenous administration of MSC modifies cardiac dysfunction in obese mice. To this end, C57BL/6 mice were fed a regular (normal) or high-fat diet (obese). Obese animals received the vehicle (obese), a single dose (obese + 1x MSC) or three doses (obese + 3x MSC) of 0.5x10(6) syngeneic MSC. Two to three months following MSC administration, cardiac function was assessed by cardiac catheterization, at basal condition and after a pharmacological stress. Compared to normal mice, obese mice presented hyperglycemia, hyperinsulinemia, hypercholesterolemia and cardiac dysfunction after stress condition. Exogenous MSC neither improved nor impaired this cardiac dysfunction. Thus, intravenous administration of MSC has neutral effect on obesity-induced diabetic cardiomyopathy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Calligaris</LastName>
            <ForeName>Sebasti&#xE1;n D</ForeName>
            <Initials>SD</Initials>
            <Affiliation>Instituto de Ciencias, Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile, scalligaris@udd.cl.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conget</LastName>
            <ForeName>Paulette</ForeName>
            <Initials>P</Initials>
            <Affiliation>Instituto de Ciencias, Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile, scalligaris@udd.cl.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Chile</Country>
        <MedlineTA>Biol Res</MedlineTA>
        <NlmUniqueID>9308271</NlmUniqueID>
        <ISSNLinking>0716-9760</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>08</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0716-97602013000300005</ArticleId>
        <ArticleId IdType="doi">10.4067/S0716-97602013000300005</ArticleId>
        <ArticleId IdType="pubmed">24346072</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24345049</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1549-7852</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>Critical reviews in food science and nutrition</Title>
          <ISOAbbreviation>Crit Rev Food Sci Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Strawberry as a functional food: an evidence-based review.</ArticleTitle>
        <Pagination>
          <MedlinePgn>790-806</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10408398.2011.608174</ELocationID>
        <Abstract>
          <AbstractText>Emerging research provides substantial evidence to classify strawberries as a functional food with several preventive and therapeutic health benefits. Strawberries, a rich source of phytochemicals (ellagic acid, anthocyanins, quercetin, and catechin) and vitamins (ascorbic acid and folic acid), have been highly ranked among dietary sources of polyphenols and antioxidant capacity. It should however be noted that these bioactive factors can be significantly affected by differences in strawberry cultivars, agricultural practices, storage, and processing methods: freezing versus dry heat has been associated with maximum retention of strawberry bioactives in several studies. Nutritional epidemiology shows inverse association between strawberry consumption and incidence of hypertension or serum C-reactive protein; controlled feeding studies have identified the ability of strawberries to attenuate high-fat diet induced postprandial oxidative stress and inflammation, or postprandial hyperglycemia, or hyperlipidemia in subjects with cardiovascular risk factors. Mechanistic studies have elucidated specific biochemical pathways that might confer these protective effects of strawberries: upregulation of endothelial nitric oxide synthase (eNOS) activity, downregulation of NF-kB activity and subsequent inflammation, or inhibitions of carbohydrate digestive enzymes. These health effects may be attributed to the synergistic effects of nutrients and phytochemicals in strawberries. Further studies are needed to define the optimal dose and duration of strawberry intake in affecting levels of biomarkers or pathways related to chronic diseases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Basu</LastName>
            <ForeName>Arpita</ForeName>
            <Initials>A</Initials>
            <Affiliation>a Department of Nutritional Sciences , 301 Human Environmental Sciences, Oklahoma State University (OSU) , Stillwater , OK , 74078 , USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Angel</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Betts</LastName>
            <ForeName>Nancy M</ForeName>
            <Initials>NM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lyons</LastName>
            <ForeName>Timothy J</ForeName>
            <Initials>TJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Crit Rev Food Sci Nutr</MedlineTA>
        <NlmUniqueID>8914818</NlmUniqueID>
        <ISSNLinking>1040-8398</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1080/10408398.2011.608174</ArticleId>
        <ArticleId IdType="pubmed">24345049</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24342780</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>151</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
              <Day>3</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Cydonia oblonga Mill. leaf extract on serum lipids and liver function in a rat model of hyperlipidaemia.</ArticleTitle>
        <Pagination>
          <MedlinePgn>970-4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2013.12.010</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(13)00873-8</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Cydonia oblonga Mill. leaves are traditionally used in Uyghur medicine to treat or prevent cardiovascular disease. Beyond a demonstrated effect on thrombosis, we tested it for an effect on dyslipidemia, in a rat model of hyperlipidemia.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Seventy healthy Sprague Dawley rats were randomly divided into 6 groups: normal controls, model controls, simvastatin, and low-, medium- and high-dose Cydonia oblonga Mill. leaf extracts (COM), orally for 56 days. The normal controls were fed a normal diet, all other groups a high fat diet. Rat weights were recorded over time. Total cholesterol (TC), triglycerides (TG), low and high-density lipoproteins (LDL, HDL), as well as AST, ALT and total protein (TP) were measured in serum at the end of the study. The antioxidant capacity of glutathione peroxidase (GSH-PX), superoxide dismutase (SOD), malondialdehyde (MDA) was measured in liver samples, along with lipoprotein lipase (LPL), and hepatic lipase (HL). Liver pathology was described.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">COM dose-dependently reduced TC, TG, LDL-C and MDA, inhibited the activity of ALT, AST and LPS, increased HDL-C content, increased the activity of SOD, GSH-PX, LPL and HL, and reduced liver steatosis in hyperlipidaemia rats, which was significant at medium and high doses. The effect of COM was similar to that of simvastatin except for increased LPL and HL which were reduced by COM but not by simvastatin.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cydonia oblonga Mill. leaf extracts have hypolipidaemic and hepatoprotective effects, probably related to increasing antioxidant capacity and lipoprotein metabolism in the liver, and inhibition of lipogenesis.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abliz</LastName>
            <ForeName>Ablat</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aji</LastName>
            <ForeName>Qimangul</ForeName>
            <Initials>Q</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdusalam</LastName>
            <ForeName>Elzira</ForeName>
            <Initials>E</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xiaowei</ForeName>
            <Initials>X</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdurahman</LastName>
            <ForeName>Adil</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Wenting</ForeName>
            <Initials>W</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moore</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China; Department of Pharmacology, University Bordeaux Segalen, 146 rue Leo Saignat, 33076 Bordeaux, France. Electronic address: nicholas.moore@pharmaco.u-bordeaux2.fr.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Umar</LastName>
            <ForeName>Anwar</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Pharmacology, Xinjiang Medical University, 393 Xinyi Road, 830011 Urumqi, PR China; Department of Pharmacology, University Bordeaux Segalen, 146 rue Leo Saignat, 33076 Bordeaux, France. Electronic address: anwar.umar@126.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALT</Keyword>
        <Keyword MajorTopicYN="N">AST</Keyword>
        <Keyword MajorTopicYN="N">Antioxidant</Keyword>
        <Keyword MajorTopicYN="N">COM</Keyword>
        <Keyword MajorTopicYN="N">Cydonia oblonga Mill.</Keyword>
        <Keyword MajorTopicYN="N">Cydonia oblonga Mill. leaf extract</Keyword>
        <Keyword MajorTopicYN="N">GSH-PX</Keyword>
        <Keyword MajorTopicYN="N">HDL-C</Keyword>
        <Keyword MajorTopicYN="N">HL</Keyword>
        <Keyword MajorTopicYN="N">Hypercholesterolemia</Keyword>
        <Keyword MajorTopicYN="N">Hyperlipidaemia</Keyword>
        <Keyword MajorTopicYN="N">Hypolipidemic effect</Keyword>
        <Keyword MajorTopicYN="N">LDL-C</Keyword>
        <Keyword MajorTopicYN="N">LPL</Keyword>
        <Keyword MajorTopicYN="N">LPS</Keyword>
        <Keyword MajorTopicYN="N">MDA</Keyword>
        <Keyword MajorTopicYN="N">SOD</Keyword>
        <Keyword MajorTopicYN="N">TC</Keyword>
        <Keyword MajorTopicYN="N">TG</Keyword>
        <Keyword MajorTopicYN="N">TP</Keyword>
        <Keyword MajorTopicYN="N">Traditional Uyghur medicine</Keyword>
        <Keyword MajorTopicYN="N">alanine transaminase</Keyword>
        <Keyword MajorTopicYN="N">aspartate transaminase</Keyword>
        <Keyword MajorTopicYN="N">glutathione peroxidase</Keyword>
        <Keyword MajorTopicYN="N">hepatic lipase</Keyword>
        <Keyword MajorTopicYN="N">high density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">lipase</Keyword>
        <Keyword MajorTopicYN="N">lipoprotein lipase</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">malondialdehyde</Keyword>
        <Keyword MajorTopicYN="N">superoxide dismutase</Keyword>
        <Keyword MajorTopicYN="N">total cholesterol</Keyword>
        <Keyword MajorTopicYN="N">total protein</Keyword>
        <Keyword MajorTopicYN="N">triglycerides</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24342780</ArticleId>
        <ArticleId IdType="pii">S0378-8741(13)00873-8</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2013.12.010</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24340336</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-7294</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of family practice</Title>
          <ISOAbbreviation>J Fam Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PURLs: Mediterranean diet: Higher fat but lower risk.</ArticleTitle>
        <Pagination>
          <MedlinePgn>745-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>For patients at high risk for cardiovascular disease, a Mediterranean diet may be the best bet.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gwynne</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <Affiliation>Department of Family Medicine, University of North Carolina at Chapel Hill, NC, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mounsey</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Fam Pract</MedlineTA>
        <NlmUniqueID>7502590</NlmUniqueID>
        <ISSNLinking>0094-3509</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jfp_6212m</ArticleId>
        <ArticleId IdType="pubmed">24340336</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24338487</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1534-6315</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current allergy and asthma reports</Title>
          <ISOAbbreviation>Curr Allergy Asthma Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of "western diet" in inflammatory autoimmune diseases.</ArticleTitle>
        <Pagination>
          <MedlinePgn>404</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11882-013-0404-6</ELocationID>
        <Abstract>
          <AbstractText>Developed societies, although having successfully reduced the burden of infectious disease, constitute an environment where metabolic, cardiovascular, and autoimmune diseases thrive. Living in westernized countries has not fundamentally changed the genetic basis on which these diseases emerge, but has strong impact on lifestyle and pathogen exposure. In particular, nutritional patterns collectively termed the "Western diet", including high-fat and cholesterol, high-protein, high-sugar, and excess salt intake, as well as frequent consumption of processed and 'fast foods', promote obesity, metabolic syndrome, and cardiovascular disease. These factors have also gained high interest as possible promoters of autoimmune diseases. Underlying metabolic and immunologic mechanisms are currently being intensively explored. This review discusses the current knowledge relative to the association of "Western diet" with autoimmunity, and highlights the role of T cells as central players linking dietary influences to autoimmune pathology.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Manzel</LastName>
            <ForeName>Arndt</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Neurology, University of Erlangen, Erlangen, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muller</LastName>
            <ForeName>Dominik N</ForeName>
            <Initials>DN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hafler</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erdman</LastName>
            <ForeName>Susan E</ForeName>
            <Initials>SE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linker</LastName>
            <ForeName>Ralf A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleinewietfeld</LastName>
            <ForeName>Markus</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Allergy Asthma Rep</MedlineTA>
        <NlmUniqueID>101096440</NlmUniqueID>
        <ISSNLinking>1529-7322</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1007/s11882-013-0404-6</ArticleId>
        <ArticleId IdType="pubmed">24338487</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24333965</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-9649</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13C</Volume>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Ageing research reviews</Title>
          <ISOAbbreviation>Ageing Res. Rev.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of SIRT1 and AMPK in mesenchymal stem cells differentiation.</ArticleTitle>
        <Pagination>
          <MedlinePgn>55-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii">S1568-1637(13)00092-5</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.arr.2013.12.002</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">The differentiation capabilities of mesenchymal stem cells (MSCs) compromise with age and with in vitro passages which could impair the efficacy of cell therapy and tissue engineering. However, how to maintain these capabilities is not fully understood. Calorie restriction (CR, decreasing caloric intake by 30-40%) could extend longevity and reduce aging-related diseases. Recent studies revealed that CR could influence the lineage determination of stem cells including MSCs. Two important mediators of CR might be silent mating type information regulation 2 homolog 1 (SIRT1), a NAD(+)-dependent deacetylase, and AMP-activated protein kinase (AMPK), an energy-sensing kinase. Evidences are mounting that both SIRT1 and AMPK play important roles in cell fate determination of MSCs. Herein, we intend to sum up our understanding about the role of SIRT1 and AMPK in osteogenic and adipogenic potential of MSCs. Metabolic process of MSCs differentiation and the putative interplay of SIRT1 and AMPK in this process was also discussed.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Chen</LastName>
            <ForeName>Huiqiang</ForeName>
            <Initials>H</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China; Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Liu</LastName>
            <ForeName>Xianbao</ForeName>
            <Initials>X</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China; Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Chen</LastName>
            <ForeName>Han</ForeName>
            <Initials>H</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China; Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Cao</LastName>
            <ForeName>Jiang</ForeName>
            <Initials>J</Initials>
            <Affiliation>Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <Affiliation>Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Hu</LastName>
            <ForeName>Xinyang</ForeName>
            <Initials>X</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China; Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.</Affiliation>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Jian&#xB4;an</ForeName>
            <Initials>J</Initials>
            <Affiliation>Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China; Key Lab of Cardiovascular Disease, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China. Electronic address: jian_an_wang@yahoo.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ageing Res Rev</MedlineTA>
        <NlmUniqueID>101128963</NlmUniqueID>
        <ISSNLinking>1568-1637</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALP</Keyword>
        <Keyword MajorTopicYN="N">AMP-activated protein kinase</Keyword>
        <Keyword MajorTopicYN="N">AMPK</Keyword>
        <Keyword MajorTopicYN="N">BAT</Keyword>
        <Keyword MajorTopicYN="N">C/EBP</Keyword>
        <Keyword MajorTopicYN="N">CCAAT/enhancer binding protein</Keyword>
        <Keyword MajorTopicYN="N">CR</Keyword>
        <Keyword MajorTopicYN="N">Calorie restriction</Keyword>
        <Keyword MajorTopicYN="N">ER</Keyword>
        <Keyword MajorTopicYN="N">ERK</Keyword>
        <Keyword MajorTopicYN="N">FOXO1</Keyword>
        <Keyword MajorTopicYN="N">Forkhead box protein O1</Keyword>
        <Keyword MajorTopicYN="N">H3K9</Keyword>
        <Keyword MajorTopicYN="N">HFD</Keyword>
        <Keyword MajorTopicYN="N">KLF2</Keyword>
        <Keyword MajorTopicYN="N">Kruppel-like factor 2</Keyword>
        <Keyword MajorTopicYN="N">MIF</Keyword>
        <Keyword MajorTopicYN="N">MSCKO</Keyword>
        <Keyword MajorTopicYN="N">MSCs</Keyword>
        <Keyword MajorTopicYN="N">MSCs specific SIRT1 knock-out</Keyword>
        <Keyword MajorTopicYN="N">Mesenchymal stem cells differentiation</Keyword>
        <Keyword MajorTopicYN="N">Nampt</Keyword>
        <Keyword MajorTopicYN="N">PARP-1</Keyword>
        <Keyword MajorTopicYN="N">PARylation</Keyword>
        <Keyword MajorTopicYN="N">PDLGA</Keyword>
        <Keyword MajorTopicYN="N">PPAR?</Keyword>
        <Keyword MajorTopicYN="N">PTH</Keyword>
        <Keyword MajorTopicYN="N">Poly-d,l-Lactide-Glycolide</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">Resveratrol</Keyword>
        <Keyword MajorTopicYN="N">SIRT1</Keyword>
        <Keyword MajorTopicYN="N">SIRT1 heterozygous</Keyword>
        <Keyword MajorTopicYN="N">SIRT1(+/-)</Keyword>
        <Keyword MajorTopicYN="N">SIRT1(-/-)</Keyword>
        <Keyword MajorTopicYN="N">SIRT1-null</Keyword>
        <Keyword MajorTopicYN="N">alkaline phosphatase</Keyword>
        <Keyword MajorTopicYN="N">brown adipocyte tissue</Keyword>
        <Keyword MajorTopicYN="N">calorie restriction</Keyword>
        <Keyword MajorTopicYN="N">estrogen receptors</Keyword>
        <Keyword MajorTopicYN="N">extracellular signal-related kinases</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">histone 3 at lysine 9</Keyword>
        <Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword>
        <Keyword MajorTopicYN="N">migration inhibitory factor</Keyword>
        <Keyword MajorTopicYN="N">nicotinamide phosphoribosyltransferase</Keyword>
        <Keyword MajorTopicYN="N">parathyroid hormone</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator-activated receptor gamma</Keyword>
        <Keyword MajorTopicYN="N">poly(ADP-ribose) polymerase 1</Keyword>
        <Keyword MajorTopicYN="N">poly(ADP-ribosyl)ation</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen species</Keyword>
        <Keyword MajorTopicYN="N">silent mating type information regulation 2 homolog 1</Keyword>
        <Keyword MajorTopicYN="N">t10c12CLA</Keyword>
        <Keyword MajorTopicYN="N">trans-10, cis-12 conjugated linoleic acid</Keyword>
        <Keyword MajorTopicYN="N">&#xDF;-CS</Keyword>
        <Keyword MajorTopicYN="N">&#xDF;-calcium silicate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24333965</ArticleId>
        <ArticleId IdType="pii">S1568-1637(13)00092-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.arr.2013.12.002</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24333561</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1089-8611</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society</Title>
          <ISOAbbreviation>Nitric Oxide</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cardioprotective mechanism of S-nitroso-N-acetylcysteine via S-nitrosated betadrenoceptor-2 in the LDLr-/- mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>58-66</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.niox.2013.12.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1089-8603(13)00342-X</ELocationID>
        <Abstract>
          <AbstractText>Previous studies from our group have demonstrated the protective effect of S-nitroso-N-acetylcysteine (SNAC) on the cardiovascular system in dyslipidemic LDLr-/- mice that develop atheroma and left ventricular hypertrophy after 15days on a high fat diet. We have shown that SNAC treatment attenuates plaque development via the suppression of vascular oxidative stress and protects the heart from structural and functional myocardial alterations, such as heart arrhythmia, by reducing cardiomyocyte sensitivity to catecholamines. Here we investigate the ability of SNAC to modulate oxidative stress and cell survival in cardiomyocytes during remodeling and correlation with &#xDF;2-AR signaling in mediating this protection. Ventricular superoxide (O2(-)) and hydrogen peroxide (H2O2) generation was measured by HPLC methods to allow quantification of dihydroethidium (DHE) products. Ventricular histological sections were stained using terminal dUTP nick-end labeling (TUNEL) to identify nuclei with DNA degradation (apoptosis) and this was confirmed by Western blot for cleaved caspase-3 and caspase-7 protein expression. The findings show that O2(-) and H2O2 production and also cell apoptosis were increased during left ventricular hypertrophy (LVH). SNAC treatment reduced oxidative stress during on cardiac remodeling, measured by decreased H2O2 and O2(-) production (65% and 52%, respectively), and a decrease in the ratio of p-Ser1177 eNOS/total eNOS. Left ventricle (LV) from SNAC-treated mice revealed a 4-fold increase in &#xDF;2-AR expression associated with coupling change to Gi; &#xDF;2-ARs-S-nitrosation (&#xDF;2-AR-SNO) increased 61%, while apoptosis decreased by 70%. These results suggest that the cardio-protective effect of SNAC treatment is primarily through its anti-oxidant role and is associated with &#xDF;2-ARs overexpression and &#xDF;2-AR-SNO via an anti-apoptotic pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wanschel</LastName>
            <ForeName>Amarylis Claudine Bonito Azeredo</ForeName>
            <Initials>AC</Initials>
            <Affiliation>Marc and Ruti Bell Vascular Biology and Disease Program, Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA; Department of Anatomy, Cellular Biology and Physiology, State University of Campinas (UNICAMP), Biology Institute, S&#xE3;o Paulo, Brazil. Electronic address: amarylisclaudine.wanschel@nyumc.org.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caceres</LastName>
            <ForeName>Viviane Menezes</ForeName>
            <Initials>VM</Initials>
            <Affiliation>Department of Biosciences, Federal University of S&#xE3;o Paulo (UNIFESP), S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moretti</LastName>
            <ForeName>Ana Iochabel Soares</ForeName>
            <Initials>AI</Initials>
            <Affiliation>Department of Emergency Medicine, University of S&#xE3;o Paulo (USP), S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bruni-Cardoso</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <Affiliation>Department of Anatomy, Cellular Biology and Physiology, State University of Campinas (UNICAMP), Biology Institute, S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Carvalho</LastName>
            <ForeName>Hernandes Faustino</ForeName>
            <Initials>HF</Initials>
            <Affiliation>Department of Anatomy, Cellular Biology and Physiology, State University of Campinas (UNICAMP), Biology Institute, S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Souza</LastName>
            <ForeName>Heraldo Possolo</ForeName>
            <Initials>HP</Initials>
            <Affiliation>Department of Emergency Medicine, University of S&#xE3;o Paulo (USP), S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laurindo</LastName>
            <ForeName>Francisco Rafael Martins</ForeName>
            <Initials>FR</Initials>
            <Affiliation>Heart Institute (InCor), University of S&#xE3;o Paulo School of Medicine, S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spadari</LastName>
            <ForeName>Regina C&#xE9;lia</ForeName>
            <Initials>RC</Initials>
            <Affiliation>Department of Biosciences, Federal University of S&#xE3;o Paulo (UNIFESP), S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krieger</LastName>
            <ForeName>Marta Helena</ForeName>
            <Initials>MH</Initials>
            <Affiliation>Department of Anatomy, Cellular Biology and Physiology, State University of Campinas (UNICAMP), Biology Institute, S&#xE3;o Paulo, Brazil.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nitric Oxide</MedlineTA>
        <NlmUniqueID>9709307</NlmUniqueID>
        <ISSNLinking>1089-8603</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Betadrenoceptor-2</Keyword>
        <Keyword MajorTopicYN="N">Hydrogen peroxide</Keyword>
        <Keyword MajorTopicYN="N">S-nitrosated</Keyword>
        <Keyword MajorTopicYN="N">S-nitroso-N-acetylscysteine</Keyword>
        <Keyword MajorTopicYN="N">Superoxide</Keyword>
        <Keyword MajorTopicYN="N">Ventricular hypertrophy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24333561</ArticleId>
        <ArticleId IdType="pii">S1089-8603(13)00342-X</ArticleId>
        <ArticleId IdType="doi">10.1016/j.niox.2013.12.003</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24333157</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-7714</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>4</Day>
            </PubDate>
          </JournalIssue>
          <Title>General hospital psychiatry</Title>
          <ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Integrated medical care management and behavioral risk factor reduction for multicondition patients: behavioral outcomes of the TEAMcare trial.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0163-8343(13)00309-5</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.genhosppsych.2013.10.017</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of the study was to compare behavioral outcomes (physical activity, sedentary behavior, smoking cessation, diet) between the intervention and usual care conditions from the TEAMcare trial.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">TEAMcare was a randomized trial among 214 adults with depression and poorly controlled diabetes and/or coronary heart disease that promoted health behavior change and pharmacotherapy to improve health. Behavioral outcomes were measured with the International Physical Activity Questionnaire (physical activity, sitting time) and the Summary of Diabetes Self-Care Activities Measure (smoking, diet, exercise). Poisson regression models among completers (N=185) were conducted adjusting for age, education, smoking status and depression.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Intervention participants had more days/week following a healthy eating plan [relative rate=1.2, 95% confidence interval (CI)=1.1-1.4] and more days of participation in 30 min of physical activity (relative rate=1.2, 95% CI=1.1-2.0) compared to usual care. Intervention participants were more likely to meet physical activity guidelines (7.5% increase) compared to usual care (12% decrease; P=.053).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Diet and activity generally improved for those receiving the intervention, while there were no differences in some aspects of diet (fruit and vegetable and high-fat food intake), smoking status and sitting time between conditions in the TEAMcare trial.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Rosenberg</LastName>
            <ForeName>Dori</ForeName>
            <Initials>D</Initials>
            <Affiliation>Group Health Research Institute, 1730 Minor Ave Suite 1600, Seattle, WA 98101, USA. Electronic address: rosenberg.d@ghc.org.</Affiliation>
          </Author>
          <Author>
            <LastName>Lin</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <Affiliation>Group Health Research Institute, 1730 Minor Ave Suite 1600, Seattle, WA 98101, USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Peterson</LastName>
            <ForeName>Do</ForeName>
            <Initials>D</Initials>
            <Affiliation>Group Health Research Institute, 1730 Minor Ave Suite 1600, Seattle, WA 98101, USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Ludman</LastName>
            <ForeName>Evette</ForeName>
            <Initials>E</Initials>
            <Affiliation>Group Health Research Institute, 1730 Minor Ave Suite 1600, Seattle, WA 98101, USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Von Korff</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <Affiliation>Group Health Research Institute, 1730 Minor Ave Suite 1600, Seattle, WA 98101, USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Katon</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
            <Affiliation>Group Health Research Institute, University of Washington School of Medicine, Box 356560, Seattle, WA 98195-6560.</Affiliation>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>4</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Gen Hosp Psychiatry</MedlineTA>
        <NlmUniqueID>7905527</NlmUniqueID>
        <ISSNLinking>0163-8343</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">Depression</Keyword>
        <Keyword MajorTopicYN="N">Diabetes</Keyword>
        <Keyword MajorTopicYN="N">Diet</Keyword>
        <Keyword MajorTopicYN="N">Physical activity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0163-8343(13)00309-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.genhosppsych.2013.10.017</ArticleId>
        <ArticleId IdType="pubmed">24333157</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24330576</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1475-2891</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition journal</Title>
          <ISOAbbreviation>Nutr J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry.</ArticleTitle>
        <Pagination>
          <MedlinePgn>159</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1475-2891-12-159</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dietary fiber is beneficial for the treatment of type 2 diabetes mellitus, although it is consumed differently in ethnic foods around the world. We investigated the association between dietary fiber intake and obesity, glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese type 2 diabetic patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 4,399 patients were assessed for dietary fiber intake using a brief self-administered diet history questionnaire. The associations between dietary fiber intake and various cardiovascular risk factors were investigated cross-sectionally.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Body mass index, fasting plasma glucose, HbA1c, triglyceride and high-sensitivity C-reactive protein negatively associated with dietary fiber intake after adjusting for age, sex, duration of diabetes, current smoking, current drinking, total energy intake, fat intake, saturated fatty acid intake, leisure-time physical activity and use of oral hypoglycemic agents or insulin. The homeostasis model assessment insulin sensitivity and HDL cholesterol positively associated with dietary fiber intake. Dietary fiber intake was associated with reduced prevalence of abdominal obesity, hypertension and metabolic syndrome after multivariate adjustments including obesity. Furthermore, dietary fiber intake was associated with lower prevalence of albuminuria, low estimated glomerular filtration rate and chronic kidney disease after multivariate adjustments including protein intake. Additional adjustments for obesity, hypertension or metabolic syndrome did not change these associations.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We demonstrated that increased dietary fiber intake was associated with better glycemic control and more favorable cardiovascular disease risk factors including chronic kidney disease in Japanese type 2 diabetic patients. Diabetic patients should be encouraged to consume more dietary fiber in daily life.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fujii</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwase</LastName>
            <ForeName>Masanori</ForeName>
            <Initials>M</Initials>
            <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. iwase@intmed2.med.kyushu-u.ac.jp.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohkuma</LastName>
            <ForeName>Toshiaki</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogata-Kaizu</LastName>
            <ForeName>Shinako</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ide</LastName>
            <ForeName>Hitoshi</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Idewaki</LastName>
            <ForeName>Yasuhiro</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joudai</LastName>
            <ForeName>Tamaki</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirakawa</LastName>
            <ForeName>Yoichiro</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchida</LastName>
            <ForeName>Kazuhiro</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sasaki</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Udai</ForeName>
            <Initials>U</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitazono</LastName>
            <ForeName>Takanari</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nutr J</MedlineTA>
        <NlmUniqueID>101152213</NlmUniqueID>
        <ISSNLinking>1475-2891</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(10):e46552</RefSource>
          <PMID Version="1">23077514</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Endocrinol Metab. 2012 Sep;97(9):3326-32</RefSource>
          <PMID Version="1">22745235</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2013 Jan;36 Suppl 1:S11-66</RefSource>
          <PMID Version="1">23264422</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Intern Med. 2012 Nov 26;172(21):1653-60</RefSource>
          <PMID Version="1">23089999</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2013 Nov;36(11):3821-42</RefSource>
          <PMID Version="1">24107659</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504</RefSource>
          <PMID Version="1">10993420</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Nutr. 2002 Oct;41(5):222-7</RefSource>
          <PMID Version="1">12395216</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ J. 2002 Nov;66(11):987-92</RefSource>
          <PMID Version="1">12419927</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hum Hypertens. 2003 Sep;17(9):623-30</RefSource>
          <PMID Version="1">13679952</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2004 Feb;27(2):538-46</RefSource>
          <PMID Version="1">14747241</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2004 Jun;27(6):1487-95</RefSource>
          <PMID Version="1">15161807</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Intern Med. 2005 Jan 24;165(2):150-6</RefSource>
          <PMID Version="1">15668359</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hypertens. 2005 Mar;23(3):475-81</RefSource>
          <PMID Version="1">15716684</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2006 Feb;29(2):207-11</RefSource>
          <PMID Version="1">16443861</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2006 Apr;29(4):775-80</RefSource>
          <PMID Version="1">16567814</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Gastroenterol. 2006 Mar;40(3):235-43</RefSource>
          <PMID Version="1">16633129</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2007 Jan;61(1):99-103</RefSource>
          <PMID Version="1">16885928</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2008 Jan;87(1):79-90</RefSource>
          <PMID Version="1">18175740</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2009 Jan;63(1):127-33</RefSource>
          <PMID Version="1">17882139</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Kidney Dis. 2009 Jun;53(6):982-92</RefSource>
          <PMID Version="1">19339088</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2009 Oct;139(10):1950-5</RefSource>
          <PMID Version="1">19726588</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2009 Oct 20;120(16):1640-5</RefSource>
          <PMID Version="1">19805654</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2010 Jan;140(1):68-74</RefSource>
          <PMID Version="1">19889808</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2010 Jan;103(1):82-90</RefSource>
          <PMID Version="1">19664300</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2010 Feb;91(2):329-36</RefSource>
          <PMID Version="1">20016015</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2010 May 25;121(20):2162-8</RefSource>
          <PMID Version="1">20458012</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertens Res. 2010 Jun;33(6):548-54</RefSource>
          <PMID Version="1">20224573</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabet Med. 2010 Apr;27(4):391-7</RefSource>
          <PMID Version="1">20536509</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2010 Aug;140(8):1445-53</RefSource>
          <PMID Version="1">20573945</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2011 Jul;80(1):17-28</RefSource>
          <PMID Version="1">21150873</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Nutr. 2011 Apr;30(2):141-8</RefSource>
          <PMID Version="1">21730222</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2011 Nov;65(11):1233-41</RefSource>
          <PMID Version="1">21654702</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Board Fam Med. 2012 Jan-Feb;25(1):16-23</RefSource>
          <PMID Version="1">22218620</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2012 Feb;81(3):300-6</RefSource>
          <PMID Version="1">22012132</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2012 Feb;35(2):434-45</RefSource>
          <PMID Version="1">22275443</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Nutr. 2011 May;2(3):293-4</RefSource>
          <PMID Version="1">22332062</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Epidemiol. 2012;22(2):151-9</RefSource>
          <PMID Version="1">22343326</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Public Health Nutr. 2011 Jul;14(7):1200-11</RefSource>
          <PMID Version="1">21477414</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Crit Rev Food Sci Nutr. 2012;52(10):899-935</RefSource>
          <PMID Version="1">22747080</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2012 Aug;55(8):2132-41</RefSource>
          <PMID Version="1">22526612</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(7):e40834</RefSource>
          <PMID Version="1">22815837</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 2012 Aug;61(8):1058-66</RefSource>
          <PMID Version="1">22401879</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2013 Jan;56(1):70-7</RefSource>
          <PMID Version="1">23064292</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3878841</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1475-2891-12-159</ArticleId>
        <ArticleId IdType="doi">10.1186/1475-2891-12-159</ArticleId>
        <ArticleId IdType="pubmed">24330576</ArticleId>
        <ArticleId IdType="pmc">PMC3878841</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24325088</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0035-7715</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>64</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Roczniki Panstwowego Zakladu Higieny</Title>
          <ISOAbbreviation>Rocz Panstw Zakl Hig</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nutritional assessment in Polish men with cardiovascular diseases.</ArticleTitle>
        <Pagination>
          <MedlinePgn>211-5</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular disease is the most common cause of death in Poland, where many factors have been found responsible such as obesity, smoking cigarettes and a lack of physical activity. Amongst these are also nutritional determinants, which principally include the amount and types of dietary fatty acids consumed, coupled with low intakes of antioxidant-rich fruit and vegetables.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess nutrition in male subjects suffering from cardiovascular disease.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Subjects were 95 men with cardiovascular disease aged 30-90 years. Nutrition was assessed by weighed food records over 3 days. The calorific dietary intake, as well as the proportions of calories derived from dietary protein, carbohydrates and fat were also calculated; this included vitamins and minerals.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Only 18% subjects had a normal Body Mass Index (BMI); the rest falling into the overweight or obesity ranges. The average dietary calorific daily intakes were abnormally low at 1582 kcal/person, however the proportions of fat and protein making up this value were too high; respectively at 36% and 19%. The average daily consumption per person of cholesterol, fibre and vegetables were respectively 251 mg, 19 g and 608 g. A significant number were deficient in dietary minerals (eg. calcium, potassium and magnesium) as well as vitamins; especially A, B, and B2.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Persons suffering from cardiovascular disease require a diet with sufficient calories for their body needs. It is also vital that the dietary sources of energy are properly balanced between protein, carbohydrates and fats as well as having appropriate intakes of both vitamins and minerals (eg. calcium, magnesium and potassium).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Anyzewska</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <Affiliation>Chair of Nutritional Assessment, Department of Human Nutrition, Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences - SGGW, Warsaw, Poland. anna_anyzewska@sggw.pl</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wawrzyniak</LastName>
            <ForeName>Agata</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wozniak</LastName>
            <ForeName>Agnieszka</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krotki</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>G&#xF3;rnicka</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Poland</Country>
        <MedlineTA>Rocz Panstw Zakl Hig</MedlineTA>
        <NlmUniqueID>0414756</NlmUniqueID>
        <ISSNLinking>0035-7715</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Causality</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Comorbidity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Educational Status</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Energy Intake</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Food Habits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Nutrition Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nutritional Status</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N" Type="Geographic">Poland</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24325088</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24312343</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Extracts of Rhizoma polygonati odorati prevent high-fat diet-induced metabolic disorders in C57BL/6 mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e81724</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0081724</ELocationID>
        <Abstract>
          <AbstractText>Polygonatum odoratum (Mill.) Druce belongs to the genus Polygonatum family of plants. In traditional Chinese medicine, the root of Polygonatum odoratum, Rhizoma Polygonati Odorati, is used both for food and medicine to prevent and treat metabolic disorders such as hyperlipidemia, hyperglycemia, obesity and cardiovascular disease. However, there is no solid experimental evidence to support these applications, and the underlying mechanism is also needed to be elucidated. Here, we examined the effect of the extract of Rhizoma Polygonati Odorati (ER) on metabolic disorders in diet-induced C57BL/6 obese mice. In the preventive experiment, the ER blocked body weight gain, and lowered serum total cholesterol (TC), triglyceride (TG) and fasting blood glucose, improved glucose tolerance test (GTT) and insulin tolerance test (ITT), reduced the levels of serum insulin and leptin, and increased serum adiponectin levels in mice fed with a high-fat diet significantly. In the therapeutic study, we induced obesity in the mice and treated the obese mice with ER for two weeks. We found that ER treatments reduced serum TG and fasting blood glucose, and improved glucose tolerance in the mice. Gene expression analysis showed that ER increased the mRNA levels of peroxisome proliferator-activated receptors (PPAR) ? and a and their downstream target genes in mice livers, adipose tissues and HepG2 cells. Our data suggest that ER ameliorates metabolic disorders and enhances the mRNA expression of PPARs in obese C57BL/6 mice induced by high-fat diet.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <Affiliation>School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Shengjie</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Xiaobo</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Guang</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Ethnopharmacol. 2001 Mar 3;74(3):225-9</RefSource>
          <PMID Version="1">11274822</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Yao Xue Xue Bao. 1994;29(3):215-22</RefSource>
          <PMID Version="1">8079648</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2002 Jun;43(6):936-43</RefSource>
          <PMID Version="1">12032169</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biosci Biotechnol Biochem. 2002 Oct;66(10):2036-43</RefSource>
          <PMID Version="1">12450112</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2002 Dec;76(6):1191-201</RefSource>
          <PMID Version="1">12450882</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2003 May;133(5):1238-43</RefSource>
          <PMID Version="1">12730403</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Agric Food Chem. 2003 Oct 8;51(21):6347-53</RefSource>
          <PMID Version="1">14518966</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2008 Jun;99(6):1208-16</RefSource>
          <PMID Version="1">18053305</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Drug Discov. 2008 Jun;7(6):489-503</RefSource>
          <PMID Version="1">18511927</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Clin Endocrinol Diabetes. 2008 Aug;116(8):468-74</RefSource>
          <PMID Version="1">18924264</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Atheroscler Rep. 2009 Jan;11(1):71-9</RefSource>
          <PMID Version="1">19080732</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2009 Jan;150(1):104-13</RefSource>
          <PMID Version="1">18818299</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2009 Aug;1790(8):840-4</RefSource>
          <PMID Version="1">19414060</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Ethnopharmacol. 2009 Jul 30;124(3):539-43</RefSource>
          <PMID Version="1">19454312</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2009 Aug 7;138(3):476-88</RefSource>
          <PMID Version="1">19646743</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2009 Sep;150(9):4287-94</RefSource>
          <PMID Version="1">19520784</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>IUBMB Life. 2009 Dec;61(12):1123-31</RefSource>
          <PMID Version="1">19946892</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2010 Mar 25;362(12):1090-101</RefSource>
          <PMID Version="1">20335585</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr J. 2010;9:54</RefSource>
          <PMID Version="1">21087484</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Mol Med. 2012 Jan;18(1):52-8</RefSource>
          <PMID Version="1">21917523</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2012 Feb 3;148(3):556-67</RefSource>
          <PMID Version="1">22304921</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Ethnopharmacol. 2012 May 7;141(1):228-33</RefSource>
          <PMID Version="1">22366676</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(5):e37633</RefSource>
          <PMID Version="1">22662181</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Crit Rev Food Sci Nutr. 2012;52(10):899-935</RefSource>
          <PMID Version="1">22747080</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Diabetol. 2012;11:63</RefSource>
          <PMID Version="1">22681646</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Pharm Res. 2012 Oct;35(10):1793-801</RefSource>
          <PMID Version="1">23139131</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Nutr Food Res. 2013 Jan;57(1):20-33</RefSource>
          <PMID Version="1">23180608</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMC Complement Altern Med. 2012;12:261</RefSource>
          <PMID Version="1">23259700</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Biol Macromol. 2013 Mar;54:16-23</RefSource>
          <PMID Version="1">23200976</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Integr Med. 2013 May;11(3):153-6</RefSource>
          <PMID Version="1">23743159</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Phytother Res. 2003 Dec;17(10):1127-34</RefSource>
          <PMID Version="1">14669243</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2004 Feb;53 Suppl 1:S60-5</RefSource>
          <PMID Version="1">14749267</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1994 Oct 7;269(40):24527-30</RefSource>
          <PMID Version="1">7929119</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Biochem Biophys. 1996 Feb 15;326(2):281-9</RefSource>
          <PMID Version="1">8611035</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1997 Feb 1;99(3):385-90</RefSource>
          <PMID Version="1">9022070</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1997 Jul;273(1 Pt 2):R113-20</RefSource>
          <PMID Version="1">9249540</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 1999 May 1;269(2):337-41</RefSource>
          <PMID Version="1">10222007</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2004 Dec;114(11):1666-75</RefSource>
          <PMID Version="1">15578099</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Basic Clin Pharmacol Toxicol. 2005 Jan;96(1):3-14</RefSource>
          <PMID Version="1">15667590</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2005 Apr 9-15;365(9467):1333-46</RefSource>
          <PMID Version="1">15823385</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Pharmacol Sci. 2005 May;26(5):244-51</RefSource>
          <PMID Version="1">15860371</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1195-205</RefSource>
          <PMID Version="1">15644454</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Front Biosci. 2005;10:2082-96</RefSource>
          <PMID Version="1">15970480</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Life Sci. 2005 Nov 12;77(26):3344-54</RefSource>
          <PMID Version="1">15979095</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pharmacol Ther. 2006 Jul;111(1):145-73</RefSource>
          <PMID Version="1">16305809</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2006 Jul 7;345(3):1232-9</RefSource>
          <PMID Version="1">16716264</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2006 Aug;55(8):2180-91</RefSource>
          <PMID Version="1">16873680</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocr Rev. 2006 Dec;27(7):728-35</RefSource>
          <PMID Version="1">17018837</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2007 Mar;56(3):735-42</RefSource>
          <PMID Version="1">17327444</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Anim Sci. 2007 May;85(5):1144-55</RefSource>
          <PMID Version="1">17264235</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2007 May;5(5):357-70</RefSource>
          <PMID Version="1">17488638</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Intern Med. 2007 Aug;262(2):184-98</RefSource>
          <PMID Version="1">17645586</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2007 Aug;1771(8):961-71</RefSource>
          <PMID Version="1">17604218</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gastroenterology. 2008 Feb;134(2):556-67</RefSource>
          <PMID Version="1">18242221</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Drug Discov. 2004 Aug;3(8):695-710</RefSource>
          <PMID Version="1">15286736</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1985 Mar;75(3):809-17</RefSource>
          <PMID Version="1">3884667</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2001 Dec;50(12):2786-91</RefSource>
          <PMID Version="1">11723062</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3843710</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0081724</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-10116</ArticleId>
        <ArticleId IdType="pubmed">24312343</ArticleId>
        <ArticleId IdType="pmc">PMC3843710</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24303175</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2051-817X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Physiological reports</Title>
          <ISOAbbreviation>Physiol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e00103</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/phy2.103</ELocationID>
        <Abstract>
          <AbstractText>Glucocorticoid (GC) overexposure period as observed in Cushing's syndrome (CS) is associated with the metabolic syndrome and cardiovascular disease, which persist after long-term correction of GC excess. We performed a mouse study to identify factors that modulate metabolic recovery from a GC overexposure period. Male C57Bl/6J mice, fed a low-fat diet (LFD) or a high-fat diet (HFD), received corticosterone (CORT) (50 &#xB5;g/mL) or vehicle in the drinking water for 4 weeks, followed by an 8-week washout period. Plasma circadian CORT, lipids, insulin, and glucose levels were assessed regularly. Hyperinsulinemic-euglycemic clamp and body composition were analyzed at week 12 under anesthesia. CORT treatment increased plasma CORT levels, food intake, and plasma insulin and lipid levels on both diets. CORT treatment abrogation normalized CORT levels, food intake, and body weight, whereas plasma insulin levels remained significantly higher in CORT-treated mice on both diets. Only on a HFD, CORT-treated mice had decreased lean body mass and higher fat mass. In conclusion, CORT excess period induces long-lasting metabolic changes and some are present only on a HFD. These observations indicate that diet-dependent CORT effects might contribute to the adverse cardiovascular risk profile observed in CS patients, and possibly also in subjects exposed to chronic stress.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Auvinen</LastName>
            <ForeName>Hanna E</ForeName>
            <Initials>HE</Initials>
            <Affiliation>Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center PO Box 9600, Leiden, 2300 RC, The Netherlands.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coomans</LastName>
            <ForeName>Claudia P</ForeName>
            <Initials>CP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boon</LastName>
            <ForeName>Mari&#xEB;tte R</ForeName>
            <Initials>MR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romijn</LastName>
            <ForeName>Johannes A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biermasz</LastName>
            <ForeName>Nienke R</ForeName>
            <Initials>NR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meijer</LastName>
            <ForeName>Onno C</ForeName>
            <Initials>OC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Havekes</LastName>
            <ForeName>Louis M</ForeName>
            <Initials>LM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smit</LastName>
            <ForeName>Johannes W A</ForeName>
            <Initials>JW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rensen</LastName>
            <ForeName>Patrick C N</ForeName>
            <Initials>PC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereira</LastName>
            <ForeName>Alberto M</ForeName>
            <Initials>AM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Physiol Rep</MedlineTA>
        <NlmUniqueID>101607800</NlmUniqueID>
        <ISSNLinking>2051-817X</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3841039</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Body composition</Keyword>
        <Keyword MajorTopicYN="N">corticosterone</Keyword>
        <Keyword MajorTopicYN="N">metabolic syndrome</Keyword>
        <Keyword MajorTopicYN="N">mice</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>03</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/phy2.103</ArticleId>
        <ArticleId IdType="pubmed">24303175</ArticleId>
        <ArticleId IdType="pmc">PMC3841039</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24298777</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0255-2930</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>33</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion</Title>
          <ISOAbbreviation>Zhongguo Zhen Jiu</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Effects of electroacupuncture on the expression of oxidized low-density lipoprotein and its receptors in rats with coronary atherosclerotic heart disease].</ArticleTitle>
        <Pagination>
          <MedlinePgn>817-23</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore action mechanism of electroacupuncture for coronary atherosclerotic heart disease (CHD) in order to provide experimental support for clinical acupoint selection.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Among sixty clean-grade healthy male Wistar rats, twenty-four cases were randomly selected as a normal control group and an electroacupuncture (EA) preconditioning group, 12 cases in each one. Then rats in the EA preconditioning group and the rest 36 rats were fed with high fat diet for 12 weeks to duplicate the CHD model. When the models were successfully established, the rats were randomly divided into a model control group, an EA group and a medication group, 12 cases in each one. EA was applied with Hwa-to SDZ-IV apparatus in the EA preconditioning group at "Neiguan" (PC 6) and "Xinshu" (BL 15), 1 mA in current intensity, 2 Hz in frequency, 30 min per times, once every other day for 14 weeks. When model was established, the same acupoint and method was used in the EA group for 2 weeks while intragastric administration of atorvastatin mixed suspension, 0.25 mg/kg, once a day, was applied in the medication group for 2 weeks. The content of oxidized low-density lipoprotein (oxLDL) in the serum was tested by double antibody enzyme-linked immunosorbent assay (ELISA) while content of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) in coronary arterial tissue was test by western blot method. Expression of LOX-1 mRNA was tested by fluorogenic quantitative polymerase chain reaction (PCR).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After model was duplicated successfully, the content of oxLDL in the serum and the expression of LOX-1 and its mRNA in coronary arterial tissue in the model control group were increased significantly compared with those in the normal control group (all P &lt; 0.01). Compared with the model control group, the content of oxLDL in the serum and the expression of LOX-1 and its mRNA in coronary arterial tissue in the EA preconditioning group, EA group and medication group were significantly reduced (all P &lt; 0.01).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The electroacupuncture at "Neiguan" (PC 6) and "Xinshu" (BL 15) could effectively reduce the content of oxLDL in the serum and expression of LOX-1 and its mRAN in coronary arterial tissue in CHD rats. The oxidative modificatory low-density lipoprotein and its specific receptor system could be one of the ways to prevention and treatment of acupuncture for CHD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <Affiliation>Department of Science and Technology, Anhui University of TCM, Hefei 230038, China. limeng2024@yahoo.com.cn</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Rong-Lin</ForeName>
            <Initials>RL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Zi-Jian</ForeName>
            <Initials>ZJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ke-Ming</ForeName>
            <Initials>KM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Chuan-Yu</ForeName>
            <Initials>CY</Initials>
          </Author>
        </AuthorList>
        <Language>chi</Language>
        <PublicationTypeList>
          <PublicationType>English Abstract</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>Zhongguo Zhen Jiu</MedlineTA>
        <NlmUniqueID>8600658</NlmUniqueID>
        <ISSNLinking>0255-2930</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Oldlr1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Scavenger Receptors, Class E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>oxidized low density lipoprotein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Coronary Disease</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Electroacupuncture</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Scavenger Receptors, Class E</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24298777</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24290571</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1876-7591</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>JACC. Cardiovascular imaging</Title>
          <ISOAbbreviation>JACC Cardiovasc Imaging</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnesium intake is inversely associated with coronary artery calcification: the framingham heart study.</ArticleTitle>
        <Pagination>
          <MedlinePgn>59-69</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcmg.2013.10.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1936-878X(13)00778-X</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to examine whether magnesium intake is associated with coronary artery calcification (CAC) and abdominal aortic calcification (AAC).</AbstractText>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Animal and cell studies suggest that magnesium may prevent calcification within atherosclerotic plaques underlying cardiovascular disease. Little is known about the association of magnesium intake and atherosclerotic calcification in humans.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We examined cross-sectional associations of self-reported total (dietary and supplemental) magnesium intake estimated by food frequency questionnaire with CAC and AAC in participants of the Framingham Heart Study who were free of cardiovascular disease and underwent Multi-Detector Computed Tomography (MDCT) of the heart and abdomen (n&#xA0;= 2,695; age: 53 &#xB1; 11 years), using multivariate-adjusted Tobit regression. CAC and AAC were quantified using modified Agatston scores (AS). Models were adjusted for age, sex, body mass index, smoking status, systolic blood pressure, fasting insulin, total-to-high-density lipoprotein cholesterol ratio, use of hormone replacement therapy (women only), menopausal status (women only), treatment for hyperlipidemia, hypertension, cardiovascular disease prevention, or diabetes, as well as self-reported intake of calcium, vitamins D and K, saturated fat, fiber, alcohol, and energy. Secondary analyses included logistic regressions of CAC and AAC outcomes as cut-points (AS &gt;0 and AS =90th percentile for age and sex), as well as sex-stratified analyses.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In fully adjusted models, a 50-mg/day increment in self-reported total magnesium intake was associated with 22% lower CAC (p &lt; 0.001) and 12% lower AAC (p&#xA0;= 0.07). Consistent with these observations, the odds of having any CAC were 58% lower (p trend: &lt;0.001) and any AAC were 34% lower (p trend: 0.01), in those with the highest compared to those with the lowest magnesium intake. Stronger inverse associations were observed in women than in men.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In community-dwelling participants free of cardiovascular disease, self-reported magnesium intake was inversely associated with arterial calcification, which may play a contributing role in magnesium's protective associations in stroke and fatal coronary heart disease.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hruby</LastName>
            <ForeName>Adela</ForeName>
            <Initials>A</Initials>
            <Affiliation>Nutritional Epidemiology Program, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Donnell</LastName>
            <ForeName>Christopher J</ForeName>
            <Initials>CJ</Initials>
            <Affiliation>National Heart, Lung, and Blood Institute (NHLBI) Division of Intramural Research, and NHLBI's Framingham Heart Study, Framingham, Massachusetts; Cardiovascular Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacques</LastName>
            <ForeName>Paul F</ForeName>
            <Initials>PF</Initials>
            <Affiliation>Nutritional Epidemiology Program, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meigs</LastName>
            <ForeName>James B</ForeName>
            <Initials>JB</Initials>
            <Affiliation>Harvard Medical School, Boston, Massachusetts; General Medicine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffmann</LastName>
            <ForeName>Udo</ForeName>
            <Initials>U</Initials>
            <Affiliation>Harvard Medical School, Boston, Massachusetts; Massachusetts General Hospital Cardiac MR PET CT Program and the Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKeown</LastName>
            <ForeName>Nicola M</ForeName>
            <Initials>NM</Initials>
            <Affiliation>Nutritional Epidemiology Program, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts. Electronic address: nicola.mckeown@tufts.edu.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K24 DK080140</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01 HC025195</GrantID>
            <Acronym>HC</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JACC Cardiovasc Imaging</MedlineTA>
        <NlmUniqueID>101467978</NlmUniqueID>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AAC</Keyword>
        <Keyword MajorTopicYN="N">AS</Keyword>
        <Keyword MajorTopicYN="N">Agatston score</Keyword>
        <Keyword MajorTopicYN="N">CAC</Keyword>
        <Keyword MajorTopicYN="N">CKD</Keyword>
        <Keyword MajorTopicYN="N">CT</Keyword>
        <Keyword MajorTopicYN="N">ESRD</Keyword>
        <Keyword MajorTopicYN="N">Framingham Heart Study</Keyword>
        <Keyword MajorTopicYN="N">Framingham Heart Study Multi-Detector Computed Tomography Sub-study</Keyword>
        <Keyword MajorTopicYN="N">GFR</Keyword>
        <Keyword MajorTopicYN="N">IMT</Keyword>
        <Keyword MajorTopicYN="N">MDCT</Keyword>
        <Keyword MajorTopicYN="N">PWV</Keyword>
        <Keyword MajorTopicYN="N">abdominal aortic calcification</Keyword>
        <Keyword MajorTopicYN="N">chronic kidney disease</Keyword>
        <Keyword MajorTopicYN="N">computed tomography</Keyword>
        <Keyword MajorTopicYN="N">coronary artery calcification</Keyword>
        <Keyword MajorTopicYN="N">diet</Keyword>
        <Keyword MajorTopicYN="N">end-stage renal disease</Keyword>
        <Keyword MajorTopicYN="N">glomerular filtration rate</Keyword>
        <Keyword MajorTopicYN="N">intima-medial thickness</Keyword>
        <Keyword MajorTopicYN="N">magnesium</Keyword>
        <Keyword MajorTopicYN="N">pulse-wave velocity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24290571</ArticleId>
        <ArticleId IdType="pii">S1936-878X(13)00778-X</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jcmg.2013.10.006</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24287404</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-2191</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>184</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of pathology</Title>
          <ISOAbbreviation>Am. J. Pathol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Diuretics Prevent Thiazolidinedione-Induced Cardiac Hypertrophy without Compromising Insulin-Sensitizing Effects in Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>442-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajpath.2013.10.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0002-9440(13)00732-3</ELocationID>
        <Abstract>
          <AbstractText>Much concern has arisen regarding critical adverse effects of thiazolidinediones (TZDs), including rosiglitazone and pioglitazone, on cardiac tissue. Although TZD-induced cardiac hypertrophy (CH) has been attributed to an increase in plasma volume or a change in cardiac nutrient preference, causative roles have not been established. To test the hypothesis that volume expansion directly mediates rosiglitazone-induced CH, mice were fed a high-fat diet with rosiglitazone, and cardiac and metabolic consequences were examined. Rosiglitazone treatment induced volume expansion and CH in wild-type and PPAR? heterozygous knockout (Pparg(+/-)) mice, but not in mice defective for ligand binding (Pparg(P465L/+)). Cotreatment with the diuretic furosemide in wild-type mice attenuated rosiglitazone-induced CH, hypertrophic gene reprogramming, cardiomyocyte apoptosis, hypertrophy-related signal activation, and left ventricular dysfunction. Similar changes were observed in mice treated with pioglitazone. The diuretics spironolactone and trichlormethiazide, but not amiloride, attenuated rosiglitazone effects on volume expansion and CH. Interestingly, expression of glucose and lipid metabolism genes in the heart was altered by rosiglitazone, but these changes were not attenuated by furosemide cotreatment. Importantly, rosiglitazone-mediated whole-body metabolic improvements were not affected by furosemide cotreatment. We conclude that releasing plasma volume reduces adverse effects of TZD-induced volume expansion and cardiac events without compromising TZD actions in metabolic switch in the heart and whole-body insulin sensitivity.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Cherng-Shyang</ForeName>
            <Initials>CS</Initials>
            <Affiliation>Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan; Cardiovascular Research Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsai</LastName>
            <ForeName>Pei-Jane</ForeName>
            <Initials>PJ</Initials>
            <Affiliation>Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan, Taiwan; Research Center of Infectious Disease and Signaling, National Cheng Kung University, Tainan, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sung</LastName>
            <ForeName>Junne-Ming</ForeName>
            <Initials>JM</Initials>
            <Affiliation>Division of Nephrology, National Cheng Kung University Hospital, Tainan, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ju-Yi</ForeName>
            <Initials>JY</Initials>
            <Affiliation>Division of Cardiology, National Cheng Kung University Hospital, Tainan, Taiwan; Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ho</LastName>
            <ForeName>Li-Chun</ForeName>
            <Initials>LC</Initials>
            <Affiliation>Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Nephrology, Department of Internal Medicine, E-DA Hospital/I-Shou University, Kaohsiung, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pandya</LastName>
            <ForeName>Kumar</ForeName>
            <Initials>K</Initials>
            <Affiliation>Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, North Carolina.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maeda</LastName>
            <ForeName>Nobuyo</ForeName>
            <Initials>N</Initials>
            <Affiliation>Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, North Carolina.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsai</LastName>
            <ForeName>Yau-Sheng</ForeName>
            <Initials>YS</Initials>
            <Affiliation>Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan; Cardiovascular Research Center, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: yaustsai@mail.ncku.edu.tw.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Pathol</MedlineTA>
        <NlmUniqueID>0370502</NlmUniqueID>
        <ISSNLinking>0002-9440</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0002-9440(13)00732-3</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajpath.2013.10.020</ArticleId>
        <ArticleId IdType="pubmed">24287404</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24283215</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1743-7075</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition &amp; metabolism</Title>
          <ISOAbbreviation>Nutr Metab (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status - a cohort study.</ArticleTitle>
        <Pagination>
          <MedlinePgn>58</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-7075-10-58</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Low levels of high-density lipoproteins (HDL) are considered an important risk factor for cardiovascular disease and constitute one of the criteria for the Metabolic Syndrome (MetS). Lifestyle interventions promoting a low-fat, plant-based eating pattern appear to paradoxically reduce cardiovascular risk but also HDL levels. This study examined the changes in MetS risk factors, in particular HDL, in a large cohort participating in a 30-day lifestyle intervention that promoted a low-fat, plant-based eating pattern.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Individuals (n = 5,046; mean age = 57.3 &#xB1; 12.9 years; 33.5% men, 66.5% women) participating in a in a Complete Health Improvement Program (CHIP) lifestyle intervention within the United States were assessed at baseline and 30 days for changes in body mass index (BMI), blood pressure (BP), lipid profile and fasting plasma glucose (FPG).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">HDL levels decreased by 8.7% (p&lt;0.001) despite significant reductions (p&lt;0.001) in BMI (-3.2%), systolic BP (-5.2%), diastolic BP (-5.2%), triglycerides (TG; -7.7%), FPG (-6.3%), LDL (-13.0%), total cholesterol (TC, -11.1%), TC: HDL ratio (-3.2%), and LDL: HDL ratio (-5.3%). While 323 participants classified as having MetS at program entry no longer had this status after the 30 days, 112 participants acquired the MetS classification as a result of reduction in their HDL levels.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">When people move towards a low-fat, plant-based diet, HDL levels decrease while other indicators of cardiovascular risk improve. This observation raises questions regarding the value of using HDL levels as a predictor of cardiovascular risk in populations who do not consume a typical western diet. As HDL is part of the assemblage of risk factors that constitute MetS, classifying individuals with MetS may not be appropriate in clinical practice or research when applying lifestyle interventions that promote a plant-based eating pattern.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kent</LastName>
            <ForeName>Lillian</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morton</LastName>
            <ForeName>Darren</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rankin</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ward</LastName>
            <ForeName>Ewan</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grant</LastName>
            <ForeName>Ross</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gobble</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diehl</LastName>
            <ForeName>Hans</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nutr Metab (Lond)</MedlineTA>
        <NlmUniqueID>101231644</NlmUniqueID>
        <ISSNLinking>1743-7075</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3849684</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1743-7075-10-58</ArticleId>
        <ArticleId IdType="doi">10.1186/1743-7075-10-58</ArticleId>
        <ArticleId IdType="pubmed">24283215</ArticleId>
        <ArticleId IdType="pmc">PMC3849684</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24281397</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2825</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms3825</ELocationID>
        <Abstract>
          <AbstractText>Diet-induced obesity is a lifestyle-associated medical condition that increases the risk of developing cardiovascular disease, type 2 diabetes and certain types of cancer. Here we report the design of a closed-loop genetic circuit that constantly monitors blood fatty acid levels in the setting of diet-associated hyperlipidemia and coordinates reversible and adjustable expression of the clinically licensed appetite-suppressing peptide hormone pramlintide. Grafting of the peroxisome proliferator-activated receptor-a onto the phloretin-responsive repressor TtgR produces a synthetic intracellular lipid-sensing receptor (LSR) that reversibly induces chimeric TtgR-specific promoters in a fatty acid-adjustable manner. Mice with diet-induced obesity in which microencapsulated cells engineered for LSR-driven expression of pramlintide are implanted show significant reduction in food consumption, blood lipid levels and body weight when put on a high-fat diet. Therapeutic designer circuits that monitor levels of pathologic metabolites and link these with the tailored expression of protein pharmaceuticals may provide new opportunities for the treatment of metabolic disorders.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>R&#xF6;ssger</LastName>
            <ForeName>Katrin</ForeName>
            <Initials>K</Initials>
            <Affiliation>Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charpin-El-Hamri</LastName>
            <ForeName>Ghislaine</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fussenegger</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Biol. 2000 Mar;20(5):1868-76</RefSource>
          <PMID Version="1">10669761</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2013 Jul;56(7):1605-14</RefSource>
          <PMID Version="1">23620058</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2001 Jan;7(1):53-8</RefSource>
          <PMID Version="1">11135616</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2001 Aug;50(8):1698-705</RefSource>
          <PMID Version="1">11473027</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Rev Endocr Metab Disord. 2001 Oct;2(4):403-18</RefSource>
          <PMID Version="1">11725727</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gene. 2002 Jan 9;282(1-2):19-31</RefSource>
          <PMID Version="1">11814674</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Biotechnol. 2002 Jun;20(6):592-6</RefSource>
          <PMID Version="1">12042863</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Biotechnol. 2002 Sep;20(9):901-7</RefSource>
          <PMID Version="1">12205509</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Immunol. 2002 Oct;2(10):748-59</RefSource>
          <PMID Version="1">12360213</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2003 Mar;133 Suppl 3:925S-932S</RefSource>
          <PMID Version="1">12612178</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochemistry. 2003 Aug 12;42(31):9278-87</RefSource>
          <PMID Version="1">12899614</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Biotechnol. 2004 Feb;22(2):87-92</RefSource>
          <PMID Version="1">14757043</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1965 Nov;17(5):281-95</RefSource>
          <PMID Version="1">5846902</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 1974 Jul;15(4):339-51</RefSource>
          <PMID Version="1">4852070</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1997 May;65(5 Suppl):1628S-1644S</RefSource>
          <PMID Version="1">9129503</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Endocrinol. 1997 Jun;11(6):779-91</RefSource>
          <PMID Version="1">9171241</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1997 Aug 1;100(3):705-12</RefSource>
          <PMID Version="1">9239419</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1999 May 28;274(22):15901-7</RefSource>
          <PMID Version="1">10336495</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Steroids. 1999 May;64(5):310-9</RefSource>
          <PMID Version="1">10406480</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Drug Discov. 2005 Mar;4(3):221-35</RefSource>
          <PMID Version="1">15738978</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Ther. 2005 Aug;12(2):283-9</RefSource>
          <PMID Version="1">15935736</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2005 Oct 1;366(9492):1197-209</RefSource>
          <PMID Version="1">16198769</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Pharmacol. 2005;52:19-45</RefSource>
          <PMID Version="1">16492539</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2006 Mar 17;281(11):7102-9</RefSource>
          <PMID Version="1">16407274</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):475-84</RefSource>
          <PMID Version="1">17115344</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am Psychol. 2007 Apr;62(3):220-33</RefSource>
          <PMID Version="1">17469900</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2007 Jun 14;356(24):2457-71</RefSource>
          <PMID Version="1">17517853</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Ther. 2007 Apr;29(4):535-62</RefSource>
          <PMID Version="1">17617279</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cosmet Dermatol. 2008 Dec;7(4):290-7</RefSource>
          <PMID Version="1">19146606</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10638-43</RefSource>
          <PMID Version="1">19549857</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Genet. 2010 May;11(5):367-79</RefSource>
          <PMID Version="1">20395970</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Endocrinol. 2010 May;6(5):255-69</RefSource>
          <PMID Version="1">20234354</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Endocrinol. 2010 Jun;6(6):326-34</RefSource>
          <PMID Version="1">20404854</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Control Release. 2010 Aug 17;146(1):93-8</RefSource>
          <PMID Version="1">20580914</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Struct Mol Biol. 2011 Feb;18(2):177-84</RefSource>
          <PMID Version="1">21240272</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Expert Rev Cardiovasc Ther. 2011 Mar;9(3):265-77</RefSource>
          <PMID Version="1">21438803</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Expert Opin Pharmacother. 2011 Jun;12(9):1439-51</RefSource>
          <PMID Version="1">21564002</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2011 Aug 27;378(9793):815-25</RefSource>
          <PMID Version="1">21872750</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 2011 Sep 2;333(6047):1248-52</RefSource>
          <PMID Version="1">21885773</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2012 Mar 29;366(13):1209-17</RefSource>
          <PMID Version="1">22455415</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metab Eng. 2012 May;14(3):252-60</RefSource>
          <PMID Version="1">21722748</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Obes Rev. 2012 Jun;13(6):483-98</RefSource>
          <PMID Version="1">22288431</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Med Chem. 2012 Jul;53:190-202</RefSource>
          <PMID Version="1">22534184</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):117-28</RefSource>
          <PMID Version="1">22435392</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMJ. 2012;345:e5085</RefSource>
          <PMID Version="1">22867649</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Biotechnol. 2012 Sep;30(9):810-1</RefSource>
          <PMID Version="1">22965032</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Biotechnol. 2012 Oct;23(5):641-3</RefSource>
          <PMID Version="1">22857952</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Drug Deliv Rev. 2012 Oct;64(13):1477-87</RefSource>
          <PMID Version="1">22721864</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Rheumatol. 2012 Dec;8(12):729-37</RefSource>
          <PMID Version="1">22907293</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Sci Transl Med. 2013 Apr 3;5(179):179ps7</RefSource>
          <PMID Version="1">23552369</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2000 May 25;405(6785):421-4</RefSource>
          <PMID Version="1">10839530</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3868331</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>09</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ncomms3825</ArticleId>
        <ArticleId IdType="doi">10.1038/ncomms3825</ArticleId>
        <ArticleId IdType="pubmed">24281397</ArticleId>
        <ArticleId IdType="pmc">PMC3868331</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24275089</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>20</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-6351</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
          <ISOAbbreviation>Food Chem. Toxicol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Monascin and ankaflavin act as natural AMPK activators with PPARa agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>94-103</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fct.2013.11.015</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0278-6915(13)00774-6</ELocationID>
        <Abstract>
          <AbstractText>Yellow pigments monascin (MS) and ankaflavin (AK) are secondary metabolites derived from Monascus-fermented products. The hypolipidemic and anti-inflammatory effects of MS and AK indicate that they have potential on preventing or curing nonalcoholic fatty liver disease (NAFLD). Oleic acid (OA) and high-fat diet were used to induce steatosis in FL83B hepatocytes and NAFLD in mice, respectively. We found that both MS and AK prevented fatty acid accumulation in hepatocytes by inhibiting fatty acid uptake, lipogenesis, and promoting fatty acid beta-oxidation mediated by activating peroxisome proliferator-activated receptor (PPAR)-a and AMP-activated kinase (AMPK). Furthermore, MS and AK significantly attenuated high-fat diet-induced elevation of total cholesterol (TC), triaceylglycerol (TG), free fatty acid (FFA), and low density lipoprotein-cholesterol (LDL-C) in plasma. MS and AK promoted AMPK phosphorylation, suppressed the steatosis-related mRNA expression and inflammatory cytokines secretion, as well as upregulated farnesoid X receptor (FXR), peroxisome proliferator-activated receptor gamma co-activator (PGC)-1a, and PPARa expression to induce fatty acid oxidation in the liver of mice. We provided evidence that MS and AK act as PPARa agonists to upregulate AMPK activity and attenuate NAFLD. MS and AK may be supplied in food supplements or developed as functional foods to reduce the risk of diabetes and obesity.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Wei-Hsuan</ForeName>
            <Initials>WH</Initials>
            <Affiliation>Department of Biochemical Science &amp; Technology, College of Life Science, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ting-Hung</ForeName>
            <Initials>TH</Initials>
            <Affiliation>Department of Biochemical Science &amp; Technology, College of Life Science, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Bao-Hong</ForeName>
            <Initials>BH</Initials>
            <Affiliation>Department of Biochemical Science &amp; Technology, College of Life Science, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Ya-Wen</ForeName>
            <Initials>YW</Initials>
            <Affiliation>R&amp;D Division, SunWay Biotechnology Company Limited, Taipei, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Tzu-Ming</ForeName>
            <Initials>TM</Initials>
            <Affiliation>Department of Biochemical Science &amp; Technology, College of Life Science, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan. Electronic address: tmpan@ntu.edu.tw.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Food Chem Toxicol</MedlineTA>
        <NlmUniqueID>8207483</NlmUniqueID>
        <ISSNLinking>0278-6915</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ACC</Keyword>
        <Keyword MajorTopicYN="N">ACOX</Keyword>
        <Keyword MajorTopicYN="N">ACS</Keyword>
        <Keyword MajorTopicYN="N">AK</Keyword>
        <Keyword MajorTopicYN="N">ALT</Keyword>
        <Keyword MajorTopicYN="N">AMP-activated kinase</Keyword>
        <Keyword MajorTopicYN="N">AMPK</Keyword>
        <Keyword MajorTopicYN="N">AST</Keyword>
        <Keyword MajorTopicYN="N">Ankaflavin (AK)</Keyword>
        <Keyword MajorTopicYN="N">BSA</Keyword>
        <Keyword MajorTopicYN="N">CPT-1</Keyword>
        <Keyword MajorTopicYN="N">CV</Keyword>
        <Keyword MajorTopicYN="N">DMSO</Keyword>
        <Keyword MajorTopicYN="N">ELISA</Keyword>
        <Keyword MajorTopicYN="N">FABP</Keyword>
        <Keyword MajorTopicYN="N">FAS</Keyword>
        <Keyword MajorTopicYN="N">FAT</Keyword>
        <Keyword MajorTopicYN="N">FBS</Keyword>
        <Keyword MajorTopicYN="N">FFA</Keyword>
        <Keyword MajorTopicYN="N">FXR</Keyword>
        <Keyword MajorTopicYN="N">GLUT</Keyword>
        <Keyword MajorTopicYN="N">H&amp;E</Keyword>
        <Keyword MajorTopicYN="N">HAECs</Keyword>
        <Keyword MajorTopicYN="N">HDL-C</Keyword>
        <Keyword MajorTopicYN="N">HPLC</Keyword>
        <Keyword MajorTopicYN="N">HUVECs</Keyword>
        <Keyword MajorTopicYN="N">IACUC</Keyword>
        <Keyword MajorTopicYN="N">ICAM-1</Keyword>
        <Keyword MajorTopicYN="N">IL-6</Keyword>
        <Keyword MajorTopicYN="N">Institutional Animal Care and Use Committee</Keyword>
        <Keyword MajorTopicYN="N">JNK</Keyword>
        <Keyword MajorTopicYN="N">LDL-C</Keyword>
        <Keyword MajorTopicYN="N">MS</Keyword>
        <Keyword MajorTopicYN="N">MTP</Keyword>
        <Keyword MajorTopicYN="N">Monascin (MS)</Keyword>
        <Keyword MajorTopicYN="N">NAFLD</Keyword>
        <Keyword MajorTopicYN="N">NASH</Keyword>
        <Keyword MajorTopicYN="N">NCBI</Keyword>
        <Keyword MajorTopicYN="N">NF-?B</Keyword>
        <Keyword MajorTopicYN="N">National Center for Biotechnology Information</Keyword>
        <Keyword MajorTopicYN="N">Nonalcoholic fatty liver disease (NAFLD)</Keyword>
        <Keyword MajorTopicYN="N">Nrf2</Keyword>
        <Keyword MajorTopicYN="N">OA</Keyword>
        <Keyword MajorTopicYN="N">Oleic acid (OA)</Keyword>
        <Keyword MajorTopicYN="N">PCR</Keyword>
        <Keyword MajorTopicYN="N">PGC-1a</Keyword>
        <Keyword MajorTopicYN="N">PPARa</Keyword>
        <Keyword MajorTopicYN="N">PPAR?</Keyword>
        <Keyword MajorTopicYN="N">PPREs</Keyword>
        <Keyword MajorTopicYN="N">PTP1B</Keyword>
        <Keyword MajorTopicYN="N">Peroxisome proliferator-activated receptor (PPAR)-a</Keyword>
        <Keyword MajorTopicYN="N">SDS</Keyword>
        <Keyword MajorTopicYN="N">SPPARMs</Keyword>
        <Keyword MajorTopicYN="N">SREBP-1c</Keyword>
        <Keyword MajorTopicYN="N">TC</Keyword>
        <Keyword MajorTopicYN="N">TG</Keyword>
        <Keyword MajorTopicYN="N">TGF&#xDF;</Keyword>
        <Keyword MajorTopicYN="N">TLC</Keyword>
        <Keyword MajorTopicYN="N">TNF-a</Keyword>
        <Keyword MajorTopicYN="N">TR-FRET</Keyword>
        <Keyword MajorTopicYN="N">TZDs</Keyword>
        <Keyword MajorTopicYN="N">Tyr</Keyword>
        <Keyword MajorTopicYN="N">VCAM-1</Keyword>
        <Keyword MajorTopicYN="N">acetyl-CoA carboxylase</Keyword>
        <Keyword MajorTopicYN="N">acyl-CoA oxidase</Keyword>
        <Keyword MajorTopicYN="N">acyl-CoA synthetase</Keyword>
        <Keyword MajorTopicYN="N">alanine aminotranferase</Keyword>
        <Keyword MajorTopicYN="N">ankaflavin</Keyword>
        <Keyword MajorTopicYN="N">aspartate transaminase</Keyword>
        <Keyword MajorTopicYN="N">bovine serum albumin</Keyword>
        <Keyword MajorTopicYN="N">c-Jun NH(2)-terminal kinase</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular</Keyword>
        <Keyword MajorTopicYN="N">carnitine palmitoyl transferase I</Keyword>
        <Keyword MajorTopicYN="N">dimethyl sulfoxide</Keyword>
        <Keyword MajorTopicYN="N">enzyme-linked immunosorbent assay</Keyword>
        <Keyword MajorTopicYN="N">farnesoid X receptor</Keyword>
        <Keyword MajorTopicYN="N">fatty acid synthase</Keyword>
        <Keyword MajorTopicYN="N">fatty acid transporter</Keyword>
        <Keyword MajorTopicYN="N">fatty acid-binding protein</Keyword>
        <Keyword MajorTopicYN="N">fetal bovine serum</Keyword>
        <Keyword MajorTopicYN="N">free fatty acid</Keyword>
        <Keyword MajorTopicYN="N">glucose transporter</Keyword>
        <Keyword MajorTopicYN="N">hematoxylin and eosin</Keyword>
        <Keyword MajorTopicYN="N">high-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">high-performance liquid chromatography</Keyword>
        <Keyword MajorTopicYN="N">human aortic endothelial cells</Keyword>
        <Keyword MajorTopicYN="N">human umbilical vein endothelial cells</Keyword>
        <Keyword MajorTopicYN="N">iNOS</Keyword>
        <Keyword MajorTopicYN="N">inducible nitric oxide synthase</Keyword>
        <Keyword MajorTopicYN="N">intercellular adhesion molecule-1</Keyword>
        <Keyword MajorTopicYN="N">interleukin-6</Keyword>
        <Keyword MajorTopicYN="N">low density lipoprotein-cholesterol</Keyword>
        <Keyword MajorTopicYN="N">microsomal triglyceride transfer protein</Keyword>
        <Keyword MajorTopicYN="N">monascin</Keyword>
        <Keyword MajorTopicYN="N">nonalcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">nonalcoholic steatohepatitis</Keyword>
        <Keyword MajorTopicYN="N">nuclear factor erythroid 2-related factor 2</Keyword>
        <Keyword MajorTopicYN="N">nuclear factor-kappaB</Keyword>
        <Keyword MajorTopicYN="N">oleic acid</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator activated receptor alpha</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator activated receptor gamma</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator-activated receptor gamma co-activator 1-alpha</Keyword>
        <Keyword MajorTopicYN="N">peroxisome-proliferator-response elements</Keyword>
        <Keyword MajorTopicYN="N">polymerase chain reaction</Keyword>
        <Keyword MajorTopicYN="N">protein tyrosine phosphatase 1B</Keyword>
        <Keyword MajorTopicYN="N">selective PPAR modulators</Keyword>
        <Keyword MajorTopicYN="N">sodium dodecyl sulfate</Keyword>
        <Keyword MajorTopicYN="N">sterol regulatory element-binding protein</Keyword>
        <Keyword MajorTopicYN="N">thiazolidinediones</Keyword>
        <Keyword MajorTopicYN="N">thin layer chromatography</Keyword>
        <Keyword MajorTopicYN="N">time-resolved fluorescence resonance energy transfer</Keyword>
        <Keyword MajorTopicYN="N">total cholesterol</Keyword>
        <Keyword MajorTopicYN="N">transformation growth factor beta</Keyword>
        <Keyword MajorTopicYN="N">triaceylglycerol</Keyword>
        <Keyword MajorTopicYN="N">tumor necrosis factor-alpha</Keyword>
        <Keyword MajorTopicYN="N">tyrosine</Keyword>
        <Keyword MajorTopicYN="N">vascular cell adhesion molecule-1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24275089</ArticleId>
        <ArticleId IdType="pii">S0278-6915(13)00774-6</ArticleId>
        <ArticleId IdType="doi">10.1016/j.fct.2013.11.015</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24267039</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0739</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition research (New York, N.Y.)</Title>
          <ISOAbbreviation>Nutr Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exercise attenuates the increase in plasma monounsaturated fatty acids and high-density lipoprotein cholesterol but not high-density lipoprotein 2b cholesterol caused by high-oleic ground beef in women.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1003-11</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2013.09.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(13)00215-7</ELocationID>
        <Abstract>
          <AbstractText>We hypothesized that dietary monounsaturated fatty acids (MUFA) and exercise increase high-density lipoprotein cholesterol (HDL-C) by independent mechanisms, so there would be additive effects between a single, intensive session of exercise and high-MUFA ground beef on HDL-C and blood risk factors for cardiovascular disease. Seventeen postmenopausal women completed a 2-way crossover design in which they consumed five 114-g ground beef patties per week for two 6-week periods separated by a 4-week washout (habitual diet) period. The ground beef patties contained 21% total fat with either 9.97 (low-MUFA) or 12.72 (high-MUFA) g total MUFA. Blood was taken at entry, at the end of each 6-week diet period, after the 4-week washout period, and 24 hours after aerobic exercise sessions (75% VO2peak, 2.07 MJ). After the ground beef intervention, the high-MUFA ground beef increased plasma palmitoleic acid and oleic acid, low-density lipoprotein (LDL) particle density, HDL-C, and HDL2b-C (all P &lt; .05), whereas the low-MUFA ground beef increased LDL density. After the washout (habitual diet) period, the single exercise session increased serum LDL cholesterol, HDL-C, and HDL2a and decreased TAG and oleic acid. After the low-MUFA ground beef diet, exercise increased LDL size and HDL density and decreased LDL density and very low-density lipoprotein cholesterol, but had no effect on HDL-C fractions. After the high-MUFA ground beef intervention, exercise decreased palmitioleic acid, oleic acid, HDL-C, and HDL2a-C, but not HDL2b-C. Contrary to our hypothesis, the effects of exercise and a high-MUFA diet were not additive; instead, exercise attenuated the effects of the high-MUFA ground beef on HDL-C and plasma MUFAs. The differential effects of high-MUFA ground beef and exercise on HDL2a-C and HDL2b-C indicate that diet and exercise affect HDL-C by different mechanisms.</AbstractText>
          <CopyrightInformation>&#xA9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gilmore</LastName>
            <ForeName>L Anne</ForeName>
            <Initials>LA</Initials>
            <Affiliation>Department of Animal Science, 2471 TAMU, Texas A&amp;M University, College Station, TX 77843, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crouse</LastName>
            <ForeName>Stephen F</ForeName>
            <Initials>SF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carbuhn</LastName>
            <ForeName>Aaron</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klooster</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calles</LastName>
            <ForeName>Jos&#xE9; Antonio Elias</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meade</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Stephen B</ForeName>
            <Initials>SB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nutr Res</MedlineTA>
        <NlmUniqueID>8303331</NlmUniqueID>
        <ISSNLinking>0271-5317</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AHA</Keyword>
        <Keyword MajorTopicYN="N">American Heart Association</Keyword>
        <Keyword MajorTopicYN="N">BMI</Keyword>
        <Keyword MajorTopicYN="N">CETP</Keyword>
        <Keyword MajorTopicYN="N">CVD</Keyword>
        <Keyword MajorTopicYN="N">Cholesterol</Keyword>
        <Keyword MajorTopicYN="N">Exercise</Keyword>
        <Keyword MajorTopicYN="N">Fatty acids</Keyword>
        <Keyword MajorTopicYN="N">HDL-C</Keyword>
        <Keyword MajorTopicYN="N">LDL-C</Keyword>
        <Keyword MajorTopicYN="N">Lipoproteins</Keyword>
        <Keyword MajorTopicYN="N">Lp(a)</Keyword>
        <Keyword MajorTopicYN="N">MUFA</Keyword>
        <Keyword MajorTopicYN="N">Oleic acid</Keyword>
        <Keyword MajorTopicYN="N">RLP-C</Keyword>
        <Keyword MajorTopicYN="N">SCD</Keyword>
        <Keyword MajorTopicYN="N">SFA</Keyword>
        <Keyword MajorTopicYN="N">TAG</Keyword>
        <Keyword MajorTopicYN="N">TC</Keyword>
        <Keyword MajorTopicYN="N">VLDL-C</Keyword>
        <Keyword MajorTopicYN="N">Women</Keyword>
        <Keyword MajorTopicYN="N">body mass index</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">cholesterol ester transferase protein</Keyword>
        <Keyword MajorTopicYN="N">high-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">lipoprotein a</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">monounsaturated fatty acids</Keyword>
        <Keyword MajorTopicYN="N">remnant lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">saturated fatty acids</Keyword>
        <Keyword MajorTopicYN="N">stearoyl-CoA desaturase</Keyword>
        <Keyword MajorTopicYN="N">total cholesterol</Keyword>
        <Keyword MajorTopicYN="N">triacylglycerol</Keyword>
        <Keyword MajorTopicYN="N">very low-density lipoprotein cholesterol</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0271-5317(13)00215-7</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nutres.2013.09.003</ArticleId>
        <ArticleId IdType="pubmed">24267039</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24266602</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-3841</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>78</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of food science</Title>
          <ISOAbbreviation>J. Food Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Taioba (Xanthosoma sagittifolium) leaves: nutrient composition and physiological effects on healthy rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>H1929-34</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/1750-3841.12301</ELocationID>
        <Abstract>
          <AbstractText>Several studies have shown that fruits and vegetables contribute to protect against degenerative pathologies such as cardiovascular diseases, diabetes, and cancer, mainly due to the presence of dietary fiber (DF) and polyphenols. Taioba (Xanthosoma sagittifolium) is an edible aroid widely grown in many parts of Africa, America, and Asia. The tubers portions of taioba are widely consumed; however, the leafy portions are generally discarded, despite their high nutritive value. In this study, we have partly characterized the DF of lyophiized taioba leaf (LTL), and assessed the possible protective effects on biochemical parameters and on bile acid (BA) production in colon and cecum, when fed to healthy rats for 4 wk. Forty-five Wistar rats were assigned to either of 5 groups: group 1 received AIN 93G diet (CG: Control); group 2 received AIN 93G containing 2.5% of cellulose + 2.5% inulin (CEIN_5%); group 3 received AIN 93G containing 2.5% of cellulose + 2.5% taioba fiber (CETA_5%); group 4 received AIN 93G containing 5% cellulose + 2.5% taioba fiber (CETA_7.5%); group 5 received AIN 93G containing 5% cellulose + 2.5% of inulin (CEIN_7.5%). LTL showed high contents of total fiber, predominantly comprising insoluble DF with glucose as the major monomer. Rats receiving LTL had increased fecal mass and fat excretion, and improved BA profiles by diminishing the proportion of secondary acids, thus suggesting that consumption of taioba leaf may have the property of lowering the risk of colon cancer.</AbstractText>
          <CopyrightInformation>&#xA9; 2013 Institute of Food Technologists&#xAE;</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Almeida Jackix</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <Affiliation>Dept. of Food and Nutrition, School of Food Engineering, Univ. of Campinas - Unicamp, R. Monteiro Lobato, 80, PO Box 6121, Campinas, SP 13083-862, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monteiro</LastName>
            <ForeName>Elisa Bernardes</ForeName>
            <Initials>EB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raposo</LastName>
            <ForeName>Helena Fonseca</ForeName>
            <Initials>HF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vanzela</LastName>
            <ForeName>Emerielle Cristine</ForeName>
            <Initials>EC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amaya-Farf&#xE1;n</LastName>
            <ForeName>Jaime</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Food Sci</MedlineTA>
        <NlmUniqueID>0014052</NlmUniqueID>
        <ISSNLinking>0022-1147</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">bile acids</Keyword>
        <Keyword MajorTopicYN="N">cholesterol</Keyword>
        <Keyword MajorTopicYN="N">dietary fiber</Keyword>
        <Keyword MajorTopicYN="N">functional properties in vivo</Keyword>
        <Keyword MajorTopicYN="N">taioba (Xanthosoma sagittifolium)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24266602</ArticleId>
        <ArticleId IdType="doi">10.1111/1750-3841.12301</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24263037</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition, metabolism, and cardiovascular diseases : NMCD</Title>
          <ISOAbbreviation>Nutr Metab Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>"Towards an even healthier Mediterranean diet".</ArticleTitle>
        <Pagination>
          <MedlinePgn>1163-6</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.numecd.2013.09.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0939-4753(13)00204-4</ELocationID>
        <Abstract>
          <AbstractText>Dietary guidelines to promote good health are usually based on foods, nutrients, and dietary patterns predictive of chronic disease risk in epidemiologic studies. However, sound nutritional recommendations for cardiovascular prevention should be based on the results of large randomized clinical trials with "hard" end-points as the main outcome. Such evidence has been obtained for the Mediterranean diet from the PREDIMED (Prevenci&#xF3;n con Dieta Mediterr&#xE1;nea) trial and the Lyon Heart Study. The traditional Mediterranean diet was that found in olive growing areas of Crete, Greece, and Southern Italy in the late 1950s. Their major characteristics include: a) a high consumption of cereals, legumes, nuts, vegetables, and fruits; b) a relatively high-fat consumption, mostly provided by olive oil; c) moderate to high fish consumption; d) poultry and dairy products consumed in moderate to small amounts; e) low consumption of red meats, and meat products; and f) moderate alcohol intake, usually in the form of red wine. However, these protective effects of the traditional Mediterranean diet may be even greater if we upgrade the health effects of this dietary pattern changing the common olive oil used for extra-virgin olive oil, increasing the consumption of nuts, fatty fish and whole grain cereals, reducing sodium intake, and maintaining a moderate consumption of wine with meals.</AbstractText>
          <CopyrightInformation>&#xA9; 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Estruch</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <Affiliation>Department of Internal Medicine, Hospital Clinic, Institut d'Investigaci&#xF3;, August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; CIBER Obn, Physiopathology of Obesity and Nutrition, Institute of Health "Carlos III", Government of Spain, Santiago de Compostela, Spain. Electronic address: restruch@clinic.ub.es.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salas-Salvad&#xF3;</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Nutr Metab Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>9111474</NlmUniqueID>
        <ISSNLinking>0939-4753</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">Cardiovascular risk factors</Keyword>
        <Keyword MajorTopicYN="N">Mediterranean diet</Keyword>
        <Keyword MajorTopicYN="N">Nutrition</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24263037</ArticleId>
        <ArticleId IdType="pii">S0939-4753(13)00204-4</ArticleId>
        <ArticleId IdType="doi">10.1016/j.numecd.2013.09.003</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24259558</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1541-6100</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>144</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of nutrition</Title>
          <ISOAbbreviation>J. Nutr.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk.</ArticleTitle>
        <Pagination>
          <MedlinePgn>55-60</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3945/jn.113.183012</ELocationID>
        <Abstract>
          <AbstractText>The relation between dietary magnesium intake and cardiovascular disease (CVD) or mortality was evaluated in several prospective studies, but few of them have assessed the risk of all-cause mortality, which has never been evaluated in Mediterranean adults at high cardiovascular risk. The aim of this study was to assess the association between magnesium intake and CVD and mortality risk in a Mediterranean population at high cardiovascular risk with high average magnesium intake. The present study included 7216 men and women aged 55-80 y from the PREDIMED (Prevenci&#xF3;n con Dieta Mediterr&#xE1;nea) study, a randomized clinical trial. Participants were assigned to 1 of 2 Mediterranean diets (supplemented with nuts or olive oil) or to a control diet (advice on a low-fat diet). Mortality was ascertained by linkage to the National Death Index and medical records. We fitted multivariable-adjusted Cox regressions to assess associations between baseline energy-adjusted tertiles of magnesium intake and relative risk of CVD and mortality. Multivariable analyses with generalized estimating equation models were used to assess the associations between yearly repeated measurements of magnesium intake and mortality. After a median follow-up of 4.8 y, 323 total deaths, 81 cardiovascular deaths, 130 cancer deaths, and 277 cardiovascular events occurred. Energy-adjusted baseline magnesium intake was inversely associated with cardiovascular, cancer, and all-cause mortality. Compared with lower consumers, individuals in the highest tertile of magnesium intake had a 34% reduction in mortality risk (HR: 0.66; 95% CI: 0.45, 0.95; P &lt; 0.01). Dietary magnesium intake was inversely associated with mortality risk in Mediterranean individuals at high risk of CVD. This trial was registered at controlled-trials.com as ISRCTN35739639.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guasch-Ferr&#xE9;</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <Affiliation>Human Nutrition Unit, University Hospital of Sant Joan de Reus, Faculty of Medicine and Health Sciences, IISPV, Rovira i Virgili University, Reus, Spain.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bull&#xF3;</LastName>
            <ForeName>M&#xF2;nica</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Estruch</LastName>
            <ForeName>Ramon</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corella</LastName>
            <ForeName>Dolores</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mart&#xED;nez-Gonz&#xE1;lez</LastName>
            <ForeName>Miguel A</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ros</LastName>
            <ForeName>Emilio</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covas</LastName>
            <ForeName>Maribel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ar&#xF3;s</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>G&#xF3;mez-Gracia</LastName>
            <ForeName>Enrique</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiol</LastName>
            <ForeName>Miquel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lapetra</LastName>
            <ForeName>Jos&#xE9;</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mu&#xF1;oz</LastName>
            <ForeName>Miguel &#xC1;ngel</ForeName>
            <Initials>M&#xC1;</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serra-Majem</LastName>
            <ForeName>Llu&#xED;s</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Babio</LastName>
            <ForeName>Nancy</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pint&#xF3;</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamuela-Ravent&#xF3;s</LastName>
            <ForeName>Rosa M</ForeName>
            <Initials>RM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruiz-Guti&#xE9;rrez</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salas-Salvad&#xF3;</LastName>
            <ForeName>Jordi</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>PREDIMED Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nutr</MedlineTA>
        <NlmUniqueID>0404243</NlmUniqueID>
        <ISSNLinking>0022-3166</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jn.113.183012</ArticleId>
        <ArticleId IdType="doi">10.3945/jn.113.183012</ArticleId>
        <ArticleId IdType="pubmed">24259558</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24247152</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1421-9778</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>
          <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>T-box20 suppresses oxidized low-density lipoprotein-induced human vascular endothelial cell injury by upregulation of PPAR-?.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1137-50</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000354514</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atherosclerosis is a chronic inflammation disease which is initiated by endothelial cell injury Oxidized low-density lipoprotein (ox-LDL) is directly associated with chronic vascular inflammation. Many transcription factors take part in the initiation and progression of atherosclerosis. As a transcription factor mainly expressed in cardiovascular system, T-box20 (Tbx20) plays an important role in embryonic cardiovascular system development and homeostasis. However, the role of Tbx20 in endothelial cell injury and atherosclerosis is still not clear. We showed that Tbx20 might affect ox-LDL-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs).</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">First, Tbx20 expression was down regulated in the C57BL/6 mice with high-fat diet-induced artery injury, which was accompanied by elevated reactive oxygen species (ROS) generation and cell adhesion molecule expression. Second, ox-LDL led to concurrent decreased Tbx20 expression and increased levels of ROS and adhesion molecules in the HUVECs. Third, over-expression of Tbx20 by adenovirus reduced ox-LDL-induced HUVEC injury via attenuation of ROS generation and cell adhesion molecule expression. Fourth, knock down of Tbx20 by siRNA significantly increased adhesion molecule expression and decreased cell viability. Moreover, Tbx20 could directly regulate PPAR-? expression, as shown by Tbx20 knock down and PPAR-? inhibition, which significantly reversed Tbx20's HUVEC protection effect.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that misregulation of Tbx20 could reduce HUVEC tolerance of ox-LDL-induced cell injury, suggesting that Tbx20 might be a crucial regulator and potential therapeutic target for atherosclerosis.</AbstractText>
          <CopyrightInformation>&#xA9; 2013 S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <Affiliation>Key Laboratory of Geriatrics, BeijingHospital and Beijing Institute of Geriatrics, Ministry of Health, Beijing, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yuping</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Jigar</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Beidong</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Gexin</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Hangbang</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hongxia</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Man</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shu</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Cell Physiol Biochem</MedlineTA>
        <NlmUniqueID>9113221</NlmUniqueID>
        <ISSNLinking>1015-8987</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">000354514</ArticleId>
        <ArticleId IdType="doi">10.1159/000354514</ArticleId>
        <ArticleId IdType="pubmed">24247152</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24234673</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-0259</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular toxicology</Title>
          <ISOAbbreviation>Cardiovasc. Toxicol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chronic Exposure to Bisphenol A can Accelerate Atherosclerosis in High-Fat-Fed Apolipoprotein E Knockout Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">In epidemiological studies, there is growing concern regarding the association between human exposure to bisphenol A (BPA) and an increased risk for cardiovascular disease. Therefore, we investigated whether BPA accelerates atherosclerosis in mouse model. Apolipoprotein E knockout (ApoE(-/-)) mice were fed a high-fat and high-cholesterol diet with or without 50&#xA0;&#xB5;g/kg body weight/day BPA for 12&#xA0;weeks. Atherosclerotic lesions of the aorta and aortic sinus were evaluated by Oil red O staining. After the 12-week BPA treatment, BPA significantly increased atherosclerotic lesions in the aortas of ApoE(-/-) mice by 1.7-fold (p&#xA0;=&#xA0;0.03). Non-high-density lipoprotein (HDL) cholesterol levels in the BPA group were significantly higher compared to those in the control group (1,035&#xA0;&#xB1;&#xA0;70 vs. 484&#xA0;&#xB1;&#xA0;48&#xA0;mg/dL, p&#xA0;=&#xA0;0.02) although body weight and blood glucose levels were not different between groups. Human umbilical vein endothelial cells (HUVECs) were treated with 0.1-10&#xA0;nM BPA but BPA did not affect HUVEC proliferation or migration. BPA could accelerate atherosclerosis in ApoE(-/-) mice, which may have resulted from an increase in non-HDL cholesterol levels.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Kim</LastName>
            <ForeName>Min Joo</ForeName>
            <Initials>MJ</Initials>
            <Affiliation>Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul, 110-744, Republic of Korea.</Affiliation>
          </Author>
          <Author>
            <LastName>Moon</LastName>
            <ForeName>Min Kyong</ForeName>
            <Initials>MK</Initials>
          </Author>
          <Author>
            <LastName>Kang</LastName>
            <ForeName>Geun Hyung</ForeName>
            <Initials>GH</Initials>
          </Author>
          <Author>
            <LastName>Lee</LastName>
            <ForeName>Kwan Jae</ForeName>
            <Initials>KJ</Initials>
          </Author>
          <Author>
            <LastName>Choi</LastName>
            <ForeName>Sung Hee</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author>
            <LastName>Lim</LastName>
            <ForeName>Soo</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Oh</LastName>
            <ForeName>Byung-Chul</ForeName>
            <Initials>BC</Initials>
          </Author>
          <Author>
            <LastName>Park</LastName>
            <ForeName>Do Joon</ForeName>
            <Initials>DJ</Initials>
          </Author>
          <Author>
            <LastName>Park</LastName>
            <ForeName>Kyong Soo</ForeName>
            <Initials>KS</Initials>
          </Author>
          <Author>
            <LastName>Jang</LastName>
            <ForeName>Hak Chul</ForeName>
            <Initials>HC</Initials>
          </Author>
          <Author>
            <LastName>Park</LastName>
            <ForeName>Young Joo</ForeName>
            <Initials>YJ</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cardiovasc Toxicol</MedlineTA>
        <NlmUniqueID>101135818</NlmUniqueID>
        <ISSNLinking>1530-7905</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1007/s12012-013-9235-x</ArticleId>
        <ArticleId IdType="pubmed">24234673</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24229349</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1741-7015</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>BMC medicine</Title>
          <ISOAbbreviation>BMC Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mediterranean dietary pattern and depression: the PREDIMED randomized trial.</ArticleTitle>
        <Pagination>
          <MedlinePgn>208</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1741-7015-11-208</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A few observational studies have found an inverse association between adherence to a Mediterranean diet and the risk of depression. Randomized trials with an intervention based on this dietary pattern could provide the most definitive answer to the findings reported by observational studies. The aim of this study was to compare in a randomized trial the effects of two Mediterranean diets versus a low-fat diet on depression risk after at least 3 years of intervention.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicenter, randomized, primary prevention field trial of cardiovascular disease (Prevenci&#xF3;n con Dieta Mediterr&#xE1;nea (PREDIMED Study)) based on community-dwelling men aged 55 to 80 years and women aged 60 to 80 years at high risk of cardiovascular disease (51% of them had type 2 diabetes; DM2) attending primary care centers affiliated with 11 Spanish teaching hospitals. Primary analyses were performed on an intention-to-treat basis. Cox regression models were used to assess the relationship between the nutritional intervention groups and the incidence of depression.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 224 new cases of depression during follow-up. There was an inverse association with depression for participants assigned to a Mediterranean diet supplemented with nuts (multivariate hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.55 to 1.10) compared with participants assigned to the control group, although this was not significant. However, when the analysis was restricted to participants with DM2, the magnitude of the effect of the intervention with the Mediterranean diet supplemented with nuts did reach statistical significance (multivariate HR = 0.59; 95% CI 0.36 to 0.98).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The result suggest that a Mediterranean diet supplemented with nuts could exert a beneficial effect on the risk of depression in patients with DM2.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This trial has been registered in the Current Controlled Trials with the number ISRCTN 35739639.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>S&#xE1;nchez-Villegas</LastName>
            <ForeName>Almudena</ForeName>
            <Initials>A</Initials>
            <Affiliation>Biomedical Research Center Network on Obesity and Nutrition (CIBERobn) Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain. asanchez@dcc.ulpgc.es.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mart&#xED;nez-Gonz&#xE1;lez</LastName>
            <ForeName>Miguel Angel</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Estruch</LastName>
            <ForeName>Ram&#xF3;n</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salas-Salvad&#xF3;</LastName>
            <ForeName>Jordi</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corella</LastName>
            <ForeName>Dolores</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covas</LastName>
            <ForeName>Maria Isabel</ForeName>
            <Initials>MI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ar&#xF3;s</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romaguera</LastName>
            <ForeName>Dora</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>G&#xF3;mez-Gracia</LastName>
            <ForeName>Enrique</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lapetra</LastName>
            <ForeName>Jos&#xE9;</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pint&#xF3;</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mart&#xED;nez</LastName>
            <ForeName>Jose Alfredo</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamuela-Ravent&#xF3;s</LastName>
            <ForeName>Rosa Mar&#xED;a</ForeName>
            <Initials>RM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ros</LastName>
            <ForeName>Emilio</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gea</LastName>
            <ForeName>Alfredo</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>W&#xE4;rnberg</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serra-Majem</LastName>
            <ForeName>Lluis</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ISRCTN</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>ISRCTN35739639</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Med</MedlineTA>
        <NlmUniqueID>101190723</NlmUniqueID>
        <ISSNLinking>1741-7015</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2013 Mar;97(3):505-16</RefSource>
          <PMID Version="1">23364002</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Psychosom Med. 2011 Jul-Aug;73(6):483-90</RefSource>
          <PMID Version="1">21715296</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2013 Apr;36(4):928-34</RefSource>
          <PMID Version="1">23230097</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2013 Apr 4;368(14):1279-90</RefSource>
          <PMID Version="1">23432189</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Diet Assoc. 2008 Jul;108(7):1134-44; discussion 1145</RefSource>
          <PMID Version="1">18589019</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2000 Oct 31;102(18):2284-99</RefSource>
          <PMID Version="1">11056107</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1985 Oct;42(4):639-43</RefSource>
          <PMID Version="1">2413754</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 1994 Jun 15;139(12):1197-209</RefSource>
          <PMID Version="1">8209878</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1995 Jun;61(6 Suppl):1402S-1406S</RefSource>
          <PMID Version="1">7754995</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2006 Apr 18;113(15):1888-904</RefSource>
          <PMID Version="1">16618833</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Intern Med. 2006 Jul 4;145(1):1-11</RefSource>
          <PMID Version="1">16818923</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2006 Nov;189(1):47-60</RefSource>
          <PMID Version="1">16580676</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Epidemiol. 2007 Jul;60(7):663-9</RefSource>
          <PMID Version="1">17573981</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Affect Disord. 2008 Apr;107(1-3):221-5</RefSource>
          <PMID Version="1">17727958</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2008 Nov 13;359(20):2105-20</RefSource>
          <PMID Version="1">19005195</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Appetite. 2009 Feb;52(1):238-40</RefSource>
          <PMID Version="1">18801397</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2009 May;1792(5):401-8</RefSource>
          <PMID Version="1">19130879</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):563-70</RefSource>
          <PMID Version="1">19176282</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Gen Psychiatry. 2009 Oct;66(10):1090-8</RefSource>
          <PMID Version="1">19805699</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Psychiatry. 2009 Nov;195(5):408-13</RefSource>
          <PMID Version="1">19880930</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Psychiatry. 2010 Mar;167(3):305-11</RefSource>
          <PMID Version="1">20048020</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Gen Psychiatry. 2010 Mar;67(3):220-9</RefSource>
          <PMID Version="1">20194822</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2010 Jun;210(2):630-6</RefSource>
          <PMID Version="1">20138282</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2010 Jun;103(12):1808-16</RefSource>
          <PMID Version="1">20102675</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann N Y Acad Sci. 2010 Jun;1199:1-14</RefSource>
          <PMID Version="1">20633104</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2010 Aug;64(8):832-9</RefSource>
          <PMID Version="1">20485303</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(9):e24805</RefSource>
          <PMID Version="1">21957462</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr Neurosci. 2011 Sep;14(5):195-201</RefSource>
          <PMID Version="1">22005283</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Proteome Res. 2011 Nov 4;10(11):5047-58</RefSource>
          <PMID Version="1">21905751</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 2012 Feb 1;175(3):210-7</RefSource>
          <PMID Version="1">22262640</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMC Psychiatry. 2012;12:2</RefSource>
          <PMID Version="1">22230487</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Public Health Nutr. 2012 Mar;15(3):424-32</RefSource>
          <PMID Version="1">21835082</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Public Health Nutr. 2012 Apr;15(4):673-82</RefSource>
          <PMID Version="1">22115495</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Epidemiol. 2012 Apr;41(2):377-85</RefSource>
          <PMID Version="1">21172932</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2012 May;35(5):1171-80</RefSource>
          <PMID Version="1">22517938</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2012 Jun;142(6):1019-25</RefSource>
          <PMID Version="1">22535754</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Psychosom Med. 2012 Jun;74(5):483-8</RefSource>
          <PMID Version="1">22582314</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Psychiatry. 2012 Sep;73(9):1205-11</RefSource>
          <PMID Version="1">22687702</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2012 Dec;35(12):2443-6</RefSource>
          <PMID Version="1">23033243</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2013 Jan;67(1):75-82</RefSource>
          <PMID Version="1">23212131</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hum Nutr Diet. 2013 Feb;26(1):56-70</RefSource>
          <PMID Version="1">23078460</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biol Psychiatry. 2013 Mar 1;73(5):406-13</RefSource>
          <PMID Version="1">23237315</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMC Med. 2013;11:3</RefSource>
          <PMID Version="1">23286788</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Public Health Nutr. 2010 Sep;13(9):1364-72</RefSource>
          <PMID Version="1">20105389</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>World J Biol Psychiatry. 2010 Sep;11(6):763-73</RefSource>
          <PMID Version="1">20334574</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Psychosom Med. 2010 Sep;72(7):613-9</RefSource>
          <PMID Version="1">20498292</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2011 Feb;93(2):267-74</RefSource>
          <PMID Version="1">21123460</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(1):e16268</RefSource>
          <PMID Version="1">21298116</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2011 Feb 24;364(8):719-29</RefSource>
          <PMID Version="1">21345101</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Pharm Des. 2011;17(8):769-77</RefSource>
          <PMID Version="1">21443484</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Pharmacol. 2011 Jun 11;660(1):2-12</RefSource>
          <PMID Version="1">21211525</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2011 Jun;141(6):1140-5</RefSource>
          <PMID Version="1">21508208</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Nutr. 2013 Apr;32(2):172-8</RefSource>
          <PMID Version="1">22999065</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3848350</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1741-7015-11-208</ArticleId>
        <ArticleId IdType="doi">10.1186/1741-7015-11-208</ArticleId>
        <ArticleId IdType="pubmed">24229349</ArticleId>
        <ArticleId IdType="pmc">PMC3848350</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24225358</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-3207</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>99</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of clinical nutrition</Title>
          <ISOAbbreviation>Am. J. Clin. Nutr.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III.</ArticleTitle>
        <Pagination>
          <MedlinePgn>320-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3945/ajcn.113.073148</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elevated serum phosphorus is associated with all-cause mortality, but little is known about risk associated with dietary phosphorus intake.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We investigated the association between phosphorus intake and mortality in a prospective cohort of healthy US adults (NHANES III; 1998-1994).</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">Study participants were 9686 nonpregnant adults aged 20-80 y without diabetes, cancer, or kidney or cardiovascular disease. Exposure to dietary phosphorus, which was assessed by using a 24-h dietary recall, was expressed as the absolute intake and phosphorus density (phosphorus intake divided by energy intake). All-cause and cardiovascular mortality was assessed through 31 December 2006.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median phosphorus intake was 1166 mg/d (IQR: 823-1610 mg/d); median phosphorus density was 0.58 mg/kcal (0.48-0.70 mg/kcal). Individuals who consumed more phosphorus-dense diets were older, were less often African American, and led healthier lifestyles (smoking, physical activity, and Healthy Eating Index). In analyses adjusted for demographics, cardiovascular risk factors, kidney function, and energy intake, higher phosphorus intake was associated with higher all-cause mortality in individuals who consumed &gt;1400 mg/d [adjusted HR (95% CI): 2.23 (1.09, 4.5) per 1-unit increase in ln(phosphorus intake); P = 0.03]. At &lt;1400 mg/d, there was no association. A similar association was seen between higher phosphorus density and all-cause mortality at a phosphorus density amount &gt;0.35 mg/kcal [adjusted HR (95% CI): 2.27 (1.19, 4.33) per 0.1-mg/kcal increase in phosphorus density; P = 0.01]. At &lt;0.35 mg/kcal (approximately the fifth percentile), lower phosphorus density was associated with increased mortality risk. Phosphorus density was associated with cardiovascular mortality [adjusted HR (95% CI): 3.39 (1.43, 8.02) per 0.1 mg/kcal at &gt;0.35 mg/kcal; P = 0.01], whereas no association was shown in analyses with phosphorus intake. Results were similar by subgroups of diet quality and in analyses adjusted for sodium and saturated fat intakes.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High phosphorus intake is associated with increased mortality in a healthy US population. Because of current patterns in phosphorus consumption in US adults, these findings may have important public health implications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Alex R</ForeName>
            <Initials>AR</Initials>
            <Affiliation>Division of Nephrology, Geisinger Health System, Danville, PA (ARC); the Welch Center for Prevention, Epidemiology, and Clinical Research (ARC, ML, LJA, and MEG) and Divisions of Nephrology (ARC and MEG) and General Internal Medicine (LJA), Johns Hopkins University, Baltimore, MD; and the Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL (OMG).</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lazo</LastName>
            <ForeName>Mariana</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Appel</LastName>
            <ForeName>Lawrence J</ForeName>
            <Initials>LJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guti&#xE9;rrez</LastName>
            <ForeName>Orlando M</ForeName>
            <Initials>OM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grams</LastName>
            <ForeName>Morgan E</ForeName>
            <Initials>ME</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Clin Nutr</MedlineTA>
        <NlmUniqueID>0376027</NlmUniqueID>
        <ISSNLinking>0002-9165</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ajcn.113.073148</ArticleId>
        <ArticleId IdType="doi">10.3945/ajcn.113.073148</ArticleId>
        <ArticleId IdType="pubmed">24225358</ArticleId>
        <ArticleId IdType="pmc">PMC3893724</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24220118</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>16</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0301-1526</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>42</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>VASA. Zeitschrift f&#xFC;r Gef&#xE4;sskrankheiten</Title>
          <ISOAbbreviation>VASA</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alpha-linolenic acid intake prevents endothelial dysfunction in high-fat diet-fed streptozotocin rats and underlying mechanisms.</ArticleTitle>
        <Pagination>
          <MedlinePgn>421-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1024/0301-1526/a000311</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endothelial dysfunction is an important factor in the pathogenesis of diabetes related vascular complications, and acute alpha-linolenic acid (ALA) intake can increase flow-mediated dilation of the diabetic artery at 4 h postprandially. However, whether chronic ALA supplementation may prevent endothelial dysfunction in the process of diabetes and underlying mechanisms remains largely unknown.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The high-fat diet-fed streptozotocin (HFD-STZ) rats provided an animal model for T2DM. Age-matched normal and HFD-STZ rats randomly received normal diet or ALA (500 mg/kg per day). After 5 weeks of feeding, endothelial function was determined.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Diabetes caused significant endothelial dysfunction (maximal vasorelaxation responses to ACh) in aortic segments, and ALA intake alleviated endothelial dysfunction. Superoxide production and peroxynitrite (ONOO-) formation were reduced with ALA supplement in diabetic vascular segments. Interestingly, ALA intake enhanced eNOS but inhibited iNOS activity in diabetic vessels. Moreover, ALA intake significantly increased eNOS phosphorylation. On the other hand, gp91phox and iNOS overexpression were reduced moderately with ALA intake in diabetic vessels.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We concluded that ALA prevents diabetes-induced endothelial dysfunction by enhancing eNOS activity and attenuates oxidative/nitrative stress by inhibiting iNOS and NADPH oxidase expression and ONOO- production.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Affiliation>Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi?an, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tie</LastName>
            <ForeName>Ru</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Xiangyan</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Wenjuan</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Lele</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Jinliang</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Haifeng</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Vasa</MedlineTA>
        <NlmUniqueID>0317051</NlmUniqueID>
        <ISSNLinking>0301-1526</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Membrane Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Vasodilator Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0RBV727H71</RegistryNumber>
          <NameOfSubstance>alpha-Linolenic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11062-77-4</RegistryNumber>
          <NameOfSubstance>Superoxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>14691-52-2</RegistryNumber>
          <NameOfSubstance>Peroxynitrous Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5W494URQ81</RegistryNumber>
          <NameOfSubstance>Streptozocin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance>Nitric Oxide Synthase Type II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance>Nitric Oxide Synthase Type III</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance>Nos2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance>Nos3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.-</RegistryNumber>
          <NameOfSubstance>Cybb protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.3.1</RegistryNumber>
          <NameOfSubstance>NADPH Oxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetic Angiopathies</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Dietary Supplements</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NADPH Oxidase</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nitric Oxide Synthase Type III</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Peroxynitrous Acid</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Streptozocin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Superoxides</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vasodilation</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vasodilator Agents</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">alpha-Linolenic Acid</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Language="ger" Type="Publisher">
        <AbstractText>Abstract available from the publisher.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">diabetes</Keyword>
        <Keyword MajorTopicYN="N">endothelial function</Keyword>
        <Keyword MajorTopicYN="N">peroxynitrite</Keyword>
        <Keyword MajorTopicYN="N">superoxide</Keyword>
        <Keyword MajorTopicYN="N">a-Linolenic acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">E8Q5U2NV26585473</ArticleId>
        <ArticleId IdType="doi">10.1024/0301-1526/a000311</ArticleId>
        <ArticleId IdType="pubmed">24220118</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24219891</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>08</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of clinical nutrition</Title>
          <ISOAbbreviation>Eur J Clin Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, e-selectin and C-reactive protein levels in response to 4-week very-high-fructose or -glucose diets.</ArticleTitle>
        <Pagination>
          <MedlinePgn>97-100</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/ejcn.2013.228</ELocationID>
        <Abstract>
          <AbstractText>Background/objectives:High intake of added sweeteners is considered to have a causal role in the pathogenesis of cardiometabolic disorders. Especially, high-fructose intake is regarded as potentially harmful to cardiometabolic health. It may cause not only weight gain but also low-grade inflammation, which represents an independent risk factor for developing type 2 diabetes and cardiovascular disease. In particular, fructose has been suggested to induce plasminogen activator inhibitor-1 (PAI-1) expression in the liver and to increase circulating inflammatory cytokines. We therefore aimed to investigate, whether high-fructose diet has an impact on PAI-1, monocyte chemoattractant protein-1 (MCP-1), e-selectin and C-reactive protein (CRP) concentrations in healthy humans.Subjects/methods:We studied 20 participants (12 males and 8 females) of the TUebingen FRuctose Or Glucose study. This is an exploratory, parallel, prospective, randomized, single-blinded, outpatient, hypercaloric, intervention study. The participants had a mean age of 30.9&#xB1;2.1 years and a mean body mass index of 26.0&#xB1;0.5?kg/m(2) and they received 150?g of either fructose or glucose per day for 4 weeks.Results:There were neither significant changes of PAI-1, MCP-1, e-selectin and CRP after fructose (n=10) and glucose (n=10) intervention nor treatment effects (all P&gt;0.2). Moreover, we did not observe longitudinal associations of the inflammatory parameters with triglycerides, liver fat, visceral fat and body weight in the fructose group.Conclusions:Temporary high-fructose intake does not seem to cause inflammation in apparently healthy people in this secondary analysis of a small feeding trial.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Silbernagel</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <Affiliation>1] Department of Angiology, Swiss Cardiovascular Center, Inselspital, University of Bern, Bern, Switzerland [2] Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls University, T&#xFC;bingen, Germany [3] Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the Eberhard-Karls University, Member of the German Center for Diabetes Research (DZD), T&#xFC;bingen, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Machann</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <Affiliation>Section on Experimental Radiology, Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, T&#xFC;bingen, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>H&#xE4;ring</LastName>
            <ForeName>H-U</ForeName>
            <Initials>HU</Initials>
            <Affiliation>1] Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls University, T&#xFC;bingen, Germany [2] Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the Eberhard-Karls University, Member of the German Center for Diabetes Research (DZD), T&#xFC;bingen, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fritsche</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Affiliation>1] Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls University, T&#xFC;bingen, Germany [2] Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the Eberhard-Karls University, Member of the German Center for Diabetes Research (DZD), T&#xFC;bingen, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peter</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Affiliation>1] Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls University, T&#xFC;bingen, Germany [2] Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the Eberhard-Karls University, Member of the German Center for Diabetes Research (DZD), T&#xFC;bingen, Germany.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Clin Nutr</MedlineTA>
        <NlmUniqueID>8804070</NlmUniqueID>
        <ISSNLinking>0954-3007</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ejcn2013228</ArticleId>
        <ArticleId IdType="doi">10.1038/ejcn.2013.228</ArticleId>
        <ArticleId IdType="pubmed">24219891</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24202306</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4636</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
          <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>26-33</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.113.302355</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Recent studies support a role for cholesterol in the development of obesity and nonalcoholic fatty liver disease. Mice lacking the ABCG5 ABCG8 (G5G8) sterol transporter have reduced biliary cholesterol secretion and are more susceptible to steatosis, hepatic insulin resistance, and loss of glycemic control when challenged with a high-fat diet. We hypothesized that accelerating G5G8-mediated biliary cholesterol secretion would correct these phenotypes in obese mice.</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="RESULTS">Obese (db/db) male and their lean littermates were administered a cocktail of control adenovirus or adenoviral vectors encoding ABCG5 and ABCG8 (AdG5G8). Three days after viral administration, measures of lipid and glucose homeostasis were determined, and tissues were collected for biochemical analyses. AdG5G8 increased biliary cholesterol and fecal sterol elimination. Fasting glucose and triglycerides declined, and glucose tolerance improved in obese mice expressing G5G8 compared with mice receiving control adenovirus. These changes were associated with a reduction in phosphorylated eukaryotic initiation factor 2a and c-Jun N-terminal kinase in liver, suggesting alleviation of endoplasmic reticulum stress. Phosphorylated insulin receptor and protein kinase B were increased, indicating restored hepatic insulin signaling. However, there was no reduction in hepatic triglycerides after the 3-day treatment period.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Accelerating biliary cholesterol secretion restores glycemic control and reduces plasma triglycerides in obese db/db mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <Affiliation>From the Department of Pharmaceutical Sciences, Graduate Center for Nutritional Sciences and Saha Cardiovascular Research Center, University of Kentucky, Lexington (K.S., Y.W., X.L., J.D.L., G.A.G.); Department of Neuroscience, Universidad Central del Caribe, Bayamon, Puerto Rico (N.S.S.); Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas (J.L.); and Department of Clinical Laboratories, Jinshan Branch of the Sixth People's Hospital of Shanghai, Shanghai, China (S.L.).</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabeva</LastName>
            <ForeName>Nadezhda S</ForeName>
            <Initials>NS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuhuan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaoxi</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lester</LastName>
            <ForeName>Joshua D</ForeName>
            <Initials>JD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Graf</LastName>
            <ForeName>Gregory A</ForeName>
            <Initials>GA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>8 P20GM103527-05</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01DK080874</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
        <NlmUniqueID>9505803</NlmUniqueID>
        <ISSNLinking>1079-5642</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">bile</Keyword>
        <Keyword MajorTopicYN="N">cholesterol</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">liver steatosis</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24202306</ArticleId>
        <ArticleId IdType="pii">ATVBAHA.113.302355</ArticleId>
        <ArticleId IdType="doi">10.1161/ATVBAHA.113.302355</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24196354</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>07</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hepatic adverse effects of fructose consumption independent of overweight/obesity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>21873-86</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms141121873</ELocationID>
        <Abstract>
          <AbstractText>The chronic intake of fructose has been linked to insulin resistance, obesity, dyslipidemia and nonalcoholic fatty liver disease (NAFLD), which in turn, may progress to nonalcoholic steatohepatitis (NASH). We aimed to evaluate the magnitude of the effects of the chronic consumption of high-fructose (HFr) and high fat (HF) alone or combined. Four groups of male mice were fed different diets for 16 weeks: standard chow (9% fat: SC), HF diet (42% fat), HFr diet (34% fructose) and HF/HFr diet (42% fat, 34% fructose). The food intake was not different among the groups, and the body mass was not greater in the HFr group than in the SC group. The homeostasis model assessment for insulin resistance (HOMA-IR), as well as plasmatic total cholesterol and triglycerides were greater in the groups HF, HFr, and HF/HFr group than in the SC group. We observed in the groups HF, HFr and HF/HFr, compared to the group SC, nonalcoholic fatty liver disease (NAFLD) with a predominance of lipogenesis mediated by SREBP-1c and PPAR-?, and a reduction of the oxidation mediated by PPAR-a. We also observed an increase in gluconeogenesis mediated by the GLUT-2 and the PEPCK. Importantly, we identified areas of necroinflammation indicating a transition from NAFLD to nonalcoholic steatohepatitis in the HFr and HF/HFr groups. This study is relevant in demonstrating that fructose consumption, even in the absence of obesity, causes serious and deleterious changes in the liver with the presence of the dyslipidemia, insulin resistance (IR), and NAFLD with areas of necroinflammation. These conditions are associated with a poor prognosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schultz</LastName>
            <ForeName>Alini</ForeName>
            <Initials>A</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Av. 28 de Setembro 87 fds, Rio de Janeiro 20551-030, Brazil. mandarim@uerj.br.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neil</LastName>
            <ForeName>Debora</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aguila</LastName>
            <ForeName>Marcia B</ForeName>
            <Initials>MB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandarim-de-Lacerda</LastName>
            <ForeName>Carlos A</ForeName>
            <Initials>CA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2009 Nov;139(11):2067-71</RefSource>
          <PMID Version="1">19776184</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cleve Clin J Med. 2008 Oct;75(10):721-8</RefSource>
          <PMID Version="1">18939388</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Life Sci. 2010 Jun 19;86(25-26):965-71</RefSource>
          <PMID Version="1">20470786</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2010 Sep;52(3):934-44</RefSource>
          <PMID Version="1">20607689</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutrition. 2010 Nov-Dec;26(11-12):1044-9</RefSource>
          <PMID Version="1">20471804</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2011 Jan;53(1):372-3</RefSource>
          <PMID Version="1">20814895</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Endocrinol. 2011 Mar;208(3):273-83</RefSource>
          <PMID Version="1">21212096</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FASEB J. 2011 Aug;25(8):2538-50</RefSource>
          <PMID Version="1">21507897</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Virchows Arch. 2011 Nov;459(5):477-85</RefSource>
          <PMID Version="1">21901430</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2012 Feb 2;482(7383):27-9</RefSource>
          <PMID Version="1">22297952</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Food Funct. 2012 Feb;3(2):141-9</RefSource>
          <PMID Version="1">22159273</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Biochem. 2012 Mar;23(3):203-8</RefSource>
          <PMID Version="1">22129639</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Toxicol Pathol. 2012 May;64(4):273-82</RefSource>
          <PMID Version="1">20869214</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>World J Gastroenterol. 2012 May 21;18(19):2300-8</RefSource>
          <PMID Version="1">22654421</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2012 Sep;56(3):952-60</RefSource>
          <PMID Version="1">22467259</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 2013 Jan;62(1):62-9</RefSource>
          <PMID Version="1">22854109</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2013 Jan;36(1):150-6</RefSource>
          <PMID Version="1">22933433</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2013 Mar;62(3):753-61</RefSource>
          <PMID Version="1">23223020</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Semin Liver Dis. 2008 Nov;28(4):360-9</RefSource>
          <PMID Version="1">18956292</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cell Sci. 2000 Mar;113 ( Pt 5):841-7</RefSource>
          <PMID Version="1">10671373</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2000 Jun;130(6):1531-5</RefSource>
          <PMID Version="1">10827205</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):663-78</RefSource>
          <PMID Version="1">12406438</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2003 Oct;78(4):827S-833S</RefSource>
          <PMID Version="1">14522746</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Liver Int. 2003 Oct;23(5):363-70</RefSource>
          <PMID Version="1">14708898</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 1985 Jul;28(7):412-9</RefSource>
          <PMID Version="1">3899825</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 1991 Mar 29;175(3):995-1002</RefSource>
          <PMID Version="1">2025268</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1993 Nov;123(11):1939-51</RefSource>
          <PMID Version="1">8229312</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9151-4</RefSource>
          <PMID Version="1">8090784</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Soc Trans. 1995 Aug;23(3):481-5</RefSource>
          <PMID Version="1">8566378</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Obes Relat Metab Disord. 1996 Feb;20(2):130-6</RefSource>
          <PMID Version="1">8646249</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gastroenterology. 1998 Apr;114(4):842-5</RefSource>
          <PMID Version="1">9547102</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1195-205</RefSource>
          <PMID Version="1">15644454</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112</RefSource>
          <PMID Version="1">16447287</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64</RefSource>
          <PMID Version="1">20368739</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3856040</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ijms141121873</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms141121873</ArticleId>
        <ArticleId IdType="pubmed">24196354</ArticleId>
        <ArticleId IdType="pmc">PMC3856040</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24194732</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>6</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>4</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial Stiffness.</ArticleTitle>
        <Pagination>
          <MedlinePgn>161</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Epidemiological studies support the notion that arterial stiffness is an independent predictor of adverse cardiovascular events contributing significantly to systolic hypertension, impaired ventricular-arterial coupling and diastolic dysfunction, impairment in myocardial oxygen supply and demand, and progression of kidney disease. Although arterial stiffness is associated with aging, it is accelerated in the presence of obesity and diabetes. The prevalence of arterial stiffness parallels the increase of obesity that is occurring in epidemic proportions and is partly driven by a sedentary life style and consumption of a high fructose, high salt, and high fat western diet. Although the underlying mechanisms and mediators of arterial stiffness are not well understood, accumulating evidence supports the role of insulin resistance and endothelial dysfunction. The local tissue renin-angiotensin-aldosterone system (RAAS) in the vascular tissue and immune cells and perivascular adipose tissue is recognized as an important element involved in endothelial dysfunction which contributes significantly to arterial stiffness. Activation of vascular RAAS is seen in humans and animal models of obesity and diabetes, and associated with enhanced oxidative stress and inflammation in the vascular tissue. The cross talk between angiotensin and aldosterone underscores the importance of mineralocorticoid receptors in modulation of insulin resistance, decreased bioavailability of nitric oxide, endothelial dysfunction, and arterial stiffness. In addition, both innate and adaptive immunity are involved in this local tissue activation of RAAS. In this review we will attempt to present a unifying mechanism of how environmental and immunological factors are involved in this local tissue RAAS activation, and the role of this process in the development of endothelial dysfunction and arterial stiffness and targeting tissue RAAS activation.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Aroor</LastName>
            <ForeName>Annayya R</ForeName>
            <Initials>AR</Initials>
            <Affiliation>Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Missouri Columbia School of Medicine , Columbia, MO , USA ; Harry S. Truman Memorial Veterans Hospital , Columbia, MO , USA.</Affiliation>
          </Author>
          <Author>
            <LastName>Demarco</LastName>
            <ForeName>Vincent G</ForeName>
            <Initials>VG</Initials>
          </Author>
          <Author>
            <LastName>Jia</LastName>
            <ForeName>Guanghong</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author>
            <LastName>Sun</LastName>
            <ForeName>Zhe</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author>
            <LastName>Nistala</LastName>
            <ForeName>Ravi</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Meininger</LastName>
            <ForeName>Gerald A</ForeName>
            <Initials>GA</Initials>
          </Author>
          <Author>
            <LastName>Sowers</LastName>
            <ForeName>James R</ForeName>
            <Initials>JR</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>REVIEW</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">arterial stiffness</Keyword>
        <Keyword MajorTopicYN="N">diabetes</Keyword>
        <Keyword MajorTopicYN="N">endothelial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">renin-angiotensin-aldosterone system</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.3389/fendo.2013.00161</ArticleId>
        <ArticleId IdType="pubmed">24194732</ArticleId>
        <ArticleId IdType="pmc">PMC3810594</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24176230</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>01</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0739</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition research (New York, N.Y.)</Title>
          <ISOAbbreviation>Nutr Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins.</ArticleTitle>
        <Pagination>
          <MedlinePgn>905-12</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nutres.2013.07.022</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0271-5317(13)00186-3</ELocationID>
        <Abstract>
          <AbstractText>Statins positively impact plasma low-density lipoprotein cholesterol, inflammation and vascular endothelial function (VEF). Carbohydrate restricted diets (CRD) improve atherogenic dyslipidemia, and similar to statins, have been shown to favorably affect markers of inflammation and VEF. No studies have examined whether a CRD provides additional benefit beyond that achieved by habitual statin use. We hypothesized that a CRD (&lt;50 g carbohydrate/d) for 6 weeks would improve lipid profiles and insulin sensitivity, reduce blood pressure, decrease cellular adhesion and inflammatory biomarkers, and augment VEF (flow-mediated dilation and forearm blood flow) in statin users. Participants (n = 21; 59.3 &#xB1; 9.3 y, 29.5 &#xB1; 3.0 kg/m(2)) decreased total caloric intake by approximately 415 kcal at 6 weeks (P &lt; .001). Daily nutrient intakes at baseline (46/36/17% carb/fat/pro) and averaged across the intervention (11/58/28% carb/fat/pro) demonstrated dietary compliance, with carbohydrate intake at baseline nearly 5-fold greater than during the intervention (P &lt; .001). Compared to baseline, both systolic and diastolic blood pressure decreased after 3 and 6 weeks (P &lt; .01). Peak forearm blood flow, but not flow-mediated dilation, increased at week 6 compared to baseline and week 3 (P = .03). Serum triglyceride, insulin, soluble E-Selectin and intracellular adhesion molecule-1 decreased (P &lt; .01) from baseline at week 3, and this effect was maintained at week 6. In conclusion, these findings demonstrate that individuals undergoing statin therapy experience additional improvements in metabolic and vascular health from a 6 weeks CRD as evidenced by increased insulin sensitivity and resistance vessel endothelial function, and decreased blood pressure, triglycerides, and adhesion molecules.</AbstractText>
          <CopyrightInformation>&#xA9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ballard</LastName>
            <ForeName>Kevin D</ForeName>
            <Initials>KD</Initials>
            <Affiliation>Departments of Kinesiology, University of Connecticut, Storrs, CT 06269, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quann</LastName>
            <ForeName>Erin E</ForeName>
            <Initials>EE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kupchak</LastName>
            <ForeName>Brian R</ForeName>
            <Initials>BR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volk</LastName>
            <ForeName>Brittanie M</ForeName>
            <Initials>BM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawiecki</LastName>
            <ForeName>Diana M</ForeName>
            <Initials>DM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandez</LastName>
            <ForeName>Maria Luz</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seip</LastName>
            <ForeName>Richard L</ForeName>
            <Initials>RL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maresh</LastName>
            <ForeName>Carl M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kraemer</LastName>
            <ForeName>William J</ForeName>
            <Initials>WJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volek</LastName>
            <ForeName>Jeff S</ForeName>
            <Initials>JS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nutr Res</MedlineTA>
        <NlmUniqueID>8303331</NlmUniqueID>
        <ISSNLinking>0271-5317</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">C-reactive protein</Keyword>
        <Keyword MajorTopicYN="N">CRD</Keyword>
        <Keyword MajorTopicYN="N">CRP</Keyword>
        <Keyword MajorTopicYN="N">CVD</Keyword>
        <Keyword MajorTopicYN="N">DBP</Keyword>
        <Keyword MajorTopicYN="N">FMD</Keyword>
        <Keyword MajorTopicYN="N">Flow mediated dilation</Keyword>
        <Keyword MajorTopicYN="N">HDL-C</Keyword>
        <Keyword MajorTopicYN="N">HOMA-IR</Keyword>
        <Keyword MajorTopicYN="N">Human</Keyword>
        <Keyword MajorTopicYN="N">IL</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">LDL-C</Keyword>
        <Keyword MajorTopicYN="N">Low-carbohydrate diets</Keyword>
        <Keyword MajorTopicYN="N">MCP-1</Keyword>
        <Keyword MajorTopicYN="N">R-FBF</Keyword>
        <Keyword MajorTopicYN="N">RH-FBF</Keyword>
        <Keyword MajorTopicYN="N">SBP</Keyword>
        <Keyword MajorTopicYN="N">TNF-a</Keyword>
        <Keyword MajorTopicYN="N">VEF</Keyword>
        <Keyword MajorTopicYN="N">Vascular endothelial function</Keyword>
        <Keyword MajorTopicYN="N">carbohydrate restricted diet</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">diastolic blood pressure</Keyword>
        <Keyword MajorTopicYN="N">flow mediated dilation</Keyword>
        <Keyword MajorTopicYN="N">high-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">homeostatic model of assessment-insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">interleukin</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">monocyte chemotactic protein-1</Keyword>
        <Keyword MajorTopicYN="N">reactive hyperemia forearm blood flow</Keyword>
        <Keyword MajorTopicYN="N">resting forearm blood flow</Keyword>
        <Keyword MajorTopicYN="N">sE-Selectin</Keyword>
        <Keyword MajorTopicYN="N">sICAM-1</Keyword>
        <Keyword MajorTopicYN="N">sVCAM-1</Keyword>
        <Keyword MajorTopicYN="N">soluble E-selectin</Keyword>
        <Keyword MajorTopicYN="N">soluble intracellular adhesion molecule-1</Keyword>
        <Keyword MajorTopicYN="N">soluble vascular cell adhesion molecule-1</Keyword>
        <Keyword MajorTopicYN="N">systolic blood pressure</Keyword>
        <Keyword MajorTopicYN="N">tumor necrosis factor-a</Keyword>
        <Keyword MajorTopicYN="N">vascular endothelial function</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0271-5317(13)00186-3</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nutres.2013.07.022</ArticleId>
        <ArticleId IdType="pubmed">24176230</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24172199</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>31</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1881-7122</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Experimental animals / Japanese Association for Laboratory Animal Science</Title>
          <ISOAbbreviation>Exp. Anim.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Porcine adiponectin receptor 1 transgene resists high-fat/sucrose diet-induced weight gain, hepatosteatosis and insulin resistance in mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>347-60</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Adiponectin and its receptors have been demonstrated to play important roles in regulating glucose and lipid metabolism in mice. Obesity, type II diabetes and cardiovascular disease are highly correlated with down-regulated adiponectin signaling. In this study, we generated mice overexpressing the porcine Adipor1 transgene (pAdipor1) to study its beneficial effects in metabolic syndromes as expressed in diet-induced obesity, hepatosteatosis and insulin resistance. Wild-type (WT) and pAdipor1 transgenic mice were fed ad libitum with a standard chow diet (Chow) or a high-fat/sucrose diet (HFSD) for 24 weeks, beginning at 6 to 7 weeks of age. There were 12 mice per genetic/diet/sex group. When challenged with HFSD to induce obesity, the pAdipor1 transgenic mice resisted development of weight gain, hepatosteatosis and insulin resistance. These mice had lowered plasma adiponectin, triglyceride and glycerol concentrations compared to WT mice. Moreover, we found that (indicated by mRNA levels) fatty acid oxidation was enhanced in skeletal muscle and adipose tissue, and liver lipogenesis was inhibited. The pAdipor1 transgene also restored HFSD-reduced phosphoenolpyruvate carboxykinase 1 (Pck1) and glucose transporter 4 mRNA in the adipose tissues, implying that the increased Pck1 may promote glyceroneogenesis to reduce glucose intolerance and thus activate the flux of glyceride-glycerol to resist diet-induced weight gain in the adipose tissues. Taken together, we demonstrated that pAdipor1 can prevent diet-induced weight gain and insulin resistance. Our findings may provide potential therapeutic strategies for treating metabolic syndromes and obesity, such as treatment with an ADIPOR1 agonist or activation of Adipor1 downstream targets.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Bing-Hsien</ForeName>
            <Initials>BH</Initials>
            <Affiliation>Department of Animal Science and Technology, National Taiwan University, No. 50, Ln. 155, Sec. 3, Keelung Rd., Da'an Dist., Taipei City 106, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Yuan-Yu</ForeName>
            <Initials>YY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ya-Chin</ForeName>
            <Initials>YC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Chao-Wei</ForeName>
            <Initials>CW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chih-Chien</ForeName>
            <Initials>CC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Shinn-Chih</ForeName>
            <Initials>SC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mersmann</LastName>
            <ForeName>Harry J</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Winston T K</ForeName>
            <Initials>WT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Shih-Torng</ForeName>
            <Initials>ST</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Exp Anim</MedlineTA>
        <NlmUniqueID>9604830</NlmUniqueID>
        <ISSNLinking>1341-1357</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">DN/JST.JSTAGE/expanim/62.347</ArticleId>
        <ArticleId IdType="pubmed">24172199</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24171041</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>30</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1741-427X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>2013</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
          <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Corni Fructus Containing Formulation Attenuates Weight Gain in Mice with Diet-Induced Obesity and Regulates Adipogenesis through AMPK.</ArticleTitle>
        <Pagination>
          <MedlinePgn>423741</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/423741</ELocationID>
        <Abstract>
          <AbstractText>Obesity is a metabolic disorder characterized by chronic inflammation and dyslipidemia and is a strong predictor for the development of hypertension, diabetes mellitus, and cardiovascular disease. This study examined the antiobesity effect of an ethanol extract of Corni Fructus containing formulation (CDAP), which is a combination of four natural components: Corni Fructus, Dioscoreae Rhizoma, Aurantii Fructus Immaturus, and Platycodonis Radix. The cellular lipid content in 3T3-L1 adipocytes was assessed by Oil Red O staining. Expressions of peroxisome proliferator-activated receptor- ? (PPAR- ? ), CCAAT/enhancer-binding protein- a (C/EBP- a ), and lipin-1 were determined by real-time RT-PCR. Western blot was used to determine the protein levels of PPAR- ? , C/EBP- a , and AMP-activated protein kinase- a (AMPK- a ). The CDAP extract suppressed the differentiation of 3T3-L1 adipocytes by downregulating cellular induction of PPAR- ? , C/EBP- a , and lipin-1. The CDAP extract also significantly upregulated phosphorylation of AMPK- a . An in vivo study showed that CDAP induced weight loss in mice with high-fat-diet-induced obesity. These results indicate that CDAP has a potent anti-obesity effect due to the inhibition of adipocyte differentiation and adipogenesis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Hye-Lin</ForeName>
            <Initials>HL</Initials>
            <Affiliation>College of Korean Medicine, Institute of Korean Medicine, Kyung Hee University, Hoegi-Dong, Dongdaemun-Gu, Seoul 130-701, Republic of Korea.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeon</LastName>
            <ForeName>Yong-Deok</ForeName>
            <Initials>YD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Jinbong</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rim</LastName>
            <ForeName>Hong-Kun</ForeName>
            <Initials>HK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeong</LastName>
            <ForeName>Mi-Young</ForeName>
            <Initials>MY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lim</LastName>
            <ForeName>Hara</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ko</LastName>
            <ForeName>Seong-Gyu</ForeName>
            <Initials>SG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jang</LastName>
            <ForeName>Hyeung-Jin</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Byung-Cheol</ForeName>
            <Initials>BC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kyung-Tae</ForeName>
            <Initials>KT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kang-Min</ForeName>
            <Initials>KM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Hyejung</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sung-Hoon</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Su-Jin</ForeName>
            <Initials>SJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Seung-Heon</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Um</LastName>
            <ForeName>Jae-Young</ForeName>
            <Initials>JY</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
        <NlmUniqueID>101215021</NlmUniqueID>
        <ISSNLinking>1741-427X</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3792538</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1155/2013/423741</ArticleId>
        <ArticleId IdType="pubmed">24171041</ArticleId>
        <ArticleId IdType="pmc">PMC3792538</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24170386</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>26</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>128</Volume>
            <Issue>22</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation</Title>
          <ISOAbbreviation>Circulation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2364-71</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.113.001551</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Abnormal glucose metabolism is a central feature of disorders with increased rates of cardiovascular disease. Low levels of high-density lipoprotein (HDL) are a key predictor for cardiovascular disease. We used genetic mouse models with increased HDL levels (apolipoprotein A-I transgenic [apoA-I tg]) and reduced HDL levels (apoA-I-deficient [apoA-I ko]) to investigate whether HDL modulates mitochondrial bioenergetics in skeletal muscle.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">ApoA-I ko mice exhibited fasting hyperglycemia and impaired glucose tolerance test compared with wild-type mice. Mitochondria isolated from gastrocnemius muscle of apoA-I ko mice displayed markedly blunted ATP synthesis. Endurance capacity during exercise exhaustion test was impaired in apoA-I ko mice. HDL directly enhanced glucose oxidation by increasing glycolysis and mitochondrial respiration rate in C2C12 muscle cells. ApoA-I tg mice exhibited lower fasting glucose levels, improved glucose tolerance test, increased lactate levels, reduced fat mass, associated with protection against age-induced decline of endurance capacity compared with wild-type mice. Circulating levels of fibroblast growth factor 21, a novel biomarker for mitochondrial respiratory chain deficiencies and inhibitor of white adipose lipolysis, were significantly reduced in apoA-I tg mice. Consistent with an increase in glucose utilization of skeletal muscle, genetically increased HDL and apoA-I levels in mice prevented high-fat diet-induced impairment of glucose homeostasis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In view of impaired mitochondrial function and decreased HDL levels in type 2 diabetes mellitus, our findings indicate that HDL-raising therapies may preserve muscle mitochondrial function and address key aspects of type 2 diabetes mellitus beyond cardiovascular disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lehti</LastName>
            <ForeName>Maarit</ForeName>
            <Initials>M</Initials>
            <Affiliation>Diabetes Research Department (IDO and IDR), Helmholtz Zentrum M&#xFC;nchen, German Research Center for Environmental Health, M&#xFC;nchen/Neuherberg, Germany (M.L., M.K., T.O., C.S., S.C., P.T.P., S.M.H.); Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH (M.L., E.D., W.A., O.A.-M., K.M.H., J.W., C.R., J.M., S.S., C.T., R.K., S.M.G., R.A.G.D.S., D.D., W.S.D., S.M.H.); LIKES Research Center for Sport and Health Sciences, Jyv&#xE4;skyl&#xE4;, Finland (M.L.); Energy Metabolism Laboratory ETH Zurich (Swiss Federal Institute of Technology), Zurich, Switzerland (J.M.); Department of Pharmacology and Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India (C.T.); Univ Paris Diderot, Sorbonne Paris Cit&#xE9;, Unit&#xE9; de Biologie Fonctionnelle et Adaptative, Paris, France (S.L., J.C., S.M.); Centre National de la Recherche Scientifique, Paris, France (S.L., J.C., S.M.); and Medizinische Klinik, Ludwig Maximilians University, Munich, Germany (S.M.H.).</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Donelan</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abplanalp</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Massadi</LastName>
            <ForeName>Omar</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Habegger</LastName>
            <ForeName>Kirk M</ForeName>
            <Initials>KM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>Jon</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ress</LastName>
            <ForeName>Chandler</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mansfeld</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Somvanshi</LastName>
            <ForeName>Sonal</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trivedi</LastName>
            <ForeName>Chitrang</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keuper</LastName>
            <ForeName>Michaela</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ograjsek</LastName>
            <ForeName>Teja</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Striese</LastName>
            <ForeName>Cynthia</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cucuruz</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pfluger</LastName>
            <ForeName>Paul T</ForeName>
            <Initials>PT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krishna</LastName>
            <ForeName>Radhakrishna</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>Scott M</ForeName>
            <Initials>SM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>R A Gangani D</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luquet</LastName>
            <ForeName>Serge</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castel</LastName>
            <ForeName>Julien</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinez</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Alessio</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davidson</LastName>
            <ForeName>W Sean</ForeName>
            <Initials>WS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hofmann</LastName>
            <ForeName>Susanna M</ForeName>
            <Initials>SM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2K12HD051953-06</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U24 DK059630</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circulation</MedlineTA>
        <NlmUniqueID>0147763</NlmUniqueID>
        <ISSNLinking>0009-7322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoprotein A-I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Fatty Acids, Nonesterified</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipoproteins, HDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>fibroblast growth factor 21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>62031-54-3</RegistryNumber>
          <NameOfSubstance>Fibroblast Growth Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Circulation. 2013 Nov 26;128(22):2349-50</RefSource>
          <PMID Version="1">24170387</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoprotein A-I</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cell Respiration</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Acids, Nonesterified</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose Intolerance</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hyperglycemia</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipoproteins, HDL</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mitochondria, Muscle</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Physical Endurance</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cellular respiration</Keyword>
        <Keyword MajorTopicYN="N">cholesterol, HDL</Keyword>
        <Keyword MajorTopicYN="N">exercise</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24170386</ArticleId>
        <ArticleId IdType="pii">CIRCULATIONAHA.113.001551</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001551</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24163396</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateCreated>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1741-7899</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>147</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Reproduction (Cambridge, England)</Title>
          <ISOAbbreviation>Reproduction</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of the use of assisted reproduction and high-caloric diet consumption on body weight and cardiovascular health of juvenile mouse offspring.</ArticleTitle>
        <Pagination>
          <MedlinePgn>111-23</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1530/REP-13-0354</ELocationID>
        <Abstract>
          <AbstractText>Maternal obesity and the use of assisted reproductive technologies (ART) are two suboptimal developmental environments that can lead to offspring obesity and cardiovascular disease. We hypothesized that these environments independently and synergistically adversely affect the offspring's weight and cardiovascular performance at ~7 weeks of age. Mice were fed either 24% fat and 17.5% high-fructose (HF) corn syrup or maintenance chow (5% fat; low-fat, no-fructose (LF)). Dams were subdivided into no ART and ART groups. ART embryos were cultured in Whitten's medium and transferred into pseudopregnant recipients consuming the same diet as the donor. Offspring were fed the same diet as the mother. Body weights (BW) were measured weekly and mean arterial pressure (MAP) was collected through carotid artery catheterization at killing (55&#xB1;0.5 days old). Expression of genes involved in cardiovascular remodeling was measured in thoracic aorta using qRT-PCR, and levels of reactive oxygen species (ROS) were measured intracellularly and extracellularly in mesenteric resistance arteries. ART resulted in increased BW at weaning. This effect decreased over time and diet was the predominant determinant of BW by killing. Males had greater MAP than females (P=0.002) and HF consumption was associated with greater MAP regardless of sex (P&lt;0.05). Gene expression was affected by sex (P&lt;0.05) and diet (P&lt;0.1). Lastly, the use of ART resulted in offspring with increased intracellular ROS (P=0.05). In summary, exposure to an obesogenic diet pre- and/or post-natally affects weight, MAP, and gene expression while ART increases oxidative stress in mesenteric resistance arteries of juvenile offspring, no synergistic effects were observed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schenewerk</LastName>
            <ForeName>Angela L</ForeName>
            <Initials>AL</Initials>
            <Affiliation>Division of Animal Sciences, 164 Animal Science Research Center, University of Missouri, 920 East Campus Drive, Columbia, Missouri 65211, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ram&#xED;rez</LastName>
            <ForeName>Francisco &#xCD;</ForeName>
            <Initials>F&#xCD;</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foote</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Tieming</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mart&#xED;nez-Lemus</LastName>
            <ForeName>Luis A</ForeName>
            <Initials>LA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rivera</LastName>
            <ForeName>Roc&#xED;o Melissa</ForeName>
            <Initials>RM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL088105</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL088105</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Reproduction</MedlineTA>
        <NlmUniqueID>100966036</NlmUniqueID>
        <ISSNLinking>1470-1626</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">NIHMS535217 [Available on 02/01/14]</OtherID>
      <OtherID Source="NLM">PMC3864551 [Available on 02/01/14]</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ppublish">
          <Year>2014</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">REP-13-0354</ArticleId>
        <ArticleId IdType="doi">10.1530/REP-13-0354</ArticleId>
        <ArticleId IdType="pubmed">24163396</ArticleId>
        <ArticleId IdType="pmc">PMC3864551</ArticleId>
        <ArticleId IdType="mid">NIHMS535217</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24163066</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>28</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>129</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation</Title>
          <ISOAbbreviation>Circulation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>471-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.113.003645</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inflammation and insulin resistance (IR) are associated processes that potentiate risk for cardiovascular disease in obesity. The temporal relation between IR and inflammation is not completely characterized. We hypothesized that endothelial cell adhesion molecule expression in large arteries is an early event that coincides with diet-induced obesity and IR in primates.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Ten adult male rhesus macaques were studied at baseline and every 4 to 6 months on a high-fat diet for 2 years. Truncal fat, carotid intima-media thickness, plasma inflammatory biomarkers, and carotid P-selectin and vascular cell adhesion molecule-1 expression by contrast-enhanced ultrasound molecular imaging were assessed. Intravenous glucose tolerance test was performed at baseline and at 4 and 18 months. A high-fat diet produced a rapid increase (P&lt;0.01) in weight, truncal fat, and degree of IR indicated by the insulin area under the curve and glucose disappearance rate on intravenous glucose tolerance test, all of which worsened minimally thereafter. Molecular imaging detected a progressive increase in endothelial cell adhesion molecule expression over time (5- to 7-fold greater than control agent signal at 2 years; P&lt;0.01). Changes in intima-media thickness were not detected until 2 years and, although there was a trend toward an increase in plasma markers of inflammation (monocyte chemotactic protein-1, C-reactive protein), the pattern of increase varied considerably over time.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In primates with diet-induced obesity, endothelial inflammatory activation is an early event that occurs coincident with the development of IR and long before any measurable change in carotid intima-media thickness. Endothelial activation is related more to the duration rather than to the severity of IR and is not mirrored by changes in plasma biomarkers.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chadderdon</LastName>
            <ForeName>Scott M</ForeName>
            <Initials>SM</Initials>
            <Affiliation>From Knight Cardiovascular Institute, Oregon Health and Science University (S.M.C., J.T.B., D.M.P., J.R.L.), and Oregon National Primate Research Center (L.B., M.A.K., P.K., K.L.G.), Portland, OR.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Belcik</LastName>
            <ForeName>J Todd</ForeName>
            <Initials>JT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bader</LastName>
            <ForeName>Lindsay</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirigiti</LastName>
            <ForeName>Melissa A</ForeName>
            <Initials>MA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peters</LastName>
            <ForeName>Dawn M</ForeName>
            <Initials>DM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kievit</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grove</LastName>
            <ForeName>Kevin L</ForeName>
            <Initials>KL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lindner</LastName>
            <ForeName>Jonathan R</ForeName>
            <Initials>JR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK063508</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL078610</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RC1 HL100659</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circulation</MedlineTA>
        <NlmUniqueID>0147763</NlmUniqueID>
        <ISSNLinking>0009-7322</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">endothelium</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">molecular imaging</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24163066</ArticleId>
        <ArticleId IdType="pii">CIRCULATIONAHA.113.003645</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.003645</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24148349</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1555</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Endocrinology and metabolism</Title>
          <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction.</ArticleTitle>
        <Pagination>
          <MedlinePgn>E1444-51</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpendo.00434.2013</ELocationID>
        <Abstract>
          <AbstractText>Insulin resistance, a hallmark of metabolic disorders, is a risk factor for diabetes and cardiovascular disease. Impairment of insulin responsiveness in vascular endothelium contributes to insulin resistance. The reciprocal relationship between insulin resistance and endothelial dysfunction augments the pathophysiology of metabolism and cardiovascular functions. The most abundant green tea polyphenol, epigallocatechin-3-gallate (EGCG), has been shown to have vasodilator action in vessels by activation of endothelial nitric oxide synthase (eNOS). However, it is not known whether EGCG has a beneficial effect in high-fat diet (HFD)-induced endothelial dysfunction. Male C57BL/6J mice were fed either a normal chow diet (NCD) or HFD with or without EGCG supplement (50 mg&#xB7;kg(-1)&#xB7;day(-1)) for 10 wk. Mice fed a HFD with EGCG supplement gained less body weight and showed improved insulin sensitivity. In vehicle-treated HFD mice, endothelial function was impaired in response to insulin but not to acetylcholine, whereas the EGCG-treated HFD group showed improved insulin-stimulated vasodilation. Interestingly, EGCG intake reduced macrophage infiltration into aortic tissues in HFD mice. Treatment with EGCG restored the insulin-stimulated phosphorylation of eNOS, insulin receptor substrate-1 (IRS-1), and protein kinase B (Akt), which was inhibited by palmitate (200 &#xB5;M, 5 h) in primary bovine aortic endothelial cells. From these results, we conclude that supplementation of EGCG improves glucose tolerance, insulin sensitivity, and endothelial function. The results suggest that EGCG may have beneficial health effects in glucose metabolism and endothelial function through modulating HFD-induced inflammatory response.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jang</LastName>
            <ForeName>Hyun-Ju</ForeName>
            <Initials>HJ</Initials>
            <Affiliation>Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama;</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ridgeway</LastName>
            <ForeName>Simone D</ForeName>
            <Initials>SD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jeong-A</ForeName>
            <Initials>JA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
        <NlmUniqueID>100901226</NlmUniqueID>
        <ISSNLinking>0193-1849</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">PMC3882381 [Available on 12/15/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">endothelial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">epigallocatechin-3-gallate</Keyword>
        <Keyword MajorTopicYN="N">green tea</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">vasodilation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24148349</ArticleId>
        <ArticleId IdType="pii">ajpendo.00434.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpendo.00434.2013</ArticleId>
        <ArticleId IdType="pmc">PMC3882381</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24148164</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>23</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">0038-2469</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>103</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</Title>
          <ISOAbbreviation>S. Afr. Med. J.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Women's Health Initiative Randomized Controlled Dietary Modification Trial: an inconvenient finding and the diet-heart hypothesis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>824-5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7196/samj.7343</ELocationID>
        <Abstract>
          <AbstractText>One goal of the US$700 million Women's Health Initiative Randomized Controlled Dietary Modification Trial was to determine whether post-menopausal women who adopted what was regarded as a 'heart healthy' low-fat diet, high in vegetables, fruits and grains, reduced their risk of developing cardiovascular disease. The trial substantially favoured the outcome in the intervention group, who also received an intensive nutritional and behaviour education programme not offered to the control group. These studies neatly disprove the diet-heart hypothesis since adoption of 'heart healthy' eating not only failed to influence future cardiac events in the healthy but it increased such events in the unhealthy and worsened diabetic control in those with type 2 diabetes mellitus.&#xA0;</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Noakes</LastName>
            <ForeName>Timothy David</ForeName>
            <Initials>TD</Initials>
            <Affiliation>UCT/MRC Research Unit for Exercise and Sports Science in the Department of Human Biology, University of Cape Town and the Sports Science Institute of South Africa, Cape Town, South Africa. noakes@iafrica.com.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>South Africa</Country>
        <MedlineTA>S Afr Med J</MedlineTA>
        <NlmUniqueID>0404520</NlmUniqueID>
        <ISSNLinking>0038-2469</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>03</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24148164</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24140661</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-3597</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American College of Cardiology</Title>
          <ISOAbbreviation>J. Am. Coll. Cardiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients with Suspected Cardiac Sarcoidosis.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0735-1097(13)05455-7</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.jacc.2013.09.022</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We sought to relate imaging findings on PET to adverse cardiac events in patients referred for evaluation of known or suspected cardiac sarcoidosis (CS).</AbstractText>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although cardiac positron emission tomography (PET) is commonly used to evaluate patients with suspected CS, the relationship between PET findings and clinical outcomes has not been reported.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We studied 118 consecutive patients with no history of CAD who were referred for PET using (18)F-fluorodeoxyglucose (FDG) [to assess for inflammation] and (82)Rubidium [to evaluate for perfusion defects (PD)] following a high fat / low carbohydrate diet to suppress normal myocardial glucose uptake. Blind reads of the PET data categorized cardiac findings as (a) normal; (b) positive PD or FDG; (c) positive PD and FDG. Images were also used to identify if findings for extra cardiac sarcoidosis were present. Adverse events (AE) -- death or sustained ventricular tachycardia (VT) -- were ascertained by electronic medical records, defibrillator interrogation, patient questionnaires and phone interviews.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 118 patients (age 52&#xB1;11; males 57%, mean ejection fraction 47%&#xB1;16%), 47 (40%) had normal and 71 (60%) abnormal cardiac PET findings. Over a median follow-up of 1.5 years, there were 31 (26%) adverse events (27 VT and 8 deaths). Cardiac PET findings were predictive of AE with the presence of both a PD and abnormal FDG (29% of patients) being associated with hazard ratio of 3.9 (p&lt;0.01) and remaining significant after adjusting for left ventricular ejection fraction (LVEF) and clinical criteria. Extra-cardiac FDG uptake (26% of patients) was not associated with AE.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presence of focal PD and FDG uptake on cardiac PET identifies patients at higher risk of death or VT. These findings offer prognostic value beyond Japanese clinical criteria, the presence of extra cardiac sarcoidosis and LVEF.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Blankstein</LastName>
            <ForeName>Ron</ForeName>
            <Initials>R</Initials>
            <Affiliation>Non-Invasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: rblankstein@partners.org.</Affiliation>
          </Author>
          <Author>
            <LastName>Osborne</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author>
            <LastName>Naya</LastName>
            <ForeName>Masanao</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author>
            <LastName>Waller</LastName>
            <ForeName>Alfonso</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author>
            <LastName>Kim</LastName>
            <ForeName>Chun K</ForeName>
            <Initials>CK</Initials>
          </Author>
          <Author>
            <LastName>Murthy</LastName>
            <ForeName>Venkatesh L</ForeName>
            <Initials>VL</Initials>
          </Author>
          <Author>
            <LastName>Kazemian</LastName>
            <ForeName>Pedram</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author>
            <LastName>Kwong</LastName>
            <ForeName>Raymond Y</ForeName>
            <Initials>RY</Initials>
          </Author>
          <Author>
            <LastName>Tokuda</LastName>
            <ForeName>Michifumi</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author>
            <LastName>Skali</LastName>
            <ForeName>Hicham</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author>
            <LastName>Padera</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Hainer</LastName>
            <ForeName>Jon</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Stevenson</LastName>
            <ForeName>William G</ForeName>
            <Initials>WG</Initials>
          </Author>
          <Author>
            <LastName>Dorbala</LastName>
            <ForeName>Sharmila</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Di Carli</LastName>
            <ForeName>Marcelo F</ForeName>
            <Initials>MF</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <GrantList>
          <Grant>
            <GrantID>R01 HL091157</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Am Coll Cardiol</MedlineTA>
        <NlmUniqueID>8301365</NlmUniqueID>
        <ISSNLinking>0735-1097</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CAD</Keyword>
        <Keyword MajorTopicYN="N">CMR</Keyword>
        <Keyword MajorTopicYN="N">CS</Keyword>
        <Keyword MajorTopicYN="N">CT</Keyword>
        <Keyword MajorTopicYN="N">EMBx</Keyword>
        <Keyword MajorTopicYN="N">FDG</Keyword>
        <Keyword MajorTopicYN="N">ICD</Keyword>
        <Keyword MajorTopicYN="N">LVEF</Keyword>
        <Keyword MajorTopicYN="N">PET</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
        <Keyword MajorTopicYN="N">Sarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">VT</Keyword>
        <Keyword MajorTopicYN="N">cardiac magnetic resonance imaging</Keyword>
        <Keyword MajorTopicYN="N">cardiac sarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">computed tomography</Keyword>
        <Keyword MajorTopicYN="N">coronary artery disease</Keyword>
        <Keyword MajorTopicYN="N">endomyocardial biopsy</Keyword>
        <Keyword MajorTopicYN="N">fluorodeoxyglucose</Keyword>
        <Keyword MajorTopicYN="N">implantable cardiac defibrillator</Keyword>
        <Keyword MajorTopicYN="N">left ventricular ejection fraction</Keyword>
        <Keyword MajorTopicYN="N">positron emission tomography</Keyword>
        <Keyword MajorTopicYN="N">ventricular tachycardia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0735-1097(13)05455-7</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jacc.2013.09.022</ArticleId>
        <ArticleId IdType="pubmed">24140661</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24139973</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2212-2672</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the Academy of Nutrition and Dietetics</Title>
          <ISOAbbreviation>J Acad Nutr Diet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1640-61</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jand.2013.07.010</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2212-2672(13)01128-3</ELocationID>
        <Abstract>
          <AbstractText>Dietary fat plays an important role in the primary prevention of cardiovascular disease, but long-term (=12 months) effects of different percentages of fat in the diet on blood lipid levels remain to be established. Our systematic review and meta-analysis focused on randomized controlled trials assessing the long-term effects of low-fat diets compared with diets with high amounts of fat on blood lipid levels. Relevant randomized controlled trials were identified searching MEDLINE, EMBASE, and the Cochrane Trial Register until March 2013. Thirty-two studies were included in the meta-analysis. Decreases in total cholesterol (weighted mean difference -4.55 mg/dL [-0.12 mmol/L], 95% CI -8.03 to -1.07; P=0.01) and low-density lipoprotein (LDL) cholesterol (weighted mean difference -3.11 mg/dL [-0.08 mmol/L], 95% CI -4.51 to -1.71; P&lt;0.0001) were significantly more pronounced following low-fat diets, whereas rise in high-density lipoprotein (HDL) cholesterol (weighted mean difference 2.35 mg/dL [0.06 mmol/L], 95% CI 1.29 to 3.42; P&lt;0.0001) and reduction in triglyceride levels (weighted mean difference -8.38 mg/dL [-0.095 mmol/L], 95% CI -13.50 to -3.25; P=0.001) were more distinct in the high-fat diet groups. Including only hypocaloric diets, the effects of low-fat vs high-fat diets on total cholesterol and LDL cholesterol levels were abolished. Meta-regression revealed that lower total cholesterol level was associated with lower intakes of saturated fat and higher intakes of polyunsaturated fat, and increases in HDL cholesterol levels were related to higher amounts of total fat largely derived from monounsaturated fat (of either plant or animal origin) in high-fat diets (composition of which was ~17% of total energy content in the form of monounsaturated fatty acids, ~8% of total energy content in the form of polyunsaturated fatty acids), whereas increases in triglyceride levels were associated with higher intakes of carbohydrates. In addition, lower LDL cholesterol level was marginally associated with lower saturated fat intake. The results of our meta-analysis do not allow for an unequivocal recommendation of either low-fat or high-fat diets in the primary prevention of cardiovascular disease.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Academy of Nutrition and Dietetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schwingshackl</LastName>
            <ForeName>Lukas</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffmann</LastName>
            <ForeName>Georg</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Comparative Study</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Meta-Analysis</PublicationType>
          <PublicationType>Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Acad Nutr Diet</MedlineTA>
        <NlmUniqueID>101573920</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Cholesterol, HDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Dietary Carbohydrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Fatty Acids, Unsaturated</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Triglycerides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>97C5T2UQ7J</RegistryNumber>
          <NameOfSubstance>Cholesterol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cholesterol</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cholesterol, HDL</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, Fat-Restricted</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Carbohydrates</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Energy Intake</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Acids, Unsaturated</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">MEDLINE</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Overweight</DescriptorName>
          <QualifierName MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Triglycerides</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Blood lipids</Keyword>
        <Keyword MajorTopicYN="N">Low carbohydrate</Keyword>
        <Keyword MajorTopicYN="N">Low fat</Keyword>
        <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">Systematic review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24139973</ArticleId>
        <ArticleId IdType="pii">S2212-2672(13)01128-3</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jand.2013.07.010</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24124374</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1178-2048</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Vascular health and risk management</Title>
          <ISOAbbreviation>Vasc Health Risk Manag</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.</ArticleTitle>
        <Pagination>
          <MedlinePgn>563-73</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/VHRM.S50464</ELocationID>
        <Abstract>
          <AbstractText>The systemic bioavailability of free fatty acid (FFA) forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared with ethyl ester (EE) forms is dependent on the presence of intestinal lipases and is highest during consumption of high-fat meals. Given that patients with cardiovascular disease are advised to reduce dietary fat intake, potentially lowering the bioavailability and therapeutic benefit, the hypothesis that FFA forms provide for higher bioavailability compared with EE forms under low-fat diet conditions was tested where the pharmacokinetics of the FFA form (Epanova&#x2122;) were compared with those of an ethyl ester form (Lovaza&#xAE;) following repeat dosing. Fifty-two healthy male and female subjects were equally allocated to one of two open-label, parallel-group cohorts. Following a Therapeutic Lifestyle Changes diet for a minimum of 7 days, blood samples were drawn for endogenous values for EPA and DHA over a 24-hour period. Subjects were then administered 4 &#xD7; 1 g capsules of either Epanova (OM3 FFA) or Lovaza (OM3 EE) once daily for 14 days, following which serial blood samples were drawn over a 24-hour period to characterize the bioavailability of EPA and DHA from the respective formulations. In addition, changes from baseline in lipid profile were explored. Systemic bioavailability, as measured by area under the curve from time zero to 24 hours (AUC(0-t)) and the maximum measured plasma concentrations during the 0-24 hour dosing interval (C(max,ss)) of unadjusted total plasma EPA + DHA were approximately 3-fold and 3.9-fold higher, respectively, for Epanova relative to Lovaza. Following baseline adjustment, the magnitude of difference in bioavailability was approximately 5.8-fold and 6.5-fold higher in AUC(0-t) and C(max,ss), respectively, for Epanova relative to Lovaza. Serum triglycerides were reduced by a significantly greater extent (P = 0.013) for Epanova relative to Lovaza (21% versus 8%). The bioavailability of the FFA forms of EPA and DHA in Epanova are significantly greater than the bioavailability from the EE forms present in Lovaza under low-fat dietary conditions normally recommended for patients with cardiovascular disease. This increased bioavailability may lead to improved triglyceride-lowering in patients with hypertriglyceridemia.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Offman</LastName>
            <ForeName>Elliot</ForeName>
            <Initials>E</Initials>
            <Affiliation>Clinical Pharmacology Sciences, Celerion, Montreal, QC, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marenco</LastName>
            <ForeName>Ted</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferber</LastName>
            <ForeName>Sandy</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Judith</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kling</LastName>
            <ForeName>Douglas</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curcio</LastName>
            <ForeName>Danielle</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davidson</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Vasc Health Risk Manag</MedlineTA>
        <NlmUniqueID>101273479</NlmUniqueID>
        <ISSNLinking>1176-6344</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1999 Dec 10;274(50):35840-4</RefSource>
          <PMID Version="1">10585468</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Ther. 2013 Sep;35(9):1400-11.e1-3</RefSource>
          <PMID Version="1">23998969</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 1998 Feb;33(2):131-8</RefSource>
          <PMID Version="1">9507234</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Cardiol. 2006 Aug 21;98(4A):27i-33i</RefSource>
          <PMID Version="1">16919514</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2007 Mar 31;369(9567):1090-8</RefSource>
          <PMID Version="1">17398308</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr Clin Pract. 2007 Dec;22(6):664-72</RefSource>
          <PMID Version="1">18042955</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Cardiol. 2011 Mar 15;107(6):891-7</RefSource>
          <PMID Version="1">21247544</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur Heart J. 2011 Jul;32(14):1769-818</RefSource>
          <PMID Version="1">21712404</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS Genet. 2011 Jul;7(7):e1002193</RefSource>
          <PMID Version="1">21829377</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Clin Nutr. 2012 May;66(5):600-5</RefSource>
          <PMID Version="1">22215136</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Lipidol. 2012 Nov-Dec;6(6):573-84</RefSource>
          <PMID Version="1">23312053</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 1995 Dec 7;1259(3):297-304</RefSource>
          <PMID Version="1">8541338</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Annu Rev Nutr. 1991;11:413-34</RefSource>
          <PMID Version="1">1892708</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arzneimittelforschung. 1990 Jun;40(6):700-4</RefSource>
          <PMID Version="1">2144420</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 1988 Oct 31;156(2):960-3</RefSource>
          <PMID Version="1">2847723</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 1988 Apr 15;152(1):328-35</RefSource>
          <PMID Version="1">3358766</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 1987 Oct;22(10):711-4</RefSource>
          <PMID Version="1">2828810</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2003 Feb;77(2):300-7</RefSource>
          <PMID Version="1">12540386</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Dec 17;106(25):3143-421</RefSource>
          <PMID Version="1">12485966</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3794864</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">docosahexaenoic acid</Keyword>
        <Keyword MajorTopicYN="N">eicosapentaenoic acid</Keyword>
        <Keyword MajorTopicYN="N">hypertriglyceridemia</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>01</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.2147/VHRM.S50464</ArticleId>
        <ArticleId IdType="pii">vhrm-9-563</ArticleId>
        <ArticleId IdType="pubmed">24124374</ArticleId>
        <ArticleId IdType="pmc">PMC3794864</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24123166</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-3350</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interferon regulatory factor 3 constrains IKK&#xDF;/NF-?B signaling to alleviate hepatic steatosis and insulin resistance.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="doi">10.1002/hep.26751</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Obesity and related metabolic diseases associated with chronic low-grade inflammation greatly compromise human health. Our previous observations on the roles of interferon regulatory factors (IRFs) in the regulation of metabolism prompted us to investigate the involvement of a key family member, IRF3, in metabolic disorders. Here we demonstrate that IRF3 expression in the liver is decreased in subjects with diet-induced and genetic obesity. The global knockout (KO) of IRF3 significantly promotes chronic high-fat diet (HFD)-induced hepatic insulin resistance and steatosis; in contrast, adenoviral-mediated hepatic IRF3 overexpression preserves glucose and lipid homeostasis. Furthermore, systemic and hepatic inflammation, which is increased in IRF3 KO mice, is attenuated by the overexpression of hepatic IRF3. Importantly, inhibitor of nuclear factor kappa B kinase beta subunit / nuclear factor kappa B (IKK&#xDF;/NF-?B) signaling is repressed by IRF3, and hepatic overexpression of the inhibitor of ?B-a (I?Ba) reverses HFD-induced insulin resistance and steatosis in IRF3 KO mice. Mechanistically, IRF3 interacts with the kinase domain of IKK&#xDF; in the cytoplasm and inhibits its downstream signaling. Moreover, deletion of the region of IRF3 responsible for the IRF3/IKK&#xDF; interaction inhibits the capacity of IRF3 to preserve glucose and lipid homeostasis. Conclusion: IRF3 interacts with IKK&#xDF; in the cytoplasm to inhibit IKK&#xDF;/NF-?B signaling, thus alleviating hepatic inflammation, insulin resistance, and hepatic steatosis. (Hepatology 2013).</AbstractText>
          <CopyrightInformation>&#xA9; 2013 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Xin-An</ForeName>
            <Initials>XA</Initials>
            <Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, P.R. China; Cardiovascular Research Institute, Wuhan University, Wuhan, P.R. China.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>She</LastName>
            <ForeName>Zhi-Gang</ForeName>
            <Initials>ZG</Initials>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Xiao-Fei</ForeName>
            <Initials>XF</Initials>
          </Author>
          <Author>
            <LastName>Jiang</LastName>
            <ForeName>Ding-Sheng</ForeName>
            <Initials>DS</Initials>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author>
            <LastName>Gao</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author>
            <LastName>Deng</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Shu-Min</ForeName>
            <Initials>SM</Initials>
          </Author>
          <Author>
            <LastName>Zhu</LastName>
            <ForeName>Li-Hua</ForeName>
            <Initials>LH</Initials>
          </Author>
          <Author>
            <LastName>Guo</LastName>
            <ForeName>Sen</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Chen</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author>
            <LastName>Zhang</LastName>
            <ForeName>Xiao-Dong</ForeName>
            <Initials>XD</Initials>
          </Author>
          <Author>
            <LastName>Liu</LastName>
            <ForeName>De-Pei</ForeName>
            <Initials>DP</Initials>
          </Author>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Hongliang</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">diabetes</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/hep.26751</ArticleId>
        <ArticleId IdType="pubmed">24123166</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24117264</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1205-7541</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Canadian journal of physiology and pharmacology</Title>
          <ISOAbbreviation>Can. J. Physiol. Pharmacol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The effects of fish oil consumption on cardiovascular remodeling in ApoE deficient mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>960-5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1139/cjpp-2013-0077</ELocationID>
        <Abstract>
          <AbstractText>Owing to their spontaneous development of atherosclerosis, apolipoprotein E knockout mice (ApoE(KO)) are one of the best studied animal models for this disease. Little is known about the utility of various omega-3 fatty acid regimens, in particular fish oils, in preventing cardiac disease in ApoE(KO) mice. The purpose of this study was to determine the cardiovascular effects of omega-3 fatty acid supplementation with either safflower oil (control), fish oil, flaxseed oil, or designed oil in ApoE(KO) mice fed a high-fat diet for a total of 16 weeks. In-vivo cardiac function was assessed weekly using murine echocardiography. Blood pressure, plasma lipid levels, and brain natriuretic peptide (BNP) were serially measured. The results show that ApoE(KO) mice fed fish oil demonstrated an increase in left ventricular wall thickness as a result of increased afterload. Despite chronic treatment with fish oil over 16 weeks, blood pressure increased in ApoE(KO) mice by 20% compared with the baseline. Both echocardiographic evidence of left ventricular hypertrophy and biochemical increase in BNP levels confirmed diastolic dysfunction in ApoE(KO) mice fed fish oil. This suggests that high-fat diet supplemented with fish oil may lead to adverse cardiovascular effects in ApoE deficient mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cleverley</LastName>
            <ForeName>Kelby</ForeName>
            <Initials>K</Initials>
            <Affiliation>a Institute of Cardiovascular Sciences, St. Boniface Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Xiaozhou</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Premecz</LastName>
            <ForeName>Sheena</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Khuong</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeglinski</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicholson</LastName>
            <ForeName>Tiffany</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goh</LastName>
            <ForeName>Chun Y</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Hope D</ForeName>
            <Initials>HD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moghadasian</LastName>
            <ForeName>Mohammed H</ForeName>
            <Initials>MH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jassal</LastName>
            <ForeName>Davinder S</ForeName>
            <Initials>DS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Canada</Country>
        <MedlineTA>Can J Physiol Pharmacol</MedlineTA>
        <NlmUniqueID>0372712</NlmUniqueID>
        <ISSNLinking>0008-4212</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1139/cjpp-2013-0077</ArticleId>
        <ArticleId IdType="pubmed">24117264</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24116221</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rapid inhibition of pyruvate dehydrogenase: an initiating event in high dietary fat-induced loss of metabolic flexibility in the heart.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e77280</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0077280</ELocationID>
        <Abstract>
          <AbstractText>Cardiac function depends on the ability to switch between fatty acid and glucose oxidation for energy production in response to changes in substrate availability and energetic stress. In obese and diabetic individuals, increased reliance on fatty acids and reduced metabolic flexibility are thought to contribute to the development of cardiovascular disease. Mechanisms by which cardiac mitochondria contribute to diet-induced metabolic inflexibility were investigated. Mice were fed a high fat or low fat diet for 1 d, 1 wk, and 20 wk. Cardiac mitochondria isolated from mice fed a high fat diet displayed a diminished ability to utilize the glycolytically derived substrate pyruvate. This response was rapid, occurring within the first day on the diet, and persisted for up to 20 wk. A selective increase in the expression of pyruvate dehydrogenase kinase 4 and inhibition of pyruvate dehydrogenase are responsible for the rapid suppression of pyruvate utilization. An important consequence is that pyruvate dehydrogenase is sensitized to inhibition when mitochondria respire in the presence of fatty acids. Additionally, increased expression of pyruvate dehydrogenase kinase 4 preceded any observed diet-induced reductions in the levels of glucose transporter type 4 and glycolytic enzymes and, as judged by Akt phosphorylation, insulin signaling. Importantly, diminished insulin signaling evident at 1 wk on the high fat diet did not occur in pyruvate dehydrogenase kinase 4 knockout mice. Dietary intervention leads to a rapid decline in pyruvate dehydrogenase kinase 4 levels and recovery of pyruvate dehydrogenase activity indicating an additional form of regulation. Finally, an overnight fast elicits a metabolic response similar to that induced by high dietary fat obscuring diet-induced metabolic changes. Thus, our data indicate that diet-induced inhibition of pyruvate dehydrogenase may be an initiating event in decreased oxidation of glucose and increased reliance of the heart on fatty acids for energy production.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Crewe</LastName>
            <ForeName>Clair</ForeName>
            <Initials>C</Initials>
            <Affiliation>Free Radical Biology and Aging Research Program Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America ; Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kinter</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szweda</LastName>
            <ForeName>Luke I</ForeName>
            <Initials>LI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01AG016339</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H936-43</RefSource>
          <PMID Version="1">18083902</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FEBS Lett. 2012 Apr 5;586(7):996-1003</RefSource>
          <PMID Version="1">22569253</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2009 May 1;82(2):351-60</RefSource>
          <PMID Version="1">19147655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 2009 Jun 15;389(2):157-64</RefSource>
          <PMID Version="1">19341700</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2009 Aug;58(8):1766-75</RefSource>
          <PMID Version="1">19478144</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E578-91</RefSource>
          <PMID Version="1">19531645</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2009 Oct 15;423(2):243-52</RefSource>
          <PMID Version="1">19627255</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2010 Jan;90(1):207-58</RefSource>
          <PMID Version="1">20086077</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(11):e50016</RefSource>
          <PMID Version="1">23166812</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2013 Jan 18;288(3):1979-90</RefSource>
          <PMID Version="1">23204527</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Acta Physiol Scand. 2000 Apr;168(4):657-65</RefSource>
          <PMID Version="1">10759602</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2000 May;49(5):775-81</RefSource>
          <PMID Version="1">10905486</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2001 Sep 21;287(2):391-6</RefSource>
          <PMID Version="1">11554740</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2001 Dec;50(12):2809-14</RefSource>
          <PMID Version="1">11723064</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2002 Jun 15;364(Pt 3):687-94</RefSource>
          <PMID Version="1">12049632</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2002 Aug 1;347(5):305-13</RefSource>
          <PMID Version="1">12151467</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2002 Nov 22;277(47):44784-90</RefSource>
          <PMID Version="1">12237311</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 1983 May;67(5):968-77</RefSource>
          <PMID Version="1">6219830</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1991 Dec;261(6 Pt 2):H1756-62</RefSource>
          <PMID Version="1">1750532</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FEBS Lett. 1993 Dec 28;336(3):501-5</RefSource>
          <PMID Version="1">8282119</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 1998 Jan 1;329 ( Pt 1):191-6</RefSource>
          <PMID Version="1">9405293</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 1998 Jan 1;329 ( Pt 1):197-201</RefSource>
          <PMID Version="1">9405294</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Metab Rev. 1998 Dec;14(4):263-83</RefSource>
          <PMID Version="1">10095997</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 1963 Apr 13;1(7285):785-9</RefSource>
          <PMID Version="1">13990765</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2005 Jul;85(3):1093-129</RefSource>
          <PMID Version="1">15987803</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2005 Dec;54(12):3530-40</RefSource>
          <PMID Version="1">16306372</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Biol. 2005 Dec;25(24):10684-94</RefSource>
          <PMID Version="1">16314495</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Soc Trans. 2006 Apr;34(Pt 2):217-22</RefSource>
          <PMID Version="1">16545080</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2006 Aug 1;397(3):417-25</RefSource>
          <PMID Version="1">16606348</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Physiol Biochem. 2006 Jul;112(3):139-49</RefSource>
          <PMID Version="1">17132539</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2007 Sep 15;406(3):457-67</RefSource>
          <PMID Version="1">17550347</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2010 Feb 19;285(8):5748-58</RefSource>
          <PMID Version="1">20032466</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2009 Mar;119(3):573-81</RefSource>
          <PMID Version="1">19188683</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2011 Apr 1;286(13):11155-62</RefSource>
          <PMID Version="1">21321124</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2011 May 1;90(2):210-9</RefSource>
          <PMID Version="1">21398307</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(11):e27401</RefSource>
          <PMID Version="1">22102892</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Endocrinol Metab. 2012 Mar;23(3):142-53</RefSource>
          <PMID Version="1">22305519</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2012 May 1;94(2):359-69</RefSource>
          <PMID Version="1">22436846</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2012 May 2;15(5):595-605</RefSource>
          <PMID Version="1">22560212</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2008 Apr;88(2):389-419</RefSource>
          <PMID Version="1">18391168</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3792029</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0077280</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-20818</ArticleId>
        <ArticleId IdType="pubmed">24116221</ArticleId>
        <ArticleId IdType="pmc">PMC3792029</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24107491</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>22</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1942-0080</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Circulation. Cardiovascular imaging</Title>
          <ISOAbbreviation>Circ Cardiovasc Imaging</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Positron emission tomography/computed tomographic and magnetic resonance imaging in a murine model of progressive atherosclerosis using (64)Cu-labeled glycoprotein VI-Fc.</ArticleTitle>
        <Pagination>
          <MedlinePgn>957-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCIMAGING.113.000488</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Plaque erosion leads to exposure of subendothelial collagen, which may be targeted by glycoprotein VI (GPVI). We aimed to detect plaque erosion using (64)Cu-labeled GPVI-Fc (fragment crystallized).</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Four-week-old male apolipoprotein E-deficient (ApoE(-/-)) mice (n=6) were fed a high-fat diet for 12 weeks. C57BL/6J wild-type (WT) mice served as controls (n=6). Another group of WT mice received a ligation injury of the left carotid artery (n=6) or sham procedure (n=4). All mice received a total activity of &#x2DC;12 MBq (64)Cu-GPVI-Fc by tail vein injection followed by delayed (24 hours) positron emission tomography using a NanoPET/computed tomographic scanner (Mediso, Hungary; Bioscan, USA) with an acquisition time of 1800 seconds. Seventy-two hours after positron emission tomography/computed tomography, all mice were scanned 2 hours after intravenous administration of 0.2 mmol/kg body weight of a gadolinium-based elastin-specific MR contrast agent. MRI was performed on a 3-T clinical scanner (Philips Healthcare, Best, The Netherlands). In ApoE(-/-) mice, the (64)Cu-GPVI-Fc uptake in the aortic arch was significantly higher compared with WT mice (ApoE(-/-): 13.2&#xB1;1.5 Bq/cm(3) versus WT mice: 5.1&#xB1;0.5 Bq/cm(3); P=0.028). (64)Cu-GPVI-Fc uptake was also higher in the injured left carotid artery wall compared with the intact right carotid artery of WT mice and as a trend compared with sham procedure (injured: 20.7&#xB1;1.3 Bq/cm(3) versus intact: 2.3&#xB1;0.5 Bq/cm(3); P=0.028 versus sham: 12.7&#xB1;1.7 Bq/cm(3); P=0.068). Results were confirmed by ex vivo histology and in vivo MRI with elastin-specific MR contrast agent that measures plaque burden and vessel wall remodeling. Higher R1 relaxation rates were found in the injured carotid wall with a T1 mapping sequence (injured: 1.44&#xB1;0.08 s(-1) versus intact: 0.91&#xB1;0.02 s(-1); P=0.028 versus sham: 0.97&#xB1;0.05 s(-1); P=0.068) and in the aortic arch of ApoE(-/-) mice compared with WT mice (ApoE(-/-): 1.49&#xB1;0.05 s(-1) versus WT: 0.92&#xB1;0.04 s(-1); P=0.028).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">(64)Cu-GPVI-Fc positron emission tomographic imaging allows identification of exposed subendothelial collagen in injured WT and high-fat diet-fed ApoE(-/-) mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bigalke</LastName>
            <ForeName>Boris</ForeName>
            <Initials>B</Initials>
            <Affiliation>Medizinische Klinik III, Kardiologie und Kreislauferkrankungen.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Phinikaridou</LastName>
            <ForeName>Alkystis</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andia</LastName>
            <ForeName>Marcelo E</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cooper</LastName>
            <ForeName>Margaret S</ForeName>
            <Initials>MS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuster</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sch&#xF6;nberger</LastName>
            <ForeName>Tanja</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Griessinger</LastName>
            <ForeName>Christoph M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wurster</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onthank</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ungerer</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gawaz</LastName>
            <ForeName>Meinrad</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagel</LastName>
            <ForeName>Eike</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botnar</LastName>
            <ForeName>Rene M</ForeName>
            <Initials>RM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>WT088641/Z/09/Z</GrantID>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Comparative Study</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circ Cardiovasc Imaging</MedlineTA>
        <NlmUniqueID>101479935</NlmUniqueID>
        <ISSNLinking>1941-9651</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Copper Radioisotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Platelet Membrane Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>platelet membrane glycoprotein VI</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Carotid Artery, Common</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Copper Radioisotopes</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
          <QualifierName MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Platelet Membrane Glycoproteins</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
          <QualifierName MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
          <QualifierName MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword>
        <Keyword MajorTopicYN="N">positron-emission tomography and computed tomography</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24107491</ArticleId>
        <ArticleId IdType="pii">CIRCIMAGING.113.000488</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCIMAGING.113.000488</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">24106600</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">2008-3866</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>16</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Iranian journal of basic medical sciences</Title>
          <ISOAbbreviation>Iran J Basic Med Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ghrelin Does not Alter Aortic Intima-Media Thickness and Adipose Tissue Characteristics in Control and Obese Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>942-5</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Objective(s): Atherosclerosis is a chronic immune-inflammatory disease that generally leads to ischemic heart disease. Ghrelin has several modulatory effects on cardiovascular system. In this study, we investigated the effect of ghrelin on aortic intima-media thickness, size and the number of adipocyte cells in obese and control mice. Materials and Methods: This study was conducted on 24 male C57BL/6 mice. The animals were divided into four groups: control, obese (received high fat diet), control+ghrelin (injected with 100 &#xB5;g/Kg subcutaneously, bid) and obese+ghrelin (n=6 each). After 10 days, animals were sacrificed and epididymal adipose tissue and thoracic aortae were removed. Adipocyte cell number, size and aortic intima-media thickness were evaluated. Results: Ghrelin did not change adipocyte cell number and size and aortic intima-media thickness in obese and control mice. In this study, high fat diet significantly decreased the number of adipocyte cells while increased their size (P&lt;0.05). Ghrelin administration had no significant effect on adipocyte cell number and size in obese and control groups (P &gt;0.05). In addition, it could not alter aortic intima-media thickness in both groups. Conclusion: Although ghrelin has several cardiovascular effects, it seems that it could not alter the size and number of adipocyte cells and aortic intima-media thickness in diet-induced obese mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tahergorabi</LastName>
            <ForeName>Zoya</ForeName>
            <Initials>Z</Initials>
            <Affiliation>Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rashidi</LastName>
            <ForeName>Bahman</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khazaei</LastName>
            <ForeName>Majid</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Iran</Country>
        <MedlineTA>Iran J Basic Med Sci</MedlineTA>
        <NlmUniqueID>101517966</NlmUniqueID>
        <ISSNLinking>2008-3866</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3786108</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adipocyte</Keyword>
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Ghrelin</Keyword>
        <Keyword MajorTopicYN="N">Obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24106600</ArticleId>
        <ArticleId IdType="pmc">PMC3786108</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24101673</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1939-327X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes</Title>
          <ISOAbbreviation>Diabetes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>HDAC9 Knockout Mice Are Protected From Adipose Tissue Dysfunction and Systemic Metabolic Disease During High-Fat Feeding.</ArticleTitle>
        <Pagination>
          <MedlinePgn>176-87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1148</ELocationID>
        <Abstract>
          <AbstractText>During chronic caloric excess, adipose tissue expands primarily by enlargement of individual adipocytes, which become stressed with lipid overloading, thereby contributing to obesity-related disease. Although adipose tissue contains numerous preadipocytes, differentiation into functionally competent adipocytes is insufficient to accommodate the chronic caloric excess and prevent adipocyte overloading. We report for the first time that a chronic high-fat diet (HFD) impairs adipogenic differentiation, leading to accumulation of inefficiently differentiated adipocytes with blunted expression of adipogenic differentiation-specific genes. Preadipocytes from these mice likewise exhibit impaired adipogenic differentiation, and this phenotype persists during in vitro cell culture. HFD-induced impaired adipogenic differentiation is associated with elevated expression of histone deacetylase 9 (HDAC9), an endogenous negative regulator of adipogenic differentiation. Genetic ablation of HDAC9 improves adipogenic differentiation and systemic metabolic state during an HFD, resulting in diminished weight gain, improved glucose tolerance and insulin sensitivity, and reduced hepatosteatosis. Moreover, compared with wild-type mice, HDAC9 knockout mice exhibit upregulated expression of beige adipocyte marker genes, particularly during an HFD, in association with increased energy expenditure and adaptive thermogenesis. These results suggest that targeting HDAC9 may be an effective strategy for combating obesity-related metabolic disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chatterjee</LastName>
            <ForeName>Tapan K</ForeName>
            <Initials>TK</Initials>
            <Affiliation>Department of Internal Medicine, Division of Cardiovascular Diseases, University of Cincinnati, Cincinnati, OH.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basford</LastName>
            <ForeName>Joshua E</ForeName>
            <Initials>JE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Knoll</LastName>
            <ForeName>Ellen</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tong</LastName>
            <ForeName>Wilson S</ForeName>
            <Initials>WS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blanco</LastName>
            <ForeName>Victor</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blomkalns</LastName>
            <ForeName>Andra L</ForeName>
            <Initials>AL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rudich</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lentsch</LastName>
            <ForeName>Alex B</ForeName>
            <Initials>AB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hui</LastName>
            <ForeName>David Y</ForeName>
            <Initials>DY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weintraub</LastName>
            <ForeName>Neal L</ForeName>
            <Initials>NL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Diabetes</MedlineTA>
        <NlmUniqueID>0372763</NlmUniqueID>
        <ISSNLinking>0012-1797</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">PMC3868044 [Available on 01/01/15]</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">db13-1148</ArticleId>
        <ArticleId IdType="doi">10.2337/db13-1148</ArticleId>
        <ArticleId IdType="pubmed">24101673</ArticleId>
        <ArticleId IdType="pmc">PMC3868044</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24098813</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e76912</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0076912</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS AND METHODS" NlmCategory="OBJECTIVE">We evaluated the modulation of liver stearoyl-CoA desaturase-1 (Scd1) by dietary factors and insulin resistance (IR) in two experimental models of high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD). The first model included Sprague Dawley (SD) rats that developed NAFLD without IR, and the second one included a rat model of genetic IR and cardiovascular disease, the spontaneously hypertensive rats (SHR) and its normotensive, insulin-sensitive control Wistar-Kyoto (WKY). The adult rats were given standard chow diet (CD) or HFD for 10 weeks. In all the animals, we explored the hepatic Scd1 transcriptional activity and protein levels.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">HFD-fed rats of both strains developed severe NAFLD. Liver abundance of Scd1 mRNA was significantly decreased in HFD-fed rats regardless of the strain; SD-CD: 235&#xB1;195 vs. SD-HFD 4.5&#xB1;2.9, p&lt;0.0004, and SHR-CD: 75.6&#xB1;10.8 vs. SHR-HFD: 4.48&#xB1;17.4, and WKY-CD: 168.7&#xB1;17.4 vs. WKY-HFD: 12.9&#xB1;17.4, p&lt;0.000001 (mean&#xB1;SE, ANCOVA adjusted by HOMA). Analysis of liver Scd1 protein expression showed a particular pattern in the HFD groups, characterized by the presence of high levels of a monomeric protein band (32.2-36.6 Kda, p&lt;0.003) and decreased levels of a dimeric protein band (61.9-66.1 Kda, p&lt;0.02) regardless of the rat strain. Pharmacologic intervention with the peroxisome proliferator-activated receptor a agonist clofibrate reverted the liver phenotype and significantly modified the hepatic Scd1 transcriptional activity and protein expression.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Diet-induced fatty liver is associated with the downregulation of hepatic Scd1 transcript and de-dimerization of the protein, and these changes were not much affected by the status of peripheral IR.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fern&#xE1;ndez Gianotti</LastName>
            <ForeName>Tomas</ForeName>
            <Initials>T</Initials>
            <Affiliation>Department of Molecular Genetics and Biology of Complex Diseases, Institute of Medical Research A Lanari-IDIM, University of Buenos Aires-National Council of Scientific and Technological Research (CONICET), Ciudad Aut&#xF3;noma de Buenos Aires, Argentina.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burgue&#xF1;o</LastName>
            <ForeName>Adriana</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonzales Mansilla</LastName>
            <ForeName>Noelia</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pirola</LastName>
            <ForeName>Carlos Jose</ForeName>
            <Initials>CJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sookoian</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Cardiovasc Med. 2004 Feb;14(2):77-81</RefSource>
          <PMID Version="1">15030794</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2005 May 15;388(Pt 1):135-42</RefSource>
          <PMID Version="1">15610069</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Obes Res. 2004 Aug;12(8):1264-70</RefSource>
          <PMID Version="1">15340109</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Biochem Sci. 2004 Nov;29(11):618-25</RefSource>
          <PMID Version="1">15501681</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1992 May 25;267(15):10925-30</RefSource>
          <PMID Version="1">1350282</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 1994 Apr 29;200(2):763-8</RefSource>
          <PMID Version="1">7910016</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 1996 Mar 27;220(3):990-5</RefSource>
          <PMID Version="1">8607881</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1996 Nov 22;271(47):29854-8</RefSource>
          <PMID Version="1">8939925</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Gastroenterol. 1999 Sep;94(9):2467-74</RefSource>
          <PMID Version="1">10484010</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E381-7</RefSource>
          <PMID Version="1">15494611</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Jul 8;280(27):25339-49</RefSource>
          <PMID Version="1">15851470</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2006 Jun;116(6):1686-95</RefSource>
          <PMID Version="1">16741579</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2007 May;292(5):E1388-94</RefSource>
          <PMID Version="1">17227965</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27-38</RefSource>
          <PMID Version="1">17690317</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2008 Apr;51(4):648-56</RefSource>
          <PMID Version="1">18286258</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2008 Sep 30;118(14):1467-75</RefSource>
          <PMID Version="1">18794388</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2009 Jan;58(1):203-8</RefSource>
          <PMID Version="1">18952834</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):341-7</RefSource>
          <PMID Version="1">19095997</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2009 Feb 27;284(9):5637-44</RefSource>
          <PMID Version="1">19119140</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nucleic Acids Res. 2009 Apr;37(6):e45</RefSource>
          <PMID Version="1">19237396</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15430-5</RefSource>
          <PMID Version="1">19706383</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20</RefSource>
          <PMID Version="1">20576703</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2010 Dec;52(6):1992-2000</RefSource>
          <PMID Version="1">20890895</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biol Pharm Bull. 2012;35(2):184-91</RefSource>
          <PMID Version="1">22293348</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pharmacol Res. 2012 Oct;66(4):283-91</RefSource>
          <PMID Version="1">22750665</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Endocrinol Metab. 2012 Dec;97(12):E2288-92</RefSource>
          <PMID Version="1">23015656</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Prog Lipid Res. 2013 Jan;52(1):15-42</RefSource>
          <PMID Version="1">23000367</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11482-6</RefSource>
          <PMID Version="1">12177411</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1996 Jul;271(1 Pt 1):E44-9</RefSource>
          <PMID Version="1">8760080</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9443-8</RefSource>
          <PMID Version="1">8790349</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82</RefSource>
          <PMID Version="1">12629214</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):271-80</RefSource>
          <PMID Version="1">14683458</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2005 May;54(5):1314-23</RefSource>
          <PMID Version="1">15855315</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2004 Aug 13;279(33):35017-24</RefSource>
          <PMID Version="1">15180999</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3786952</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0076912</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-22979</ArticleId>
        <ArticleId IdType="pubmed">24098813</ArticleId>
        <ArticleId IdType="pmc">PMC3786952</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24098551</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e76703</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0076703</ELocationID>
        <Abstract>
          <AbstractText>Metabolic syndrome can induce chronic kidney disease in humans. Genetically engineered mice on a C57BL/6 background are highly used for mechanistic studies. Although it has been shown that metabolic syndrome induces cardiovascular lesions in C57BL/6 mice, in depth renal phenotyping has never been performed. Therefore in this study we characterized renal function and injury in C57BL/6 mice with long-term metabolic syndrome induced by a high fat and fructose diet (HFFD). C57BL/6 mice received an 8 months HFFD diet enriched with fat (45% energy from fat) and drinking water enriched with fructose (30%). Body weight, food/water consumption, energy intake, fat/lean mass ratio, plasma glucose, HDL, LDL, triglycerides and cholesterol levels were monitored. At 3, 6 and 8 months, renal function was determined by inulin clearance and measure of albuminuria. At sacrifice, kidneys and&#xA0;liver were collected. Metabolic syndrome in C57BL/6 mice fed a HFFD was observed as early 4 weeks with development of type 2 diabetes at 8 weeks after initiation of diet. However, detailed analysis of kidney structure and function showed only minimal renal injury after 8 months of HFFD. HFFD induced moderate glomerular hyperfiltration (436,4 &#xB5;L/min vs 289,8 &#xB5;L/min; p-value=0.0418) together with a 2-fold increase in albuminuria only after 8 months of HFFD. This was accompanied by a 2-fold increase in renal inflammation (p-value=0.0217) but without renal fibrosis or mesangial matrix expansion. In addition, electron microscopy did not show alterations in glomeruli such as basal membrane thickening and foot process effacement. Finally, comparison of the urinary peptidome of these mice with the urinary peptidome from humans with diabetic nephropathy also suggested absence of diabetic nephropathy in this model. This study provides evidence that the HFFD C57BL/6 model is not the optimal model to study the effects of metabolic syndrome on the development of diabetic kidney disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dissard</LastName>
            <ForeName>Romain</ForeName>
            <Initials>R</Initials>
            <Affiliation>Institut National de la Sant&#xE9; et de la Recherche M&#xE9;dicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France ; Universit&#xE9; Toulouse III Paul-Sabatier, Toulouse, France.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>Julie</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caubet</LastName>
            <ForeName>C&#xE9;cile</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Breuil</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siwy</LastName>
            <ForeName>Justyna</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffman</LastName>
            <ForeName>Janosch</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sicard</LastName>
            <ForeName>Laurent</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ducass&#xE9;</LastName>
            <ForeName>Laure</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rascalou</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payre</LastName>
            <ForeName>Bruno</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bul&#xE9;on</LastName>
            <ForeName>Marie</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mullen</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mischak</LastName>
            <ForeName>Harald</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tack</LastName>
            <ForeName>Ivan</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bascands</LastName>
            <ForeName>Jean-Loup</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buffin-Meyer</LastName>
            <ForeName>B&#xE9;n&#xE9;dicte</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schanstra</LastName>
            <ForeName>Joost P</ForeName>
            <Initials>JP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2003 Jul;64(1):350-5</RefSource>
          <PMID Version="1">12787428</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr Rev. 1997 Feb;55(2):31-43</RefSource>
          <PMID Version="1">9155216</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Chromatogr A. 2003 Sep 26;1013(1-2):173-81</RefSource>
          <PMID Version="1">14604118</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Jan 27;109(3):433-8</RefSource>
          <PMID Version="1">14744958</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Intern Med. 2004 Feb 3;140(3):167-74</RefSource>
          <PMID Version="1">14757614</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2004 May;65(5):1870-6</RefSource>
          <PMID Version="1">15086929</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2010 May;151(5):2040-9</RefSource>
          <PMID Version="1">20211973</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1560-70</RefSource>
          <PMID Version="1">20357025</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Dis Model Mech. 2010 Sep-Oct;3(9-10):525-34</RefSource>
          <PMID Version="1">20713647</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2010 Sep;21(9):1533-42</RefSource>
          <PMID Version="1">20634301</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Res Clin Pract. 1998 Feb;39(2):93-9</RefSource>
          <PMID Version="1">9597378</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hered. 1950 Dec;41(12):317-8</RefSource>
          <PMID Version="1">14824537</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2005 Jul;16(7):2134-40</RefSource>
          <PMID Version="1">15901764</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Obes Res. 2005 Jul;13(7):1146-56</RefSource>
          <PMID Version="1">16076983</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2005 Sep;54(9):2628-37</RefSource>
          <PMID Version="1">16123351</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2006 Jan;290(1):F214-22</RefSource>
          <PMID Version="1">16118394</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Obesity (Silver Spring). 2006 Mar;14(3):405-14</RefSource>
          <PMID Version="1">16648611</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hypertens. 2006 Jun;24(6):1157-63</RefSource>
          <PMID Version="1">16685216</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Electrophoresis. 2006 Jun;27(11):2111-25</RefSource>
          <PMID Version="1">16645980</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2006 Aug;84(2):274-88</RefSource>
          <PMID Version="1">16895873</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Public Health. 2007 Apr;97(4):667-75</RefSource>
          <PMID Version="1">17329656</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2007 Oct;18(10):2715-23</RefSource>
          <PMID Version="1">17855643</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2007 Oct;293(4):F1256-61</RefSource>
          <PMID Version="1">17670904</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2008 May;294(5):F1249-56</RefSource>
          <PMID Version="1">18367657</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Regul Integr Comp Physiol. 2008 Jun;294(6):R1840-6</RefSource>
          <PMID Version="1">18417648</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E981-6</RefSource>
          <PMID Version="1">18664598</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G987-95</RefSource>
          <PMID Version="1">18772365</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2009 Jan;296(1):F118-26</RefSource>
          <PMID Version="1">18971213</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2009 Jan;89(1):372-81</RefSource>
          <PMID Version="1">19056548</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2009 Dec;20(12):2503-12</RefSource>
          <PMID Version="1">19729434</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2010 Jan;90(1):23-46</RefSource>
          <PMID Version="1">20086073</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2010 Apr;298(4):F1024-32</RefSource>
          <PMID Version="1">20089676</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2010 May;298(5):E1049-57</RefSource>
          <PMID Version="1">20159856</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2001 Sep;44(9):1148-54</RefSource>
          <PMID Version="1">11596670</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2002 Jan 16;287(3):356-9</RefSource>
          <PMID Version="1">11790215</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Diab Rep. 2003 Feb;3(1):80-6</RefSource>
          <PMID Version="1">12643150</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Diet Assoc. 2010 Oct;110(10):1477-84</RefSource>
          <PMID Version="1">20869486</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutrition. 2010 Nov-Dec;26(11-12):1044-9</RefSource>
          <PMID Version="1">20471804</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2010 Nov;299(5):E685-94</RefSource>
          <PMID Version="1">20823452</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Proteomics. 2010 Nov;9(11):2424-37</RefSource>
          <PMID Version="1">20616184</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biomed Biotechnol. 2011;2011:351982</RefSource>
          <PMID Version="1">21253582</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2011 Mar;57(3):561-9</RefSource>
          <PMID Version="1">21199994</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cardiovasc Pharmacol. 2011 May;57(5):611-24</RefSource>
          <PMID Version="1">21572266</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proteomics Clin Appl. 2011 Jun;5(5-6):367-74</RefSource>
          <PMID Version="1">21591268</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 2011 Nov;60(11):1590-7</RefSource>
          <PMID Version="1">21550075</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2012 Feb 1;307(5):491-7</RefSource>
          <PMID Version="1">22253363</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2012 Feb 1;307(5):483-90</RefSource>
          <PMID Version="1">22253364</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2012 Mar 9;419(2):244-9</RefSource>
          <PMID Version="1">22342673</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(3):e32746</RefSource>
          <PMID Version="1">22412919</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Aliment Pharmacol Ther. 2012 May;35(10):1135-44</RefSource>
          <PMID Version="1">22469071</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Proteomics. 2012 Jul;11(7):M111.013847</RefSource>
          <PMID Version="1">22371488</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Proteomics. 2012 Oct 22;75(18):5888-97</RefSource>
          <PMID Version="1">22842158</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proteomics Clin Appl. 2012 Oct;6(9-10):437-42</RefSource>
          <PMID Version="1">22821927</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2012 Dec;61(12):3304-13</RefSource>
          <PMID Version="1">22872235</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2013 Feb;56(2):259-67</RefSource>
          <PMID Version="1">23086559</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Biochem. 2013 Apr;46(6):432-43</RefSource>
          <PMID Version="1">23041249</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Electrophoresis. 2013 Jun;34(11):1452-64</RefSource>
          <PMID Version="1">23512263</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2000 Nov;11 Suppl 16:S101-5</RefSource>
          <PMID Version="1">11065339</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2004 Nov;66(5):1901-6</RefSource>
          <PMID Version="1">15496161</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 1983 May;32 Suppl 2:64-78</RefSource>
          <PMID Version="1">6400670</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1990 Apr;258(4 Pt 2):F973-9</RefSource>
          <PMID Version="1">2184677</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 1993 Nov;42(11):1405-9</RefSource>
          <PMID Version="1">8231834</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Metabolism. 1995 May;44(5):645-51</RefSource>
          <PMID Version="1">7752914</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Hypertens. 2003 Nov;16(11 Pt 1):952-8</RefSource>
          <PMID Version="1">14573334</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3789664</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0076703</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-22819</ArticleId>
        <ArticleId IdType="pubmed">24098551</ArticleId>
        <ArticleId IdType="pmc">PMC3789664</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24098525</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e76538</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0076538</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Simvastatin exerts pleiotropic effects on cardiovascular system. However, its effect on non-alcoholic fatty liver disease, especially the liver fibrosis, remains obscure. We aimed to clarify the relationship between simvastatin and liver fibrosis both in vivo and in vitro.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A High-fat diet was given to establish rat models with non-alcoholic steatohepatitis (NASH)-related liver fibrosis and simvastatin (4mg&#xB7;kg(-1)&#xB7;d(-1)) was administrated intragastrically until hepatic histological findings confirmed the appearance of fibrosis. Human hepatic stellate cell (HSC) line lx-2 cells were cultured in an adipogenic differentiating mixture (ADM) and then were treated with transforming growth factor&#xDF;1 (TGF-&#xDF;1), served as a positive control, simvastatin, TGF-&#xDF;1 plus simvastatin, N?-nitro-L-arginine methyl ester hydrochloride (L-NAME, a inhibitor of nitric oxide synthase), and L-NAME plus simvastatin, respectively. The expressions of endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), and Collagen ? as well as cellular a-smooth muscle actin (a-SMA) were measured by real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) and Western blot in liver tissue and HSC.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">With the progress of NASH-related fibrosis, hepatic mRNA and protein expressions of iNOS, a-SMA, and Collagen ? were increased while those of eNOS were decreased. Compared with model rats in 24(th) week group, rats in simvastatin group had less expressions of iNOS, a-SMA, and Collagen ? and more expressions of eNOS. In vitro, LX-2 cells acquired quiescent phenotype when cultured in ADM, and TGF-&#xDF;1 could activate the quiescent HSC. Simvastatin inhibited LX-2 cells activation due to TGF-&#xDF;1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Simvastatin improves the prognosis of NASH-related fibrosis by increasing the expression of eNOS, decreasing the expression of iNOS, and inhibiting the activation of HSC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Affiliation>Department of Infectious Diseases, the Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Caiyan</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Junying</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhen</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yadong</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Chuan</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2006 Nov 17;350(2):385-91</RefSource>
          <PMID Version="1">17010940</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arthritis Rheum. 2013 Mar;65(3):639-49</RefSource>
          <PMID Version="1">23239110</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hepatol. 2007 Jul;47(1):135-41</RefSource>
          <PMID Version="1">17400325</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>World J Gastroenterol. 2007 Sep 14;13(34):4539-50</RefSource>
          <PMID Version="1">17729403</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hepatol. 2008;48 Suppl 1:S104-12</RefSource>
          <PMID Version="1">18304679</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Aliment Pharmacol Ther. 2008 Jul;28(1):2-12</RefSource>
          <PMID Version="1">18410557</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Exp Pathol. 2008 Aug;89(4):241-50</RefSource>
          <PMID Version="1">18429990</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>QJM. 2010 Feb;103(2):71-83</RefSource>
          <PMID Version="1">19914930</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Dig Dis Sci. 2010 Apr;55(4):931-40</RefSource>
          <PMID Version="1">19459046</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pharmacol Rep. 2010 Mar-Apr;62(2):343-51</RefSource>
          <PMID Version="1">20508290</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Prog Lipid Res. 2009 Jan;48(1):1-26</RefSource>
          <PMID Version="1">18824034</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Transl Med. 2008;6:72</RefSource>
          <PMID Version="1">19038040</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2009 Jan;49(1):306-17</RefSource>
          <PMID Version="1">19065650</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Hepatol. 2009;8 Suppl 1:S51-9</RefSource>
          <PMID Version="1">19381125</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gastroenterology. 2009 May;136(5):1651-8</RefSource>
          <PMID Version="1">19208350</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Gastroenterol Hepatol. 2009 Oct;24(10):1669-76</RefSource>
          <PMID Version="1">19788607</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Gastroenterol. 2009 Nov-Dec;43(10):990-4</RefSource>
          <PMID Version="1">19448566</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2009 Dec;150(12):5262-72</RefSource>
          <PMID Version="1">19819942</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Med Sci Monit. 2009 Dec;15(12):MS6-11</RefSource>
          <PMID Version="1">19946244</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hepatol. 2003 May;38(5):564-72</RefSource>
          <PMID Version="1">12713866</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gastroenterology. 2004 Mar;126(3):749-55</RefSource>
          <PMID Version="1">14988829</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Feb 11;280(6):4959-67</RefSource>
          <PMID Version="1">15537655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2005 Jun;41(6):1313-21</RefSource>
          <PMID Version="1">15915461</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arq Gastroenterol. 2010 Jan-Mar;47(1):86-92</RefSource>
          <PMID Version="1">20520981</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>World J Gastroenterol. 2010 Oct 14;16(38):4773-83</RefSource>
          <PMID Version="1">20939105</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2012 Aug 1;123(3):161-71</RefSource>
          <PMID Version="1">22364258</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Dig Liver Dis. 2012 Jun;44(6):492-6</RefSource>
          <PMID Version="1">22265683</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Dig Liver Dis. 2012 Jun;44(6):451-2</RefSource>
          <PMID Version="1">22487461</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Transl Med. 2012;10:50</RefSource>
          <PMID Version="1">22424154</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2012 Jun;55(6):2005-23</RefSource>
          <PMID Version="1">22488764</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Rom J Intern Med. 2012 Jan-Mar;50(1):19-25</RefSource>
          <PMID Version="1">22788090</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hepatol. 2013 Jan;58(1):119-25</RefSource>
          <PMID Version="1">22902550</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Liver Int. 2013 Feb;33(2):301-11</RefSource>
          <PMID Version="1">23295058</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hepatol. 2007 Jun;46(6):1040-6</RefSource>
          <PMID Version="1">17335931</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3788732</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0076538</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-13438</ArticleId>
        <ArticleId IdType="pubmed">24098525</ArticleId>
        <ArticleId IdType="pmc">PMC3788732</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24084690</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>03</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4571</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>114</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>3</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation research</Title>
          <ISOAbbreviation>Circ. Res.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Systemic Delivery of MicroRNA-181b Inhibits Nuclear Factor-?B Activation, Vascular Inflammation, and Atherosclerosis in Apolipoprotein E-Deficient Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>32-40</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.113.302089</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Activated nuclear factor (NF)-?B signaling in the vascular endothelium promotes the initiation and progression of atherosclerosis. Targeting endothelial NF-?B may provide a novel strategy to limit chronic inflammation.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the role of microRNA-181b (miR-181b) in endothelial NF-?B signaling and effects on atherosclerosis.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">MiR-181b expression was reduced in the aortic intima and plasma in apolipoprotein E-deficient mice fed a high-fat diet. Correspondingly, circulating miR-181b in the plasma was markedly reduced in human subjects with coronary artery disease. Systemic delivery of miR-181b resulted in a 2.3-fold overexpression of miR-181b in the aortic intima of apolipoprotein E-deficient mice and suppressed NF-?B signaling revealed by bioluminescence imaging and reduced target gene expression in the aortic arch in apolipoprotein E-deficient/NF-?B-luciferase transgenic mice. MiR-181b significantly inhibited atherosclerotic lesion formation, proinflammatory gene expression and the influx of lesional macrophages and CD4+ T cells in the vessel wall. Mechanistically, miR-181b inhibited the expression of the target gene importin-a3, an effect that reduced NF-?B nuclear translocation specifically in the vascular endothelium of lesions, whereas surprisingly leukocyte NF-?B signaling was unaffected despite a 7-fold overexpression of miR-181b. Our findings uncover that NF-?B nuclear translocation in leukocytes does not involve importin-a3, but rather importin-a5, which miR-181b does not target, highlighting that inhibition of NF-?B signaling in the endothelium is sufficient to mediate miR-181b's protective effects.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Systemic delivery of miR-181b inhibits the activation of NF-?B and atherosclerosis through cell-specific mechanisms in the vascular endothelium. These findings support the rationale that delivery of miR-181b may provide a novel therapeutic approach to treat chronic inflammatory diseases such as atherosclerosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xinghui</ForeName>
            <Initials>X</Initials>
            <Affiliation>From the Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (X.S., S.H., A.K.M.W., B.I., E.S., Y.T., N.B., G.K.S., K.C., M.W.F.); Department of Cardiology, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (S.H., D.L.); and Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN (T.S.B.).</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Shaolin</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wara</LastName>
            <ForeName>A K M</ForeName>
            <Initials>AK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Icli</LastName>
            <ForeName>Basak</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shvartz</LastName>
            <ForeName>Eugenia</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tesmenitsky</LastName>
            <ForeName>Yevgenia</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Belkin</LastName>
            <ForeName>Nathan</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Dazhu</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blackwell</LastName>
            <ForeName>Timothy S</ForeName>
            <Initials>TS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sukhova</LastName>
            <ForeName>Galina K</ForeName>
            <Initials>GK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Croce</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feinberg</LastName>
            <ForeName>Mark W</ForeName>
            <Initials>MW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circ Res</MedlineTA>
        <NlmUniqueID>0047103</NlmUniqueID>
        <ISSNLinking>0009-7330</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NF-?B</Keyword>
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">endothelial cells</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">karyopherins</Keyword>
        <Keyword MajorTopicYN="N">microRNAs</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24084690</ArticleId>
        <ArticleId IdType="pii">CIRCRESAHA.113.302089</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCRESAHA.113.302089</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24081993</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1550-6606</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>191</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
          <ISOAbbreviation>J. Immunol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein.</ArticleTitle>
        <Pagination>
          <MedlinePgn>4849-57</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1300053</ELocationID>
        <Abstract>
          <AbstractText>Atherosclerosis has been widely recognized as an inflammatory disease of the arterial wall in which macrophages play a major role. Yet, how macrophage-mediated pathology is regulated during atherosclerosis is poorly understood. TNF-a-induced protein 8-like 2 (TIPE2, also known as TNFAIP8L2) is highly expressed in resting macrophages and can negatively regulate inflammation through inhibiting immune receptor signaling. We report in this article that TIPE2 plays a crucial atheroprotective role likely by regulating macrophage responses to oxidized low-density lipoprotein (ox-LDL). TIPE2-deficient macrophages treated with ox-LDL produced more oxidative stress and proinflammatory cytokines, and exhibited heightened activation of the JNK, NF-?B, and p38 signaling pathways. As a consequence, TIPE2 deficiency in bone marrow-derived cells exacerbated atherosclerosis development in Ldlr(-/-) mice fed a high-fat diet. Importantly, ox-LDL markedly downregulated TIPE2 mRNA and protein levels in macrophages, suggesting that ox-LDL mediates atherosclerosis by TIPE2 inhibition. These results indicate that TIPE2 is a new inhibitor of atherosclerosis and a potential drug target for treating the disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lou</LastName>
            <ForeName>Yunwei</ForeName>
            <Initials>Y</Initials>
            <Affiliation>Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Shandong University Qilu Hospital, Jinan, Shandong, 250012 China;</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Suxia</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Guizhong</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Mei</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Guipeng</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>Mei</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaoling</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Faliang</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wenqian</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Youhai H</ForeName>
            <Initials>YH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunol</MedlineTA>
        <NlmUniqueID>2985117R</NlmUniqueID>
        <ISSNLinking>0022-1767</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Receptors, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>TIPE2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance>JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance>p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Receptors, LDL</DescriptorName>
          <QualifierName MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jimmunol.1300053</ArticleId>
        <ArticleId IdType="doi">10.4049/jimmunol.1300053</ArticleId>
        <ArticleId IdType="pubmed">24081993</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24080184</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-8584</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>65</Volume>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of molecular and cellular cardiology</Title>
          <ISOAbbreviation>J. Mol. Cell. Cardiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress.</ArticleTitle>
        <Pagination>
          <MedlinePgn>33-42</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yjmcc.2013.09.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-2828(13)00276-9</ELocationID>
        <Abstract>
          <AbstractText>Acute inhibition of the NHE1 Na(+)/H(+) exchanger protects against ischemia-reperfusion injury and chronic inhibition attenuates development of cardiac hypertrophy and failure. To determine the cardiac effects of chronic inhibition of NHE1 under non-pathological conditions we used NHE1-null mice as a model of long-term NHE1 inhibition. Cardiovascular performance was relatively normal in Nhe1(-/-) mice although cardiac contractility and relaxation were slightly improved in mutant mice of the FVB/N background. GSH levels and GSH:GSSG ratios were elevated in Nhe1(-/-) hearts indicating an enhanced redox potential. Consistent with a reduced need for antioxidant protection, expression of heat shock proteins Hsp60 and Hsp25 was lower in Nhe1(-/-) hearts. Similarly, expression of mitochondrial superoxide dismutase 2 was reduced, with no increase in expression of other ROS scavenging enzymes. GLUT1 levels were increased in Nhe1(-/-) hearts, the number of lipid droplets in myocytes was reduced, and PDK4 expression was refractory to high-fat diet-induced upregulation observed in wild-type hearts. High-fat diet-induced stress was attenuated in Nhe1(-/-) hearts, as indicated by smaller increases in phosphorylation of Hsp25 and a-B crystallin, and there was better preservation of insulin sensitivity, as evidenced by PKB/Akt phosphorylation. Plasma glucose and insulin levels were lower and high-fat diet-induced hepatic lipid accumulation was reduced in Nhe1(-/-) mice, demonstrating extracardiac effects of NHE1 ablation. These data indicate that long-term ablation of NHE1 activity increases the redox potential, mitigates high-fat diet-induced myocardial stress and fatty liver disease, leads to better preservation of insulin sensitivity, and may alter both cardiac and systemic metabolic substrate handling in mice.</AbstractText>
          <CopyrightInformation>&#xA9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Prasad</LastName>
            <ForeName>Vikram</ForeName>
            <Initials>V</Initials>
            <Affiliation>Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0524, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lorenz</LastName>
            <ForeName>John N</ForeName>
            <Initials>JN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miller</LastName>
            <ForeName>Marian L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vairamani</LastName>
            <ForeName>Kanimozhi</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nieman</LastName>
            <ForeName>Michelle L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yigang</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shull</LastName>
            <ForeName>Gary E</ForeName>
            <Initials>GE</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK050594</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK059630</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL061974</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30ES006096</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Mol Cell Cardiol</MedlineTA>
        <NlmUniqueID>0262322</NlmUniqueID>
        <ISSNLinking>0022-2828</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">NIHMS529475 [Available on 12/01/14]</OtherID>
      <OtherID Source="NLM">PMC3883452 [Available on 12/01/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Diabetes</Keyword>
        <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">Metabolic syndrome</Keyword>
        <Keyword MajorTopicYN="N">NHE-1</Keyword>
        <Keyword MajorTopicYN="N">Slc9a1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24080184</ArticleId>
        <ArticleId IdType="pii">S0022-2828(13)00276-9</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yjmcc.2013.09.013</ArticleId>
        <ArticleId IdType="pmc">PMC3883452</ArticleId>
        <ArticleId IdType="mid">NIHMS529475</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24075193</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>9</Month>
        <Day>30</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2210-741X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinics and research in hepatology and gastroenterology</Title>
          <ISOAbbreviation>Clin Res Hepatol Gastroenterol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S2210-7401(13)00180-0</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.clinre.2013.08.006</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Serum inflammatory biomarkers are closely associated with the risk of cardiovascular disease. However, the major source of these biomarkers is not yet determined. Therefore, we aimed to assess whether simple steatosis or visceral adiposity was a more relevant predictor for serum inflammatory biomarkers.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A double approach was used: i) clinical: 50&#xA0;patients with biopsy-proven simple steatosis, 50 non-simple steatosis overweight patients, and 50 controls were explored for their serum biomarkers (high-sensitivity C-reactive protein, plasminogen activator inhibitor-1 activity, tumor necrosis factor a, and fibrinogen levels) and for visceral adiposity (measured by computed tomography); ii) experimental: using a rat simple steatosis model the effect of omentectomy on inflammatory biomarkers was investigated.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum inflammatory biomarkers were significantly higher in the simple steatosis group than in the overweight group. Using multivariate analysis, simple steatosis, visceral adiposity index and visceral adiposity were independently associated with inflammatory biomarkers. In particular, serum inflammatory biomarkers increased with the severity of liver histology (p&lt;0.05), but no with visceral adipose tissue increase. In rats with simple steatosis, the omentectomy treatment was not associated with a decrease of serum inflammatory biomarkers in rats with simple steatosis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical and experimental data both indicate that simple steatosis may be more associated with inflammatory biomarkers than omental adipose tissue.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <Affiliation>Department of Gastroenterology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, 10, Changjiang Zhilu, Da Ping, Chongqing 400042, China.</Affiliation>
          </Author>
          <Author>
            <LastName>Liu</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author>
            <LastName>Wang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Chen</LastName>
            <ForeName>Dongfeng</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Res Hepatol Gastroenterol</MedlineTA>
        <NlmUniqueID>101553659</NlmUniqueID>
        <ISSNLinking>2210-7401</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALT</Keyword>
        <Keyword MajorTopicYN="N">AST</Keyword>
        <Keyword MajorTopicYN="N">BMI</Keyword>
        <Keyword MajorTopicYN="N">CT</Keyword>
        <Keyword MajorTopicYN="N">CVD</Keyword>
        <Keyword MajorTopicYN="N">FBG</Keyword>
        <Keyword MajorTopicYN="N">HDL</Keyword>
        <Keyword MajorTopicYN="N">HFD</Keyword>
        <Keyword MajorTopicYN="N">HOMA</Keyword>
        <Keyword MajorTopicYN="N">LDC</Keyword>
        <Keyword MajorTopicYN="N">LSR</Keyword>
        <Keyword MajorTopicYN="N">NAFLD</Keyword>
        <Keyword MajorTopicYN="N">NASH</Keyword>
        <Keyword MajorTopicYN="N">ND</Keyword>
        <Keyword MajorTopicYN="N">Nonalcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">OM</Keyword>
        <Keyword MajorTopicYN="N">PAI-1</Keyword>
        <Keyword MajorTopicYN="N">SHAM</Keyword>
        <Keyword MajorTopicYN="N">TG</Keyword>
        <Keyword MajorTopicYN="N">TNF-a</Keyword>
        <Keyword MajorTopicYN="N">Triglycerides</Keyword>
        <Keyword MajorTopicYN="N">VAI</Keyword>
        <Keyword MajorTopicYN="N">VAT</Keyword>
        <Keyword MajorTopicYN="N">WC</Keyword>
        <Keyword MajorTopicYN="N">alanine aminotransferase</Keyword>
        <Keyword MajorTopicYN="N">aspartate aminotransferase</Keyword>
        <Keyword MajorTopicYN="N">body mass index</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">computed tomography</Keyword>
        <Keyword MajorTopicYN="N">fibrinogen fasting levels of glucose</Keyword>
        <Keyword MajorTopicYN="N">high-density lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">high-sensitivity C-reactive protein</Keyword>
        <Keyword MajorTopicYN="N">homeostasis model assessment</Keyword>
        <Keyword MajorTopicYN="N">hs-CRP</Keyword>
        <Keyword MajorTopicYN="N">liver&#x2013;to&#x2013;spleen attenuation ratio</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoproteins</Keyword>
        <Keyword MajorTopicYN="N">nonalcoholic steatohepatitis</Keyword>
        <Keyword MajorTopicYN="N">normal diet</Keyword>
        <Keyword MajorTopicYN="N">omentectomy</Keyword>
        <Keyword MajorTopicYN="N">plasminogen activator inhibitor-1 activity</Keyword>
        <Keyword MajorTopicYN="N">sham-surgery</Keyword>
        <Keyword MajorTopicYN="N">tumor necrosis factor a</Keyword>
        <Keyword MajorTopicYN="N">visceral adipose tissue</Keyword>
        <Keyword MajorTopicYN="N">visceral adiposity index</Keyword>
        <Keyword MajorTopicYN="N">waist circumference</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S2210-7401(13)00180-0</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clinre.2013.08.006</ArticleId>
        <ArticleId IdType="pubmed">24075193</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24072533</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>27</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-9980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Heart Association</Title>
          <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e000402</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.113.000402</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endothelial dysfunction promotes atherosclerosis. We investigated whether in vivo magnetic resonance imaging (MRI) using an albumin-binding contrast agent, gadofosveset, could monitor the efficacy of minocycline and ebselen in reducing endothelial permeability and atherosclerotic burden in the brachiocephalic artery of high-fat diet (HFD)-fed ApoE-/- mice.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">ApoE-/- mice were scanned 12 weeks after commencement of either a normal diet (controls) or an HFD. HFD-fed ApoE-/- mice were either untreated or treated with minocycline or ebselen for 12 weeks. Delayed-enhancement MRI and T1 mapping of the brachiocephalic artery, 30 minutes after injection of gadofosveset, showed increased vessel wall enhancement and relaxation rate (R1, s(-1)) in untreated HFD-fed ApoE-/- mice (R1 = 3.8 &#xB1; 0.52 s(-1)) compared with controls (R1 = 2.15 &#xB1; 0.34 s(-1), P &lt; 0.001). Conversely, minocycline-treated (R1 = 2.7 &#xB1; 0.17 s(-1), P &lt; 0.001) and ebselen-treated (R1 = 2.7 &#xB1; 0.23 s(-1), P &lt; 0.001) ApoE-/- mice showed less vessel wall enhancement compared with untreated HFD-fed ApoE-/- mice. Mass spectroscopy showed a lower gadolinium concentration in the brachiocephalic artery of treated (minocycline = 28.5 &#xB1; 3 &#xB5;mol/L, ebselen = 32.4 &#xB1; 4 &#xB5;mol/L) compared with untreated HFD-fed ApoE-/- mice (191 &#xB1; 4.8 &#xB5;mol/L) (P &lt; 0.02). Both interventions resulted in a lower plaque burden as measured by delayed-enhancement MRI (minocycline = 0.14 &#xB1; 0.02 mm2, ebselen= 0.20 &#xB1; 0.09 mm2), untreated = 0.44 &#xB1; 0.01 mm2; P &lt; 0.001) and histology (minocycline = 0.13 &#xB1; 0.05 mm2, ebselen = 0.18 &#xB1; 0.02 mm2, untreated = 0.32 &#xB1; 0.04 mm2; P &lt; 0.002). Endothelium cells displayed fewer structural changes and smaller gap junction width in treated compared with untreated animals as seen by electron microscopy (minocycline=42.3 &#xB1; 8.4 nm, ebselen = 56.5 &#xB1; 17 nm, untreated = 2400 &#xB1; 39 nm; P &lt; 0.001). Tissue flow cytometry of the brachiocephalic artery showed lower monocyte/macrophage content in both ebselen- and minocycline-treated mice (8.06 &#xB1; 3.2% and 7.62 &#xB1; 1.73%, respectively) compared with untreated animals (20.1 &#xB1; 2.2%) (P = 0.03), with significant attenuation of the proinflammatory Ly6Chigh subtype (untreated mice, 42.64 &#xB1; 6.1% of total monocytes; ebselen, 14.07 &#xB1; 9.5% of total monocytes; minocycline, 26.42 &#xB1; 0.6% of total monocytes).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We demonstrate that contrast-enhanced MRI with an albumin-binding contrast agent can be used to noninvasively monitor the effect of interventions on endothelial permeability and plaque burden. Blood albumin leakage could be a surrogate marker for the in vivo evaluation of interventions that aim at restoring endothelial integrity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Phinikaridou</LastName>
            <ForeName>Alkystis</ForeName>
            <Initials>A</Initials>
            <Affiliation>Division of Imaging Science and Biomedical Engineering, King's College London, London, United Kingdom.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andia</LastName>
            <ForeName>Marcelo E</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Passacquale</LastName>
            <ForeName>Gabriella</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferro</LastName>
            <ForeName>Albert</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botnar</LastName>
            <ForeName>Rene M</ForeName>
            <Initials>RM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>BHF RE/08/003</GrantID>
            <Agency>British Heart Foundation</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>PG/10/044/28343</GrantID>
            <Agency>British Heart Foundation</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Am Heart Assoc</MedlineTA>
        <NlmUniqueID>101580524</NlmUniqueID>
        <ISSNLinking>2047-9980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Albumins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Azoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Contrast Media</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Organometallic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Organoselenium Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>40X2P7DPGH</RegistryNumber>
          <NameOfSubstance>ebselen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AU0V1LM3JT</RegistryNumber>
          <NameOfSubstance>Gadolinium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FYY3R43WGO</RegistryNumber>
          <NameOfSubstance>Minocycline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XM33Q67UVH</RegistryNumber>
          <NameOfSubstance>gadofosveset trisodium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Exp Med. 2007 Nov 26;204(12):3037-47</RefSource>
          <PMID Version="1">18025128</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 2007 Aug 3;317(5838):666-70</RefSource>
          <PMID Version="1">17673663</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cardiovasc Magn Reson. 2008;10:28</RefSource>
          <PMID Version="1">18513419</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Immunol. 2008 Oct 15;181(8):5579-86</RefSource>
          <PMID Version="1">18832716</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Radiology. 2009 Mar;250(3):682-91</RefSource>
          <PMID Version="1">19244042</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JACC Cardiovasc Imaging. 2008 Mar;1(2):167-73</RefSource>
          <PMID Version="1">19356424</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):823-30</RefSource>
          <PMID Version="1">19325139</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2009 May 26;119(20):2708-17</RefSource>
          <PMID Version="1">19433759</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2009 Aug 18;120(7):592-9</RefSource>
          <PMID Version="1">19652086</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1424-32</RefSource>
          <PMID Version="1">19372462</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1412-8</RefSource>
          <PMID Version="1">19759373</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2009 Nov 27;389(4):634-9</RefSource>
          <PMID Version="1">19765544</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>MAGMA. 2009 Dec;22(6):375-83</RefSource>
          <PMID Version="1">19946791</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Cardiol. 2010 Feb;7(2):77-86</RefSource>
          <PMID Version="1">20065951</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2010 Mar 23;55(12):1240-9</RefSource>
          <PMID Version="1">20298932</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Invest Radiol. 2010 May;45(5):275-81</RefSource>
          <PMID Version="1">20351652</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Cardiovasc Imaging. 2010 May;3(3):323-32</RefSource>
          <PMID Version="1">20194634</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2010 Nov 9;56(20):1657-65</RefSource>
          <PMID Version="1">21050976</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2010 Dec;59(12):3198-207</RefSource>
          <PMID Version="1">20823099</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cardiovasc Magn Reson. 2011;13:10</RefSource>
          <PMID Version="1">21269470</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2011 Mar;17(3):383-8</RefSource>
          <PMID Version="1">21336283</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2011 Nov;219(1):74-83</RefSource>
          <PMID Version="1">21719015</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Thromb Haemost. 2011 Nov;106(5):757-62</RefSource>
          <PMID Version="1">21901241</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2012 Aug 7;126(6):707-19</RefSource>
          <PMID Version="1">22753191</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2000 Nov 21;102(21):2582-7</RefSource>
          <PMID Version="1">11085960</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Neurosci. 2001 Apr 15;21(8):2580-8</RefSource>
          <PMID Version="1">11306611</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Magn Reson Imaging. 2002 Jan;15(1):62-7</RefSource>
          <PMID Version="1">11793458</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Pathol. 2002 Mar;160(3):1089-95</RefSource>
          <PMID Version="1">11891205</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Chem Soc. 2002 Mar 27;124(12):3152-62</RefSource>
          <PMID Version="1">11902904</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Radiology. 2002 May;223(2):566-73</RefSource>
          <PMID Version="1">11997569</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Sep 10;106(11):1368-73</RefSource>
          <PMID Version="1">12221054</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Immunity. 2003 Jul;19(1):71-82</RefSource>
          <PMID Version="1">12871640</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cardiovasc Pharmacol. 2003 Oct;42(4):469-76</RefSource>
          <PMID Version="1">14508231</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2003 Oct 23;349(17):1605-13</RefSource>
          <PMID Version="1">14573732</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2003 Nov 4;108(18):2270-4</RefSource>
          <PMID Version="1">14557370</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2004 Feb 20;94(3):377-84</RefSource>
          <PMID Version="1">14670841</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2004 Aug 20;95(4):364-71</RefSource>
          <PMID Version="1">15256478</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32</RefSource>
          <PMID Version="1">15198963</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Apr 27;109(16):2023-9</RefSource>
          <PMID Version="1">15066940</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Acad Radiol. 1996 Aug;3 Suppl 2:S356-8</RefSource>
          <PMID Version="1">8796603</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FEBS Lett. 1996 Dec 2;398(2-3):179-82</RefSource>
          <PMID Version="1">8977102</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Stroke. 1998 Jan;29(1):12-7</RefSource>
          <PMID Version="1">9445321</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur Heart J. 2006 Jul;27(14):1732-6</RefSource>
          <PMID Version="1">16787955</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Immunobiology. 2006;211(6-8):609-18</RefSource>
          <PMID Version="1">16920499</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2007 Jan;117(1):185-94</RefSource>
          <PMID Version="1">17200718</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2007 Jan;117(1):195-205</RefSource>
          <PMID Version="1">17200719</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):961-6</RefSource>
          <PMID Version="1">17215360</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertens Res. 2006 Nov;29(11):905-13</RefSource>
          <PMID Version="1">17345791</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2007 Jul 31;50(5):441-7</RefSource>
          <PMID Version="1">17662397</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am Heart J. 2008 Mar;155(3):584.e1-8</RefSource>
          <PMID Version="1">18294500</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Albumins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Azoles</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Contrast Media</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gadolinium</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName>
          <QualifierName MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Minocycline</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName>
          <QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Organoselenium Compounds</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Permeability</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3835253</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MRI</Keyword>
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">endothelial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">gadofosveset</Keyword>
        <Keyword MajorTopicYN="N">monocytes</Keyword>
        <Keyword MajorTopicYN="N">permeability</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jah3292</ArticleId>
        <ArticleId IdType="doi">10.1161/JAHA.113.000402</ArticleId>
        <ArticleId IdType="pubmed">24072533</ArticleId>
        <ArticleId IdType="pmc">PMC3835253</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24072531</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>27</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-9980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Heart Association</Title>
          <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Loss of cellular inhibitor of apoptosis protein 2 reduces atherosclerosis in atherogenic apoE-/- C57BL/6 mice on high-fat diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e000259</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.113.000259</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cellular inhibitor of apoptosis protein 2 (cIAP2) is predicted to participate in atherosclerosis; however, its direct role in atherosclerosis development has not been investigated. We aimed to examine and assess the loss of cIAP2 on atherosclerosis lesion development.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We used apoE-/- C57BL/6 male mice, either cIAP2-/- or cIAP2+/+. At 8 weeks, mice were fed a high-fat diet (HFD) for 4 and 12 weeks. Aortic root was serially sectioned and stained with Sudan IV, CD68, a-actin, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). cIAP2-/- mice displayed a significant decrease in atherosclerotic lesion's macrophage number after 4 weeks of HFD. Similarly, decrease in lesion area at 4 and 12 weeks HFD was detected by use of en face analysis (cIAP2-/- 0.58 &#xB1; 0.37% versus cIAP2+/+ 1.51 &#xB1; 0.79% [P = 0.0056]); (cIAP2-/- 9.34 &#xB1; 4.88% versus cIAP2+/+ 17.65 &#xB1; 6.24% [P = 0.0019]). Aortic root lesion area after 4 and 12 weeks of HFD also decreased (cIAP2-/- 0.0328 &#xB1; 0.014 mm2 versus cIAP2+/+ 0.0515 &#xB1; 0.021 mm2 [P = 0.022]); (cIAP2-/- 0.3614 &#xB1; 0.1157 mm2 versus cIAP2+/+ 0.4901 &#xB1; 0.125 mm2 [P = 0.065]). TUNEL analysis after 4 and 12 weeks of HFD showed a 2.5-fold increase in TUNEL+ cells (cIAP2-/- 4.47 &#xB1; 2.26% versus cIAP2+/+ 1.74 &#xB1; 0.98% [P = 0.036]); (cIAP2-/- 2.39 &#xB1; 0.75% versus cIAP2+/+ 1.29 &#xB1; 0.47% [P = 0.032]). Smooth muscle cell content in cIAP2-/- mice was 3.075 &#xB1; 3.3% compared with cIAP2+/+ with 0.085 &#xB1; 0.1% (P = 0.0071).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results uncover a key role for cIAP2 in atherosclerotic lesion development, and targeting it may represent a novel therapeutic strategy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sleiman</LastName>
            <ForeName>Lyne</ForeName>
            <Initials>L</Initials>
            <Affiliation>Departments of Pathology and Laboratory Medicine and Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beanlands</LastName>
            <ForeName>Rob</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hasu</LastName>
            <ForeName>Mirela</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thabet</LastName>
            <ForeName>Mohamed</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Norgaard</LastName>
            <ForeName>Alex</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Y X</ForeName>
            <Initials>YX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holcik</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whitman</LastName>
            <ForeName>Stewart</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Am Heart Assoc</MedlineTA>
        <NlmUniqueID>101580524</NlmUniqueID>
        <ISSNLinking>2047-9980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoproteins E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Inhibitor of Apoptosis Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Mol Cell Cardiol. 2011 Feb;50(2):273-9</RefSource>
          <PMID Version="1">21047514</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Med Chem. 2011 Apr 28;54(8):2714-26</RefSource>
          <PMID Version="1">21443232</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cancer Ther. 2011 May;10(5):902-14</RefSource>
          <PMID Version="1">21372226</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1506-16</RefSource>
          <PMID Version="1">21677293</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Immunity. 2011 Dec 23;35(6):897-907</RefSource>
          <PMID Version="1">22195745</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Death Differ. 2012 Nov;19(11):1791-801</RefSource>
          <PMID Version="1">22576661</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2000 Jul 7;102(1):33-42</RefSource>
          <PMID Version="1">10929711</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2000 Jul 7;102(1):43-53</RefSource>
          <PMID Version="1">10929712</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Genes Dev. 2000 Sep 1;14(17):2123-33</RefSource>
          <PMID Version="1">10970876</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2000 Dec 15;1524(2-3):178-82</RefSource>
          <PMID Version="1">11113565</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2000 Dec 21-28;408(6815):1008-12</RefSource>
          <PMID Version="1">11140638</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2001 Feb 23;104(4):503-16</RefSource>
          <PMID Version="1">11239408</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2001 Apr 27;88(8):780-6</RefSource>
          <PMID Version="1">11325869</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10</RefSource>
          <PMID Version="1">12042762</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Methods Mol Biol. 2003;209:293-309</RefSource>
          <PMID Version="1">12357958</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Immunol Methods. 1983 Dec 16;65(1-2):55-63</RefSource>
          <PMID Version="1">6606682</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1991 Dec 25;266(36):24785-92</RefSource>
          <PMID Version="1">1761573</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1995 Aug;96(2):1118-24</RefSource>
          <PMID Version="1">7635947</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 1996 Jan 25;379(6563):349-53</RefSource>
          <PMID Version="1">8552191</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>EMBO J. 1996 Jun 3;15(11):2685-94</RefSource>
          <PMID Version="1">8654366</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10057-62</RefSource>
          <PMID Version="1">9294162</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1519-22</RefSource>
          <PMID Version="1">9763521</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Genes Dev. 1999 Feb 1;13(3):239-52</RefSource>
          <PMID Version="1">9990849</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FASEB J. 1999 Mar;13(3):485-94</RefSource>
          <PMID Version="1">10064615</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Blood. 1999 May 15;93(10):3418-31</RefSource>
          <PMID Version="1">10233894</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):174-9</RefSource>
          <PMID Version="1">15499039</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Oncol. 2005 Mar;16(3):455-9</RefSource>
          <PMID Version="1">15642706</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1256-61</RefSource>
          <PMID Version="1">15831805</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int Immunopharmacol. 2005 Sep;5(10):1487-506</RefSource>
          <PMID Version="1">16023601</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2005 Mar;1(3):201-13</RefSource>
          <PMID Version="1">16054063</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2255-64</RefSource>
          <PMID Version="1">16141399</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Biol. 2006 Jan;26(2):699-708</RefSource>
          <PMID Version="1">16382159</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2006 Jan 13;281(2):1080-90</RefSource>
          <PMID Version="1">16282325</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Apoptosis. 2006 Oct;11(10):1661-75</RefSource>
          <PMID Version="1">16951924</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):901-7</RefSource>
          <PMID Version="1">17255535</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Mol Pathol. 2007 Aug;83(1):11-6</RefSource>
          <PMID Version="1">17208224</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2008 Feb 1;77(3):471-80</RefSource>
          <PMID Version="1">18006460</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2008 Jun 20;102(12):1529-38</RefSource>
          <PMID Version="1">18497329</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11778-83</RefSource>
          <PMID Version="1">18697935</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2009 Jan 9;378(2):162-7</RefSource>
          <PMID Version="1">18992220</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2009 Dec;207(2):399-404</RefSource>
          <PMID Version="1">19608184</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell. 2010 Apr 9;38(1):101-13</RefSource>
          <PMID Version="1">20385093</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2010 May 18;55(20):2258-68</RefSource>
          <PMID Version="1">20381282</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11936-41</RefSource>
          <PMID Version="1">20547836</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1916-24</RefSource>
          <PMID Version="1">20671230</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Mol Pathol. 2011 Feb;90(1):1-8</RefSource>
          <PMID Version="1">21075101</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoproteins E</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Inhibitor of Apoptosis Proteins</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3835229</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">C57BL/6 mice</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">cIAP2</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jah3315</ArticleId>
        <ArticleId IdType="doi">10.1161/JAHA.113.000259</ArticleId>
        <ArticleId IdType="pubmed">24072531</ArticleId>
        <ArticleId IdType="pmc">PMC3835229</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24069865</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1898-2263</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Annals of agricultural and environmental medicine : AAEM</Title>
          <ISOAbbreviation>Ann Agric Environ Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The level of health education in the Polish population.</ArticleTitle>
        <Pagination>
          <MedlinePgn>559-65</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The study assessed factors influencing awareness of Poles concerning lifestyle factors that affect development of obesity, type 2 diabetes and cardiovascular diseases (CVD).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A questionnaire survey covering awareness of lifestyle factors performed by general practitioners in 37,557 unselected patients.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">96.1% of respondents believed that lifestyle has an impact on the occurrence of CVDs, especially: tobacco smoking (91.4%), excessive intake of fat (81.3%), alcohol (67.5%), salt (64.9%), and stress (64.9%). 79.0% respondents believed the smoking cessation, 77.5% weight loss and 66.8% healthy diet are most important to prevent diseases. Additionally, the belief in the need for an early weight reduction decreased with increasing BMI (82.9% with normal weight vs. 77.5% overweight and 70.4% obese). The most common source of health education was a physician (75.8%), the mass media, such as television and the press (62.0% and 64.8%, respectively), less often were educational materials (37.8%) and books (20.3 %), the Internet (3.8%) and radio (0.8%). Younger respondents presented a higher level of awareness about all analysed aspects of healthy lifestyle. The multiple regression analysis revealed that low education level and rural residence are the most important factors decreasing awareness of the lifestyle effect on health.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">1. The level of knowledge about non-pharmacological methods of preventing lifestyle diseases in the Polish population is high except of the role of physical activity and daily vegetables consumption. This, however, has no impact on reducing the percentage of overweight and obese people and on increasing the tendency to pursue lifestyle changes. 2. Frustrating is the fact that more than one fifth of the study population is unaware that excessive weight reduction prevents development of cardiovascular diseases. Moreover, the convince to early weight decreases with increasing BMI. 3. The highest level of the knowledge among younger subjects reflect improvement of health education in Polish population. 4. In addition to education performed by physician the main sources of patients knowledge are television and the press with the growing role of the Internet among younger. 5. Further health education programs are necessary, which should include not only activities that increase the level of health education and health awareness, but also aspects such as changes in beliefs, sense of self-efficacy and social support.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Olszanecka-Glinianowicz</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
            <Affiliation>Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, Katowice, Poland.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chudek</LastName>
            <ForeName>Jerzy</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Poland</Country>
        <MedlineTA>Ann Agric Environ Med</MedlineTA>
        <NlmUniqueID>9500166</NlmUniqueID>
        <ISSNLinking>1232-1966</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1067440</ArticleId>
        <ArticleId IdType="pubmed">24069865</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24066597</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>26</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1001-5302</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>38</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica</Title>
          <ISOAbbreviation>Zhongguo Zhong Yao Za Zhi</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Experimental study on anti-atherosclerotic effect of compatibility of active components of danshen and shanzha].</ArticleTitle>
        <Pagination>
          <MedlinePgn>1987-91</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of active components of Danshen and Shanzha of different matching proportions on atherosclerosis (AS), in the expectation of obtaining the optimum combination method.</AbstractText>
          <AbstractText Label="METHOD" NlmCategory="METHODS">Atherosclerotic rats were fed with high fat diet, and injected with vitamin D3 and ovalbumin. Aqueous extracts of Danshen (DSA) and Shanzha (SZA) and lipophilic extracts of danshen (DSL) were adopted for a low, medium and high-dose orthogonal experiment, to observe the effect of their different matching proportions on lipid level, oxidative stress, endothelial function and inflammatory reaction. The principal component analysis and cluster analysis were adopted for the multi-objective optimization of experimental results.</AbstractText>
          <AbstractText Label="RESULT" NlmCategory="RESULTS">Compared with the model group, all of samples with different proportions of DSA, DSL and SZA showed effect in lowering lipid level, scavenging free radicals, reducing endothelial dysfunction and inhibiting inflammation. According to the variance analysis, DSA2-SZA2-DSL1, DSA3-SZA2-DSL1, DSA3-SZA3 -DSL3 and DSA3-SZA1-DSL1 were the optimal proportions for lowering lipid level, scavenging free radicals, reducing endothelial dysfunction and inhibiting inflammation, respectively. According to the results of the multi-objective optimization, DSA2-SZA1-DSL2 was the optimal proportions of anti-AS.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">All of active components of Danshen and Shanzha of different matching proportions show the anti-AS effect in rats to varying degrees, but with different focus in different matching proportions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jian-Yong</ForeName>
            <Initials>JY</Initials>
            <Affiliation>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. riskeen@sina.com</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Ren-Yi</ForeName>
            <Initials>RY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lan</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jian-Lu</ForeName>
            <Initials>JL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wan-Dan</ForeName>
            <Initials>WD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Hong-Liang</ForeName>
            <Initials>HL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hong-Jun</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Ri-Xin</ForeName>
            <Initials>RX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
          </Author>
        </AuthorList>
        <Language>chi</Language>
        <PublicationTypeList>
          <PublicationType>English Abstract</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>Zhongguo Zhong Yao Za Zhi</MedlineTA>
        <NlmUniqueID>8913656</NlmUniqueID>
        <ISSNLinking>1001-5302</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Phenanthrolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>shanzha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>79483-68-4</RegistryNumber>
          <NameOfSubstance>dan-shen root extract</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Phenanthrolines</DescriptorName>
          <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Phytotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Salvia miltiorrhiza</DescriptorName>
          <QualifierName MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24066597</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24063548</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>1</Month>
        <Day>10</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-7716</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Antioxidants &amp; redox signaling</Title>
          <ISOAbbreviation>Antioxid. Redox Signal.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PTEN Phosphorylation and Nuclear Export Mediate Free Fatty Acid-Induced Oxidative Stress.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Abstract Aim: Oxidative stress induced by free fatty acids (FFA) contributes to metabolic syndrome-associated development of cardiovascular diseases, yet molecular mechanisms remain poorly understood. This study aimed at establishing whether phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and its subcellular location play a role in FFA-induced endothelial oxidative stress. Results: Exposing human endothelial cells (ECs) with FFA activated mammalian target of rapamycin (mTOR)/S6K pathway, and upon activation, S6K directly phosphorylated PTEN at S380. Phosphorylation of PTEN increased its interaction with its deubiquitinase USP7 in the nucleus, leading to PTEN deubiquitination and nuclear export. The reduction of PTEN in the nucleus, in turn, decreased p53 acetylation and transcription, reduced the expression of the p53 target gene glutathione peroxidase-1 (GPX1), resulting in reactive oxygen species (ROS) accumulation and endothelial damage. Finally, C57BL/6J mice fed with high-fat atherogenic diet (HFAD) showed PTEN nuclear export, decreased p53 and GPX1 protein expressions, elevated levels of ROS, and significant lesions in aortas. Importantly, inhibition of mTOR or S6K effectively blocked these effects, suggesting that mTOR/S6K pathway mediates HFAD-induced oxidative stress and vascular damage via PTEN/p53/GPX1 inhibition in vivo. Innovation: Our study demonstrated for the first time that S6K directly phosphorylated PTEN at S380 under high FFA conditions, and this phosphorylation mediated FFA-induced endothelial oxidative stress. Furthermore, we showed that S380 phosphorylation affected PTEN monoubiquitination and nuclear localization, providing the first example of coordinated regulation of PTEN nuclear localization via phosphorylation and ubiquitination. Conclusion: Our studies provide a novel mechanism by which hyperlipidemia causes vascular oxidative damage through the phosphorylation of PTEN, blocking of PTEN nuclear function, and inhibition of p53/GPX1 activity. Antioxid. Redox Signal. 00, 000-000.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Wu</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <Affiliation>1 Department of Biochemistry, University of California , Riverside, California.</Affiliation>
          </Author>
          <Author>
            <LastName>Zhou</LastName>
            <ForeName>Hillary</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author>
            <LastName>Wu</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author>
            <LastName>Lee</LastName>
            <ForeName>Sangkyu</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Ruijin</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author>
            <LastName>Liu</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Antioxid Redox Signal</MedlineTA>
        <NlmUniqueID>100888899</NlmUniqueID>
        <ISSNLinking>1523-0864</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1089/ars.2013.5498</ArticleId>
        <ArticleId IdType="pubmed">24063548</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24060958</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>22</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1759-5010</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Cardiology</Title>
          <ISOAbbreviation>Nat Rev Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Demystifying the management of hypertriglyceridaemia.</ArticleTitle>
        <Pagination>
          <MedlinePgn>648-61</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrcardio.2013.140</ELocationID>
        <Abstract>
          <AbstractText>Hypertriglyceridaemia (typical triglyceride level 1.7-5.0 mmol/l) is caused by interactions between many genetic and nongenetic factors, and is a common risk factor for atherosclerotic cardiovascular disease (CVD). Patients with hypertriglyceridaemia usually present with obesity, insulin resistance, hepatic steatosis, ectopic fat deposition, and diabetes mellitus. Hypertriglyceridaemia reflects the accumulation in plasma of proatherogenic lipoproteins, triglyceride-rich lipoprotein (TRL) remnants, and small, dense LDL particles. Mendelian randomization studies and research on inherited dyslipidaemias, such as type III dysbetalipoproteinaemia, testify that TRLs are causally related to atherosclerotic CVD. Extreme hypertriglyceridaemia (a triglyceride level &gt;20 mmol/l) is rare, often monogenic in aetiology, and frequently causes pancreatitis. Treatment of hypertriglyceridaemia relies on correcting secondary factors and unhealthy lifestyle habits, particularly poor diet and lack of exercise. Pharmacotherapy is indicated for patients with established CVD or individuals at moderate-to-high risk of CVD, primarily those with metabolic syndrome or diabetes. Statins are the cornerstone of treatment, followed by fibrates and n-3 fatty acids, to achieve recommended therapeutic levels of plasma LDL cholesterol, non-HDL cholesterol, and apolipoprotein (apo) B-100. The case for using niacin has been weakened by the results of clinical trials, but needs further investigation. Extreme hypertriglyceridaemia requires strict dietary measures, and patients with a diagnosis of genetic lipoprotein lipase deficiency might benefit from LPL gene replacement therapy. Several therapies for regulating TRL metabolism, including inhibitors of diacylglycerol O-acyltransferase and microsomal triglyceride transfer protein, and apoC-III antisense oligonucleotides, merit further investigation in patients with hypertriglyceridaemia.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Watts</LastName>
            <ForeName>Gerald F</ForeName>
            <Initials>GF</Initials>
            <Affiliation>Lipid Disorders Clinic and Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, PO Box X2213, Perth, WA 6847, Australia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ooi</LastName>
            <ForeName>Esther M M</ForeName>
            <Initials>EM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Dick C</ForeName>
            <Initials>DC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Cardiol</MedlineTA>
        <NlmUniqueID>101500075</NlmUniqueID>
        <ISSNLinking>1759-5002</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">nrcardio.2013.140</ArticleId>
        <ArticleId IdType="doi">10.1038/nrcardio.2013.140</ArticleId>
        <ArticleId IdType="pubmed">24060958</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
      <PMID Version="1">24050894</PMID>
      <DateCreated>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-3792</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>191</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of urology</Title>
          <ISOAbbreviation>J. Urol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Soluble Guanylyl Cyclase Activator BAY 60-2770 Ameliorates Overactive Bladder in Obese Mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>539-47</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2013.09.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-5347(13)05449-9</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Activators of soluble guanylyl cyclase are of potential interest as treatment for cardiovascular diseases but to our knowledge they have never been proposed to treat overactive bladder. We evaluated the effects of the soluble guanylyl cyclase activator BAY 60-2270 on voiding dysfunction and detrusor overactivity in a mouse model of obesity associated overactive bladder.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">C57BL/6 male mice fed for 10 weeks with standard chow or a high fat diet were treated with 1 mg/kg BAY 60-2770 per day for 2&#xA0;weeks via gavage. Cystometric evaluations were done and responses to contractile agents in isolated bladders were determined.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Obese mice showed an irregular micturition pattern characterized by&#xA0;significant increases in voiding and nonvoiding contractions, which were normalized by BAY 60-2770. Carbachol, KCl and CaCl2 produced concentration dependent contractions in isolated bladder strips, which were markedly greater in obese than in lean mice. BAY 60-2770 normalized bladder contractions in the obese group. A 78% increase in reactive oxygen species generation in the bladder tissue of obese mice was observed, which was unaffected by BAY 60-2770. Treatment with BAY 60-2770 generated a tenfold increase in cyclic guanosine monophosphate in the bladders of obese mice without affecting the nucleotide level in the lean group. Protein expression of the soluble guanylyl cyclase a1 and &#xDF;1 subunits was decreased 40% in the bladder tissue of obese mice but restored by BAY 60-2770.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Two-week BAY 60-2770 therapy increased cyclic guanosine monophosphate and rescued expression of the soluble guanylyl cyclase a1 and &#xDF;1&#xA0;subunits in bladder tissue, resulting in great amelioration of bladder dysfunction.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Leiria</LastName>
            <ForeName>Luiz O</ForeName>
            <Initials>LO</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Fabio H</ForeName>
            <Initials>FH</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davel</LastName>
            <ForeName>Ana Paula C</ForeName>
            <Initials>AP</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alexandre</LastName>
            <ForeName>Eduardo C</ForeName>
            <Initials>EC</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calixto</LastName>
            <ForeName>Marina C</ForeName>
            <Initials>MC</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Nucci</LastName>
            <ForeName>Gilberto</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>M&#xF3;nica</LastName>
            <ForeName>Fab&#xED;ola Z</ForeName>
            <Initials>FZ</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Antunes</LastName>
            <ForeName>Edson</ForeName>
            <Initials>E</Initials>
            <Affiliation>Department of Pharmacology, Faculty of Medical Sciences and Department of Anatomy, Cellular Biology, Physiology and Biophysics, Institute of Biology (APCD), University of Campinas, Campinas, Brazil. Electronic address: antunes@fcm.unicamp.br.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Urol</MedlineTA>
        <NlmUniqueID>0376374</NlmUniqueID>
        <ISSNLinking>0022-5347</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">LDL</Keyword>
        <Keyword MajorTopicYN="N">NO</Keyword>
        <Keyword MajorTopicYN="N">NVC</Keyword>
        <Keyword MajorTopicYN="N">OAB</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">cGMP</Keyword>
        <Keyword MajorTopicYN="N">cyclic guanosine monophosphate</Keyword>
        <Keyword MajorTopicYN="N">low density lipoprotein</Keyword>
        <Keyword MajorTopicYN="N">lower urinary tract symptoms</Keyword>
        <Keyword MajorTopicYN="N">nitric oxide</Keyword>
        <Keyword MajorTopicYN="N">nonvoiding contraction</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">overactive</Keyword>
        <Keyword MajorTopicYN="N">overactive bladder</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen species</Keyword>
        <Keyword MajorTopicYN="N">sGC</Keyword>
        <Keyword MajorTopicYN="N">soluble guanylate cyclase</Keyword>
        <Keyword MajorTopicYN="N">soluble guanylyl cyclase</Keyword>
        <Keyword MajorTopicYN="N">urinary bladder</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24050894</ArticleId>
        <ArticleId IdType="pii">S0022-5347(13)05449-9</ArticleId>
        <ArticleId IdType="doi">10.1016/j.juro.2013.09.020</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24050803</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1741-7015</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>BMC medicine</Title>
          <ISOAbbreviation>BMC Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial.</ArticleTitle>
        <Pagination>
          <MedlinePgn>207</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1741-7015-11-207</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypertension can be prevented by adopting healthy dietary patterns. Our aim was to assess the 4-year effect on blood pressure (BP) control of a randomized feeding trial promoting the traditional Mediterranean dietary pattern.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The PREDIMED primary prevention trial is a randomized, single-blinded, controlled trial conducted in Spanish primary healthcare centers. We recruited 7,447 men (aged 55 to 80 years) and women (aged 60 to 80 years) who had high risk for cardiovascular disease. Participants were assigned to a control group or to one of two Mediterranean diets. The control group received education on following a low-fat diet, while the groups on Mediterranean diets received nutritional education and also free foods; either extra virgin olive oil, or nuts. Trained personnel measured participants' BP at baseline and once yearly during a 4-year follow-up. We used generalized estimating equations to assess the differences between groups during the follow-up.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The percentage of participants with controlled BP increased in all three intervention groups (P-value for within-group changes: P&lt;0.001). Participants allocated to either of the two Mediterranean diet groups had significantly lower diastolic BP than the participants in the control group (-1.53 mmHg (95% confidence interval (CI) -2.01 to -1.04) for the Mediterranean diet supplemented with extra virgin olive oil, and -0.65 mmHg (95% CI -1.15 to -0.15) mmHg for the Mediterranean diet supplemented with nuts). No between-group differences in changes of systolic BP were seen.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both the traditional Mediterranean diet and a low-fat diet exerted beneficial effects on BP and could be part of advice to patients for controlling BP. However, we found lower values of diastolic BP in the two groups promoting the Mediterranean diet with extra virgin olive oil or with nuts than in the control group.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Current Controlled Trials ISRCTN35739639.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Toledo</LastName>
            <ForeName>Estefania</ForeName>
            <Initials>E</Initials>
            <Affiliation>Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Navarra, Spain. mamartinez@unav.es.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Frank B</ForeName>
            <Initials>FB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Estruch</LastName>
            <ForeName>Ramon</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buil-Cosiales</LastName>
            <ForeName>Pilar</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corella</LastName>
            <ForeName>Dolores</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salas-Salvad&#xF3;</LastName>
            <ForeName>Jordi</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covas</LastName>
            <ForeName>M Isabel</ForeName>
            <Initials>MI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ar&#xF3;s</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>G&#xF3;mez-Gracia</LastName>
            <ForeName>Enrique</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiol</LastName>
            <ForeName>Miquel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lapetra</LastName>
            <ForeName>Jose</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Serra-Majem</LastName>
            <ForeName>Luis</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinto</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamuela-Ravent&#xF3;s</LastName>
            <ForeName>Rosa M</ForeName>
            <Initials>RM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saez</LastName>
            <ForeName>Guillermo</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bull&#xF3;</LastName>
            <ForeName>M&#xF2;nica</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruiz-Guti&#xE9;rrez</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ros</LastName>
            <ForeName>Emilio</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sorli</LastName>
            <ForeName>Jos&#xE9; V</ForeName>
            <Initials>JV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinez-Gonzalez</LastName>
            <ForeName>Miguel Angel</ForeName>
            <Initials>MA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ISRCTN</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>ISRCTN35739639</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Med</MedlineTA>
        <NlmUniqueID>101190723</NlmUniqueID>
        <ISSNLinking>1741-7015</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Med Sci Sports Exerc. 2000 Aug;32(8):1431-7</RefSource>
          <PMID Version="1">10949009</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2013 May 23;368(21):2004-13</RefSource>
          <PMID Version="1">23697515</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2002 Dec 14;360(9349):1903-13</RefSource>
          <PMID Version="1">12493255</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2003 May 21;289(19):2560-72</RefSource>
          <PMID Version="1">12748199</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2003 Jun 26;348(26):2599-608</RefSource>
          <PMID Version="1">12826634</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Epidemiol. 1993 Jun;22(3):512-9</RefSource>
          <PMID Version="1">8359969</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 1994 Jun 15;139(12):1197-209</RefSource>
          <PMID Version="1">8209878</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1995 Jun;61(6 Suppl):1402S-1406S</RefSource>
          <PMID Version="1">7754995</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 1997 Apr 17;336(16):1117-24</RefSource>
          <PMID Version="1">9099655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2006 Feb;47(2):296-308</RefSource>
          <PMID Version="1">16434724</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2006 May 27;367(9524):1747-57</RefSource>
          <PMID Version="1">16731270</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Intern Med. 2006 Jul 4;145(1):1-11</RefSource>
          <PMID Version="1">16818923</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2008 May 3;371(9623):1513-8</RefSource>
          <PMID Version="1">18456100</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 2009 Feb 1;169(3):339-46</RefSource>
          <PMID Version="1">19037007</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMJ. 2009;338:b1170</RefSource>
          <PMID Version="1">19332452</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Public Health Nutr. 2010 Mar;13(3):338-49</RefSource>
          <PMID Version="1">19656442</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2010 Jun;103(12):1808-16</RefSource>
          <PMID Version="1">20102675</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2010 Nov;92(5):1189-96</RefSource>
          <PMID Version="1">20810976</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2011 Mar 15;57(11):1299-313</RefSource>
          <PMID Version="1">21392646</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2011 Jun;141(6):1140-5</RefSource>
          <PMID Version="1">21508208</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Nutr. 2011 May;2(3):293-4</RefSource>
          <PMID Version="1">22332062</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Epidemiol. 2012 Apr;41(2):377-85</RefSource>
          <PMID Version="1">21172932</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2012 May 8;125(18):2204-11</RefSource>
          <PMID Version="1">22492580</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2013 Apr 4;368(14):1279-90</RefSource>
          <PMID Version="1">23432189</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Aten Primaria. 2002 Jun 15;30(1):22-8</RefSource>
          <PMID Version="1">12106576</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3849640</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1741-7015-11-207</ArticleId>
        <ArticleId IdType="doi">10.1186/1741-7015-11-207</ArticleId>
        <ArticleId IdType="pubmed">24050803</ArticleId>
        <ArticleId IdType="pmc">PMC3849640</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24047636</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1576-8260</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Archivos espa&#xF1;oles de urolog&#xED;a</Title>
          <ISOAbbreviation>Arch. Esp. Urol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Patient with testosterone deficit syndrome and dyslipemia].</ArticleTitle>
        <Pagination>
          <MedlinePgn>752-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We define dyslipemia as the abnormally elevated presence of lipids in the blood. The main ones are hypercholesterolemia (cholesterol over 240 mg/dl), hypertrigliceridemia (triglicerides level over 200 mg/dl) and hipo-alphalipoproteinemia (High density lipoproteins,also called HDL Cholesterol, below 40 mg/dl). The presence of excessive lipids contributes to arteriosclerosis and they are an independent cardiovascular risk factor. It may be primary, if they have genetic origin and they are not associated with other diseases, but in most cases they are secondary to other pathological entities such as diabetes, hypothyroidism, obesity and metabolic syndrome (MS). In our current society, sedentary lifestyle and unadequatelly hypercaloric diets are making obesity and MS prevalences grow, and their relation to dyslipemias has become tighter. Obesity is related with all the criteria for MS. But obesity is not at all synonymous of MS. On the one hand neither fat distribution is the same in all individualas nor confers the same risk. Accordingly, we know that abdominal localization of fat is related to higher intensity of insulin resistance (IR) and MS. On the other hand, it seems that certain components of MS are determined by genetic factors, since there are morbid obese persons that are metabolically healthy and other patients develop insulin resistance without obesity. So that, it seems that the excess in visceral adiposity in the presence of certain genetic factors would be the most related cause of the appearance of peripheral insulin resistance and diabetes mellitus, hyperlipidemia (increase of very low density pipoproteins (VLDL), decrease of highdensity lipoproteins (HDL) arterial hypertension, and hypogonadotropic hypogonadism, composing what we call metabolic syndrome. In this scenario, we urologists are being first-hand witnesses.On the one hand, and in relation with cardiovascular risk factors, we know that all of them, and independently,not only can produce erectile dysfunction due to endothelial dysfunction, but also it generally appears years before the cardiovascular event. On the other hand, and in relation to the hypogonadotropic hypogonadism of patients with MS, we urologists may contributein greatly to the detection of patients with MS whose only symptom is erectile dysfunction or diminished libido, but specially we may play a key role in the improvement of these patients, since it is known that testosterone replacement therapy has a major potential to diminish or stop the progression of MS or its cardiovascular effects. Testosterone treatment not only improves the lipid profile, hypertension, insulin resistance, or reduces the abdominal circumference, but also it may help to get a better adherence to diet and exercise, so contributing to change unhealthy lifestyle habits whch are the origin of the problem.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sola Galarza</LastName>
            <ForeName>Ignacio</ForeName>
            <Initials>I</Initials>
            <Affiliation>Servicio de Urologia. Hospital Fundacion Alcorcon. Madrid.Spain.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>L&#xF3;pez L&#xF3;pez</LastName>
            <ForeName>Borja</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Llorente Abarca</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>spa</Language>
        <PublicationTypeList>
          <PublicationType>English Abstract</PublicationType>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Paciente con SDT y dislipemia.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Spain</Country>
        <MedlineTA>Arch Esp Urol</MedlineTA>
        <NlmUniqueID>0064757</NlmUniqueID>
        <ISSNLinking>0004-0614</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24047636</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24044965</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>20</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2163</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>285</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <MedlineDate>2013 Sep-Oct</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>Cellular immunology</Title>
          <ISOAbbreviation>Cell. Immunol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor--fosinopril.</ArticleTitle>
        <Pagination>
          <MedlinePgn>38-41</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cellimm.2013.08.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0008-8749(13)00145-7</ELocationID>
        <Abstract>
          <AbstractText>Recently, angiotensin-converting enzyme inhibitor (ACEI) has gained increasing attention for its anti-atherosclerosis activity, but the underlying mechanism is unknown. In our study, we used rabbits fed with high-fat forage, as an atherosclerosis model to investigate the effect of fosinopril, which is an ACEI. Animals which received both high-fat forage and fosinopril, were maintained as the drug-treated group. Ultrasonography and Sudan III staining were used to determine the process of atherosclerosis. The expression of TLR4 and activity NF-?B were determined using western blot, RT-PCR and ELISA. The results showed that the atherosclerotic plaque was visible at sixteen weeks. More importantly, the atherosclerotic plaque was significantly decreased after fosinopril treatment. In the atherosclerosis model, the levels of TLR4 and NF-?B were increased, but this increased expression was inhibited in the fosinopril treated group. Our results demonstrated that TLR4 could be used as a potential biomarker for atherosclerosis and ACEI has the potential to be a new anti-atherosclerotic drug.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Shuansuo</ForeName>
            <Initials>S</Initials>
            <Affiliation>Department of Cardiology, Central Hospital, Fengxian District, Shanghai 201400, China. Electronic address: zyqwyf347@hotmail.com.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ruogu</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qu</LastName>
            <ForeName>Xinkai</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ge</LastName>
            <ForeName>Guanghao</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Jiangwei</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Huajin</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiao</LastName>
            <ForeName>Zengyong</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Weiyi</ForeName>
            <Initials>W</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Immunol</MedlineTA>
        <NlmUniqueID>1246405</NlmUniqueID>
        <ISSNLinking>0008-8749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Biological Markers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R43D2573WO</RegistryNumber>
          <NameOfSubstance>Fosinopril</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fosinopril</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Plaque, Atherosclerotic</DescriptorName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Fosinopril</Keyword>
        <Keyword MajorTopicYN="N">NF-?B</Keyword>
        <Keyword MajorTopicYN="N">TLR4</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24044965</ArticleId>
        <ArticleId IdType="pii">S0008-8749(13)00145-7</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cellimm.2013.08.003</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24044579</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-511X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Lipids in health and disease</Title>
          <ISOAbbreviation>Lipids Health Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>136</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1476-511X-12-136</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The metabolic syndrome (MS) is characterized by variable coexistence of metabolic and pathophysiological alterations which are important risk factors for developing of type II diabetes and/or cardiovascular diseases. Increased of MS patients in worldwide has stimulated the development of experimental models. However, it is still challenging to find an dietetic model that most closely approximates human MS and, in addition, is not yet fully established the effect of different diets of MS in lipid metabolism in rats of different ages. The aim of this study was to evaluate the effect of different diets of MS in lipid metabolism and ectopic fat deposition and define the most appropriate diet for inducing the characteristic disturbances of the human MS in rats of different ages.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Young (4 weeks old) and adult rats (12 weeks old) were given a high-fat (FAT) or high-fructose diet (FRU) for 13 weeks and biochemical, physiological, histological and biometric parameters were evaluated.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In young rats, the FAT diet induced increased mean blood pressure (MAP) and heart rate (HR), body weight after 6 to 10 weeks, and in the 13th week, increased the liver, mesenteric, retroperitoneal and epididymal fat weights, fasting glucose, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and reduced HDL cholesterol; and also induced non-alcoholic fatty liver disease (NAFLD) and renal inflammatory infiltrates. In adult rats, the FRU diet induced transient elevations of MAP and HR in the 6th week, and, at 13 weeks, increased fasting glucose, triglycerides, total cholesterol, AST and ALT; increased liver, kidneys and retroperitoneal fat weights; and induced macrovesicular and microvesicular NAFLD, the presence of fat cells in the kidney, glomerular sclerosis, and liver and kidney inflammation. Additionally, the FAT and FRU diets induced, respectively, increases in liver glycogen in adults and young rats.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data show that FRU diet in adult rats causes biggest change on metabolism of serum lipids and lipid accumulation in liver and kidney, while the FAT diet in young rats induces elevation of MAP and HR and higher increased visceral lipid stores, constituting the best nutritional interventions to induce MS in rats.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>de Castro</LastName>
            <ForeName>Uberdan Guilherme Mendes</ForeName>
            <Initials>UG</Initials>
            <Affiliation>Departamento de Ci&#xEA;ncias Biol&#xF3;gicas, Instituto de Ci&#xEA;ncias Exatas e Biol&#xF3;gicas, Universidade Federal de Ouro Preto, Morro do Cruzeiro, Ouro Preto, MG 35 400-000, Brazil. andreiaalzamora@iceb.ufop.br.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>dos Santos</LastName>
            <ForeName>Robson Augusto Souza</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Marcelo Eust&#xE1;quio</ForeName>
            <Initials>ME</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Lima</LastName>
            <ForeName>Wanderson Geraldo</ForeName>
            <Initials>WG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Campagnole-Santos</LastName>
            <ForeName>Maria Jos&#xE9;</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alzamora</LastName>
            <ForeName>Andr&#xE9;ia Carvalho</ForeName>
            <Initials>AC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lipids Health Dis</MedlineTA>
        <NlmUniqueID>101147696</NlmUniqueID>
        <ISSNLinking>1476-511X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1981 Nov 25;256(22):11724-33</RefSource>
          <PMID Version="1">6271759</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R943-9</RefSource>
          <PMID Version="1">15191907</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Obes. 1990 Dec;14(12):1085-94</RefSource>
          <PMID Version="1">2086500</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1992 Oct;56(4):616-22</RefSource>
          <PMID Version="1">1414959</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1993 Nov;58(5 Suppl):796S-799S</RefSource>
          <PMID Version="1">8213612</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1995 Aug;269(2 Pt 2):H629-37</RefSource>
          <PMID Version="1">7653627</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1997 May;127(5 Suppl):838S-841S</RefSource>
          <PMID Version="1">9164249</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1998 Jan 2;273(1):17-9</RefSource>
          <PMID Version="1">9417039</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertens Res. 1998 Jun;21(2):73-80</RefSource>
          <PMID Version="1">9661802</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1998 Sep;275(3 Pt 2):R788-92</RefSource>
          <PMID Version="1">9728076</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Pharmacol. 1999 Jun 4;373(2-3):R1-4</RefSource>
          <PMID Version="1">10414447</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2005 May;45(5):1012-8</RefSource>
          <PMID Version="1">15824194</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Biochem. 2005 Jun;38(6):540-7</RefSource>
          <PMID Version="1">15885234</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2005 Oct;46(4):806-11</RefSource>
          <PMID Version="1">16157789</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2013;8(2):e56681</RefSource>
          <PMID Version="1">23451068</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Biochem. 2013 Jul;24(7):1285-94</RefSource>
          <PMID Version="1">23332601</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Food Chem. 2013 Dec 15;141(4):3627-35</RefSource>
          <PMID Version="1">23993530</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Life Sci. 2006 Feb 9;78(11):1155-62</RefSource>
          <PMID Version="1">16436285</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2006 Mar;290(3):F625-31</RefSource>
          <PMID Version="1">16234313</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Biol Med (Maywood). 2006 Apr;231(4):456-62</RefSource>
          <PMID Version="1">16565441</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Appl Physiol (1985). 2006 May;100(5):1467-74</RefSource>
          <PMID Version="1">16357064</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2006 Jul;48(1):65-72</RefSource>
          <PMID Version="1">16702491</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2007 Jan;292(1):F423-9</RefSource>
          <PMID Version="1">16940562</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Braz J Med Biol Res. 2007 Mar;40(3):323-31</RefSource>
          <PMID Version="1">17334529</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Obesity (Silver Spring). 2007 Apr;15(4):798-808</RefSource>
          <PMID Version="1">17426312</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2007 Nov;113(10):417-25</RefSource>
          <PMID Version="1">17608620</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ren Fail. 2008;30(6):645-54</RefSource>
          <PMID Version="1">18661416</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E227-37</RefSource>
          <PMID Version="1">18398011</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Diabetes Rev. 2008 Nov;4(4):280-90</RefSource>
          <PMID Version="1">18991597</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G987-95</RefSource>
          <PMID Version="1">18772365</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2009 Apr;58(4):906-16</RefSource>
          <PMID Version="1">19151199</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2009 Apr;101(8):1178-84</RefSource>
          <PMID Version="1">19007450</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2009 May;296(5):E985-92</RefSource>
          <PMID Version="1">19223655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2009 Nov;102(9):1246-53</RefSource>
          <PMID Version="1">19631025</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2010 Jan;90(1):23-46</RefSource>
          <PMID Version="1">20086073</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutrition. 2010 Jul-Aug;26(7-8):842-8</RefSource>
          <PMID Version="1">19932004</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Life Sci. 2010 Jun 19;86(25-26):965-71</RefSource>
          <PMID Version="1">20470786</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Diabetes. 2009 Dec;1(4):278-87</RefSource>
          <PMID Version="1">20923528</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E887-98</RefSource>
          <PMID Version="1">20823448</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2011 Jul;106(1):79-86</RefSource>
          <PMID Version="1">21396140</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2011 Sep;141(9):1643-51</RefSource>
          <PMID Version="1">21775526</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Biochem. 2011 Oct;22(10):979-84</RefSource>
          <PMID Version="1">21190824</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2011 Oct;106 Suppl 1:S206-10</RefSource>
          <PMID Version="1">22005430</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FEBS Lett. 2012 Feb 3;586(3):248-53</RefSource>
          <PMID Version="1">22212718</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Animal. 2012 Feb;6(2):254-61</RefSource>
          <PMID Version="1">22436183</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>World J Gastroenterol. 2012 May 21;18(19):2300-8</RefSource>
          <PMID Version="1">22654421</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2011 Jul;106(2):218-26</RefSource>
          <PMID Version="1">21429276</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(11):e49030</RefSource>
          <PMID Version="1">23145054</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Res Hepatol Gastroenterol. 2012 Dec;36(6):554-60</RefSource>
          <PMID Version="1">22795319</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2000 Mar;83 Suppl 1:S113-9</RefSource>
          <PMID Version="1">10889801</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2000 Aug;106(4):453-8</RefSource>
          <PMID Version="1">10953019</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2001 Jun;12(6):1211-7</RefSource>
          <PMID Version="1">11373344</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2002 Jun;282(6):E1352-9</RefSource>
          <PMID Version="1">12006366</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2002 Oct;51(10):3120-7</RefSource>
          <PMID Version="1">12351457</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Nov 12;106(20):2533-6</RefSource>
          <PMID Version="1">12427647</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Nephrol Hypertens. 2003 Mar;12(2):195-200</RefSource>
          <PMID Version="1">12589181</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2003 Mar;41(3 Pt 2):625-33</RefSource>
          <PMID Version="1">12623970</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Hypertens. 2003 Nov;16(11 Pt 1):973-8</RefSource>
          <PMID Version="1">14573337</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2003 Nov;26(11):3153-9</RefSource>
          <PMID Version="1">14578254</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Obes Metab. 2004 Mar;6(2):120-6</RefSource>
          <PMID Version="1">14746577</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2004 Mar;79(3):502-9</RefSource>
          <PMID Version="1">14985228</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Sep 7;110(10):1251-7</RefSource>
          <PMID Version="1">15326061</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Sep 7;110(10):1245-50</RefSource>
          <PMID Version="1">15326067</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 1988 Dec;37(12):1595-607</RefSource>
          <PMID Version="1">3056758</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3849586</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1476-511X-12-136</ArticleId>
        <ArticleId IdType="doi">10.1186/1476-511X-12-136</ArticleId>
        <ArticleId IdType="pubmed">24044579</ArticleId>
        <ArticleId IdType="pmc">PMC3849586</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24036126</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>440</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>LOX-1 deletion and macrophage trafficking in atherosclerosis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>210-4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2013.09.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(13)01491-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atherosclerosis is associated with macrophage accumulation. LOX-1 has been shown to induce macrophage attachment, and its deletion (LOX-1 knockout, KO) reduces atherosclerosis in LDLr KO mice fed a high cholesterol diet. We examined differences in macrophage trafficking in age-matched wild type, LOX-1 KO, LDLr KO, and LDLr/LOX-1 double KO mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Sections of aortas of mice fed high cholesterol diet were collected at weeks 0, 4, 8, 12 and 19 and analyzed by immunohistochemistry and flow cytometry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the LDLr KO mice aorta, CD68 positivity (macrophage accumulation) increased over time up to 12 weeks, and then the accumulation fell modestly but significantly. The periaortal fat and adventitia showed more CD68 positivity than the media and intima. This pattern was also evident in the non-atherosclerotic areas. Importantly, LOX-1 KO and LDLr-LOX-1 double KO mice showed diminished CD68 positivity in comparison to wild type and LDLR KO mice, respectively. Further, macrophages from LOX-1 KO mice revealed a marked reduction in migration (vs. macrophages from wild type mice) in in vitro migration assay.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LOX-1 deletion translates into reduction in macrophage trafficking in the aorta of LDLr KO mice. Most of the macrophage trafficking appears in the subadventitial regions.</AbstractText>
          <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Zufeng</ForeName>
            <Initials>Z</Initials>
            <Affiliation>Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR, USA. Electronic address: ZDing@uams.edu.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mizeracki</LastName>
            <ForeName>Adam Milton</ForeName>
            <Initials>AM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Changping</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehta</LastName>
            <ForeName>Jawahar L</ForeName>
            <Initials>JL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antigens, CD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antigens, Differentiation, Myelomonocytic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>CD68 antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Olr1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Receptors, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Scavenger Receptors, Class E</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Receptors, LDL</DescriptorName>
          <QualifierName MajorTopicYN="N">deficiency</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Scavenger Receptors, Class E</DescriptorName>
          <QualifierName MajorTopicYN="Y">deficiency</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">LOX-1</Keyword>
        <Keyword MajorTopicYN="N">Macrophages</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24036126</ArticleId>
        <ArticleId IdType="pii">S0006-291X(13)01491-5</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2013.09.020</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24030551</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4636</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
          <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2501-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.113.301948</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Previous studies demonstrated that apolipoprotein A-IV (apoA-IV) promotes apoB lipoprotein-mediated triglyceride (TG) secretion in transfected enterocytes and hepatoma cells; however, evidence for a role in lipid transport in vivo is lacking. Using mouse models, we explored the role of apoA-IV in hepatic very low density lipoprotein-mediated lipid efflux under conditions that promote hepatic steatosis.</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="RESULTS">Hepatic steatosis, induced by either high-fat diet or enhanced de novo lipogenesis caused by transgenic overexpression of SREBP-1a (SREBP-1a(Tg)), was associated with up to a 43-fold induction of hepatic apoA-IV mRNA and protein levels. In both models, a positive linear correlation between hepatic TG content and apoA-IV mRNA abundance was observed (r(2)=0.8965). To examine whether induction of apoA-IV affected hepatic TG secretion, SREBP-1a(Tg) mice were crossed with Apoa4 knockout mice. With Triton blockade of peripheral lipolysis, SREBP-1a(Tg)/Apoa4 knockout mice demonstrated a 24% reduction in hepatic TG secretion rate, relative to SREBP-1a(Tg) controls, but no change in apoB production. Negative stain electron microscopy revealed a 33% decrease in the abundance of secreted very low density lipoprotein particles with diameters = 120 nm. Conversely, mice infected with a recombinant human apoA-IV adenovirus demonstrated a 52% increase in the hepatic TG secretion rate, relative to controls, a 38% reduction in liver TG content, and a 43% increase in large diameter (= 120 nm) very low density lipoprotein particles, with no change in apoB secretion.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hepatic steatosis in mice induces hepatic apoA-IV expression, which in turn promotes lipoprotein particle expansion and reduces hepatic lipid burden without increasing the number of secreted atherogenic apoB-containing lipoprotein particles.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>VerHague</LastName>
            <ForeName>Melissa A</ForeName>
            <Initials>MA</Initials>
            <Affiliation>From the Department of Pathology (M.A.V., D.C., G.S.S.), Department of Internal Medicine (R.B.W.), and Department of Physiology &amp; Pharmacology (R.B.W.), Wake Forest School of Medicine, Winston-Salem, NC.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weinberg</LastName>
            <ForeName>Richard B</ForeName>
            <Initials>RB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shelness</LastName>
            <ForeName>Gregory S</ForeName>
            <Initials>GS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HL-049373</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL-30897</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
        <NlmUniqueID>9505803</NlmUniqueID>
        <ISSNLinking>1079-5642</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoproteins A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipoproteins, VLDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Srebf1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Sterol Regulatory Element Binding Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Triglycerides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>apolipoprotein A-IV</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoproteins A</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Liver</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipoproteins, VLDL</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
          <QualifierName MajorTopicYN="N">secretion</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sterol Regulatory Element Binding Protein 1</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Triglycerides</DescriptorName>
          <QualifierName MajorTopicYN="Y">secretion</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">VLDL</Keyword>
        <Keyword MajorTopicYN="N">apolipoprotein B</Keyword>
        <Keyword MajorTopicYN="N">metabolic syndrome</Keyword>
        <Keyword MajorTopicYN="N">nonalcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">triglyceride</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24030551</ArticleId>
        <ArticleId IdType="pii">ATVBAHA.113.301948</ArticleId>
        <ArticleId IdType="doi">10.1161/ATVBAHA.113.301948</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24029787</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1662-3975</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>108</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>World review of nutrition and dietetics</Title>
          <ISOAbbreviation>World Rev Nutr Diet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cow's milk and goat's milk.</ArticleTitle>
        <Pagination>
          <MedlinePgn>56-62</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000351485</ELocationID>
        <Abstract>
          <AbstractText>Cow's milk is increasingly suggested to play a role in the development of chronic degenerative, non-communicable disorders whereas goat's milk is advocated as having several health benefits. Cow's milk is a rich and cheap source of protein and calcium, and a valuable food for bone health. Despite their high content in saturated fats, consumption of full-fat dairy products does not seem to cause significant changes in cardiovascular disease risk variables. Early introduction of cow's milk is a strong negative determinant of iron status. Unmodified cow's milk does not meet nutritional requirements of infants although it is acceptable to add small volumes of cow's milk to complementary foods. Cow's milk protein allergy has a prevalence ranging from 2 to 7%, and the age of recovery is usually around 2-3 years. The evidence linking cow's milk intake to a later risk of type 1 diabetes or chronic degenerative, non-communicable disorders (obesity, metabolic syndrome, type 2 diabetes, hypertension) is not convincing. Milk probably protects against colorectal cancer, diets high in calcium are a probable cause of prostate cancer, and there is limited evidence suggesting that high consumption of milk and dairy products increases the risk for prostate cancer. There is no evidence to support the use of a cow's milk-free diet as a primary treatment for individuals with autistic spectrum disorders. Unmodified goat's milk is not suitable for infants because of the high protein and minerals content and of a low folate content. Goat's milk has no clear nutritional advantage over cow's milk and is not less allergenic. The European Food Safety Authority recently stated that proteins from goat's milk can be suitable as a protein source for infant and follow-on formula, provided the final product complies with the compositional criteria laid down in Directive 2006/141/EC.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Turck</LastName>
            <ForeName>Dominique</ForeName>
            <Initials>D</Initials>
            <Affiliation>Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Jeanne de Flandre Children's Hospital, Lille University Faculty of Medicine, INSERM U995, Lille, France.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>World Rev Nutr Diet</MedlineTA>
        <NlmUniqueID>0117263</NlmUniqueID>
        <ISSNLinking>0084-2230</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">000351485</ArticleId>
        <ArticleId IdType="doi">10.1159/000351485</ArticleId>
        <ArticleId IdType="pubmed">24029787</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24019901</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>10</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Does a nephron deficit exacerbate the renal and cardiovascular effects of obesity?</ArticleTitle>
        <Pagination>
          <MedlinePgn>e73095</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0073095</ELocationID>
        <Abstract>
          <AbstractText>It has been hypothesized that a reduced nephron endowment exacerbates the hypertensive and renal effects of obesity. We therefore examined the impact of diet-induced obesity on renal structure and function, and arterial pressure in a genetic model of reduced nephron endowment, the GDNF Heterozygous (HET) mouse. 6 wk-old male GDNF WT and HET mice were placed on control or high fat (HFF) diet for 20 weeks. 24 hr arterial pressure, heart rate and activity (radiotelemetry), creatinine clearance and albumin excretion were measured, and kidneys collected (histopathology, collagen content). Bodyweights of HFF WT (50.6 &#xB1; 1.2 g) and HET (48.8 &#xB1; 1.4 g) mice were ~14 g greater than control mice (37.3 &#xB1; 1.3 g, 36.4 &#xB1; 1.1 g respectively; Pdiet&lt;0.001). Obesity led to significantly greater 24 hr MAP (Pdiet&lt;0.001), heart rate (Pdiet&lt;0.01) and lower locomotor activity (Pdiet&lt;0.01) in HET and WT mice. Whilst there was no significant impact of genotype on 24 hr MAP response to obesity, night-time MAP of obese HET mice was significantly greater than obese WT mice (122.3 &#xB1; 1.6 vs 116.9 &#xB1; 1.3 mmHg; P&lt;0.05). 24 hr creatinine clearance was 50%, and albumin excretion 180% greater in obese WT and HET mice compared to controls (Pdiet&lt;0.05) but this response did not differ between genotypes. Obesity induced glomerulomegaly, glomerulosclerosis, tubulointerstitial expansion and increased collagen accumulation (total, collagen I, V and IV; Pdiet&lt;0.001). Obese GDNF HET mice had exacerbated total renal collagen (P&lt;0.01), and greater levels of the collagen I subtype compared to kidneys of obese WT mice. In summary, obese nephron-deficient GDNF HET mice were able to maintain the high creatinine clearances of obese WT mice but at the expense of higher MAP and greater renal fibrosis. Whilst modest, our findings support the hypothesis that a reduced nephron endowment increases the susceptibility to obesity-induced kidney disease and hypertension.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gurusinghe</LastName>
            <ForeName>Seshini</ForeName>
            <Initials>S</Initials>
            <Affiliation>Department of Physiology, Monash University, Clayton, Victoria, Australia.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Russell D</ForeName>
            <Initials>RD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Xiaochu</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Samuel</LastName>
            <ForeName>Chrishan S</ForeName>
            <Initials>CS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ricardo</LastName>
            <ForeName>Sharon D</ForeName>
            <Initials>SD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Merlin C</ForeName>
            <Initials>MC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kett</LastName>
            <ForeName>Michelle M</ForeName>
            <Initials>MM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 2005 Dec;16(12):3623-30</RefSource>
          <PMID Version="1">16221872</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2009 Mar;296(3):F583-9</RefSource>
          <PMID Version="1">19106212</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2008 Apr;294(4):F685-96</RefSource>
          <PMID Version="1">18234955</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin J Am Soc Nephrol. 2009 Jul;4(7):1230-8</RefSource>
          <PMID Version="1">19443625</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nephrol Dial Transplant. 2009 Dec;24(12):3732-8</RefSource>
          <PMID Version="1">19596742</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Nephrol Hypertens. 2010 Jan;19(1):65-71</RefSource>
          <PMID Version="1">19851105</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2010 Jun;298(6):F1384-92</RefSource>
          <PMID Version="1">20335316</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Transplantation. 2010 Nov 15;90(9):993-9</RefSource>
          <PMID Version="1">20844468</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2011 Feb;300(2):F521-30</RefSource>
          <PMID Version="1">20943767</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Hypertens. 2011 Mar;29(3):437-9</RefSource>
          <PMID Version="1">21317724</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Contrib Nephrol. 2011;170:28-35</RefSource>
          <PMID Version="1">21659755</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2011 Jul;301(1):H29-40</RefSource>
          <PMID Version="1">21536854</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Pathol. 2011 Sep;179(3):1243-56</RefSource>
          <PMID Version="1">21762674</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R244-51</RefSource>
          <PMID Version="1">22071160</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Nephrol Hypertens. 2000 Mar;9(2):85-97</RefSource>
          <PMID Version="1">10757212</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann N Y Acad Sci. 1999 Nov 18;892:91-107</RefSource>
          <PMID Version="1">10842655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2000 Nov;58(5):2111-8</RefSource>
          <PMID Version="1">11044232</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2001 Jul;60(1):31-6</RefSource>
          <PMID Version="1">11422733</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2001 Sep;38(3):337-42</RefSource>
          <PMID Version="1">11566901</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Med Sci Sports Exerc. 2002 Apr;34(4):596-601</RefSource>
          <PMID Version="1">11932566</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2003 Feb;41(2):335-40</RefSource>
          <PMID Version="1">12574104</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2004 Apr;65(4):1339-48</RefSource>
          <PMID Version="1">15086473</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2004 May;65(5):1959-67</RefSource>
          <PMID Version="1">15086941</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 1975 Jul;55(3):418-87</RefSource>
          <PMID Version="1">50603</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1990 Jan;258(1 Pt 2):H221-8</RefSource>
          <PMID Version="1">2405713</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Dis Child. 1990 Jul;65(7):728-31</RefSource>
          <PMID Version="1">2386378</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 1993 Sep;22(3):292-9</RefSource>
          <PMID Version="1">8349321</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 1996 Jul 4;382(6586):70-3</RefSource>
          <PMID Version="1">8657306</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 1996 Jul 4;382(6586):73-6</RefSource>
          <PMID Version="1">8657307</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 1996 Jul 4;382(6586):76-9</RefSource>
          <PMID Version="1">8657308</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 1996 Sep;137(9):3884-90</RefSource>
          <PMID Version="1">8756561</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2005 Jul;68(1):263-70</RefSource>
          <PMID Version="1">15954916</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertension. 2005 Jul;46(1):71-5</RefSource>
          <PMID Version="1">15956110</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Sep 16;280(37):32317-25</RefSource>
          <PMID Version="1">16046411</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nephrol Dial Transplant. 2005 Dec;20(12):2594-7</RefSource>
          <PMID Version="1">16223782</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Transplant. 2006 Jul;6(7):1653-9</RefSource>
          <PMID Version="1">16827867</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2012 Jul 15;303(2):F253-8</RefSource>
          <PMID Version="1">22573381</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Transplant. 2008 Oct;8(10):2077-85</RefSource>
          <PMID Version="1">18727700</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Renal Physiol. 2009 Jan;296(1):F118-26</RefSource>
          <PMID Version="1">18971213</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Intern Med. 2006 Jan 3;144(1):21-8</RefSource>
          <PMID Version="1">16389251</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3760915</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0073095</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-05140</ArticleId>
        <ArticleId IdType="pubmed">24019901</ArticleId>
        <ArticleId IdType="pmc">PMC3760915</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24015695</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>10</Day>
      </DateCreated>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1541-1087</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American College of Nutrition</Title>
          <ISOAbbreviation>J Am Coll Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improvements in glucose metabolism and insulin sensitivity with a low-carbohydrate diet in obese patients with type 2 diabetes.</ArticleTitle>
        <Pagination>
          <MedlinePgn>11-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07315724.2013.767630</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The optimal diet for weight loss in type 2 diabetes remains controversial. This study examined a low-carbohydrate, high-fat diet with detailed physiological assessments of insulin sensitivity, glycemic control, and risk factors for cardiovascular disease.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Fourteen obese patients (body mass index [BMI] 40.6 &#xB1; 4.9 kg/m(2)) with type 2 diabetes were recruited for an "Atkins"-type low-carbohydrate diet. Measurements were made at 0, 12, and 24 weeks of weight, insulin sensitivity, HbA1c, lipids, and blood pressure.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve completers lost a mean of 9.7 &#xB1; 1.8 kg over 24 weeks attributable to a major reduction in carbohydrates and resultant reduction in total energy intake. Glycemic control significantly improved (HbA1c -1.1 &#xB1; 0.25%) with reductions in hypoglycemic medication. Fasting glucose, homeostasis model assessment (HOMA), and area under the curve (AUC) glucose (intravenous glucose tolerance test [IVGTT]) were significantly reduced by week 12 ( p &lt; 0.05). There were nonsignificant improvements in insulin sensitivity (SI) at week 12 ( p = 0.19) and week 24 ( p = 0.31). Systolic blood pressure was reduced (mean -10.0 mmHg between weeks 0 and 24, p = 0.13). Mean high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol all increased. The ratio of total: HDL cholesterol and triglycerides was reduced.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A low-carbohydrate diet was well tolerated and achieved weight loss over 24 weeks in subjects with diabetes. Glycemic control improved with a reduction in requirements for hypoglycemic agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Krebs</LastName>
            <ForeName>Jeremy D</ForeName>
            <Initials>JD</Initials>
            <Affiliation>Endocrine, Diabetes and Research Centre, Wellington Hospital, Wellington, New Zealand. Jeremy.krebs@ccdhb.org.nz</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bell</LastName>
            <ForeName>Damon</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hall</LastName>
            <ForeName>Rosemary</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parry-Strong</LastName>
            <ForeName>Amber</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Docherty</LastName>
            <ForeName>Paul D</ForeName>
            <Initials>PD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clarke</LastName>
            <ForeName>Kristen</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chase</LastName>
            <ForeName>J Geoffry</ForeName>
            <Initials>JG</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Coll Nutr</MedlineTA>
        <NlmUniqueID>8215879</NlmUniqueID>
        <ISSNLinking>0731-5724</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1080/07315724.2013.767630</ArticleId>
        <ArticleId IdType="pubmed">24015695</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24015188</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>09</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>HDL-apoA-I exchange: rapid detection and association with atherosclerosis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e71541</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0071541</ELocationID>
        <Abstract>
          <AbstractText>High density lipoprotein (HDL) cholesterol levels are associated with decreased risk of cardiovascular disease, but not all HDL are functionally equivalent. A primary determinant of HDL functional status is the conformational adaptability of its main protein component, apoA-I, an exchangeable apolipoprotein. Chemical modification of apoA-I, as may occur under conditions of inflammation or diabetes, can severely impair HDL function and is associated with the presence of cardiovascular disease. Chemical modification of apoA-I also impairs its ability to exchange on and off HDL, a critical process in reverse cholesterol transport. In this study, we developed a method using electron paramagnetic resonance spectroscopy (EPR) to quantify HDL-apoA-I exchange. Using this approach, we measured the degree of HDL-apoA-I exchange for HDL isolated from rabbits fed a high fat, high cholesterol diet, as well as human subjects with acute coronary syndrome and metabolic syndrome. We observed that HDL-apoA-I exchange was markedly reduced when atherosclerosis was present, or when the subject carries at least one risk factor of cardiovascular disease. These results show that HDL-apoA-I exchange is a clinically relevant measure of HDL function pertinent to cardiovascular disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Borja</LastName>
            <ForeName>Mark S</ForeName>
            <Initials>MS</Initials>
            <Affiliation>Children's Hospital Oakland Research Institute, Oakland, California, United States of America.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hammerson</LastName>
            <ForeName>Bradley</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Chongren</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carson</LastName>
            <ForeName>Nancy</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernando</LastName>
            <ForeName>Gayani</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaoqin</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Budamagunta</LastName>
            <ForeName>Madhu S</ForeName>
            <Initials>MS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Genest</LastName>
            <ForeName>Jacques</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shearer</LastName>
            <ForeName>Gregory C</ForeName>
            <Initials>GC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duclos</LastName>
            <ForeName>Franck</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oda</LastName>
            <ForeName>Michael N</ForeName>
            <Initials>MN</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MOP 67088</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Lipidol. 2007 Apr;18(2):147-51</RefSource>
          <PMID Version="1">17353662</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2007 Mar 23;282(12):9143-9</RefSource>
          <PMID Version="1">17204472</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Cardiol. 2007 Jul;22(4):368-72</RefSource>
          <PMID Version="1">17556891</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochemistry. 2007 Jun 26;46(25):7449-59</RefSource>
          <PMID Version="1">17530866</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2010 Jan 5;121(1):110-22</RefSource>
          <PMID Version="1">20026785</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):151-5</RefSource>
          <PMID Version="1">19679832</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Struct Biol. 2000 Sep;7(9):735-9</RefSource>
          <PMID Version="1">10966640</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1997 Feb 14;272(7):3953-60</RefSource>
          <PMID Version="1">9020099</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 1997 Apr 3;336(14):973-9</RefSource>
          <PMID Version="1">9077376</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 1999 Jan 19;99(2):237-42</RefSource>
          <PMID Version="1">9892589</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2181-7</RefSource>
          <PMID Version="1">15388521</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Jan 7;280(1):38-47</RefSource>
          <PMID Version="1">15498770</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Feb 18;280(7):5983-93</RefSource>
          <PMID Version="1">15574409</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Lipidol. 2005 Jun;16(3):287-94</RefSource>
          <PMID Version="1">15891389</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Med. 2005;37(3):173-8</RefSource>
          <PMID Version="1">16019715</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2005 Oct;46(10):2246-53</RefSource>
          <PMID Version="1">16061948</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2010 Apr;51(4):743-54</RefSource>
          <PMID Version="1">20061576</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Chem Res Toxicol. 2010 Mar 15;23(3):447-54</RefSource>
          <PMID Version="1">20043647</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):766-72</RefSource>
          <PMID Version="1">20110571</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2010 Jun 11;285(24):18473-84</RefSource>
          <PMID Version="1">20378541</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2010 Jun 11;285(24):18847-57</RefSource>
          <PMID Version="1">20385548</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2010 Jul;51(7):1849-58</RefSource>
          <PMID Version="1">20064972</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ J. 2010 Nov;74(11):2263-70</RefSource>
          <PMID Version="1">20962428</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2528-34</RefSource>
          <PMID Version="1">20847305</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2011 Jan 13;364(2):127-35</RefSource>
          <PMID Version="1">21226578</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2011 Jan 28;286(4):2966-75</RefSource>
          <PMID Version="1">21047795</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Cardiol. 2011 Apr;8(4):222-32</RefSource>
          <PMID Version="1">21304474</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2012 Mar;1821(3):448-55</RefSource>
          <PMID Version="1">22245143</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2012 Feb 24;287(9):6375-86</RefSource>
          <PMID Version="1">22219194</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2012 Nov;53(11):2429-35</RefSource>
          <PMID Version="1">22892157</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1828-36</RefSource>
          <PMID Version="1">17510466</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2007 Nov 2;282(44):31826-34</RefSource>
          <PMID Version="1">17726014</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Atheroscler Rep. 2007 Nov;9(5):417-24</RefSource>
          <PMID Version="1">18001626</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2008 Feb 12;51(6):634-42</RefSource>
          <PMID Version="1">18261682</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochemistry. 2008 Apr 22;47(16):4770-9</RefSource>
          <PMID Version="1">18366184</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12224-9</RefSource>
          <PMID Version="1">18719109</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2008 Nov;49(11):2390-401</RefSource>
          <PMID Version="1">18583707</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2008 Oct;200(2):359-67</RefSource>
          <PMID Version="1">18243217</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2009 Mar 6;284(10):6093-100</RefSource>
          <PMID Version="1">19136670</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2009 Mar 3;119(8):1135-45</RefSource>
          <PMID Version="1">19221221</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2009 May;50(5):894-907</RefSource>
          <PMID Version="1">19144994</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801</RefSource>
          <PMID Version="1">20075420</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am Heart J. 2000 Feb;139(2 Pt 1):288-96</RefSource>
          <PMID Version="1">10650302</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2000 Oct 19;343(16):1148-55</RefSource>
          <PMID Version="1">11036120</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 2000 Dec 15;352 Pt 3:693-9</RefSource>
          <PMID Version="1">11104675</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochemistry. 2001 Feb 13;40(6):1710-8</RefSource>
          <PMID Version="1">11327831</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2001 Nov 7;286(17):2136-42</RefSource>
          <PMID Version="1">11694155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Cardiol. 2003 Feb 6;91(3A):12A-16A</RefSource>
          <PMID Version="1">12645639</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Struct Biol. 2003 Jun;10(6):455-60</RefSource>
          <PMID Version="1">12754494</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2003 Sep;170(1):31-8</RefSource>
          <PMID Version="1">12957680</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2003 Oct 23;349(17):1595-604</RefSource>
          <PMID Version="1">14573731</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2004 Feb 27;279(9):7622-8</RefSource>
          <PMID Version="1">14668333</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):421-8</RefSource>
          <PMID Version="1">14592845</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2004 Apr;45(4):645-52</RefSource>
          <PMID Version="1">14729855</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2004 May 19;43(10):1731-7</RefSource>
          <PMID Version="1">15145091</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2004 Aug;114(4):529-41</RefSource>
          <PMID Version="1">15314690</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13032-7</RefSource>
          <PMID Version="1">15326314</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2004 Oct 8;279(41):42977-83</RefSource>
          <PMID Version="1">15292228</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Med. 1977 May;62(5):707-14</RefSource>
          <PMID Version="1">193398</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 1986 Nov 28;256(20):2835-8</RefSource>
          <PMID Version="1">3773200</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochemistry. 1992 May 12;31(18):4509-14</RefSource>
          <PMID Version="1">1581305</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1994 Jul;94(1):437-44</RefSource>
          <PMID Version="1">8040285</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 1995 Jun 27;1257(1):31-7</RefSource>
          <PMID Version="1">7599178</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 1996 Jan 1;313 ( Pt 1):275-82</RefSource>
          <PMID Version="1">8546695</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1995 Dec;96(6):2758-67</RefSource>
          <PMID Version="1">8675645</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 1996 Sep 15;144(6):537-47</RefSource>
          <PMID Version="1">8797513</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 1996 Sep;37(9):1962-70</RefSource>
          <PMID Version="1">8895062</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2009 Nov 6;284(45):30825-35</RefSource>
          <PMID Version="1">19726691</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2813-20</RefSource>
          <PMID Version="1">23152494</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2013 May;36(5):1312-20</RefSource>
          <PMID Version="1">23230102</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Cardiovasc Med. 2005 Aug;15(6):212-9</RefSource>
          <PMID Version="1">16182131</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Oct 7;280(40):33775-84</RefSource>
          <PMID Version="1">16091367</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Oct 28;280(43):36386-96</RefSource>
          <PMID Version="1">16126721</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2005 Nov 16;294(19):2437-45</RefSource>
          <PMID Version="1">16287954</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):12-9</RefSource>
          <PMID Version="1">16269660</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2006 Apr 7;281(14):9001-4</RefSource>
          <PMID Version="1">16497665</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Lipidol. 2006 Jun;17(3):209-13</RefSource>
          <PMID Version="1">16680023</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Cardiol. 2006 Jul;21(4):322-8</RefSource>
          <PMID Version="1">16755201</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2006 Jul 21;281(29):20418-26</RefSource>
          <PMID Version="1">16698792</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2006 Dec;49(12):2837-46</RefSource>
          <PMID Version="1">17021922</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3756009</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0071541</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-19304</ArticleId>
        <ArticleId IdType="pubmed">24015188</ArticleId>
        <ArticleId IdType="pmc">PMC3756009</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24014826</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>22</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1941-3297</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Circulation. Heart failure</Title>
          <ISOAbbreviation>Circ Heart Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1239-49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCHEARTFAILURE.113.000539</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction. They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification. The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization. Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined. Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned. At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic. Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD. The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (&#xB1;80%) attributable to titin hypophosphorylation. The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span. Titin hypophosphorylation importantly contributed to the underlying myocardial DD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hamdani</LastName>
            <ForeName>Nazha</ForeName>
            <Initials>N</Initials>
            <Affiliation>Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franssen</LastName>
            <ForeName>Constantijn</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Louren&#xE7;o</LastName>
            <ForeName>Andr&#xE9;</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Falc&#xE3;o-Pires</LastName>
            <ForeName>In&#xEA;s</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fontoura</LastName>
            <ForeName>Dulce</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leite</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Plettig</LastName>
            <ForeName>Luisa</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>L&#xF3;pez</LastName>
            <ForeName>Bego&#xF1;a</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ottenheijm</LastName>
            <ForeName>Coen A</ForeName>
            <Initials>CA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Becher</LastName>
            <ForeName>Peter Moritz</ForeName>
            <Initials>PM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonz&#xE1;lez</LastName>
            <ForeName>Arantxa</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsch&#xF6;pe</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>D&#xED;ez</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linke</LastName>
            <ForeName>Wolfgang A</ForeName>
            <Initials>WA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leite-Moreira</LastName>
            <ForeName>Adelino F</ForeName>
            <Initials>AF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paulus</LastName>
            <ForeName>Walter J</ForeName>
            <Initials>WJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Comparative Study</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Circ Heart Fail</MedlineTA>
        <NlmUniqueID>101479941</NlmUniqueID>
        <ISSNLinking>1941-3289</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Connectin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Circ Heart Fail. 2013 Nov;6(6):1112-5</RefSource>
          <PMID Version="1">24255055</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Connectin</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Heart Failure</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Inbred WKY</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Stroke Volume</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">diabetes mellitus</Keyword>
        <Keyword MajorTopicYN="N">diastole</Keyword>
        <Keyword MajorTopicYN="N">heart failure</Keyword>
        <Keyword MajorTopicYN="N">myocardium</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24014826</ArticleId>
        <ArticleId IdType="pii">CIRCHEARTFAILURE.113.000539</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.113.000539</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24014675</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Heart and circulatory physiology</Title>
          <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias.</ArticleTitle>
        <Pagination>
          <MedlinePgn>H1530-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00196.2013</ELocationID>
        <Abstract>
          <AbstractText>Obesity increases the risk of arrhythmias and sudden cardiac death, but the mechanisms are unknown. This study tested the hypothesis that obesity-induced cardiac sympathetic outgrowth and hyperinnervation promotes the development of arrhythmic events. Male Sprague-Dawley rats (250-275 g), fed a high-fat diet (33% kcal/fat), diverged into obesity-resistant (OR) and obesity-prone (OP) groups and were compared with rats fed normal chow (13% kcal/fat; CON). In vitro experiments showed that both OR and OP rats exhibited hyperinnervation of the heart and high sympathetic outgrowth compared with CON rats, even though OR rats are not obese. Despite the hyperinnervation and outgrowth, we showed that, in vivo, OR rats were less susceptible to arrhythmic events after an intravenous epinephrine challenge compared with OP rats. On examining total and stimulus-evoked neurotransmitter levels in an ex vivo system, we demonstrate that atrial acetylcholine content and release were attenuated in OP compared with OR and CON groups. OP rats also expressed elevated atrial norepinephrine content, while norepinephrine release was suppressed. These findings suggest that the consumption of a high-fat diet, even in the absence of overt obesity, stimulates sympathetic outgrowth and hyperinnervation of the heart. However, normalized cardiac parasympathetic nervous system control may protect the heart from arrhythmic events.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McCully</LastName>
            <ForeName>Belinda H</ForeName>
            <Initials>BH</Initials>
            <Affiliation>Department of Physiology and Pharmacology, Oregon Health &amp; Science University, Portland, Oregon; and.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hasan</LastName>
            <ForeName>Wohaib</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Streiff</LastName>
            <ForeName>Cole T</ForeName>
            <Initials>CT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Houle</LastName>
            <ForeName>Jennifer C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woodward</LastName>
            <ForeName>William R</ForeName>
            <Initials>WR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giraud</LastName>
            <ForeName>George D</ForeName>
            <Initials>GD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brooks</LastName>
            <ForeName>Virginia L</ForeName>
            <Initials>VL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Habecker</LastName>
            <ForeName>Beth A</ForeName>
            <Initials>BA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HL-068231</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL-088552</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL-093056</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>NS077063</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Comparative Study</PublicationType>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
        <NlmUniqueID>100901228</NlmUniqueID>
        <ISSNLinking>0363-6135</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance>Acetylcholine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance>Norepinephrine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YKH834O4BH</RegistryNumber>
          <NameOfSubstance>Epinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Acetylcholine</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Epinephrine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Heart</DescriptorName>
          <QualifierName MajorTopicYN="Y">innervation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Heart Atria</DescriptorName>
          <QualifierName MajorTopicYN="N">innervation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Norepinephrine</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="N">complications</QualifierName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Parasympathetic Nervous System</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sympathetic Nervous System</DescriptorName>
          <QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3840265 [Available on 11/15/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">arrhythmia</Keyword>
        <Keyword MajorTopicYN="N">autonomic imbalance</Keyword>
        <Keyword MajorTopicYN="N">neurite outgrowth</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24014675</ArticleId>
        <ArticleId IdType="pii">ajpheart.00196.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpheart.00196.2013</ArticleId>
        <ArticleId IdType="pmc">PMC3840265</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">24009777</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>06</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of choline deficiency in the Fatty liver&#xA0;phenotype of mice fed a low protein, very low carbohydrate ketogenic diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e74806</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0074806</ELocationID>
        <Abstract>
          <AbstractText>Though widely employed for clinical intervention in obesity, metabolic syndrome, seizure disorders and other neurodegenerative diseases, the mechanisms through which low carbohydrate ketogenic diets exert their ameliorative effects still remain to be elucidated. Rodent models have been used to identify the metabolic and physiologic alterations provoked by ketogenic diets. A commonly used rodent ketogenic diet (Bio-Serv F3666) that is very high in fat (~94% kcal), very low in carbohydrate (~1% kcal), low in protein (~5% kcal), and choline restricted (~300 mg/kg) provokes robust ketosis and weight loss in mice, but through unknown mechanisms, also causes significant hepatic steatosis, inflammation, and cellular injury. To understand the independent and synergistic roles of protein restriction and choline deficiency on the pleiotropic effects of rodent ketogenic diets, we studied four custom diets that differ only in protein (5% kcal vs. 10% kcal) and choline contents (300 mg/kg vs. 5 g/kg). C57BL/6J mice maintained on the two 5% kcal protein diets induced the most significant ketoses, which was only partially diminished by choline replacement. Choline restriction in the setting of 10% kcal protein also caused moderate ketosis and hepatic fat accumulation, which were again attenuated when choline was replete. Key effects of the 5% kcal protein diet - weight loss, hepatic fat accumulation, and mitochondrial ultrastructural disarray and bioenergetic dysfunction - were mitigated by choline repletion. These studies indicate that synergistic effects of protein restriction and choline deficiency influence integrated metabolism and hepatic pathology in mice when nutritional fat content is very high, and support the consideration of dietary choline content in ketogenic diet studies in rodents to limit hepatic mitochondrial dysfunction and fat accumulation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schugar</LastName>
            <ForeName>Rebecca C</ForeName>
            <Initials>RC</Initials>
            <Affiliation>Department of Medicine, Center for Cardiovascular Research, Washington University, St. Louis, Missouri, USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Xiaojing</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moll</LastName>
            <ForeName>Ashley R</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brunt</LastName>
            <ForeName>Elizabeth M</ForeName>
            <Initials>EM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crawford</LastName>
            <ForeName>Peter A</ForeName>
            <Initials>PA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK020579</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK056341</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK091538</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL007275</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK052574</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK056341</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2013 Feb 8;288(6):4158-73</RefSource>
          <PMID Version="1">23250747</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40</RefSource>
          <PMID Version="1">23537027</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1060-76</RefSource>
          <PMID Version="1">23396451</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2013;8(6):e65021</RefSource>
          <PMID Version="1">23755170</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2013;8(6):e65522</RefSource>
          <PMID Version="1">23755243</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Child Neurol. 2013 Aug;28(8):1027-33</RefSource>
          <PMID Version="1">23670253</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>EMBO J. 2002 Feb 1;21(3):221-30</RefSource>
          <PMID Version="1">11823415</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Liver Int. 2003 Oct;23(5):363-70</RefSource>
          <PMID Version="1">14708898</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19</RefSource>
          <PMID Version="1">14769489</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2004 Mar;10(3):268-74</RefSource>
          <PMID Version="1">14770177</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1969 Sep 10;244(17):4607-16</RefSource>
          <PMID Version="1">4390110</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1969 Sep 10;244(17):4617-27</RefSource>
          <PMID Version="1">5808508</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 1970 Dec;24(4):1005-11</RefSource>
          <PMID Version="1">5484721</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem J. 1970 Sep;119(3):525-33</RefSource>
          <PMID Version="1">5500312</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 1971 Dec 3;249(2):462-92</RefSource>
          <PMID Version="1">5134192</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 1985 Jun 12;822(1):1-42</RefSource>
          <PMID Version="1">2408671</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1986 Jun;116(6):936-43</RefSource>
          <PMID Version="1">3755165</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Biochem Biophys. 1995 Aug 20;321(2):421-8</RefSource>
          <PMID Version="1">7646068</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E1-15</RefSource>
          <PMID Version="1">15585595</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Braz J Med Biol Res. 2006 Feb;39(2):189-94</RefSource>
          <PMID Version="1">16470305</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2006 May;3(5):321-31</RefSource>
          <PMID Version="1">16679290</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2006 Jul;55(7):2015-20</RefSource>
          <PMID Version="1">16804070</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pediatr Res. 2006 Oct;60(4):413-7</RefSource>
          <PMID Version="1">16940251</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1724-39</RefSource>
          <PMID Version="1">17299079</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2007 Jun;5(6):426-37</RefSource>
          <PMID Version="1">17550778</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2007 Aug;86(2):276-84</RefSource>
          <PMID Version="1">17684196</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2007 Oct;1767(10):1260-7</RefSource>
          <PMID Version="1">17900521</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Diet Assoc. 2008 Jan;108(1):91-100</RefSource>
          <PMID Version="1">18155993</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E110-9</RefSource>
          <PMID Version="1">17986629</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H185-96</RefSource>
          <PMID Version="1">18487436</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2008 Jul 17;359(3):229-41</RefSource>
          <PMID Version="1">18635428</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2009 Jan;1793(1):5-19</RefSource>
          <PMID Version="1">18620004</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mitochondrion. 2008 Dec;8(5-6):367-76</RefSource>
          <PMID Version="1">18765303</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Brain Res Rev. 2009 Mar;59(2):293-315</RefSource>
          <PMID Version="1">18845187</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11276-81</RefSource>
          <PMID Version="1">19549860</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Endocrinology. 2009 Nov;150(11):4931-40</RefSource>
          <PMID Version="1">19819944</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2009;4(11):e7929</RefSource>
          <PMID Version="1">19936233</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Innate Immun. 2009 Dec;15(6):337-49</RefSource>
          <PMID Version="1">19710104</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2010 Feb;51(2):679-89</RefSource>
          <PMID Version="1">20041406</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2010 Jun 11;285(24):18528-36</RefSource>
          <PMID Version="1">20395294</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2010 Aug 6;285(32):24447-56</RefSource>
          <PMID Version="1">20529848</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Intern Med. 2010 Aug 3;153(3):147-57</RefSource>
          <PMID Version="1">20679559</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Mol Neurosci. 2010 Oct;42(2):145-53</RefSource>
          <PMID Version="1">20333481</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Liver Int. 2010 Sep;30(8):1229-39</RefSource>
          <PMID Version="1">20536716</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2009 Oct;50(10):2072-82</RefSource>
          <PMID Version="1">19295183</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2010 Nov;299(5):E808-15</RefSource>
          <PMID Version="1">20807839</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1946 Feb;31:141-59</RefSource>
          <PMID Version="1">21015910</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Pediatr. 2010;57(1):315-29</RefSource>
          <PMID Version="1">21056745</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E65-76</RefSource>
          <PMID Version="1">20943751</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cell Biol. 2011 Jan 10;192(1):7-16</RefSource>
          <PMID Version="1">21220505</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2011 May;93(5):1048-52</RefSource>
          <PMID Version="1">21367948</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochim Biophys Acta. 2011 Jun;1807(6):577-94</RefSource>
          <PMID Version="1">20804725</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G956-67</RefSource>
          <PMID Version="1">21454445</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Antioxid Redox Signal. 2011 Jul 15;15(2):535-50</RefSource>
          <PMID Version="1">21126212</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(7):e21788</RefSource>
          <PMID Version="1">21747957</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Med Food. 2011 Jul-Aug;14(7-8):677-80</RefSource>
          <PMID Version="1">21688989</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(9):e24084</RefSource>
          <PMID Version="1">21909411</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19678-82</RefSource>
          <PMID Version="1">22106289</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2011 Dec 7;14(6):804-10</RefSource>
          <PMID Version="1">22152305</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1197-204</RefSource>
          <PMID Version="1">19738035</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Gastroenterol. 2012 Mar;28(2):159-65</RefSource>
          <PMID Version="1">22134222</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2012 Apr;95(4):892-900</RefSource>
          <PMID Version="1">22338037</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(12):e51357</RefSource>
          <PMID Version="1">23236485</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>IUBMB Life. 2013 Jan;65(1):58-66</RefSource>
          <PMID Version="1">23233333</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3756977</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0074806</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-14617</ArticleId>
        <ArticleId IdType="pubmed">24009777</ArticleId>
        <ArticleId IdType="pmc">PMC3756977</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">24005471</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>16</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1466</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Renal physiology</Title>
          <ISOAbbreviation>Am. J. Physiol. Renal Physiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Assessment of impaired vascular reactivity in a rat model of diabetic nephropathy: effect of nitric oxide synthesis inhibition on intrarenal diffusion and oxygenation measured by magnetic resonance imaging.</ArticleTitle>
        <Pagination>
          <MedlinePgn>F1428-35</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajprenal.00123.2013</ELocationID>
        <Abstract>
          <AbstractText>Diabetes is associated with impaired vascular reactivity and the development of diabetic nephropathy. In a rat model of streptozotocin-induced diabetic nephropathy, the effects of systemic nitric oxide (NO) synthesis inhibition on intrarenal diffusion and oxygenation were determined by noninvasive magnetic resonance diffusion tensor imaging and blood O2 level-dependent (BOLD) imaging, respectively. Eight weeks after the induction of diabetes, 21 rats [n = 7 rats each in the untreated control group, diabetes mellitus (DM) group, and DM with uninephrectomy (DM UNX) group] were examined by MRI. Diffusion tensor imaging and BOLD sequences were acquired before and after NO synthesis inhibition with N-nitro-L-arginine methyl ester (L-NAME). In the same rats, mean arterial pressure and vascular conductance were determined with and without the influence of L-NAME. In control animals, NO synthesis inhibition was associated with a significant increase of mean arterial pressure of 33.8 &#xB1; 4.3 mmHg (P &lt; 0.001) and a decrease of vascular conductance of -17.8 &#xB1; 2.0 &#xB5;l&#xB7;min(-1)&#xB7;100 mmHg(-1) (P &lt; 0.001). These changes were attenuated in both DM and DM UNX groups with no significant difference between before and after L-NAME measurements in DM UNX animals. Similarly, L-NAME challenge induced a significant reduction of renal transverse relaxation time (T2*) at MRI in control animals, indicating reduced renal oxygenation after L-NAME injection compared with baseline. DM UNX animals did not show a significant T2* reduction after NO synthesis inhibition in the renal cortex and attenuated T2* reduction in the outer medulla. MRI parameters of tissue diffusion were not affected by L-NAME in all groups. In conclusion, BOLD imaging proved valuable to noninvasively measure renal vascular reactivity upon NO synthesis inhibition in control animals and to detect impaired vascular reactivity in animals with diabetic nephropathy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hueper</LastName>
            <ForeName>Katja</ForeName>
            <Initials>K</Initials>
            <Affiliation>Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover 30625, Germany. hueper.katja@mh-hannover.de.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hartung</LastName>
            <ForeName>Dagmar</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gutberlet</LastName>
            <ForeName>Marcel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gueler</LastName>
            <ForeName>Faikah</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sann</LastName>
            <ForeName>Holger</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Husen</LastName>
            <ForeName>Bettina</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wacker</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reiche</LastName>
            <ForeName>Dania</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Renal Physiol</MedlineTA>
        <NlmUniqueID>100901990</NlmUniqueID>
        <ISSNLinking>1522-1466</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance>Nitric Oxide Synthase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance>Oxygen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>V55S2QJN2X</RegistryNumber>
          <NameOfSubstance>NG-Nitroarginine Methyl Ester</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Arteries</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetic Angiopathies</DescriptorName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetic Nephropathies</DescriptorName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diffusion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diffusion Tensor Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hemodynamics</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName MajorTopicYN="Y">blood supply</QualifierName>
          <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NG-Nitroarginine Methyl Ester</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nephrectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName>
          <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Renal Circulation</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">N-nitro-l-arginine methyle ester</Keyword>
        <Keyword MajorTopicYN="N">blood oxygen level-dependent imaging</Keyword>
        <Keyword MajorTopicYN="N">diabetic nephropathy</Keyword>
        <Keyword MajorTopicYN="N">diffusion tensor imaging</Keyword>
        <Keyword MajorTopicYN="N">nitric oxide</Keyword>
        <Keyword MajorTopicYN="N">vascular reactivity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24005471</ArticleId>
        <ArticleId IdType="pii">ajprenal.00123.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajprenal.00123.2013</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">24000103</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>9</Month>
        <Day>3</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1099-1573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
              <Day>2</Day>
            </PubDate>
          </JournalIssue>
          <Title>Phytotherapy research : PTR</Title>
          <ISOAbbreviation>Phytother Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dark Chocolate: An Obesity Paradox or a Culprit for Weight Gain?</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="doi">10.1002/ptr.5062</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Obesity remains a major public health challenge, and its prevalence is dramatically increasing. Diet and exercise are typically recommended to prevent and manage obesity; however, the results are often conflicting. Polyphenols, a class of phytochemicals that have been shown to reduce the risk factors for diabetes type II and cardiovascular diseases, are recently suggested as complementary agents in the management of obesity through several mechanisms such as decreasing fat absorption and/or fat synthesis. Dark chocolate, a high source of polyphenols, and flavanols in particular, has lately received attention for its possible role in modulating obesity because of its potential effect on fat and carbohydrate metabolism, as well as on satiety. This outcome was investigated in animal models of obesity, cell cultures and few human observational and clinical studies. The research undertaken to date has shown promising results, with the possible implication of cocoa/dark chocolate in the modulation of obesity and body weight through several mechanisms including decreasing the expression of genes involved in fatty acid synthesis, reducing the digestion and absorption of fats and carbohydrates and increasing satiety. Copyright &#xA9; 2013 John Wiley &amp; Sons, Ltd.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Farhat</LastName>
            <ForeName>Grace</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Dietetics, Nutrition and Biological Sciences, Queen Margaret University, Musselburgh, East Lothian, EH21 6UU, UK.</Affiliation>
          </Author>
          <Author>
            <LastName>Drummond</LastName>
            <ForeName>Sandra</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Fyfe</LastName>
            <ForeName>Lorna</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author>
            <LastName>Al-Dujaili</LastName>
            <ForeName>E A S</ForeName>
            <Initials>EA</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>2</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Phytother Res</MedlineTA>
        <NlmUniqueID>8904486</NlmUniqueID>
        <ISSNLinking>0951-418X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">dark chocolate</Keyword>
        <Keyword MajorTopicYN="N">flavanol</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">polyphenol</Keyword>
        <Keyword MajorTopicYN="N">satiety</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/ptr.5062</ArticleId>
        <ArticleId IdType="pubmed">24000103</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23999430</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>123</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J. Clin. Invest.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kruppel-like factor 15 is critical for vascular inflammation.</ArticleTitle>
        <Pagination>
          <MedlinePgn>4232-41</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI68552</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">68552</ELocationID>
        <Abstract>
          <AbstractText>Activation of cells intrinsic to the vessel wall is central to the initiation and progression of vascular inflammation. As the dominant cellular constituent of the vessel wall, vascular smooth muscle cells (VSMCs) and their functions are critical determinants of vascular disease. While factors that regulate VSMC proliferation and migration have been identified, the endogenous regulators of VSMC proinflammatory activation remain incompletely defined. The Kruppel-like family of transcription factors (KLFs) are important regulators of inflammation. In this study, we identified Kruppel-like factor 15 (KLF15) as an essential regulator of VSMC proinflammatory activation. KLF15 levels were markedly reduced in human atherosclerotic tissues. Mice with systemic and smooth muscle-specific deficiency of KLF15 exhibited an aggressive inflammatory vasculopathy in two distinct models of vascular disease: orthotopic carotid artery transplantation and diet-induced atherosclerosis. We demonstrated that KLF15 alters the acetylation status and activity of the proinflammatory factor NF-?B through direct interaction with the histone acetyltransferase p300. These studies identify a previously unrecognized KLF15-dependent pathway that regulates VSMC proinflammatory activation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lisheng</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Xudong</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sangwung</LastName>
            <ForeName>Panjamaporn</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prosdocimo</LastName>
            <ForeName>Domenick A</ForeName>
            <Initials>DA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Guangjin</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Votruba</LastName>
            <ForeName>Alexander R</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brian</LastName>
            <ForeName>Leigh</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Yuh Jung</ForeName>
            <Initials>YJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Huiyun</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yunmei</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Koichi</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weinert-Stein</LastName>
            <ForeName>Kaitlyn</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khrestian</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simon</LastName>
            <ForeName>Daniel I</ForeName>
            <Initials>DI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freedman</LastName>
            <ForeName>Neil J</ForeName>
            <Initials>NJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jain</LastName>
            <ForeName>Mukesh K</ForeName>
            <Initials>MK</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>F32 HL110538</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL112486</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL57506</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL77185</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>KLF15 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Kruppel-Like Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Nuclear Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.1.48</RegistryNumber>
          <NameOfSubstance>p300-CBP Transcription Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>JACC Cardiovasc Interv. 2011 Oct;4(10):1057-66</RefSource>
          <PMID Version="1">22017929</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Immunol. 2011 Aug;12(8):709-14</RefSource>
          <PMID Version="1">21772279</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2012 Mar 7;15(3):311-23</RefSource>
          <PMID Version="1">22405069</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6739-44</RefSource>
          <PMID Version="1">22493257</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2012 May 11;110(10):1294-302</RefSource>
          <PMID Version="1">22474254</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Atheroscler Rep. 2012 Oct;14(5):438-49</RefSource>
          <PMID Version="1">22850980</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Can J Cardiol. 2012 Nov-Dec;28(6):631-41</RefSource>
          <PMID Version="1">22985787</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Can J Cardiol. 2012 Nov-Dec;28(6):619-22</RefSource>
          <PMID Version="1">23073353</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2836-8</RefSource>
          <PMID Version="1">23065827</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2012 Dec 3;122(12):4727-31</RefSource>
          <PMID Version="1">23160196</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Leukoc Biol. 2000 May;67(5):591-602</RefSource>
          <PMID Version="1">10810997</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cancer Res. 2000 Jul 1;60(13):3655-61</RefSource>
          <PMID Version="1">10910082</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2001 May;107(10):1255-62</RefSource>
          <PMID Version="1">11375415</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2001 Jun;50(3):556-65</RefSource>
          <PMID Version="1">11376631</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cancer Res. 2001 Sep 15;61(18):6952-7</RefSource>
          <PMID Version="1">11559575</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Mar 5;105(9):1135-43</RefSource>
          <PMID Version="1">11877368</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2002 Sep 13;277(37):34322-8</RefSource>
          <PMID Version="1">12097321</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Nephrol Hypertens. 2003 Mar;12(2):181-7</RefSource>
          <PMID Version="1">12589179</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pharmacol Rev. 2003 Mar;55(1):133-66</RefSource>
          <PMID Version="1">12615956</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Immunol. 2003 Jun 1;170(11):5630-5</RefSource>
          <PMID Version="1">12759443</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Mol Med (Berl). 2003 Sep;81(9):549-57</RefSource>
          <PMID Version="1">12920522</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5634-9</RefSource>
          <PMID Version="1">15064395</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cytokine Growth Factor Rev. 2004 Aug;15(4):237-54</RefSource>
          <PMID Version="1">15207815</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Cardiovasc Med. 2004 Aug;14(6):241-6</RefSource>
          <PMID Version="1">15451516</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cancer Res. 1995 Dec 15;55(24):6161-5</RefSource>
          <PMID Version="1">8521408</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Physiol. 1997 Mar;82(2):297-304</RefSource>
          <PMID Version="1">9129944</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 1999 Jan 14;340(2):115-26</RefSource>
          <PMID Version="1">9887164</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2005 Mar 11;280(10):9719-27</RefSource>
          <PMID Version="1">15623517</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Genesis. 2005 Apr;41(4):179-84</RefSource>
          <PMID Version="1">15789423</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Nephrol Hypertens. 2006 Mar;15(2):152-8</RefSource>
          <PMID Version="1">16481882</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2006 May;186(1):140-5</RefSource>
          <PMID Version="1">16084515</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11015-20</RefSource>
          <PMID Version="1">16835303</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2007 Apr 13;100(7):967-78</RefSource>
          <PMID Version="1">17431198</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2007 May;27(5):1087-94</RefSource>
          <PMID Version="1">17442899</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann Rheum Dis. 2007 Sep;66(9):1132-6</RefSource>
          <PMID Version="1">17251223</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMC Cardiovasc Disord. 2007;7:30</RefSource>
          <PMID Version="1">17963506</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2008 Jun 20;102(12):1548-57</RefSource>
          <PMID Version="1">18483411</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 2009 Jul 31;284(31):20522-30</RefSource>
          <PMID Version="1">19491109</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Cycle. 2010 Feb 1;9(3):601-11</RefSource>
          <PMID Version="1">20107328</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Vasc Pharmacol. 2010 Mar;8(2):285-92</RefSource>
          <PMID Version="1">19485909</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Sci Transl Med. 2010 Apr 7;2(26):26ra26</RefSource>
          <PMID Version="1">20375365</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Signal. 2010 Sep;22(9):1282-90</RefSource>
          <PMID Version="1">20363318</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1550-2</RefSource>
          <PMID Version="1">20508206</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Cardiol. 2011 Feb;8(2):92-102</RefSource>
          <PMID Version="1">21079638</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Pharmacol. 2011 Apr;162(7):1453-69</RefSource>
          <PMID Version="1">21133894</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Atheroscler Rep. 2011 Apr;13(2):162-9</RefSource>
          <PMID Version="1">21271310</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Drug Discov. 2011 May;10(5):365-76</RefSource>
          <PMID Version="1">21532566</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Immunity. 2011 May 27;34(5):715-28</RefSource>
          <PMID Version="1">21565532</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10484-9</RefSource>
          <PMID Version="1">21670263</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2011 Jul;121(7):2736-49</RefSource>
          <PMID Version="1">21670502</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Chem. 2012 Feb;58(2):411-20</RefSource>
          <PMID Version="1">22179741</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
          <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Kruppel-Like Transcription Factors</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nuclear Proteins</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vasculitis</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">p300-CBP Transcription Factors</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3785338</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">68552</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI68552</ArticleId>
        <ArticleId IdType="pubmed">23999430</ArticleId>
        <ArticleId IdType="pmc">PMC3785338</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23999279</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>22</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2212-2672</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the Academy of Nutrition and Dietetics</Title>
          <ISOAbbreviation>J Acad Nutr Diet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The influence of a physician and patient intervention program on dietary intake.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1465-75</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jand.2013.06.343</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2212-2672(13)01021-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efficient dietary interventions for patients with hypertension in clinical settings are needed.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the separate and combined influence of a physician intervention (MD-I) and a patient intervention (PT-I) on dietary intakes of patients with hypertension.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">A nested 2&#xD7;2 design, randomized controlled trial conducted over 18 months.</AbstractText>
          <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 32 physicians and 574 outpatients with hypertension.</AbstractText>
          <AbstractText Label="INTERVENTION" NlmCategory="METHODS">MD-I included training modules addressing the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure hypertension management guidelines and lifestyle modification. PT-I included lifestyle coaching to adopt the Dietary Approaches to Stop Hypertension (DASH) eating pattern, reduce sodium intake, manage weight, increase exercise, and moderate alcohol intake.</AbstractText>
          <AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Dietary intakes were measured by the Block Food Frequency Questionnaire. Concordance with the DASH dietary pattern was estimated by a DASH score.</AbstractText>
          <AbstractText Label="STATISTICAL ANALYSES" NlmCategory="METHODS">The main effects of MD-I and PT-I, and their interaction, were evaluated using analysis of covariance.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After 6 months of intervention, MD-I participants significantly increased intakes of potassium, fruits, juices, and carbohydrate; decreased intake of fat; and improved overall dietary quality as measured by the Healthy Eating Index. PT-I intervention resulted in increased intakes of carbohydrate, protein, fiber, calcium, potassium, fruits and fruit juices, vegetables, dairy and Healthy Eating Index score, and decreased intakes in fat, saturated fat, cholesterol, sodium, sweets, and added fats/oils/sweets. In addition, PT-I improved overall DASH concordance score. The change in DASH score was significantly associated with the changes in blood pressure and weight at 6 months. At 18 months, most changes reversed back toward baseline levels, including the DASH score.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both MD-I and PT-I improved eating patterns at 6 months with some sustained effects at 18 months. Even though all dietary changes observed were consistent with the DASH nutrient targets or food group guidelines, only the PT-I intervention was effective in improving the overall DASH concordance score. This finding affirms the role of medical nutrition therapy in long-term intensive interventions for hypertension risk reduction and weight management and underlines the need for development of maintenance strategies. Furthermore, this study emphasizes the importance of collaborations among physicians, registered dietitians and other dietetics practitioners, and lay health advisors while assisting patients to make healthy behavior changes.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Academy of Nutrition and Dietetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Pao-Hwa</ForeName>
            <Initials>PH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yancy</LastName>
            <ForeName>William S</ForeName>
            <Initials>WS</Initials>
            <Suffix>Jr</Suffix>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollak</LastName>
            <ForeName>Kathryn I</ForeName>
            <Initials>KI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dolor</LastName>
            <ForeName>Rowena J</ForeName>
            <Initials>RJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marcello</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Samsa</LastName>
            <ForeName>Gregory P</ForeName>
            <Initials>GP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batch</LastName>
            <ForeName>Bryan C</ForeName>
            <Initials>BC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Svetkey</LastName>
            <ForeName>Laura P</ForeName>
            <Initials>LP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01-HL75373</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Randomized Controlled Trial</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Acad Nutr Diet</MedlineTA>
        <NlmUniqueID>101573920</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Dietary Carbohydrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Dietary Fats</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Potassium, Dietary</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Alcohol Drinking</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Blood Pressure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, Sodium-Restricted</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Carbohydrates</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Fats</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Fiber</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Exercise</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fruit</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Health Behavior</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="Y">diet therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Life Style</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Physician's Role</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Potassium, Dietary</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Risk Reduction Behavior</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vegetables</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Weight Loss</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Diet</Keyword>
        <Keyword MajorTopicYN="N">Hypertension</Keyword>
        <Keyword MajorTopicYN="N">Intervention</Keyword>
        <Keyword MajorTopicYN="N">Lifestyle</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23999279</ArticleId>
        <ArticleId IdType="pii">S2212-2672(13)01021-6</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jand.2013.06.343</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23994198</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>93</Volume>
            <Issue>15</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gene expression in the vascular wall of the aortic arch in spontaneously hypertensive hyperlipidemic model rats using DNA microarray analysis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>495-502</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2013.08.010</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(13)00476-1</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">In recent years, there has been an increase in patients with arteriosclerosis and the risk of lifestyle-related diseases. However, the pathogenesis and medication of atherosclerosis have not been elucidated. We developed a rat model of lifestyle-related diseases by feeding a high-fat diet and 30% sucrose solution (HFDS) to spontaneously hypertensive hyperlipidemic rats (SHHR) and reported that this model is a useful model of early atherosclerosis. In order to elucidate the pathogenesis of early atherosclerosis, we searched for atherosclerosis-related genes by microarray analysis using the aortic arch rat model of lifestyle-related diseases.</AbstractText>
          <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">Four-month-old male Sprague-Dawley rats and SHHR were each divided into two normal diet (ND) groups and two HFDS groups. After a four-month treatment, the expression of mRNA in the aortic arch was detected using the oligo DNA microarray one-color method and quantified using real-time PCR.</AbstractText>
          <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">In this study, we detected 39 genes in microarray analysis. Esm1, Retnlb Mkks, and Grem2 showed particularly marked changes in gene expression in the SHHR-HFDS group. Compared with the SD-ND group, the SHHR-HFDS group had an increase in Mkks gene expression of about 26-fold and an approximately 22-fold increase in the expression of Grem2. Similarly, the expression of Esm1 increased by about 12-fold and that of Retnlg by about 10-fold as shown by quantitative real-time PCR.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">This study suggested that these four genes might be important in early atherosclerosis development.</AbstractText>
          <CopyrightInformation>&#xA9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Koizumi</LastName>
            <ForeName>Go</ForeName>
            <Initials>G</Initials>
            <Affiliation>Department of Pharmacology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; Department of Pharmacogenomics, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan; Division of Endocrinology and Metabolism, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501, Japan. Electronic address: unfiny@gmail.com.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumai</LastName>
            <ForeName>Toshio</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Egawa</LastName>
            <ForeName>Shunya</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yatomi</LastName>
            <ForeName>Kentaro</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oda</LastName>
            <ForeName>Go</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohba</LastName>
            <ForeName>Keiichiro</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwai</LastName>
            <ForeName>Shinichi</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watanabe</LastName>
            <ForeName>Minoru</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oguchi</LastName>
            <ForeName>Katsuji</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta, Thoracic</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Blood Pressure</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hyperlipidemias</DescriptorName>
          <QualifierName MajorTopicYN="N">complications</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="N">complications</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Oligonucleotide Array Sequence Analysis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Esm1</Keyword>
        <Keyword MajorTopicYN="N">Grem2</Keyword>
        <Keyword MajorTopicYN="N">Microarray analysis</Keyword>
        <Keyword MajorTopicYN="N">Mkks</Keyword>
        <Keyword MajorTopicYN="N">Retnlg</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23994198</ArticleId>
        <ArticleId IdType="pii">S0024-3205(13)00476-1</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2013.08.010</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23986204</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1563</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Cell physiology</Title>
          <ISOAbbreviation>Am. J. Physiol., Cell Physiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>C1033-40</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpcell.00234.2013</ELocationID>
        <Abstract>
          <AbstractText>Endothelial cell (EC) dysfunction is implicated in cardiovascular diseases, including diabetes. The decrease in nitric oxide (NO) bioavailability is the hallmark of endothelial dysfunction, and it leads to attenuated vascular relaxation and atherosclerosis followed by a decrease in blood flow. In the heart, decreased coronary blood flow is responsible for insufficient oxygen supply to cardiomyocytes and, subsequently, increases the incidence of cardiac ischemia. In this study we investigate whether and how reactive oxygen species (ROS) in mitochondria contribute to coronary endothelial dysfunction in type 2 diabetic (T2D) mice. T2D was induced in mice by a high-fat diet combined with a single injection of low-dose streptozotocin. ACh-induced vascular relaxation was significantly attenuated in coronary arteries (CAs) from T2D mice compared with controls. The pharmacological approach reveals that NO-dependent, but not hyperpolarization- or prostacyclin-dependent, relaxation was decreased in CAs from T2D mice. Attenuated ACh-induced relaxation in CAs from T2D mice was restored toward control level by treatment with mitoTempol (a mitochondria-specific O2(-) scavenger). Coronary ECs isolated from T2D mice exhibited a significant increase in mitochondrial ROS concentration and decrease in SOD2 protein expression compared with coronary ECs isolated from control mice. Furthermore, protein ubiquitination of SOD2 was significantly increased in coronary ECs isolated from T2D mice. These results suggest that augmented SOD2 ubiquitination leads to the increase in mitochondrial ROS concentration in coronary ECs from T2D mice and attenuates coronary vascular relaxation in T2D mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cho</LastName>
            <ForeName>Young-Eun</ForeName>
            <Initials>YE</Initials>
            <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basu</LastName>
            <ForeName>Aninda</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Anzhi</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heldak</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Makino</LastName>
            <ForeName>Ayako</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HL-115578</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Cell Physiol</MedlineTA>
        <NlmUniqueID>100901225</NlmUniqueID>
        <ISSNLinking>0363-6143</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Culture Media</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2V16EO95H1</RegistryNumber>
          <NameOfSubstance>Palmitic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance>Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance>Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance>Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance>Acetylcholine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Acetylcholine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Coronary Vessels</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Culture Media</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Immunoprecipitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Palmitic Acid</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3840199 [Available on 11/15/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">diabetic vascular complication</Keyword>
        <Keyword MajorTopicYN="N">hyperglycemia</Keyword>
        <Keyword MajorTopicYN="N">posttranslational modification</Keyword>
        <Keyword MajorTopicYN="N">ubiquitin-proteasome system</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23986204</ArticleId>
        <ArticleId IdType="pii">ajpcell.00234.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpcell.00234.2013</ArticleId>
        <ArticleId IdType="pmc">PMC3840199</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23984293</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>28</Day>
      </DateCreated>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2242-3982</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>72</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of circumpolar health</Title>
          <ISOAbbreviation>Int J Circumpolar Health</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Animal source food intake and association with blood cholesterol, glycerophospholipids and sphingolipids in a northern Swedish population.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3402/ijch.v72i0.21162</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The high intake of game meat in populations with a subsistence-based diet may affect their blood lipids and health status.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association between diet and circulating levels of blood lipid levels in a northern Swedish population.</AbstractText>
          <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">We compared a group with traditional lifestyle (TLS) based on reindeer herding (TLS group) with those from the same area with a non-traditional lifestyle (NTLS) typical of more industrialized regions of Sweden (NTLS group). The analysis was based on self-reported intake of animal source food (i.e. non-game meat, game meat, fish, dairy products and eggs) and the serum blood level of a number of lipids [total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG), glycerophospholipids and sphingolipids].</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The TLS group had higher cholesterol, LDL and HDL levels than the reference group. Of the TLS group, 65% had cholesterol levels above the threshold for increased risk of coronary heart disease (= 240 mg/dl), as compared to 38% of the NTLS group. Self-reported consumption of game meat was positively associated with TC and LDL.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The high game meat consumption of the TLS group is associated with increased cholesterol levels. High intake of animal protein and fat and low fibre is known to increase the risk of cardiovascular disease, but other studies of the TLS in northern Sweden have shown comparable incidences of cardiovascular disease to the reference (NTLS) group from the same geographical area. This indicates that factors other than TC influence disease risk. One such possible factor is dietary phospholipids, which are also found in high amounts specifically in game meat and have been shown to inhibit cholesterol absorption.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Igl</LastName>
            <ForeName>Wilmar</ForeName>
            <Initials>W</Initials>
            <Affiliation>Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamal-Eldin</LastName>
            <ForeName>Afaf</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johansson</LastName>
            <ForeName>Asa</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liebisch</LastName>
            <ForeName>Gerhard</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gnewuch</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmitz</LastName>
            <ForeName>Gerd</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gyllensten</LastName>
            <ForeName>Ulf</ForeName>
            <Initials>U</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Sweden</Country>
        <MedlineTA>Int J Circumpolar Health</MedlineTA>
        <NlmUniqueID>9713056</NlmUniqueID>
        <ISSNLinking>1239-9736</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1982 Sep;112(9):1805-8</RefSource>
          <PMID Version="1">7108644</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 1988 Sep;48(3 Suppl):739-48</RefSource>
          <PMID Version="1">3046303</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Gut. 1993 Jan;34(1):110-5</RefSource>
          <PMID Version="1">8432440</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Sci Vitaminol (Tokyo). 1993 Feb;39(1):63-71</RefSource>
          <PMID Version="1">8509902</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2339-44</RefSource>
          <PMID Version="1">9122196</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Can J Physiol Pharmacol. 1997 Mar;75(3):217-27</RefSource>
          <PMID Version="1">9164705</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 1999 Aug;40(8):1539-46</RefSource>
          <PMID Version="1">10428992</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Circumpolar Health. 2004;63 Suppl 2:292-7</RefSource>
          <PMID Version="1">15736671</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Croat Med J. 2006 Aug;47(4):553-65</RefSource>
          <PMID Version="1">16909452</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biol Cell. 2007 Mar;99(3):129-40</RefSource>
          <PMID Version="1">17064251</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Appl Physiol Nutr Metab. 2007 Jun;32(3):341-50</RefSource>
          <PMID Version="1">17510668</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Bioinformatics. 2007 May 15;23(10):1294-6</RefSource>
          <PMID Version="1">17384015</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2007;2(12):e1274</RefSource>
          <PMID Version="1">18060068</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Mol Cell Biol. 2008 Feb;9(2):162-76</RefSource>
          <PMID Version="1">18216772</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Scand J Public Health. 2008 Jan;36(1):84-91</RefSource>
          <PMID Version="1">18426788</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Prog Lipid Res. 2008 Sep;47(5):348-80</RefSource>
          <PMID Version="1">18435934</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2008 Dec;88(6):1663-9</RefSource>
          <PMID Version="1">19064529</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Intern Med. 2009 Apr 13;169(7):659-69</RefSource>
          <PMID Version="1">19364995</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Annu Rev Nutr. 2009;29:257-82</RefSource>
          <PMID Version="1">19400697</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Circumpolar Health. 2009 Sep;68(4):372-85</RefSource>
          <PMID Version="1">19917189</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Rural Remote Health. 2010 Apr-Jun;10(2):1363</RefSource>
          <PMID Version="1">20568910</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2000 Oct;72(4):912-21</RefSource>
          <PMID Version="1">11010931</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Scand J Public Health Suppl. 2001;56:59-68</RefSource>
          <PMID Version="1">11681565</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Chem. 2002 Dec;48(12):2217-24</RefSource>
          <PMID Version="1">12446479</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Mass Spectrom. 2004 Oct;15(10):1499-508</RefSource>
          <PMID Version="1">15465363</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3753141</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">animal source foods</Keyword>
        <Keyword MajorTopicYN="N">cholesterol</Keyword>
        <Keyword MajorTopicYN="N">epidemiology</Keyword>
        <Keyword MajorTopicYN="N">game</Keyword>
        <Keyword MajorTopicYN="N">lipids</Keyword>
        <Keyword MajorTopicYN="N">nutrition</Keyword>
        <Keyword MajorTopicYN="N">phospholipids</Keyword>
        <Keyword MajorTopicYN="N">sphingolipids</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ecollection">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.3402/ijch.v72i0.21162</ArticleId>
        <ArticleId IdType="pii">21162</ArticleId>
        <ArticleId IdType="pubmed">23984293</ArticleId>
        <ArticleId IdType="pmc">PMC3753141</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">23981691</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1743-7075</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition &amp; metabolism</Title>
          <ISOAbbreviation>Nutr Metab (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ProAlgaZyme subfraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites.</ArticleTitle>
        <Pagination>
          <MedlinePgn>55</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-7075-10-55</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previously, we reported that ProAlgaZyme (PAZ) and its biologically active fraction improved plasma lipids in hypercholesterolemic hamsters, by significantly increasing the high density lipoprotein cholesterol (HDL-C) while reducing non-HDL cholesterol and the ratio of total cholesterol/HDL-C. Moreover, hepatic mRNA expression of genes involved in HDL/reverse cholesterol transport were significantly increased, while cholesteryl ester transfer protein (CETP) expression was partially inhibited. In the current study, we investigated the therapeutic efficacy of the biologically active fraction of PAZ (BaP) on the plasma lipid and plasma metabolomic profiles in diet induced hypercholesterolemic hamsters.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Fifty male Golden Syrian hamsters were fed a high fat diet for 4&#xA0;weeks prior to randomization into 6 groups, based on the number of days they received subsequent treatment. Thus animals in T0, T3, T7, T10, T14, and T21 groups received BaP for 0, 3, 7, 10, 14, and 21&#xA0;days, respectively, as their drinking fluid. Plasma lipids were assayed enzymatically, while real-time reverse transcriptase polymerase chain reaction (RT-PCR) provided the transcription levels of the Apolipoprotein (Apo) A1 gene. The plasma metabolomic profile was determined using 1H nuclear magnetic resonance (NMR) spectroscopy in conjunction with multivariate analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma HDL-C was significantly increased in T3 (P?&lt;?0.05) and T21 (P?&lt;?0.001), while non-HDL cholesterol was significantly reduced in T3, T7, T10 (P?&lt;?0.001) and T14, T21 (P?&lt;?0.01). Moreover, the ratio of total cholesterol/HDL-C was significantly lower in all BaP treated groups (P?&lt;?0.001) as compared with T0. Quantitative RT-PCR showed an increase in Apo A1 expression in T10 (3-fold) and T21 (6-fold) groups. NMR data followed by multivariate analysis showed a clear separation between T0 and T21 groups, indicating a difference in their metabolomic profiles. Plasma concentrations of metabolites associated with a risk for atherosclerosis and cardiovascular disease, including choline, phosphocholine, glycerol-phosphocholine, betaine and carnitine metabolites were significantly lower in the T21 group.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with BaP significantly improved the plasma lipid profile by increasing HDL-C and lowering non-HDL cholesterol. In addition, BaP potentially improved the plasma metabolomic profile by reducing the concentration of key metabolites associated with risk for atherosclerosis and cardiovascular disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Geamanu</LastName>
            <ForeName>Andreea</ForeName>
            <Initials>A</Initials>
            <Affiliation>Nutrition and Food Science, 3009 Science Hall, Wayne State University, Detroit, MI 48202, USA. sgupta@wayne.edu.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goja</LastName>
            <ForeName>Arvind</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saadat</LastName>
            <ForeName>Nadia</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khosla</LastName>
            <ForeName>Pramod</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Smiti V</ForeName>
            <Initials>SV</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nutr Metab (Lond)</MedlineTA>
        <NlmUniqueID>101231644</NlmUniqueID>
        <ISSNLinking>1743-7075</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3844637</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1743-7075-10-55</ArticleId>
        <ArticleId IdType="doi">10.1186/1743-7075-10-55</ArticleId>
        <ArticleId IdType="pubmed">23981691</ArticleId>
        <ArticleId IdType="pmc">PMC3844637</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23981577</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>16</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>342</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.</ArticleTitle>
        <Pagination>
          <MedlinePgn>60-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2013.08.031</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(13)00606-X</ELocationID>
        <Abstract>
          <AbstractText>Non-alcoholic steatohepatitis (NASH), which involves hepatic inflammation and fibrosis, is associated with liver carcinogenesis. The activation of the renin-angiotensin system (RAS), which plays a key role in blood pressure regulation, promotes hepatic fibrogenesis. In this study, we investigated the effects of (-)-epigallocatechin-3-gallate (EGCG), a major component of green tea catechins, on the development of glutathione S-transferase placental form (GST-P)-positive (GST-P(+)) foci, a hepatic preneoplastic lesion, in SHRSP.Z-Lepr(fa)/IzmDmcr (SHRSP-ZF) obese and hypertensive rats. Male 7-week-old SHRSP-ZF rats and control non-obese and normotensive WKY rats were fed a high fat diet and received intraperitoneal injections of carbon tetrachloride twice a week for 8weeks. The rats were also provided tap water containing 0.1% EGCG during the experiment. SHRSP-ZF rats presented with obesity, insulin resistance, dyslipidemia, an imbalance of adipokines in the serum, and hepatic steatosis. The development of GST-P(+) foci and liver fibrosis was markedly accelerated in SHRSP-ZF rats compared to that in control rats. Additionally, in SHRSP-ZF rats, RAS was activated and inflammation and oxidative stress were induced. Administration of EGCG, however, inhibited the development of hepatic premalignant lesions by improving liver fibrosis, inhibiting RAS activation, and attenuating inflammation and oxidative stress in SHRSP-ZF rats. In conclusion, obese and hypertensive SHRSP-ZF rats treated with a high fat diet and carbon tetrachloride displayed the histopathological and pathophysiological characteristics of NASH and developed GST-P(+) foci hepatic premalignant lesions, suggesting the model might be useful for the evaluation of NASH-related liver tumorigenesis. EGCG might also be able to prevent NASH-related liver fibrosis and tumorigenesis.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kochi</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <Affiliation>Department of Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Masahito</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terakura</LastName>
            <ForeName>Daishi</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baba</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohno</LastName>
            <ForeName>Tomohiko</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kubota</LastName>
            <ForeName>Masaya</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shirakami</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsurumi</LastName>
            <ForeName>Hisashi</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Takuji</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moriwaki</LastName>
            <ForeName>Hisataka</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Anticarcinogenic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Receptor, Angiotensin, Type 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11128-99-7</RegistryNumber>
          <NameOfSubstance>Angiotensin II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8R1V1STN48</RegistryNumber>
          <NameOfSubstance>Catechin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BQM438CTEL</RegistryNumber>
          <NameOfSubstance>epigallocatechin gallate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.15.1</RegistryNumber>
          <NameOfSubstance>Peptidyl-Dipeptidase A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease">Non-alcoholic Fatty Liver Disease</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Angiotensin II</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Anticarcinogenic Agents</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Catechin</DescriptorName>
          <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Liver</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
          <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Precancerous Conditions</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Inbred SHR</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Inbred WKY</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Receptor, Angiotensin, Type 1</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGCG</Keyword>
        <Keyword MajorTopicYN="N">Hypertension</Keyword>
        <Keyword MajorTopicYN="N">Liver fibrosis</Keyword>
        <Keyword MajorTopicYN="N">Liver tumorigenesis</Keyword>
        <Keyword MajorTopicYN="N">Obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23981577</ArticleId>
        <ArticleId IdType="pii">S0304-3835(13)00606-X</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2013.08.031</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23974119</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1083-351X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>288</Volume>
            <Issue>41</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.</ArticleTitle>
        <Pagination>
          <MedlinePgn>29252-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M113.481473</ELocationID>
        <Abstract>
          <AbstractText>Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health. Genetic analysis has identified PCSK9 (proprotein convertase subtilisin/kexin type 9) as a crucial gene in the regulation of LDL-cholesterol via control of LDL receptor degradation. Although biochemical characteristics and clinical implications of PCSK9 have been extensively investigated, epigenetic regulation of this gene is largely unknown. In this work we have discovered that Sirt6, an NAD(+)-dependent histone deacetylase, plays a critical role in the regulation of the Pcsk9 gene expression in mice. Hepatic Sirt6 deficiency leads to elevated Pcsk9 gene expression and LDL-cholesterol as well. Mechanistically, we have demonstrated that Sirt6 can be recruited by forkhead transcription factor FoxO3 to the proximal promoter region of the Pcsk9 gene and deacetylates histone H3 at lysines 9 and 56, thereby suppressing the gene expression. Also remarkably, overexpression of Sirt6 in high fat diet-fed mice lowers LDL-cholesterol. Overall, our data suggest that FoxO3 and Sirt6, two longevity genes, can reduce LDL-cholesterol levels through regulation of the Pcsk9 gene.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tao</LastName>
            <ForeName>Rongya</ForeName>
            <Initials>R</Initials>
            <Affiliation>From the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Xiwen</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>DePinho</LastName>
            <ForeName>Ronald A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Chu-Xia</ForeName>
            <Initials>CX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>X Charlie</ForeName>
            <Initials>XC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R00DK077505</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK091592</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01DK091592</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Forkhead Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>FoxO3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Histones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.31</RegistryNumber>
          <NameOfSubstance>Sirt6 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.-</RegistryNumber>
          <NameOfSubstance>Proprotein Convertases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance>Pcsk9 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance>Serine Endopeptidases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance>Sirtuins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K3Z4F929H6</RegistryNumber>
          <NameOfSubstance>Lysine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Acetylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Histones</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lysine</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, 129 Strain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Proprotein Convertases</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Serine Endopeptidases</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sirtuins</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3795227 [Available on 10/11/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cholesterol</Keyword>
        <Keyword MajorTopicYN="N">Epigenetics</Keyword>
        <Keyword MajorTopicYN="N">Histone Deacetylase</Keyword>
        <Keyword MajorTopicYN="N">Liver</Keyword>
        <Keyword MajorTopicYN="N">Sirtuins</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23974119</ArticleId>
        <ArticleId IdType="pii">M113.481473</ArticleId>
        <ArticleId IdType="doi">10.1074/jbc.M113.481473</ArticleId>
        <ArticleId IdType="pmc">PMC3795227</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23973955</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>16</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>93</Volume>
            <Issue>12-14</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>6</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sexual dimorphism in fat distribution and metabolic profile in mice offspring from diet-induced obese mothers.</ArticleTitle>
        <Pagination>
          <MedlinePgn>454-63</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2013.08.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(13)00460-8</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To investigate whether the effects of diet-induced obesity in mothers are passed on to their offspring fed a control diet in a gender-specific manner.</AbstractText>
          <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">Mother mice received either standard chow (SC; 17% energy from fat) or high-fat (HF; 49% energy from fat) diet for eight weeks pre-pregnancy until lactation. After weaning (at 21 days of age), offspring received SC diet and were divided into four groups according to the mother's diet (Mo): male Mo-SC, female Mo-SC, male Mo-HF, and female Mo-HF. Stereology, Elisa and western blotting were performed.</AbstractText>
          <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">HF diet-fed mothers were overweight, and had metabolic abnormalities, all of which were found in their adult offspring. Male Mo-HF offspring had higher cholesterol, triglycerides, leptin and insulin levels and lower circulating adiponectin than female Mo-HF offspring. Mo-HF offspring of both genders had higher expression of tumor necrosis factor-alpha, interleukin-6 and leptin and lower expression of adiponectin than Mo-SC offspring; however, male Mo-HF were more affected than female Mo-HF offspring for these variables, demonstrating sexual dimorphism.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">Exposure to HF diet is effective in inducing obesity and metabolic alterations in mothers, and this phenotype can be passed on to their offspring. An adverse pattern in the body fat distribution in males probably has favored the intensification of a pro-inflammatory profile compared with females. In adulthood, the male offspring responds to the maternal obesity more than the female offspring, indicating a relevant sexual dimorphism that is a novel finding in this animal study.</AbstractText>
          <CopyrightInformation>&#xA9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ornellas</LastName>
            <ForeName>Fernanda</ForeName>
            <Initials>F</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mello</LastName>
            <ForeName>Vanessa Souza</ForeName>
            <Initials>VS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandarim-de-Lacerda</LastName>
            <ForeName>Carlos A</ForeName>
            <Initials>CA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aguila</LastName>
            <ForeName>Marcia B</ForeName>
            <Initials>MB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adipose tissue</Keyword>
        <Keyword MajorTopicYN="N">Maternal obesity</Keyword>
        <Keyword MajorTopicYN="N">Metabolic profile</Keyword>
        <Keyword MajorTopicYN="N">Sexual dimorphism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23973955</ArticleId>
        <ArticleId IdType="pii">S0024-3205(13)00460-8</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2013.08.005</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
      <PMID Version="1">23970917</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1735-3955</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>9</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>ARYA atherosclerosis</Title>
          <ISOAbbreviation>ARYA Atheroscler</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of quince leaf extract on biochemical markers and coronary histopathological changes in rabbits.</ArticleTitle>
        <Pagination>
          <MedlinePgn>223-31</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atherosclerosis is the main cause of cardiovascular disease which is caused by a high-fat diet. Many of these patients use boiled quince leaves for their treatment. However, the supporting scientific information is limit. The aim of this study was to evaluate the effect of quince leaf on the progression of atherosclerosis and whether it can be an appropriate alternative to statins.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">24 male rabbits were randomly divided into two groups: normal diet (6 n) and high-cholesterol diet (2% cholesterol, 18 n) for 8 weeks. At the end of the 8 weeks, both groups underwent blood sampling and their biochemical markers were measured. Then, all animals in the normal-diet group and three of the high-cholesterol diet group were killed to investigate atheromic plaque in their coronary artery. The 15 remaining rabbits of the high-cholesterol diet group were randomly divided into 3 groups (5 n) after discontinuation of the fatty diet. The first group was not given any treatment, the second received atorvastatin (0.5 mg/kg) orally, and the third received quince leaf extract (50 mg/kg) orally for 12 weeks. At the end of this period, after blood sampling, biopsy of coronary artery was performed for histological study.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that atorvastatin and quince leaf significantly decreased total cholesterol, triglyceride, LDL, AST, ALT, AP, BUN, and Cr levels compared with the first group of the high-cholesterol diet group (P &lt; 0.05). No significant difference was found between atorvastatin and quince leaf extract groups in biochemical markers and atherosclerotic plaque in coronary artery.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Atorvastatin and quince leaf extract can effectively prevent the progression of atherosclerosis in coronary arteries. According to the results of this study and also lower toxic effects of herbal medication compared to synthetic medication, leaf extract can be a substitute for statins in treatment and prevention of cardiovascular disease. The anti-atherosclerotic effect of quince leaf is most likely related to its antioxidant components.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khademi</LastName>
            <ForeName>Farzaneh</ForeName>
            <Initials>F</Initials>
            <Affiliation>PhD Candidate, Department of Tissue Engineering and Cell Therapy, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Danesh</LastName>
            <ForeName>Behnam</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delazar</LastName>
            <ForeName>Abbas</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohammad Nejad</LastName>
            <ForeName>Daryoush</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghorbani</LastName>
            <ForeName>Masoud</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soleimani Rad</LastName>
            <ForeName>Jafar</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Iran</Country>
        <MedlineTA>ARYA Atheroscler</MedlineTA>
        <NlmUniqueID>101487337</NlmUniqueID>
        <ISSNLinking>1735-3955</ISSNLinking>
      </MedlineJournalInfo>
      <OtherID Source="NLM">PMC3746946</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atheromic Plaque</Keyword>
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Atorvastatin</Keyword>
        <Keyword MajorTopicYN="N">Biochemical Markers</Keyword>
        <Keyword MajorTopicYN="N">Coronary Arteries</Keyword>
        <Keyword MajorTopicYN="N">Hyperlipidemia</Keyword>
        <Keyword MajorTopicYN="N">Quince Leaf Extract</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23970917</ArticleId>
        <ArticleId IdType="pmc">PMC3746946</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23964081</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-6860</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
          <ISOAbbreviation>FASEB J.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.</ArticleTitle>
        <Pagination>
          <MedlinePgn>4757-67</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.13-232702</ELocationID>
        <Abstract>
          <AbstractText>Excessive uptake of fatty acids and glucose by adipose tissue triggers adipocyte dysfunction and infiltration of immune cells. Altered metabolic homeostasis in adipose tissue promotes insulin resistance, type 2 diabetes, hypertension, and cardiovascular disease. Inflammatory and metabolic processes are mediated by certain proteolytic enzymes that share a common cellular target, protease-activated receptor 2 (PAR2). This study showed that human and rat obesity correlated in vivo with increased expression of PAR2 in adipose tissue, primarily in stromal vascular cells (SVCs) including macrophages. PAR2 was expressed more than other PARs on human macrophages and was increased by dietary fatty acids (palmitic, stearic, and myristic). A novel PAR2 antagonist, GB88 (5-isoxazoyl-Cha-Ile-spiroindene-1,4-piperidine), given orally at 10 mg/kg/d (wk 8-16) reduced body weight by ~10% in obese rats fed a high-carbohydrate high-fat (HCHF) diet for 16 wk, and strongly attenuated adiposity, adipose tissue inflammation, infiltrated macrophages and mast cells, insulin resistance, and cardiac fibrosis and remodeling; while reversing liver and pancreatic dysfunction and normalizing secretion of PAR2-directed glucose-stimulated insulin secretion in MIN6 &#xDF; cells. In summary, PAR2 is a new biomarker for obesity, and its expression is stimulated by dietary fatty acids; PAR2 is a substantial contributor to inflammatory and metabolic dysfunction; and a PAR2 antagonist inhibits diet-induced obesity and inflammatory, metabolic, and cardiovascular dysfunction.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lim</LastName>
            <ForeName>Junxian</ForeName>
            <Initials>J</Initials>
            <Affiliation>2D.P.F., Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. d.fairlie@imb.uq.edu.au.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyer</LastName>
            <ForeName>Abishek</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Ligong</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suen</LastName>
            <ForeName>Jacky Y</ForeName>
            <Initials>JY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lohman</LastName>
            <ForeName>Rink-Jan</ForeName>
            <Initials>RJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seow</LastName>
            <ForeName>Vernon</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yau</LastName>
            <ForeName>Mei-Kwan</ForeName>
            <Initials>MK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Lindsay</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fairlie</LastName>
            <ForeName>David P</ForeName>
            <Initials>DP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>FASEB J</MedlineTA>
        <NlmUniqueID>8804484</NlmUniqueID>
        <ISSNLinking>0892-6638</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">adipocyte</Keyword>
        <Keyword MajorTopicYN="N">biomarker</Keyword>
        <Keyword MajorTopicYN="N">inhibitor</Keyword>
        <Keyword MajorTopicYN="N">macrophage</Keyword>
        <Keyword MajorTopicYN="N">protease-activated receptor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23964081</ArticleId>
        <ArticleId IdType="pii">fj.13-232702</ArticleId>
        <ArticleId IdType="doi">10.1096/fj.13-232702</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23954796</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-9980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Heart Association</Title>
          <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hepatic extracellular signal-regulated kinase 2 suppresses endoplasmic reticulum stress and protects from oxidative stress and endothelial dysfunction.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e000361</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.113.000361</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Insulin signaling comprises 2 major cascades: the insulin receptor substrate/phosphatidylinositol 3'-kinase/protein kinase B and Ras/Raf/mitogen-activated protein kinase/kinase/ERK pathways. While many studies on the tissue-specific effects of the insulin receptor substrate/phosphatidylinositol 3' -kinase/protein kinase B pathway have been conducted, the role of the other cascade in tissue-specific insulin resistance has not been investigated. High glucose/fatty acid toxicity, inflammation, and oxidative stress, all of which are associated with insulin resistance, can activate ERK. The liver plays a central role in metabolism, and hepatosteatosis is associated with vascular diseases. The aim of study was to elucidate the role of hepatic ERK2 in hepatosteatosis, metabolic remodeling, and endothelial dysfunction.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We created liver-specific ERK2 knockout mice and fed them with a high-fat/high-sucrose diet for 20 weeks. The high-fat/high-sucrose diet-fed liver-specific ERK2 knockout mice exhibited a marked deterioration in hepatosteatosis and metabolic remodeling represented by impairment of glucose tolerance and decreased insulin sensitivity without changes in body weight, blood pressure, and serum cholesterol/triglyceride levels. In the mice, endoplasmic reticulum stress was induced together with decreased mRNA and protein expressions of hepatic sarco/endoplasmic reticulum Ca(2+)-ATPase 2. In a hepatoma cell line, inhibition of ERK activation- induced endoplasmic reticulum stress only in the presence of palmitate. Vascular reactive oxygen species were elevated with upregulation of nicotinamide adenine dinucleotide phosphate oxidase1 (Nox1) and Nox4 and decreased phosphorylation of endothelial nitric oxide synthase, which resulted in the remarkable endothelial dysfunction in high-fat/high-sucrose diet-fed liver-specific ERK2 knockout mice.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hepatic ERK2 suppresses endoplasmic reticulum stress and hepatosteatosis in vivo, which results in protection from vascular oxidative stress and endothelial dysfunction. These findings demonstrate a novel role of hepatic ERK2 in obese-induced insulin resistance in the protection from hepatovascular metabolic remodeling and vascular diseases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kujiraoka</LastName>
            <ForeName>Takehiko</ForeName>
            <Initials>T</Initials>
            <Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, National Defense Medical College, Sayama, Japan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satoh</LastName>
            <ForeName>Yasushi</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayaori</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shiraishi</LastName>
            <ForeName>Yasunaga</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arai-Nakaya</LastName>
            <ForeName>Yuko</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hakuno</LastName>
            <ForeName>Daihiko</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yada</LastName>
            <ForeName>Hirotaka</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuwada</LastName>
            <ForeName>Naruo</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Endo</LastName>
            <ForeName>Shogo</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isoda</LastName>
            <ForeName>Kikuo</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adachi</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Am Heart Assoc</MedlineTA>
        <NlmUniqueID>101580524</NlmUniqueID>
        <ISSNLinking>2047-9980</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2012 Oct;61(10):2609-20</RefSource>
          <PMID Version="1">22751695</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMB Rep. 2012 Aug;45(8):464-9</RefSource>
          <PMID Version="1">22917031</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Biophys Res Commun. 2012 Oct 12;427(1):138-42</RefSource>
          <PMID Version="1">22989749</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2000 Feb;105(3):311-20</RefSource>
          <PMID Version="1">10675357</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell. 2000 Jul;6(1):87-97</RefSource>
          <PMID Version="1">10949030</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2000 Aug;106(4):483-91</RefSource>
          <PMID Version="1">10953023</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2000 Nov 10;87(10):840-4</RefSource>
          <PMID Version="1">11073878</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2001 Feb 2;88(2):E14-22</RefSource>
          <PMID Version="1">11157681</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2001 Nov;108(9):1341-8</RefSource>
          <PMID Version="1">11696579</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2001 Dec 13;414(6865):813-20</RefSource>
          <PMID Version="1">11742414</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 2002 Nov 21;420(6913):333-6</RefSource>
          <PMID Version="1">12447443</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2004 Oct;84(4):1381-478</RefSource>
          <PMID Version="1">15383655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2004 Oct;27(10):2498-500</RefSource>
          <PMID Version="1">15451925</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 2004 Oct 15;306(5695):457-61</RefSource>
          <PMID Version="1">15486293</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 1976 May 7;72:248-54</RefSource>
          <PMID Version="1">942051</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1991 Sep 15;266(26):17067-71</RefSource>
          <PMID Version="1">1832668</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 1998 Jun 29;82(12):1298-305</RefSource>
          <PMID Version="1">9648726</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1999 Aug;104(4):447-57</RefSource>
          <PMID Version="1">10449437</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2004 Nov;10(11):1200-7</RefSource>
          <PMID Version="1">15489859</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H37-42</RefSource>
          <PMID Version="1">15345488</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 May;25(5):1045-50</RefSource>
          <PMID Version="1">15731489</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Annu Rev Biochem. 2005;74:739-89</RefSource>
          <PMID Version="1">15952902</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hepatology. 2005 Aug;42(2):473-80</RefSource>
          <PMID Version="1">15981216</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Calcium. 2005 Sep-Oct;38(3-4):291-302</RefSource>
          <PMID Version="1">16105684</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2005 Dec;54(12):3541-6</RefSource>
          <PMID Version="1">16306373</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Care. 2006 Jun;29(6):1325-30</RefSource>
          <PMID Version="1">16732016</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2454-61</RefSource>
          <PMID Version="1">16931794</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29</RefSource>
          <PMID Version="1">17565364</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2008 Jan 1;117(1):52-60</RefSource>
          <PMID Version="1">18071073</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Med. 2008 Jan;121(1):72-8</RefSource>
          <PMID Version="1">18187076</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2008 Feb;7(2):95-6</RefSource>
          <PMID Version="1">18249166</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2008 Feb;7(2):125-34</RefSource>
          <PMID Version="1">18249172</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Annu Rev Pathol. 2008;3:399-425</RefSource>
          <PMID Version="1">18039139</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Pathol. 2008 Oct;173(4):1210-9</RefSource>
          <PMID Version="1">18772329</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Pharm Des. 2008;14(25):2613-8</RefSource>
          <PMID Version="1">18991678</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2009 Jun;204(2):521-5</RefSource>
          <PMID Version="1">18947828</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2010 Jan;53(1):180-91</RefSource>
          <PMID Version="1">19894030</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):781-6</RefSource>
          <PMID Version="1">20110577</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2010 Jul 23;107(2):228-32</RefSource>
          <PMID Version="1">20508180</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Adv Pharmacol. 2010;59:165-95</RefSource>
          <PMID Version="1">20933202</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2010 Oct 15;107(8):975-83</RefSource>
          <PMID Version="1">20724704</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2010 Oct 29;107(9):1058-70</RefSource>
          <PMID Version="1">21030723</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19320-5</RefSource>
          <PMID Version="1">20974941</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Endocrinol Metab. 2010 Dec;21(12):707-13</RefSource>
          <PMID Version="1">20888782</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2011 Jan;54(1):180-9</RefSource>
          <PMID Version="1">20953578</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Free Radic Biol Med. 2011 Sep 1;51(5):978-92</RefSource>
          <PMID Version="1">21627987</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Neurosci. 2011 Aug 17;31(33):11953-67</RefSource>
          <PMID Version="1">21849556</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ J. 2011;75(10):2453-9</RefSource>
          <PMID Version="1">21785226</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):467-74</RefSource>
          <PMID Version="1">22697078</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Basic Res Cardiol. 2012 Sep;107(5):296</RefSource>
          <PMID Version="1">22890560</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2052-9</RefSource>
          <PMID Version="1">22895666</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>RNA Biol. 2012 Jun;9(6):820-7</RefSource>
          <PMID Version="1">22664916</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3828781</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">diabetes mellitus</Keyword>
        <Keyword MajorTopicYN="N">insulin</Keyword>
        <Keyword MajorTopicYN="N">liver</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">nitric oxide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jah3280</ArticleId>
        <ArticleId IdType="doi">10.1161/JAHA.113.000361</ArticleId>
        <ArticleId IdType="pubmed">23954796</ArticleId>
        <ArticleId IdType="pmc">PMC3828781</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23954368</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-6815</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental gerontology</Title>
          <ISOAbbreviation>Exp. Gerontol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aging compounds western diet-associated large artery endothelial dysfunction in mice: prevention by voluntary aerobic exercise.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1218-25</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exger.2013.08.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0531-5565(13)00238-6</ELocationID>
        <Abstract>
          <AbstractText>We tested the hypothesis that aging will exacerbate the negative vascular consequences of exposure to a common physiological stressor, i.e., consumption of a "western" (high fat/high sucrose) diet (WD), by inducing superoxide-associated reductions in nitric oxide (NO) bioavailability, and that this would be prevented by voluntary aerobic exercise. Incremental stiffness and endothelium-dependent dilation (EDD) were measured in the carotid arteries of young (5.4&#xB1;0.3 mo, N=20) and old (30.4&#xB1;0.2 mo, N=19) male B6D2F1 mice fed normal chow (NC: 17% fat, 0% sucrose) or a western diet (40% fat, 19% sucrose) and housed in either standard cages or cages equipped with running wheels for 10-14 weeks. Incremental stiffness was higher in old NC (P&lt;0.05) and both young (P&lt;0.01) and old (P&lt;0.01) WD fed mice compared with young NC mice, but WD did not further increase stiffness in the old mice. In cage control mice, maximal EDD was 17% lower in both NC fed old mice and young WD fed mice (P&lt;0.05). Consumption of WD by old mice led to a further 20% reduction in maximal EDD (P&lt;0.05). Incremental stiffness was 28% lower and maximal EDD was 38% greater in old WD fed mice with access to running wheels vs. old WD fed control mice (P&lt;0.05) and not different from young NC fed controls. Wheel running also tended to improve maximal EDD (+9%, P=0.11), but not incremental stiffness in young WD fed mice. Ex vivo treatment with the superoxide scavenger TEMPOL and NO inhibitor l-NAME abolished these respective effects of age, WD and voluntary running on EDD. Ingestion of a WD induces similar degrees of endothelial dysfunction in old and young adult B6D2F1 mice, and these effects are mediated by a superoxide-dependent impairment of NO bioavailability. However, the combination of old age and WD, a common occurrence in our aging society, results in a marked, additive reduction in endothelial function. Importantly, regular voluntary aerobic exercise reduces arterial stiffness and protects against the adverse influence of WD on endothelial function in old animals by preventing superoxide suppression of NO. These findings may have important implications for arterial aging and the prevention of age-associated cardiovascular diseases.</AbstractText>
          <CopyrightInformation>&#xA9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lesniewski</LastName>
            <ForeName>Lisa A</ForeName>
            <Initials>LA</Initials>
            <Affiliation>Department of Integrative Physiology, University of Colorado Boulder, 354 UCB, Boulder, CO 80309, United States; School of Medicine, Department of Internal Medicine, Division of Geriatrics, University of Utah, United States; Geriatrics Research Education and Clinical Center, Veterans Administration Medical Center, Salt Lake City Health Care System, 500 Foothill Dr., Salt Lake City, UT 84148, United States. Electronic address: Lisa.Lesniewski@utah.edu.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zigler</LastName>
            <ForeName>Melanie L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durrant</LastName>
            <ForeName>Jessica R</ForeName>
            <Initials>JR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nowlan</LastName>
            <ForeName>Molly J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Folian</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Donato</LastName>
            <ForeName>Anthony J</ForeName>
            <Initials>AJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seals</LastName>
            <ForeName>Douglas R</ForeName>
            <Initials>DR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL107120</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL107120</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AG033755</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AG033755</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 AG013038</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 AG013038</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Exp Gerontol</MedlineTA>
        <NlmUniqueID>0047061</NlmUniqueID>
        <ISSNLinking>0531-5565</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">NIHMS515723 [Available on 11/01/14]</OtherID>
      <OtherID Source="NLM">PMC3840721 [Available on 11/01/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aging</Keyword>
        <Keyword MajorTopicYN="N">Exercise</Keyword>
        <Keyword MajorTopicYN="N">Obesity</Keyword>
        <Keyword MajorTopicYN="N">Vasodilation</Keyword>
        <Keyword MajorTopicYN="N">Western diet</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23954368</ArticleId>
        <ArticleId IdType="pii">S0531-5565(13)00238-6</ArticleId>
        <ArticleId IdType="doi">10.1016/j.exger.2013.08.001</ArticleId>
        <ArticleId IdType="pmc">PMC3840721</ArticleId>
        <ArticleId IdType="mid">NIHMS515723</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23948693</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>10</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1421-9697</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <Issue>1-2</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Annals of nutrition &amp; metabolism</Title>
          <ISOAbbreviation>Ann. Nutr. Metab.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Health significance of fat quality in the diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>96-102</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000353207</ELocationID>
        <Abstract>
          <AbstractText>This paper summarizes three presentations on the global and Latin American perspectives on the health significance of fat quality in the diet given at the 16th Congress of the Society of Latin American Nutrition in Havana, Cuba, November 11-16, 2012. Dietary fat quality contributes to the risk of the leading chronic diseases and is more important than fat quantity in reducing the risk of chronic disease mortality, especially from cardiovascular disease (CVD). In many countries, the consumption of saturated fats exceeds the recommended limit of 10% energy (%E) and intakes of polyunsaturated fats (PUFAs) are often below the recommended range of 6-11%E. Consumption of long-chain ?-3 PUFAs is especially low. In many Latin American countries, high consumption of carbohydrates, especially sugars, contributes to obesity, diabetes, hypertension and CVD, while intakes of total fat and PUFAs may be low. Thus, dietary fat recommendations must consider the dietary fat patterns of each country. Nutrition counseling can be effective in teaching individuals and families to modify their food intake patterns and control the major risk factors for chronic disease.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nettleton</LastName>
            <ForeName>Joyce A</ForeName>
            <Initials>JA</Initials>
            <Affiliation>ScienceVoice Consulting, Denver, Colo., USA.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Villalpando</LastName>
            <ForeName>Salvador</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cassani</LastName>
            <ForeName>Roberta Soares Lara</ForeName>
            <Initials>RS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elmadfa</LastName>
            <ForeName>Ibrahim</ForeName>
            <Initials>I</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Ann Nutr Metab</MedlineTA>
        <NlmUniqueID>8105511</NlmUniqueID>
        <ISSNLinking>0250-6807</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">000353207</ArticleId>
        <ArticleId IdType="doi">10.1159/000353207</ArticleId>
        <ArticleId IdType="pubmed">23948693</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23945609</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>27</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0340-6245</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>110</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Thrombosis and haemostasis</Title>
          <ISOAbbreviation>Thromb. Haemost.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nutrition as a link between obesity and cardiovascular disease: how can we stop the obesity epidemic?</ArticleTitle>
        <Pagination>
          <MedlinePgn>689-96</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1160/TH13-01-0045</ELocationID>
        <Abstract>
          <AbstractText>Overweight and obesity are associated with excess cardiovascular risk. To reduce cardiovascular risk at the population level, the prevention of overweight and obesity is key. This requires adoption of a healthy lifestyle, including less inactivity and more moderate-to-vigorous physical activity, and a healthy diet. Diet composition may facilitate weight gain prevention and weight loss. Effects of dietary fats, carbohydrates and proteins will be discussed in this context. Current evidence indicates that moderation of the intake of (saturated) fat, a moderate increase in protein content of the diet, a replacement of refined grain/high glucose index (GI) by whole-grain/low GI carbohydrates and limitation of the consumption of calorically-sweetened beverages are likely to facilitate weight control.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Baak</LastName>
            <ForeName>Marleen A</ForeName>
            <Initials>MA</Initials>
            <Affiliation>Marleen A. van Baak, Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands, Tel.: +31 43 3881630, E-mail: m.vanbaak@maastrichtuniversity.nl.</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Thromb Haemost</MedlineTA>
        <NlmUniqueID>7608063</NlmUniqueID>
        <ISSNLinking>0340-6245</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nutrition</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">prevention</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23945609</ArticleId>
        <ArticleId IdType="pii">13-01-0045</ArticleId>
        <ArticleId IdType="doi">10.1160/TH13-01-0045</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23939686</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>03</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease.</ArticleTitle>
        <Pagination>
          <MedlinePgn>CD009825</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009825.pub2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Seven Countries study in the 1960s showed that populations in the Mediterranean region experienced lower cardiovascular disease (CVD) mortality probably as a result of different dietary patterns. Later observational studies have confirmed the benefits of adherence to a Mediterranean dietary pattern on CVD risk factors. Clinical trial evidence is limited, and is mostly in secondary prevention.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the effectiveness of a Mediterranean dietary pattern for the primary prevention of CVD.</AbstractText>
          <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 9 of 12, September 2012); MEDLINE (Ovid, 1946 to October week 1 2012); EMBASE (Ovid, 1980 to 2012 week 41); ISI Web of Science (1970 to 16 October 2012); Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database and Health Economics Evaluations Database (Issue 3 of 12, September 2012). We searched trial registers and reference lists of reviews and applied no language restrictions.</AbstractText>
          <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">We selected randomised controlled trials in healthy adults and adults at high risk of CVD. A Mediterranean dietary pattern was defined as comprising at least two of the following components: (1) high monounsaturated/saturated fat ratio, (2) low to moderate red wine consumption, (3) high consumption of legumes, (4) high consumption of grains and cereals, (5) high consumption of fruits and vegetables, (6) low consumption of meat and meat products and increased consumption of fish, and (7) moderate consumption of milk and dairy products. The comparison group received either no intervention or minimal intervention. Outcomes included clinical events and CVD risk factors.</AbstractText>
          <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently extracted data and contacted chief investigators to request additional relevant information.</AbstractText>
          <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included 11 trials (15 papers) (52,044 participants randomised). Trials were heterogeneous in the participants recruited, in the number of dietary components and follow-up periods. Seven trials described the intervention as a Mediterranean diet. Clinical events were reported in only one trial (Women's Health Initiative 48,835 postmenopausal women, intervention not described as a Mediterranean diet but increased fruit and vegetable and cereal intake) where no statistically significant effects of the intervention were seen on fatal and non-fatal endpoints at eight years. Small reductions in total cholesterol (-0.16 mmol/L, 95% confidence interval (CI) -0.26 to -0.06; random-effects model) and low-density lipoprotein (LDL) cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01) were seen with the intervention. Subgroup analyses revealed statistically significant greater reductions in total cholesterol in those trials describing the intervention as a Mediterranean diet (-0.23 mmol/L, 95% CI -0.27 to -0.2) compared with control (-0.06 mmol/L, 95% CI -0.13 to 0.01). Heterogeneity precluded meta-analyses for other outcomes. Reductions in blood pressure were seen in three of five trials reporting this outcome. None of the trials reported adverse events.</AbstractText>
          <AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">The limited evidence to date suggests some favourable effects on cardiovascular risk factors. More comprehensive interventions describing themselves as the Mediterranean diet may produce more beneficial effects on lipid levels than those interventions with fewer dietary components. More trials are needed to examine the impact of heterogeneity of both participants and the intervention on outcomes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rees</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <Affiliation>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK, CV4 7AL.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hartley</LastName>
            <ForeName>Louise</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flowers</LastName>
            <ForeName>Nadine</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clarke</LastName>
            <ForeName>Aileen</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hooper</LastName>
            <ForeName>Lee</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thorogood</LastName>
            <ForeName>Margaret</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stranges</LastName>
            <ForeName>Saverio</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/14651858.CD009825.pub2</ArticleId>
        <ArticleId IdType="pubmed">23939686</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23939398</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>05</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0006-3002</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>1831</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta</Title>
          <ISOAbbreviation>Biochim. Biophys. Acta</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Heat shock protein-27 attenuates foam cell formation and atherogenesis by down-regulating scavenger receptor-A expression via NF-?B signaling.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1721-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbalip.2013.07.015</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1388-1981(13)00160-1</ELocationID>
        <Abstract>
          <AbstractText>Previously, we showed an inverse correlation between HSP27 serum levels and experimental atherogenesis in ApoE(-/-) mice that over-express HSP27 and speculated that the apparent binding of HSP27 to scavenger receptor-A (SR-A) was of mechanistic importance in attenuating foam cell formation. However, the nature and importance of the interplay between HSP27 and SR-A in atheroprotection remained unclear. Treatment of THP-1 macrophages with recombinant HSP27 (rHSP27) inhibited acLDL binding (-34%; p&lt;0.005) and uptake (-38%, p&lt;0.05). rHSP27 reduced SR-A mRNA (-39%, p=0.02), total protein (-56%, p=0.01) and cell surface (-53%, p&lt;0.001) expression. The reduction in SR-A expression by rHSP27 was associated with a 4-fold increase in nuclear factor-kappa B (NF-?B) signaling (p&lt;0.001 versus control), while an inhibitor of NF-?B signaling, BAY11-7082, attenuated the negative effects of rHSP27 on both SR-A expression and lipid uptake. To determine if SR-A is required for HSP27 mediated atheroprotection in vivo, ApoE(-/-) and ApoE(-/-) SR-A(-/-) mice fed with a high fat diet were treated for 3weeks with rHSP25. Compared to controls, rHSP25 therapy reduced aortic en face and aortic sinus atherosclerotic lesion size in ApoE(-/-) mice by 39% and 36% (p&lt;0.05), respectively, but not in ApoE(-/-)SR-A(-/-) mice. In conclusion, rHSP27 diminishes SR-A expression, resulting in attenuated foam cell formation in vitro. Regulation of SR-A by HSP27 may involve the participation of NF-?B signaling. Lastly, SR-A is required for HSP27-mediated atheroprotection in vivo.</AbstractText>
          <CopyrightInformation>&#xA9; 2013.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Raizman</LastName>
            <ForeName>Joshua E</ForeName>
            <Initials>JE</Initials>
            <Affiliation>University of Ottawa Heart Institute, Ottawa, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yong-Xiang</ForeName>
            <Initials>YX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seibert</LastName>
            <ForeName>Tara</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hibbert</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cuerrier</LastName>
            <ForeName>Charles M</ForeName>
            <Initials>CM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salari</LastName>
            <ForeName>Samira</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xiaoling</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Tieqiang</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Chunhua</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Xiaoli</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simard</LastName>
            <ForeName>Trevor</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caravaggio</LastName>
            <ForeName>Justin</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rayner</LastName>
            <ForeName>Katey</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bowdish</LastName>
            <ForeName>Dawn</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moore</LastName>
            <ForeName>Kathryn</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Brien</LastName>
            <ForeName>Edward R</ForeName>
            <Initials>ER</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ISO110836</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta</MedlineTA>
        <NlmUniqueID>0217513</NlmUniqueID>
        <ISSNLinking>0006-3002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>3-(4-methylphenylsulfonyl)-2-propenenitrile</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoproteins E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>HSP27 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Hspb1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Hspb2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Scavenger Receptors, Class A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Sulfones</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoproteins E</DescriptorName>
          <QualifierName MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">CHO Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cricetulus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Foam Cells</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Heat-Shock Proteins</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nitriles</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Scavenger Receptors, Class A</DescriptorName>
          <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sulfones</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">Heat shock protein 27</Keyword>
        <Keyword MajorTopicYN="N">Macrophage</Keyword>
        <Keyword MajorTopicYN="N">NF-?B</Keyword>
        <Keyword MajorTopicYN="N">Scavenger receptor-A</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23939398</ArticleId>
        <ArticleId IdType="pii">S1388-1981(13)00160-1</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbalip.2013.07.015</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23936994</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>29</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0125-2208</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>96</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</Title>
          <ISOAbbreviation>J Med Assoc Thai</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Primary prevention of dementia: focus on modifiable risk factors.</ArticleTitle>
        <Pagination>
          <MedlinePgn>251-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia will inevitably increase in the aging world. Moreover there is no cure for dementia. Therefore, primary prevention is very important. There are several factors possibly and/or certainly influencing dementia risk including non-modifiable and modifiable risk factors. There are evidences that the risk of developing dementia may be reduced by modifiable risk factors. LIFESTYLE FACTORS: The strategies are to encourage regular physical and mental exercise in midlife and in late-life. Those include cognitive activity and higher education, mentally demanding occupations or participation in mentally challenging leisure activities, being more socially active, a diet that is low in saturated fat, a diet with lots of fruits and vegetables, smoking cessation, and prevention of head injury, with loss of consciousness. Chronic disease factors: The strategies are to prevent high blood pressure, especially at midlife, diabetes, high serum cholesterol, especially at midlife, and depression or high depressive symptoms.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is important to develop a systematic public-health strategy and research specific to primary prevention of dementia in Thailand with the evidence-based medicine.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Srisuwan</LastName>
            <ForeName>Patsri</ForeName>
            <Initials>P</Initials>
            <Affiliation>Outpatient Department, Phramongkutklao Hospital, Bangkok, Thailand. patsri2004@yahoo.com</Affiliation>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Thailand</Country>
        <MedlineTA>J Med Assoc Thai</MedlineTA>
        <NlmUniqueID>7507216</NlmUniqueID>
        <ISSNLinking>0125-2208</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Alcohol Drinking</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dementia</DescriptorName>
          <QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Depression</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Primary Prevention</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
          <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23936994</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23934850</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>16</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Heart and circulatory physiology</Title>
          <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cathepsin G deficiency decreases complexity of atherosclerotic lesions in apolipoprotein E-deficient mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>H1141-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00618.2012</ELocationID>
        <Abstract>
          <AbstractText>Cathepsin G is a serine protease with a broad range of catalytic activities, including production of angiotensin II, degradation of extracellular matrix and cell-cell junctions, modulation of chemotactic responses, and induction of apoptosis. Cathepsin G mRNA expression is increased in human coronary atheroma vs. the normal vessel. To assess whether cathepsin G modulates atherosclerosis, cathepsin G knockout (Cstg(-/-)) mice were bred with apolipoprotein E knockout (Apoe(-/-)) mice to obtain Ctsg(+/-)Apoe(-/-) and Ctsg(+/+)Apoe(-/-) mice. Heterozygous cathepsin G deficiency led to a 70% decrease in cathepsin G activity in bone marrow cells, but this reduced activity did not impair generation of angiotensin II in bone marrow-derived macrophages (BMDM). Atherosclerotic lesions were compared in male Cstg(+/-)Apoe(-/-) and Cstg(+/+)Apoe(-/-) mice after 8 wk on a high-fat diet. Plasma cholesterol levels and cholesterol distribution within serum lipoprotein fractions did not differ between genotypes nor did the atherosclerotic lesion areas in either the aortic root or aortic arch. Cstg(+/-)Apoe(-/-) mice, however, showed a lower percentage of complex lesions within the aortic root and a smaller number of apoptotic cells compared with Cstg(+/+)Apoe(-/-) littermates. Furthermore, apoptotic Cstg(-/-) BMDM were more efficiently engulfed by phagocytic BMDM than were apoptotic Ctsg(+/+) BMDM. Thus cathepsin G activity may impair efferocytosis, which could lead to an accumulation of lesion-associated apoptotic cells and the accelerated progression of early atherosclerotic lesions to more complex lesions in Apoe(-/-) mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rafatian</LastName>
            <ForeName>Naimeh</ForeName>
            <Initials>N</Initials>
            <Affiliation>Hypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karunakaran</LastName>
            <ForeName>Denuja</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rayner</LastName>
            <ForeName>Katey J</ForeName>
            <Initials>KJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leenen</LastName>
            <ForeName>Frans H H</ForeName>
            <Initials>FH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Milne</LastName>
            <ForeName>Ross W</ForeName>
            <Initials>RW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whitman</LastName>
            <ForeName>Stewart C</ForeName>
            <Initials>SC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
        <NlmUniqueID>100901228</NlmUniqueID>
        <ISSNLinking>0363-6135</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoproteins E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11128-99-7</RegistryNumber>
          <NameOfSubstance>Angiotensin II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.20</RegistryNumber>
          <NameOfSubstance>Cathepsin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.20</RegistryNumber>
          <NameOfSubstance>Ctsg protein, mouse</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Angiotensin II</DescriptorName>
          <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoproteins E</DescriptorName>
          <QualifierName MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cathepsin G</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Phagocytosis</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Plaque, Atherosclerotic</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apo E</Keyword>
        <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        <Keyword MajorTopicYN="N">cathepsin G</Keyword>
        <Keyword MajorTopicYN="N">lesion progression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23934850</ArticleId>
        <ArticleId IdType="pii">ajpheart.00618.2012</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpheart.00618.2012</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">23929677</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>8</Month>
        <Day>9</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-3350</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
              <Day>8</Day>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Caffeine stimulates hepatic lipid metabolism via autophagy-lysosomal pathway.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="doi">10.1002/hep.26667</ELocationID>
        <Abstract>
          <AbstractText NlmCategory="UNLABELLED">Caffeine is one of the world's most consumed drugs. Recently, several studies showed that its consumption is associated with lower risk for non-alcoholic fatty liver disease (NAFLD), an obesity-related condition that recently has become the major cause of liver disease worldwide. Although caffeine is known to stimulate hepatic fat oxidation, its mechanism of action on lipid metabolism is still not clear. Here, we show that caffeine surprisingly is a potent stimulator of hepatic autophagic flux. Using genetic, pharmacological, and metabolomic approaches, we demonstrate that caffeine reduces intra-hepatic lipid content and stimulates &#xDF;-oxidation in hepatic cells and liver via an autophagy-lysosomal pathway. Furthermore, caffeine induced autophagy involved down-regulation of mTOR signaling and alteration in hepatic amino acids and sphingolipid levels. In mice fed a high fat diet, caffeine markedly reduces hepatosteatosis and concomitantly increases autophagy and lipid uptake in lysosomes. Conclusion: Taken together, these results provide novel insight into caffeine's lipolytic actions through autophagy in mammalian liver and its potential beneficial effects in NAFLD. (Hepatology 2013;).</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 American Association for the Study of Liver Diseases.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Sinha</LastName>
            <ForeName>Rohit Anthony</ForeName>
            <Initials>RA</Initials>
            <Affiliation>Program of Cardiovascular and Metabolic Disorders, Duke-NUS Graduate Medical School, Singapore.</Affiliation>
          </Author>
          <Author>
            <LastName>Farah</LastName>
            <ForeName>Benjamin L</ForeName>
            <Initials>BL</Initials>
          </Author>
          <Author>
            <LastName>Singh</LastName>
            <ForeName>Brijesh K</ForeName>
            <Initials>BK</Initials>
          </Author>
          <Author>
            <LastName>Siddique</LastName>
            <ForeName>Monowarul Mobin</ForeName>
            <Initials>MM</Initials>
          </Author>
          <Author>
            <LastName>Li</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author>
            <LastName>Wu</LastName>
            <ForeName>Yajun</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author>
            <LastName>Ilkayeva</LastName>
            <ForeName>Olga R</ForeName>
            <Initials>OR</Initials>
          </Author>
          <Author>
            <LastName>Gooding</LastName>
            <ForeName>Jessica</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Ching</LastName>
            <ForeName>Jianhong</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Zhou</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author>
            <LastName>Martinez</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author>
            <LastName>Xie</LastName>
            <ForeName>Sherwin</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author>
            <LastName>Bay</LastName>
            <ForeName>Boon-Huat</ForeName>
            <Initials>BH</Initials>
          </Author>
          <Author>
            <LastName>Summers</LastName>
            <ForeName>Scott A</ForeName>
            <Initials>SA</Initials>
          </Author>
          <Author>
            <LastName>Newgard</LastName>
            <ForeName>Christopher B</ForeName>
            <Initials>CB</Initials>
          </Author>
          <Author>
            <LastName>Yen</LastName>
            <ForeName>Paul M</ForeName>
            <Initials>PM</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Caffeine</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">fatty acid</Keyword>
        <Keyword MajorTopicYN="N">metabolomics</Keyword>
        <Keyword MajorTopicYN="N">&#xDF;-oxidation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/hep.26667</ArticleId>
        <ArticleId IdType="pubmed">23929677</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23928364</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>11</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1876-7737</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>8</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of proteomics</Title>
          <ISOAbbreviation>J Proteomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PPAR signaling pathway is a key modulator of liver proteome in pups born to vitamin B(12) deficient rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>297-308</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jprot.2013.07.027</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1874-3919(13)00432-6</ELocationID>
        <Abstract>
          <AbstractText Label="UNLABELLED">Maternal nutritional deficiency in-utero is known to predict risk of complex disorders like cardiovascular disease, diabetes and many neurological disorders in the offspring and vitamin B12 is one such critical micronutrient. Here we performed 2D-DIGE followed by MALDI TOF/TOF analysis to identify proteins that are differentially expressed in liver of pups born to mothers fed vitamin B12 deficient diet vis-&#xE0;-vis control diet. To further establish causality, we analyzed the effect of B12 rehabilitation at parturition on the protein levels and the phenotype in pups. We identified 38 differentially expressed proteins that were enriched in pathways involved in the regulation of amino acid, lipid and carbohydrate metabolism. Further, three enzymes in the &#xDF;-oxidation pathway (hydroxyacyl-coenzyme A dehydrogenase, medium-chain specific acyl-CoA dehydrogenase, 3-ketoacyl-CoA thiolase) were down-regulated in pups born to mothers fed vitamin B12 deficient diet. We observed age-dependent differential expression of peroxisome proliferator activated-receptor (PPAR) a and ? in the deficient pups. Interestingly, expression of 27 proteins that were differentially expressed was restored to the control levels after rehabilitation of female rats with vitamin B12 from parturition. Our study thus provides the first evidence that maternal vitamin B12 deficiency influences lipid and other micronutrient metabolism in pups through regulation of PPAR signaling pathway.</AbstractText>
          <AbstractText Label="BIOLOGICAL SIGNIFICANCE" NlmCategory="UNASSIGNED">Maternal vitamin B12 deficiency has been shown to predict the onset of complex disorders like atherosclerosis, type II diabetes etc. in the next generation during their adulthood. We have shown earlier that pups born to female rats fed with vitamin B12 deficient diet were obese and developed high levels of other intermediate traits such as triglycerides, cholesterol etc. that are related to the risk of diabetes and cardiovascular disorders. In this piece of work using differential proteomic approach we have identified the altered metabolic processes in the liver of vitamin B12 deficient pups. We have also documented that the proteins involved in &#xDF;-oxidation pathway are down-regulated. Further, differential expression of PPARa and PPAR? was evidently documented as the master regulator for the alteration of lipid, amino acid and carbohydrate metabolism during maternal vitamin B12 deficiency.</AbstractText>
          <CopyrightInformation>&#xA9; 2013. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ahmad</LastName>
            <ForeName>Shadab</ForeName>
            <Initials>S</Initials>
            <Affiliation>CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>K Anand</ForeName>
            <Initials>KA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basak</LastName>
            <ForeName>Trayambak</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhardwaj</LastName>
            <ForeName>Gourav</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yadav</LastName>
            <ForeName>Dilip K</ForeName>
            <Initials>DK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lalitha</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chandak</LastName>
            <ForeName>Giriraj Ratan</ForeName>
            <Initials>GR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raghunath</LastName>
            <ForeName>Manchala</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sengupta</LastName>
            <ForeName>Shantanu</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>J Proteomics</MedlineTA>
        <NlmUniqueID>101475056</NlmUniqueID>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2-dimensional difference in-gel electrophoresis</Keyword>
        <Keyword MajorTopicYN="N">2D-DIGE</Keyword>
        <Keyword MajorTopicYN="N">3-ketoacyl-CoA thiolase</Keyword>
        <Keyword MajorTopicYN="N">ACADM</Keyword>
        <Keyword MajorTopicYN="N">ACN</Keyword>
        <Keyword MajorTopicYN="N">ALP</Keyword>
        <Keyword MajorTopicYN="N">BVA</Keyword>
        <Keyword MajorTopicYN="N">DIA</Keyword>
        <Keyword MajorTopicYN="N">DTT</Keyword>
        <Keyword MajorTopicYN="N">ECL</Keyword>
        <Keyword MajorTopicYN="N">EDTA</Keyword>
        <Keyword MajorTopicYN="N">FABPL</Keyword>
        <Keyword MajorTopicYN="N">FAS</Keyword>
        <Keyword MajorTopicYN="N">FDR</Keyword>
        <Keyword MajorTopicYN="N">FFM</Keyword>
        <Keyword MajorTopicYN="N">HCDH</Keyword>
        <Keyword MajorTopicYN="N">HRP</Keyword>
        <Keyword MajorTopicYN="N">IAA</Keyword>
        <Keyword MajorTopicYN="N">IDV</Keyword>
        <Keyword MajorTopicYN="N">IEF</Keyword>
        <Keyword MajorTopicYN="N">IPG</Keyword>
        <Keyword MajorTopicYN="N">LBM</Keyword>
        <Keyword MajorTopicYN="N">Liver proteome</Keyword>
        <Keyword MajorTopicYN="N">MALDI TOF/TOF</Keyword>
        <Keyword MajorTopicYN="N">Micronutrient deficiency</Keyword>
        <Keyword MajorTopicYN="N">NBT-BCIP</Keyword>
        <Keyword MajorTopicYN="N">Obesity</Keyword>
        <Keyword MajorTopicYN="N">PPAR</Keyword>
        <Keyword MajorTopicYN="N">PPARs</Keyword>
        <Keyword MajorTopicYN="N">PVDF</Keyword>
        <Keyword MajorTopicYN="N">S-adenosyl methionine</Keyword>
        <Keyword MajorTopicYN="N">SAM</Keyword>
        <Keyword MajorTopicYN="N">TFA</Keyword>
        <Keyword MajorTopicYN="N">TG</Keyword>
        <Keyword MajorTopicYN="N">THIM</Keyword>
        <Keyword MajorTopicYN="N">Vitamin B(12)</Keyword>
        <Keyword MajorTopicYN="N">acetonitrile</Keyword>
        <Keyword MajorTopicYN="N">alkaline phosphatase</Keyword>
        <Keyword MajorTopicYN="N">biological variant analysis</Keyword>
        <Keyword MajorTopicYN="N">differential in-gel analysis</Keyword>
        <Keyword MajorTopicYN="N">dithiotheritol</Keyword>
        <Keyword MajorTopicYN="N">enhanced chemiluminescence</Keyword>
        <Keyword MajorTopicYN="N">ethylenediaminetetraacetic acid</Keyword>
        <Keyword MajorTopicYN="N">false discovery rate</Keyword>
        <Keyword MajorTopicYN="N">fat free mass</Keyword>
        <Keyword MajorTopicYN="N">fatty acid binding protein, liver</Keyword>
        <Keyword MajorTopicYN="N">fatty acid synthase</Keyword>
        <Keyword MajorTopicYN="N">horseradish peroxidase</Keyword>
        <Keyword MajorTopicYN="N">hydroxyacyl-coenzyme A dehydrogenase</Keyword>
        <Keyword MajorTopicYN="N">immobilized pH gradient</Keyword>
        <Keyword MajorTopicYN="N">integrated density value</Keyword>
        <Keyword MajorTopicYN="N">iodoacetamide</Keyword>
        <Keyword MajorTopicYN="N">isoelectric focussing</Keyword>
        <Keyword MajorTopicYN="N">lean body mass</Keyword>
        <Keyword MajorTopicYN="N">matrix assisted lased desorption ionization, time of flight</Keyword>
        <Keyword MajorTopicYN="N">medium-chain specific acyl-CoA dehydrogenase</Keyword>
        <Keyword MajorTopicYN="N">nitro blue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate</Keyword>
        <Keyword MajorTopicYN="N">peroxisome proliferator-activated receptor</Keyword>
        <Keyword MajorTopicYN="N">polyvinylidene fluoride</Keyword>
        <Keyword MajorTopicYN="N">trifluroacetic acid</Keyword>
        <Keyword MajorTopicYN="N">triglyceride</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23928364</ArticleId>
        <ArticleId IdType="pii">S1874-3919(13)00432-6</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jprot.2013.07.027</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23926027</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>23</Day>
      </DateCompleted>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2151-4658</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>65</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Arthritis care &amp; research</Title>
          <ISOAbbreviation>Arthritis Care Res (Hoboken)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Association of metabolic risk factors with cartilage degradation assessed by T2 relaxation time at the knee: data from the osteoarthritis initiative.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1942-50</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/acr.22093</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association of metabolic risk factors with severity and 2-year progression of early degenerative cartilage changes at the knee, measured with T2 relaxation times in middle-aged subjects from the Osteoarthritis Initiative.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Cartilage segmentation and T2 map generation were performed in knee 3T magnetic resonance images from 403 subjects ages 45-60 years without radiographic osteoarthritis (OA). The influence of risk factors on baseline T2 and longitudinal progression of T2 was analyzed using linear regression, adjusting for age, sex, and other OA risk factors.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Four metabolic risk factors, i.e., high abdominal circumference (P &lt; 0.001), hypertension (P = 0.041), high fat consumption (P = 0.023), and self-reported diabetes mellitus (P = 0.010), were individually associated with higher baseline T2. When the 4 metabolic risk factors were considered in a multivariate regression model, higher T2 remained significantly associated with abdominal circumference (P &lt; 0.001) and diabetes mellitus (P = 0.026), and there was a trend for high fat consumption (P = 0.096). For the individual risk factors, only diabetes mellitus remained associated with higher baseline T2 after adjustment for body mass index (BMI). After adjustment for BMI, baseline T2 increased in a dose-response manner with the number of metabolic risk factors present (P = 0.032 for linear trend), and subjects with =3 metabolic factors (versus &lt;3) had significantly higher baseline T2 (mean difference 1.2 msec [95% confidence interval 0.3, 2.1]; P = 0.011). Metabolic risk factors were not significantly associated with increases in T2 during followup.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Metabolic risk factors are associated with higher T2, suggesting that increased cartilage degeneration may be caused by modifiable metabolic disorders.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 by the American College of Rheumatology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jungmann</LastName>
            <ForeName>P M</ForeName>
            <Initials>PM</Initials>
            <Affiliation>University of California, San Francisco; Technical University of Munich, Munich, Germany.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kraus</LastName>
            <ForeName>M S</ForeName>
            <Initials>MS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alizai</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nardo</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baum</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nevitt</LastName>
            <ForeName>M C</ForeName>
            <Initials>MC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCulloch</LastName>
            <ForeName>C E</ForeName>
            <Initials>CE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>G B</ForeName>
            <Initials>GB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lynch</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Link</LastName>
            <ForeName>T M</ForeName>
            <Initials>TM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>N01-AR-2-2259</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01-AR-2-2260</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01-AR-2-2261</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01-AR-2-2262</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01-AR-22258</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50-AR060752</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01-AR059507</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arthritis Care Res (Hoboken)</MedlineTA>
        <NlmUniqueID>101518086</NlmUniqueID>
        <ISSNLinking>2151-464X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Dietary Fats</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cartilage, Articular</DescriptorName>
          <QualifierName MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Fats</DescriptorName>
          <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Metabolic Syndrome X</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Multivariate Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Osteoarthritis, Knee</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
          <QualifierName MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Waist Circumference</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1002/acr.22093</ArticleId>
        <ArticleId IdType="pubmed">23926027</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23923985</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateCreated>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-511X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Lipids in health and disease</Title>
          <ISOAbbreviation>Lipids Health Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High conjugated linoleic acid enriched ghee (clarified butter) increases the antioxidant and antiatherogenic potency in female Wistar rats.</ArticleTitle>
        <Pagination>
          <MedlinePgn>121</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1476-511X-12-121</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypercholesterolemia and oxidative stress are the main stimulating factors responsible for coronary artery disease and progression of atherosclerosis. Dairy food products are rich in conjugated linoleic acid (CLA) which is considered as an important component due to its potential health benefits such as anticarcinogenic, antiatherogenic, antidiabetic and antiadipogenic properties. In the present study, the effect of CLA enriched ghee on the antioxidant enzyme system and antiatherogenic properties in Wistar rats has been studied.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Female Wistar rats of 21 days were taken for the study and fed with soybean diet (Control diet), low CLA diet and high CLA ghee diet (treatments) for thirty five days for studying antioxidative enzymes and sixteen weeks in case of antiatherogenic studies.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Feeding of high CLA enhanced ghee during pubescent period in rats lead to an increase in catalase (CAT) and superoxide dismutase (SOD) enzyme activities in blood and increased CAT, SOD and glutathione transferase (GST) enzymes activities in liver by 27, 130 and 168 percent, respectively. Plasma nitrate concentration and Haemoglobin levels remained the same in all the treatments. Feeding of high CLA ghee resulted in lower (P &lt; 0.01) plasma cholesterol &amp; triglyceride level (52.17 and 30.27%), and higher high density lipoproteins (33.26%) than feeding of soybean oil (control group) and thus manifested in decreased (P &lt; 0.05) atherogenic index (from 0.472 to 0.244). Lesser cholesterol and triglyceride levels were observed in the liver and aorta of high CLA fed rats than in those of the other groups. Histopathological studies of liver showed normal hepatic cords with portal triad in the high CLA ghee fed rats whereas fatty degeneration of hepatocytes containing fat vacuoles was observed in the liver of the other groups.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This paper is the first report of the antioxidant and antiatherogenic properties of the high CLA enriched ghee suggesting that high CLA ghee can be used as a potential food for decreasing the risk of cardiovascular diseases, particularly in India, where, ghee is widely used for culinary and medicinal purposes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chinnadurai</LastName>
            <ForeName>Kathirvelan</ForeName>
            <Initials>K</Initials>
            <Affiliation>Dairy Cattle Nutrition (DCN) Division, National Dairy Research Institute, Karnal, Haryana, 132001, India. amrishtyagi1963@yahoo.com.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanwal</LastName>
            <ForeName>Harpreet Kaur</ForeName>
            <Initials>HK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyagi</LastName>
            <ForeName>Amrish Kumar</ForeName>
            <Initials>AK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stanton</LastName>
            <ForeName>Catherine</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ross</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lipids Health Dis</MedlineTA>
        <NlmUniqueID>101147696</NlmUniqueID>
        <ISSNLinking>1476-511X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Physiol Biochem. 2013 Jun;69(2):313-23</RefSource>
          <PMID Version="1">23104078</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2013 May;48(5):505-12</RefSource>
          <PMID Version="1">23322076</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2012 Dec;47(12):1119-30</RefSource>
          <PMID Version="1">23086552</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2010 Nov;45(11):1035-45</RefSource>
          <PMID Version="1">20853155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids Health Dis. 2012;11:31</RefSource>
          <PMID Version="1">22364167</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Br J Nutr. 2000 May;83(5):459-65</RefSource>
          <PMID Version="1">10953669</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Eur J Biochem. 1974 Sep 16;47(3):469-74</RefSource>
          <PMID Version="1">4215654</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 1970 Mar;34:30-8</RefSource>
          <PMID Version="1">5440916</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Biol Chem. 1974 Nov 25;249(22):7130-9</RefSource>
          <PMID Version="1">4436300</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 1976 May 7;72:248-54</RefSource>
          <PMID Version="1">942051</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Biochem. 1978 May;86(1):271-8</RefSource>
          <PMID Version="1">655387</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Carcinogenesis. 1987 Dec;8(12):1881-7</RefSource>
          <PMID Version="1">3119246</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cancer Res. 1991 Nov 15;51(22):6118-24</RefSource>
          <PMID Version="1">1933874</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Methods Enzymol. 1996;268:93-105</RefSource>
          <PMID Version="1">8782576</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Dairy Sci. 1998 Jun;81(6):1630-6</RefSource>
          <PMID Version="1">9684170</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2006 Jan;41(1):41-8</RefSource>
          <PMID Version="1">16555470</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2010 Jul;92(1):34-40</RefSource>
          <PMID Version="1">20463040</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2007 Sep;42(9):845-54</RefSource>
          <PMID Version="1">17665238</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2007 May;137(5):1188-93</RefSource>
          <PMID Version="1">17449580</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lipids. 2007 Mar;42(2):123-33</RefSource>
          <PMID Version="1">17393218</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3766171</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1476-511X-12-121</ArticleId>
        <ArticleId IdType="doi">10.1186/1476-511X-12-121</ArticleId>
        <ArticleId IdType="pubmed">23923985</ArticleId>
        <ArticleId IdType="pmc">PMC3766171</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23922128</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1531-2267</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>Physiological genomics</Title>
          <ISOAbbreviation>Physiol. Genomics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Identification and comparative analyses of myocardial miRNAs involved in the fetal response to maternal obesity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>889-900</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/physiolgenomics.00050.2013</ELocationID>
        <Abstract>
          <AbstractText>Human and animal studies show that suboptimal intrauterine environments lead to fetal programming, predisposing offspring to disease in later life. Maternal obesity has been shown to program offspring for cardiovascular disease (CVD), diabetes, and obesity. MicroRNAs (miRNAs) are small, noncoding RNA molecules that act as key regulators of numerous cellular processes. Compelling evidence links miRNAs to the control of cardiac development and etiology of cardiac pathology; however, little is known about their role in the fetal cardiac response to maternal obesity. Our aim was to sequence and profile the cardiac miRNAs that are dysregulated in the hearts of baboon fetuses born to high fat/high fructose-diet (HFD) fed mothers for comparison with fetal hearts from mothers eating a regular diet. Eighty miRNAs were differentially expressed. Of those, 55 miRNAs were upregulated and 25 downregulated with HFD. Twenty-two miRNAs were mapped to human; 14 of these miRNAs were previously reported to be dysregulated in experimental or human CVD. We used an Ingenuity Pathway Analysis to integrate miRNA profiling and bioinformatics predictions to determine miRNA-regulated processes and genes potentially involved in fetal programming. We found a correlation between miRNA expression and putative gene targets involved in developmental disorders and CVD. Cellular death, growth, and proliferation were the most affected cellular functions in response to maternal obesity. Thus, the current study reveals significant alterations in cardiac miRNA expression in the fetus of obese baboons. The epigenetic modifications caused by adverse prenatal environment may represent one of the mechanisms underlying fetal programming of CVD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maloyan</LastName>
            <ForeName>Alina</ForeName>
            <Initials>A</Initials>
            <Affiliation>Center for Pregnancy and Newborn Research, Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, Texas; and.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muralimanoharan</LastName>
            <ForeName>Sribalasubashini</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huffman</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cox</LastName>
            <ForeName>Laura A</ForeName>
            <Initials>LA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nathanielsz</LastName>
            <ForeName>Peter W</ForeName>
            <Initials>PW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Myatt</LastName>
            <ForeName>Leslie</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nijland</LastName>
            <ForeName>Mark J</ForeName>
            <Initials>MJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HD-21350</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 HD021350</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P51 RR-33986</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1RR-025767</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Physiol Genomics</MedlineTA>
        <NlmUniqueID>9815683</NlmUniqueID>
        <ISSNLinking>1094-8341</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherID Source="NLM">PMC3798778 [Available on 10/01/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cardiac</Keyword>
        <Keyword MajorTopicYN="N">fibrosis</Keyword>
        <Keyword MajorTopicYN="N">maternal obesity</Keyword>
        <Keyword MajorTopicYN="N">miRNA</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23922128</ArticleId>
        <ArticleId IdType="pii">physiolgenomics.00050.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/physiolgenomics.00050.2013</ArticleId>
        <ArticleId IdType="pmc">PMC3798778</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23921137</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1555</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Endocrinology and metabolism</Title>
          <ISOAbbreviation>Am. J. Physiol. Endocrinol. Metab.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>APPL1 transgenic mice are protected from high-fat diet-induced cardiac dysfunction.</ArticleTitle>
        <Pagination>
          <MedlinePgn>E795-804</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpendo.00257.2013</ELocationID>
        <Abstract>
          <AbstractText>APPL1 (adaptor protein containing PH domain, PTB domain, and leucine zipper motif 1) has been established as an important mediator of insulin and adiponectin signaling. Here, we investigated the influence of transgenic (Tg) APPL1 overexpression in mice on high-fat diet (HFD)-induced cardiomyopathy in mice. Wild-type (WT) mice fed an HFD for 16 wk showed cardiac dysfunction, determined by echocardiography, with decreased ejection fraction, decreased fractional shortening, and increased end diastolic volume. HFD-fed APPL1 Tg mice were significantly protected from this dysfunction. Speckle tracking echocardiography to accurately assess cardiac tissue deformation strain and wall motion also indicated dysfunction in WT mice and a similar improvement in Tg vs. WT mice on HFD. APPL1 Tg mice had less HFD-induced increase in circulating nonesteridied fatty acid levels and myocardial lipid accumulation. Lipidomic analysis using LC-MS-MS showed HFD significantly increased myocardial contents of distinct ceramide, sphingomyelin, and diacylglycerol (DAG) species, of which increases in C16:0 and C18:0 ceramides plus C16:0 and C18:1 DAGs were attenuated in Tg mice. A glucose tolerance test indicated less peripheral insulin resistance in response to HFD in Tg mice, which was also apparent by measuring cardiac Akt phosphorylation and cardiomyocyte glucose uptake. In summary, APPL1 Tg mice exhibit improved peripheral metabolism, reduced cardiac lipotoxicity, and improved insulin sensitivity. These cellular effects contribute to protection from HFD-induced cardiomyopathy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <Affiliation>Department of Biology, York University, Toronto, Ontario, Canada;</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Donghai</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Taesik</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Cheol-soo</ForeName>
            <Initials>CS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ren-Ke</ForeName>
            <Initials>RK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Kenneth K Y</ForeName>
            <Initials>KK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Aimin</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sweeney</LastName>
            <ForeName>Gary</ForeName>
            <Initials>G</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
        <NlmUniqueID>100901226</NlmUniqueID>
        <ISSNLinking>0193-1849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Appl1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance>Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance>Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Body Weight</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cardiomyopathies</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
          <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose Tolerance Test</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Insulin Resistance</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cardiac function</Keyword>
        <Keyword MajorTopicYN="N">cardiomyopathy</Keyword>
        <Keyword MajorTopicYN="N">high-fat diet</Keyword>
        <Keyword MajorTopicYN="N">insulin sensitivity</Keyword>
        <Keyword MajorTopicYN="N">lipotoxicity</Keyword>
        <Keyword MajorTopicYN="N">nonesterified</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23921137</ArticleId>
        <ArticleId IdType="pii">ajpendo.00257.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpendo.00257.2013</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23913707</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1539</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>305</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
              <Day>1</Day>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Heart and circulatory physiology</Title>
          <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension.</ArticleTitle>
        <Pagination>
          <MedlinePgn>H1080-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00464.2013</ELocationID>
        <Abstract>
          <AbstractText>The sensitivity of baroreflex control of heart rate is depressed in subjects with obesity hypertension, which increases the risk for cardiac arrhythmias. The mechanisms are not fully known, and there are no therapies to improve this dysfunction. To determine the cardiovascular dynamic effects of progressive increases in body weight leading to obesity and hypertension in dogs fed a high-fat diet, 24-h continuous recordings of spontaneous fluctuations in blood pressure and heart rate were analyzed in the time and frequency domains. Furthermore, we investigated whether autonomic mechanisms stimulated by chronic baroreflex activation and renal denervation-current therapies in patients with resistant hypertension, who are commonly obese-restore cardiovascular dynamic control. Increases in body weight to ~150% of control led to a gradual increase in mean arterial pressure to 17 &#xB1; 3 mmHg above control (100 &#xB1; 2 mmHg) after 4 wk on the high-fat diet. In contrast to the gradual increase in arterial pressure, tachycardia, attenuated chronotropic baroreflex responses, and reduced heart rate variability were manifest within 1-4 days on high-fat intake, reaching 130 &#xB1; 4 beats per minute (bpm) (control = 86 &#xB1; 3 bpm) and ~45% and &lt;20%, respectively, of control levels. Subsequently, both baroreflex activation and renal denervation abolished the hypertension. However, only baroreflex activation effectively attenuated the tachycardia and restored cardiac baroreflex sensitivity and heart rate variability. These findings suggest that baroreflex activation therapy may reduce the risk factors for cardiac arrhythmias as well as lower arterial pressure.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Iliescu</LastName>
            <ForeName>Radu</ForeName>
            <Initials>R</Initials>
            <Affiliation>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi;</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tudorancea</LastName>
            <ForeName>Ionut</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Irwin</LastName>
            <ForeName>Eric D</ForeName>
            <Initials>ED</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lohmeier</LastName>
            <ForeName>Thomas E</ForeName>
            <Initials>TE</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HL-51971</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
        <NlmUniqueID>100901228</NlmUniqueID>
        <ISSNLinking>0363-6135</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Arterial Pressure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Baroreflex</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Heart Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName MajorTopicYN="Y">innervation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="Y">complications</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sympathectomy</DescriptorName>
          <QualifierName MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Tachycardia</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3798752 [Available on 10/01/14]</OtherID>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">baroreflex</Keyword>
        <Keyword MajorTopicYN="N">heart rate variability</Keyword>
        <Keyword MajorTopicYN="N">hypertension</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
        <Keyword MajorTopicYN="N">sympathetic nervous system</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23913707</ArticleId>
        <ArticleId IdType="pii">ajpheart.00464.2013</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpheart.00464.2013</ArticleId>
        <ArticleId IdType="pmc">PMC3798752</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23911141</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1014</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular oral microbiology</Title>
          <ISOAbbreviation>Mol Oral Microbiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Periodontal innate immune mechanisms relevant to obesity.</ArticleTitle>
        <Pagination>
          <MedlinePgn>331-41</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/omi.12035</ELocationID>
        <Abstract>
          <AbstractText>Obesity affects over 35% of the adult population of the USA, and obesity-related illnesses have emerged as the leading cause of preventable death worldwide, according to the World Health Organization. Obesity's secondary morbidities include increased risk of cardiovascular disease, type II diabetes, and cancer, in addition to increased occurrence and severity of infections. Sedentary lifestyle and weight gain caused by consumption of a high-fat diet contribute to the development of obesity, with individuals having a body mass index (BMI) score &gt; 30 being considered obese. Genetic models of obesity (ob/ob mice, db/db mice, and fa/fa rats) have been insufficient to study human obesity because of the overall lack of genetic causes for obesity in human populations. To date, the diet-induced obese (DIO) mouse model best serves research studies relevant to human health. Periodontal disease presents with a wide range of clinical variability and severity. Research in the past decade has shed substantial light on both the initiating infectious agents and host immunological responses in periodontal disease. Up to 46% of the general population harbors the microorganism(s) associated with periodontal disease, although many are able to limit the progression of periodontal disease or even clear the organism(s) if infected. In the last decade, several epidemiological studies have found an association between obesity and increased incidence of periodontal disease. This review focuses on exploring the immunological consequences of obesity that exacerbate effects of infection by pathogens, with focus on infection by the periodontal bacterium Porphyromonas gingivalis as a running example.</AbstractText>
          <CopyrightInformation>2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Amar</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <Affiliation>Center for Anti-inflammatory Therapeutics, Boston University, School of Dental Medicine, Boston, MA 02118, USA. samar@bu.edu</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leeman</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Denmark</Country>
        <MedlineTA>Mol Oral Microbiol</MedlineTA>
        <NlmUniqueID>101524770</NlmUniqueID>
      </MedlineJournalInfo>
      <CitationSubset>D</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Porphyromonas gingivalis</Keyword>
        <Keyword MajorTopicYN="N">bone loss</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">homotolerance</Keyword>
        <Keyword MajorTopicYN="N">infection models</Keyword>
        <Keyword MajorTopicYN="N">innate immunity</Keyword>
        <Keyword MajorTopicYN="N">obesity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23911141</ArticleId>
        <ArticleId IdType="doi">10.1111/omi.12035</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23906130</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>02</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-5347</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>93</Volume>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Social science &amp; medicine (1982)</Title>
          <ISOAbbreviation>Soc Sci Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Trading off dietary choices, physical exercise and cardiovascular disease risks.</ArticleTitle>
        <Pagination>
          <MedlinePgn>130-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.socscimed.2013.05.031</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0277-9536(13)00325-0</ELocationID>
        <Abstract>
          <AbstractText>Despite several decades of decline, cardiovascular diseases are still the most common causes of death in Western societies. Sedentary living and high fat diets contribute to the prevalence of cardiovascular diseases. This paper analyses the trade-offs between lifestyle choices defined in terms of diet, physical activity, cost, and risk of cardiovascular disease that a representative sample of the population of Northern Ireland aged 40-65 are willing to make. Using computer assisted personal interviews, we survey 493 individuals at their homes using a Discrete Choice Experiment (DCE) questionnaire administered between February and July 2011 in Northern Ireland. Unlike most DCE studies for valuing public health programmes, this questionnaire uses a tailored exercise, based on the individuals' baseline choices. A "fat screener" module in the questionnaire links personal cardiovascular disease risk to each specific choice set in terms of dietary constituents. Individuals are informed about their real status quo risk of a fatal cardiovascular event, based on an initial set of health questions. Thus, actual risks, real diet and exercise choices are the elements that constitute the choice task. Our results show that our respondents are willing to pay for reducing mortality risk and, more importantly, are willing to change physical exercise and dietary behaviours. In particular, we find that to improve their lifestyles, overweight and obese people would be more likely to do more physical activity than to change their diets. Therefore, public policies aimed to target obesity and its related illnesses in Northern Ireland should invest public money in promoting physical activity rather than healthier diets.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Grisol&#xED;a</LastName>
            <ForeName>Jos&#xE9; M</ForeName>
            <Initials>JM</Initials>
            <Affiliation>Department of Applied Economics Analysis, Universidad de Las Palmas de Gran Canaria, Campus Universitario de Tafira Baja, 35017 Las Palmas de Gran Canaria, Spain. jmgrisolia@daea.ulpgc.es</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Longo</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boeri</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hutchinson</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kee</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>06</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Soc Sci Med</MedlineTA>
        <NlmUniqueID>8303205</NlmUniqueID>
        <ISSNLinking>0277-9536</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Choice Behavior</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Costs and Cost Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet</DescriptorName>
          <QualifierName MajorTopicYN="Y">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Exercise</DescriptorName>
          <QualifierName MajorTopicYN="Y">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N" Type="Geographic">Ireland</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Qualitative Research</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Risk Reduction Behavior</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword>
        <Keyword MajorTopicYN="N">Choice experiments</Keyword>
        <Keyword MajorTopicYN="N">Dietary choices</Keyword>
        <Keyword MajorTopicYN="N">Northern Ireland</Keyword>
        <Keyword MajorTopicYN="N">Willingness to pay for risk reduction</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0277-9536(13)00325-0</ArticleId>
        <ArticleId IdType="doi">10.1016/j.socscimed.2013.05.031</ArticleId>
        <ArticleId IdType="pubmed">23906130</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23902937</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-0103</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>347</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of pharmacology and experimental therapeutics</Title>
          <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Preservation of endothelium-dependent relaxation in atherosclerotic mice with endothelium-restricted endothelin-1 overexpression.</ArticleTitle>
        <Pagination>
          <MedlinePgn>30-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.113.206532</ELocationID>
        <Abstract>
          <AbstractText>In human atherosclerosis, which is associated with elevated plasma and coronary endothelin (ET)-1 levels, ETA receptor antagonists improve coronary endothelial function. Mice overexpressing ET-1 specifically in the endothelium (eET-1) crossed with atherosclerosis-prone apolipoprotein E knockout mice (Apoe(-/-)) exhibit exaggerated high-fat diet (HFD)-induced atherosclerosis. Since endothelial dysfunction often precedes atherosclerosis development, we hypothesized that mice overexpressing endothelial ET-1 on a genetic background deficient in apolipoprotein E (eET-1/Apoe(-/-)) would have severe endothelial dysfunction. To test this hypothesis, we investigated endothelium-dependent relaxation (EDR) to acetylcholine in eET-1/Apoe(-/-) mice. EDR in mesenteric resistance arteries from 8- and 16-week-old mice fed a normal diet or HFD was improved in eET-1/Apoe(-/-) compared with Apoe(-/-) mice. Nitric oxide synthase (NOS) inhibition abolished EDR in Apoe(-/-). EDR in eET-1/Apoe(-/-) mice was resistant to NOS inhibition irrespective of age or diet. Inhibition of cyclooxygenase, the cytochrome P450 pathway, and endothelium-dependent hyperpolarization (EDH) resulted in little or no inhibition of EDR in eET-1/Apoe(-/-) compared with wild-type (WT) mice. In eET-1/Apoe(-/-) mice, blocking of EDH or soluble guanylate cyclase (sGC), in addition to NOS inhibition, decreased EDR by 36 and 30%, respectively. The activation of 4-aminopyridine-sensitive voltage-dependent potassium channels (Kv) during EDR was increased in eET-1/Apoe(-/-) compared with WT mice. We conclude that increasing eET-1 in mice that develop atherosclerosis results in decreased mutual dependence of endothelial signaling pathways responsible for EDR, and that NOS-independent activation of sGC and increased activation of Kv are responsible for enhanced EDR in this model of atherosclerosis associated with elevated endothelial and circulating ET-1.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mian</LastName>
            <ForeName>Muhammad Oneeb Rehman</ForeName>
            <Initials>MO</Initials>
            <Affiliation>Lady Davis Institute for Medical Research (M.O.R.M., N.I.-K., M.W.L., A.L., P.P., Y.R., E.L.S.), and Department of Medicine (E.L.S.), Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montr&#xE9;al, Qu&#xE9;bec, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Idris-Khodja</LastName>
            <ForeName>Noureddine</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Melissa W</ForeName>
            <Initials>MW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leibowitz</LastName>
            <ForeName>Avshalom</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paradis</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rautureau</LastName>
            <ForeName>Yohann</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schiffrin</LastName>
            <ForeName>Ernesto L</ForeName>
            <Initials>EL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>37917</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
        <NlmUniqueID>0376362</NlmUniqueID>
        <ISSNLinking>0022-3565</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Endothelin-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelin-1</DescriptorName>
          <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Organ Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Vasodilation</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">jpet.113.206532</ArticleId>
        <ArticleId IdType="doi">10.1124/jpet.113.206532</ArticleId>
        <ArticleId IdType="pubmed">23902937</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23902780</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>21</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>25</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-3207</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>98</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of clinical nutrition</Title>
          <ISOAbbreviation>Am. J. Clin. Nutr.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vivo transcriptomic profile after a Mediterranean diet in high-cardiovascular risk patients: a randomized controlled trial.</ArticleTitle>
        <Pagination>
          <MedlinePgn>845-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3945/ajcn.113.060582</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nutrients can exert healthy effects through nutrigenomic modulation. Data are scarce concerning the in vivo effect of a sustained traditional Mediterranean diet (TMD) pattern on the whole transcriptomic response.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We explored the overall nutrigenomic effect associated with a TMD.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">We focused on biological pathways related to cardiovascular disease (CVD) in a subsample (n = 34) of the Prevenci&#xF3;n Con Dieta Mediterr&#xE1;nea (PREDIMED) study, which was a large, parallel-group, multicenter, randomized controlled trial that aimed to assess the effects of TMD on the primary prevention of CVD in individuals with high cardiovascular risk. Participants were randomly assigned to a low-fat diet control group or TMD intervention groups [traditional Mediterranean diet supplemented with virgin olive oil (TMD+VOO) or traditional Mediterranean diet supplemented with nuts (TMD+Nuts)] in equal proportions. Three-month changes in whole genome peripheral blood mononuclear cells were assessed by using whole transcriptome microarray analyses.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A functional annotation analysis was performed on 241 selected responder genes after the TMD+VOO (139 upregulated and 102 downregulated genes), 312 selected responder genes after the TMD+Nuts (165 upregulated and 147 downregulated genes), and 145 selected responder genes after the low-fat (100 upregulated and 45 downregulated genes) diets. Of 18 cardiovascular canonical pathway analyses, 12 pathways were differentially expressed, and 43% of pathways were modulated by both TMDs; the most prevalent pathways were related to atherosclerosis and hypertension. After simultaneous testing adjustment, 9 pathways were modulated by the TMD+VOO diet, and 4 pathways were modulated by the TMD+Nuts diet.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">One of the mechanisms by which TMD, particularly if supplemented with virgin olive oil, can exert health benefits is through changes in the transcriptomic response of genes related to cardiovascular risk. This trial was registered at the London-based Current Controlled Trials register as ISRCTN35739639.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Casta&#xF1;er</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
            <Affiliation>Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corella</LastName>
            <ForeName>Dolores</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covas</LastName>
            <ForeName>Maria-Isabel</ForeName>
            <Initials>MI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sorl&#xED;</LastName>
            <ForeName>Jos&#xE9; V</ForeName>
            <Initials>JV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Subirana</LastName>
            <ForeName>Isaac</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flores-Mateo</LastName>
            <ForeName>Gemma</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nonell</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bull&#xF3;</LastName>
            <ForeName>Monica</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de la Torre</LastName>
            <ForeName>Rafael</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Portol&#xE9;s</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fit&#xF3;</LastName>
            <ForeName>Montserrat</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>PREDIMED study investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ISRCTN</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>ISRCTN35739639</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Multicenter Study</PublicationType>
          <PublicationType>Randomized Controlled Trial</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Clin Nutr</MedlineTA>
        <NlmUniqueID>0376027</NlmUniqueID>
        <ISSNLinking>0002-9165</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Dietary Fats</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Plant Oils</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8001-25-0</RegistryNumber>
          <NameOfSubstance>olive oil</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, Fat-Restricted</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Diet, Mediterranean</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Fats</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Dietary Supplements</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Gene Expression</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Genes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Microarray Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nutrigenomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Nuts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Plant Oils</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Transcriptome</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">ajcn.113.060582</ArticleId>
        <ArticleId IdType="doi">10.3945/ajcn.113.060582</ArticleId>
        <ArticleId IdType="pubmed">23902780</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23895132</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-511X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Lipids in health and disease</Title>
          <ISOAbbreviation>Lipids Health Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The anti-inflammatory effect of kaempferol on early atherosclerosis in high cholesterol fed rabbits.</ArticleTitle>
        <Pagination>
          <MedlinePgn>115</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/1476-511X-12-115</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atherosclerosis has been widely accepted as an inflammatory disease of vascular, adhesion molecules play an important role in the early progression of it. The aim of the present study was to evaluate the effect of kaempferol on the inflammatory molecules such as E-selectin (E-sel), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesionmolecule-1 (VCAM-1) and monocyte chemotactic protein-1 (MCP-1) in high cholesterol induced atherosclerosis rabbit models.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty male New Zealand white (NZW) rabbits were randomly divided into five groups, control group, model group, fenofibrate (12 mg/kg) group and kaempferol groups (150 mg/kg and 30 mg/kg). The rabbits were fed with a normal diet or a high cholesterol diet for 10 weeks. Levels of blood lipids, serum tumour-necrosis factor-alpha (TNF-a) and serum interleukin-1beta (IL-1&#xDF;) were detected at the end of the sixth and tenth week. Malonaldehyde (MDA) level and superoxide dismutase (SOD) activity in serum were also determined. Lesion areas of the aorta were measured with morphometry analysis after ten weeks. Gene expression of E-sel, ICAM-1, VCAM-1 and MCP-1 in aortas was determined by RT-PCR (reverse transcription-polymerase chain reaction). Immunohistochemical staining was employed to measure protein expression of E-sel, ICAM-1, VCAM-1 and MCP-1.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Model rabbits fed with ten weeks of high-cholesterol diet developed significant progression of atherosclerosis. Compared with the control, levels of blood lipids, TNF-a, IL-1&#xDF; and MDA increased markedly in serum of model rabbits, while SOD levels decreased. Gene and protein expressions of E-sel, ICAM-1, VCAM-1 and MCP-1 in atherosclerotic aortas increased remarkably in model group. However, comparing to the model rabbits, levels of TNF-a, IL-1&#xDF; and MDA decreased significantly and serum SOD activity increased, gene and protein expressions of E-sel, ICAM-1, VCAM-1 and MCP-1 in aortas decreased significantly with the treatment of kaempferol.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Kaempferol shows anti-atherosclerotic effect by modulating the gene and protein expression of inflammatory molecules.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Lingxi</ForeName>
            <Initials>L</Initials>
            <Affiliation>Clinical Pharmacology Laboratory, Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiuying</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yuanda</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Haixia</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lipids Health Dis</MedlineTA>
        <NlmUniqueID>101147696</NlmUniqueID>
        <ISSNLinking>1476-511X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Chemokine CCL2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>E-Selectin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Interleukin-1beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Kaempferols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Vascular Cell Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126547-89-5</RegistryNumber>
          <NameOfSubstance>Intercellular Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>731P2LE49E</RegistryNumber>
          <NameOfSubstance>kaempferol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>97C5T2UQ7J</RegistryNumber>
          <NameOfSubstance>Cholesterol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Soc Nephrol. 1999 Nov;10(11):2290-6</RefSource>
          <PMID Version="1">10541287</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 1999 Oct;44(1):156-65</RefSource>
          <PMID Version="1">10615399</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Agric Food Chem. 2006 Dec 27;54(26):9798-804</RefSource>
          <PMID Version="1">17177504</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ J. 2005 Dec;69(12):1484-9</RefSource>
          <PMID Version="1">16308496</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Pharmacol Rep. 2005 May-Jun;57(3):390-4</RefSource>
          <PMID Version="1">15985724</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 May;25(5):904-14</RefSource>
          <PMID Version="1">15731497</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2005 May;180(1):11-7</RefSource>
          <PMID Version="1">15823270</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 2005 Feb;135(2):172-8</RefSource>
          <PMID Version="1">15671209</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 1999 Jul 23;85(2):199-207</RefSource>
          <PMID Version="1">10417402</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 1999 Jan;79(1):181-213</RefSource>
          <PMID Version="1">9922371</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 1999 Jan 14;340(2):115-26</RefSource>
          <PMID Version="1">9887164</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell. 1998 Aug;2(2):275-81</RefSource>
          <PMID Version="1">9734366</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1093-100</RefSource>
          <PMID Version="1">9672069</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Inflamm Res. 2012 Jan;61(1):61-7</RefSource>
          <PMID Version="1">22005927</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2011 Jun;216(2):313-20</RefSource>
          <PMID Version="1">21411094</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mini Rev Med Chem. 2011 Apr;11(4):298-344</RefSource>
          <PMID Version="1">21428901</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr Biochem. 2010 Feb;21(2):116-24</RefSource>
          <PMID Version="1">19195861</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Food Chem Toxicol. 2009 Sep;47(9):2196-201</RefSource>
          <PMID Version="1">19520138</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Cardiol. 2009 Jun;53(3):317-33</RefSource>
          <PMID Version="1">19477372</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>BMB Rep. 2009 May 31;42(5):265-70</RefSource>
          <PMID Version="1">19470239</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Anal Chim Acta. 2009 Mar 16;636(1):42-50</RefSource>
          <PMID Version="1">19231354</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Cardiol. 2008 May 22;101(10A):4D-13D</RefSource>
          <PMID Version="1">18474273</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Angiology. 2007 Oct-Nov;58(5):513-22</RefSource>
          <PMID Version="1">18024933</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Epidemiol. 2007 Jun 1;165(11):1305-13</RefSource>
          <PMID Version="1">17379619</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Stem Cells. 2000;18(1):65-6</RefSource>
          <PMID Version="1">10661575</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Pharm Pharmacol. 1999 Dec;51(12):1435-40</RefSource>
          <PMID Version="1">10678500</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2000 May 9;101(18):2149-53</RefSource>
          <PMID Version="1">10801754</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cerebrovasc Dis. 2001;11 Suppl 2:1-4</RefSource>
          <PMID Version="1">11316915</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2001 Oct 9;104(15):1754-6</RefSource>
          <PMID Version="1">11591609</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Zhonghua Bing Li Xue Za Zhi. 2000 Feb;29(1):46-8</RefSource>
          <PMID Version="1">11866893</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2002 Mar 5;105(9):1135-43</RefSource>
          <PMID Version="1">11877368</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Clin Nutr. 2002 Sep;76(3):560-8</RefSource>
          <PMID Version="1">12198000</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Rev Esp Cardiol. 2003 Jan;56(1):9-15</RefSource>
          <PMID Version="1">12549993</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Atheroscler Thromb. 2003;10(2):63-71</RefSource>
          <PMID Version="1">12740479</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Phytother Res. 2003 Dec;17(10):1224-7</RefSource>
          <PMID Version="1">14669262</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2004 Apr 27;109(16):1966-72</RefSource>
          <PMID Version="1">15051633</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lab Anim. 2004 Jul;38(3):246-56</RefSource>
          <PMID Version="1">15207035</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 2004 Oct;84(4):1381-478</RefSource>
          <PMID Version="1">15383655</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 1991 Feb 15;251(4995):788-91</RefSource>
          <PMID Version="1">1990440</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5252-6</RefSource>
          <PMID Version="1">2052604</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Pathol. 1993 Dec;143(6):1551-9</RefSource>
          <PMID Version="1">7504883</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Pathol. 1993 Nov;171(3):223-9</RefSource>
          <PMID Version="1">7506307</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>FASEB J. 1995 Jul;9(10):899-909</RefSource>
          <PMID Version="1">7542214</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):12-8</RefSource>
          <PMID Version="1">8548411</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Immunol. 1996 Apr 1;156(7):2558-65</RefSource>
          <PMID Version="1">8786319</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 1997 Aug 7;337(6):408-16</RefSource>
          <PMID Version="1">9241131</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 1997 Dec 16;96(12):4219-25</RefSource>
          <PMID Version="1">9416885</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 1998 May;18(5):842-51</RefSource>
          <PMID Version="1">9598845</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Chemokine CCL2</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Cholesterol</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">E-Selectin</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
          <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Interleukin-1beta</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Kaempferols</DescriptorName>
          <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vascular Cell Adhesion Molecule-1</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3735477</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">1476-511X-12-115</ArticleId>
        <ArticleId IdType="doi">10.1186/1476-511X-12-115</ArticleId>
        <ArticleId IdType="pubmed">23895132</ArticleId>
        <ArticleId IdType="pmc">PMC3735477</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23894285</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>07</Month>
        <Day>29</Day>
      </DateCreated>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e67192</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0067192</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The associations between obesity, hypertension and diabetes are well established, and the renin-angiotensin system (RAS) may provide a link among them. The effect of RAS inhibition on type 2 diabetes is still unclear; however, RAS seems to play an important role in the regulation of the pancreas and glucose intolerance of mice fed high-fat (HF) diet.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">C57BL/6 mice fed a HF diet (8 weeks) were treated with aliskiren (50 mg/kg/day), enalapril (30 mg/kg/day) or losartan (10 mg/kg/day) for 6 weeks, and the protective effects were extensively compared among groups by morphometry, stereological tools, immunostaining, Western blotting and hormonal analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">All RAS inhibitors significantly attenuated the increased blood pressure in mice fed a HF diet. Treatment with enalapril, but not aliskiren or losartan, significantly attenuated body mass (BM) gain, glucose intolerance and insulin resistance, improved the alpha and beta cell mass and prevented the reduction of plasma adiponectin. Furthermore, enalapril treatment improved the protein expression of the pancreatic islet Pdx1, GLUT2, ACE2 and Mas receptors. Losartan treatment showed the greatest AT2R expression.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate that ACE inhibition with enalapril attenuated several of the deleterious effects of the HF diet. In summary, enalapril appears to be responsible for the normalization of islet morphology and function, of alpha and beta cell mass and of Pdx1 and GLUT2 expression. These protective effects of enalapril were attributed, primarily, to the reduction in body mass gain and food intake and the enhancement of the ACE2/Ang (1-7) /Mas receptor axis and adiponectin levels.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Frantz</LastName>
            <ForeName>Eliete Dalla Corte</ForeName>
            <Initials>ED</Initials>
            <Affiliation>Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crespo-Mascarenhas</LastName>
            <ForeName>Camila</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barreto-Vianna</LastName>
            <ForeName>Andre Rodrigues C</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aguila</LastName>
            <ForeName>Marcia Barbosa</ForeName>
            <Initials>MB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandarim-de-Lacerda</LastName>
            <ForeName>Carlos Alberto</ForeName>
            <Initials>CA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2008 May 6;105(18):6531-6</RefSource>
          <PMID Version="1">18443281</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2013 Jan;62(1):223-33</RefSource>
          <PMID Version="1">22933108</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2000 Jan 20;342(3):145-53</RefSource>
          <PMID Version="1">10639539</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E262-71</RefSource>
          <PMID Version="1">19001546</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Obes (Lond). 2009 Jun;33 Suppl 2:S1-2</RefSource>
          <PMID Version="1">19528972</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Behav. 2009 Aug 4;98(1-2):192-7</RefSource>
          <PMID Version="1">19465040</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Biochem Pharmacol. 2009 Oct 15;78(8):951-8</RefSource>
          <PMID Version="1">19549507</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Methods Mol Biol. 2010;611:211-25</RefSource>
          <PMID Version="1">19960334</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 2010 Jan;53(1):180-91</RefSource>
          <PMID Version="1">19894030</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Endocrinol Invest. 2010 Jan;33(1):13-9</RefSource>
          <PMID Version="1">20203537</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2010 May;30(5):953-61</RefSource>
          <PMID Version="1">20203301</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2010 Sep;119(6):239-50</RefSource>
          <PMID Version="1">20415664</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Behav. 2010 Jul 14;100(5):525-34</RefSource>
          <PMID Version="1">20381510</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2010 Oct;59(10):2540-8</RefSource>
          <PMID Version="1">20660625</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Kidney Int. 2011 Jan;79(2):162-8</RefSource>
          <PMID Version="1">20944545</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circ Res. 2000 Sep 1;87(5):E1-9</RefSource>
          <PMID Version="1">10969042</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Hypertens. 2001 Jun;14(6 Pt 1):530-8</RefSource>
          <PMID Version="1">11411732</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Clin Endocrinol Diabetes. 2001;109(5):273-82</RefSource>
          <PMID Version="1">11507651</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JOP. 2003 Mar;4(2):89-91</RefSource>
          <PMID Version="1">12629265</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63</RefSource>
          <PMID Version="1">12829792</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2004 Mar;106(3):337-43</RefSource>
          <PMID Version="1">14629192</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 1967 Jan;16(1):35-9</RefSource>
          <PMID Version="1">5333500</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Physiol Rev. 1977 Apr;57(2):313-70</RefSource>
          <PMID Version="1">191856</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetologia. 1985 Jul;28(7):412-9</RefSource>
          <PMID Version="1">3899825</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Nutr. 1993 Nov;123(11):1939-51</RefSource>
          <PMID Version="1">8229312</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Cardiol. 1996 May 1;77(11):1017-20</RefSource>
          <PMID Version="1">8644628</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 1997 Dec;46(12):1950-7</RefSource>
          <PMID Version="1">9392479</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 1999 Feb 20;353(9153):611-6</RefSource>
          <PMID Version="1">10030325</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol. 1999 Jul;277(1 Pt 2):R332-6</RefSource>
          <PMID Version="1">10409290</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Science. 2005 Jan 21;307(5708):384-7</RefSource>
          <PMID Version="1">15662004</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2005 Apr;54(4):991-9</RefSource>
          <PMID Version="1">15793237</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2006 Feb;55(2):367-74</RefSource>
          <PMID Version="1">16443769</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):98-107</RefSource>
          <PMID Version="1">16389635</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Lancet. 2006 Oct 21;368(9545):1449-56</RefSource>
          <PMID Version="1">17055947</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arch Intern Med. 2006 Nov 13;166(20):2191-201</RefSource>
          <PMID Version="1">17101936</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1018-29</RefSource>
          <PMID Version="1">17148757</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Genet Metab. 2007 Sep-Oct;92(1-2):43-55</RefSource>
          <PMID Version="1">17659992</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):74-83</RefSource>
          <PMID Version="1">18096375</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes. 2008 Feb;57(2):340-7</RefSource>
          <PMID Version="1">18025412</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Exp Physiol. 2008 May;93(5):519-27</RefSource>
          <PMID Version="1">18310257</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(1):e16096</RefSource>
          <PMID Version="1">21283589</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mech Ageing Dev. 2011 Mar;132(3):110-6</RefSource>
          <PMID Version="1">21291904</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Microsc. 2011 Jul;243(1):47-59</RefSource>
          <PMID Version="1">21375529</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2012 Feb;122(4):193-202</RefSource>
          <PMID Version="1">21861845</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Trends Pharmacol Sci. 2011 Dec;32(12):734-9</RefSource>
          <PMID Version="1">21880378</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2011;6(11):e28050</RefSource>
          <PMID Version="1">22140505</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Peptides. 2012 Jan;33(1):174-7</RefSource>
          <PMID Version="1">22119778</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Diabetes Obes Metab. 2012 Jul;14(7):586-95</RefSource>
          <PMID Version="1">22226145</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Regul Pept. 2012 Aug 20;177(1-3):1-11</RefSource>
          <PMID Version="1">22561450</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Endocrinol. 2012 Jul;26(7):1203-12</RefSource>
          <PMID Version="1">22570331</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Hypertens Res. 2012 Jul;35(7):704-5</RefSource>
          <PMID Version="1">22437039</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(7):e40573</RefSource>
          <PMID Version="1">22829877</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Peptides. 2012 Sep;37(1):79-85</RefSource>
          <PMID Version="1">22743141</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>PLoS One. 2012;7(11):e48387</RefSource>
          <PMID Version="1">23155382</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Sci (Lond). 2013 Apr;124(7):443-56</RefSource>
          <PMID Version="1">23249272</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Mol Cell Endocrinol. 2008 Nov 6;294(1-2):1-9</RefSource>
          <PMID Version="1">18687378</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3718820</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ppublish">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0067192</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-07860</ArticleId>
        <ArticleId IdType="pubmed">23894285</ArticleId>
        <ArticleId IdType="pmc">PMC3718820</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23887640</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>12</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>26</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4636</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
          <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>2306-15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.113.302028</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Endothelin (ET)-1 plays a role in vascular reactive oxygen species production and inflammation. ET-1 has been implicated in human atherosclerosis and abdominal aortic aneurysm (AAA) development. ET-1 overexpression exacerbates high-fat diet-induced atherosclerosis in apolipoprotein E(-/-) (Apoe(-/-)) mice. ET-1-induced reactive oxygen species and inflammation may contribute to atherosclerosis progression and AAA development.</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="RESULTS">Eight-week-old male wild-type mice, transgenic mice overexpressing ET-1 selectively in endothelium (eET-1), Apoe(-/-) mice, and eET-1/Apoe(-/-) mice were fed high-fat diet for 8 weeks. eET-1/Apoe(-/-) had a 45% reduction in plasma high-density lipoprotein (P&lt;0.05) and presented = 2-fold more aortic atherosclerotic lesions compared with Apoe(-/-) (P&lt;0.01). AAAs were detected only in eET-1/Apoe(-/-) (8/21; P&lt;0.05). Reactive oxygen species production was increased = 2-fold in perivascular fat, media, or atherosclerotic lesions in the ascending aorta and AAAs of eET-1/Apoe(-/-) compared with Apoe(-/-) (P&lt;0.05). Monocyte/macrophage infiltration was enhanced = 2.5-fold in perivascular fat of ascending aorta and AAAs in eET-1/Apoe(-/-) compared with Apoe(-/-) (P&lt;0.05). CD4(+) T cells were detected almost exclusively in perivascular fat (3/6) and atherosclerotic lesions (5/6) in ascending aorta of eET-1/Apoe(-/-) (P&lt;0.05). The percentage of spleen proinflammatory Ly-6C(hi) monocytes was enhanced 26% by ET-1 overexpression in Apoe(-/-) (P&lt;0.05), and matrix metalloproteinase-2 was increased 2-fold in plaques of eET-1/Apoe(-/-) (P&lt;0.05) compared with Apoe(-/-).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ET-1 plays a role in progression of atherosclerosis and AAA formation by decreasing high-density lipoprotein, and increasing oxidative stress, inflammatory cell infiltration, and matrix metalloproteinase-2 in perivascular fat, vascular wall, and atherosclerotic lesions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Melissa W</ForeName>
            <Initials>MW</Initials>
            <Affiliation>From the Lady Davis Institute for Medical Research (M.W.L., M.O.R.M., T.B., A.R., K.M., P.P., E.L.S.), Department of Medicine (E.L.S.), and Department of Oncology (K.M.), Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montr&#xE9;al, Qu&#xE9;bec, Canada.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mian</LastName>
            <ForeName>Muhammad Oneeb Rehman</ForeName>
            <Initials>MO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barhoumi</LastName>
            <ForeName>Tlili</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rehman</LastName>
            <ForeName>Asia</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mann</LastName>
            <ForeName>Koren</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paradis</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schiffrin</LastName>
            <ForeName>Ernesto L</ForeName>
            <Initials>EL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>115000</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
          <Grant>
            <GrantID>37917</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
        <NlmUniqueID>9505803</NlmUniqueID>
        <ISSNLinking>1079-5642</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antigens, Ly</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Apolipoproteins E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Endothelin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Lipoproteins, HDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Ly-6C antigen, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.24</RegistryNumber>
          <NameOfSubstance>Matrix Metalloproteinase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.24</RegistryNumber>
          <NameOfSubstance>Mmp2 protein, mouse</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adipose Tissue</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antigens, Ly</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Apolipoproteins E</DescriptorName>
          <QualifierName MajorTopicYN="Y">deficiency</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Atherosclerosis</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Endothelin-1</DescriptorName>
          <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Lipoproteins, HDL</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Plaque, Atherosclerotic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">T lymphocytes</Keyword>
        <Keyword MajorTopicYN="N">cholesterol, HDL</Keyword>
        <Keyword MajorTopicYN="N">elastin</Keyword>
        <Keyword MajorTopicYN="N">fibronectin</Keyword>
        <Keyword MajorTopicYN="N">inflammation</Keyword>
        <Keyword MajorTopicYN="N">monocytes</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23887640</ArticleId>
        <ArticleId IdType="pii">ATVBAHA.113.302028</ArticleId>
        <ArticleId IdType="doi">10.1161/ATVBAHA.113.302028</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23885014</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>23</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1945-7170</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>154</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Endocrinology</Title>
          <ISOAbbreviation>Endocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet.</ArticleTitle>
        <Pagination>
          <MedlinePgn>3632-42</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1210/en.2013-1256</ELocationID>
        <Abstract>
          <AbstractText>Cardiovascular disease (CVD), including heart failure, constitutes the main source of morbidity and mortality in men and women with diabetes. Although healthy young women are protected against CVD, postmenopausal and diabetic women lose this CVD protection. Obesity, insulin resistance, and diabetes promote heart failure in females, and diastolic dysfunction is the earliest manifestation of this heart failure. To examine the mechanisms promoting diastolic dysfunction in insulin-resistant females, this investigation evaluated the impact of 8 weeks of a high-fructose/high-fat Western diet (WD) on insulin sensitivity and cardiac structure and function in young C57BL6/J female versus male mice. Insulin sensitivity was determined by hyperinsulinemic-euglycemic clamps and two-dimensional echocardiograms were used to evaluate cardiac function. Both males and females developed systemic insulin resistance after 8 weeks of a WD. However, only the females developed diastolic dysfunction. The diastolic dysfunction promoted by the WD was accompanied by increases in collagen 1, a marker of stiffness, increased oxidative stress, reduced insulin metabolic signaling, and increased mitochondria and cardiac microvascular alterations as determined by electron microscopy. Aldosterone (a promoter of cardiac stiffness) levels were higher in females compared with males but were not affected by the WD in either gender. These data suggest a predisposition toward developing early diastolic heart failure in females exposed to a WD. These data are consistent with the notion that higher aldosterone levels, in concert with insulin resistance, may promote myocardial stiffness and diastolic dysfunction in response to overnutrition in females.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Manrique</LastName>
            <ForeName>Camila</ForeName>
            <Initials>C</Initials>
            <Affiliation>MD, Professor of Medicine and Medical Pharmacology and Physiology, University of Missouri, D109 Diabetes Center Health Sciences Center, One Hospital Drive, Columbia, Missouri 65212. sowersj@health.missouri.edu.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeMarco</LastName>
            <ForeName>Vincent G</ForeName>
            <Initials>VG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aroor</LastName>
            <ForeName>Annayya R</ForeName>
            <Initials>AR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mugerfeld</LastName>
            <ForeName>Irina</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garro</LastName>
            <ForeName>Mona</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Habibi</LastName>
            <ForeName>Javad</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayden</LastName>
            <ForeName>Melvin R</ForeName>
            <Initials>MR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sowers</LastName>
            <ForeName>James R</ForeName>
            <Initials>JR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01-HL1079100</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01-HL73101</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocrinology</MedlineTA>
        <NlmUniqueID>0375040</NlmUniqueID>
        <ISSNLinking>0013-7227</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Biological Markers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30237-26-4</RegistryNumber>
          <NameOfSubstance>Fructose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4964P6T9RB</RegistryNumber>
          <NameOfSubstance>Aldosterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Aldosterone</DescriptorName>
          <QualifierName MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Calcium Signaling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Compliance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
          <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fructose</DescriptorName>
          <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Heart Ventricles</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="N">ultrasonography</QualifierName>
          <QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hyperaldosteronism</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Insulin Resistance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Microvessels</DescriptorName>
          <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="N">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Sex Characteristics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Vascular Stiffness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Ventricular Dysfunction</DescriptorName>
          <QualifierName MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName MajorTopicYN="N">ultrasonography</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">en.2013-1256</ArticleId>
        <ArticleId IdType="doi">10.1210/en.2013-1256</ArticleId>
        <ArticleId IdType="pubmed">23885014</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23884889</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>25</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1939-327X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes</Title>
          <ISOAbbreviation>Diabetes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Overnutrition stimulates intestinal epithelium proliferation through &#xDF;-catenin signaling in obese mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>3736-46</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-0035</ELocationID>
        <Abstract>
          <AbstractText>Obesity is a major risk factor for type 2 diabetes and cardiovascular diseases. And overnutrition is a leading cause of obesity. After most nutrients are ingested, they are absorbed in the small intestine. Signals from &#xDF;-catenin are essential to maintain development of the small intestine and homeostasis. In this study, we used a hyperphagia db/db obese mouse model and a high-fat diet (HFD)-induced obesity mouse model to investigate the effects of overnutrition on intestinal function and &#xDF;-catenin signaling. The &#xDF;-catenin protein was upregulated along with inactivation of glycogen synthase kinase (GSK)-3&#xDF; in the intestines of both db/db and HFD mice. Proliferation of intestinal epithelial stem cells, villi length, nutrient absorption, and body weight also increased in both models. These changes were reversed by caloric restriction in db/db mice and by &#xDF;-catenin inhibitor JW55 (a small molecule that increases &#xDF;-catenin degradation) in HFD mice. Parallel, in vitro experiments showed that &#xDF;-catenin accumulation and cell proliferation stimulated by glucose were blocked by the &#xDF;-catenin inhibitor FH535. And the GSK-3 inhibitor CHIR98014 in an intestinal epithelial cell line increased &#xDF;-catenin accumulation and cyclin D1 expression. These results suggested that, besides contribution to intestinal development and homeostasis, GSK-3&#xDF;/&#xDF;-catenin signaling plays a central role in intestinal morphological and functional changes in response to overnutrition. Manipulating the GSK-3&#xDF;/&#xDF;-catenin signaling pathway in intestinal epithelium might become a therapeutic intervention for obesity induced by overnutrition.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Jiaming</ForeName>
            <Initials>J</Initials>
            <Affiliation>Institute of Molecular Medicine, Peking University, Beijing, China.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xiaomin</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jue</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Heping</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiuqin</ForeName>
            <Initials>X</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Diabetes</MedlineTA>
        <NlmUniqueID>0372763</NlmUniqueID>
        <ISSNLinking>0012-1797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance>glycogen synthase kinase 3 beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance>Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance>Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Caloric Restriction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Intestine, Small</DescriptorName>
          <QualifierName MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Obese</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Overnutrition</DescriptorName>
          <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3806619 [Available on 11/01/14]</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">db13-0035</ArticleId>
        <ArticleId IdType="doi">10.2337/db13-0035</ArticleId>
        <ArticleId IdType="pubmed">23884889</ArticleId>
        <ArticleId IdType="pmc">PMC3806619</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23884883</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>25</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1939-327X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Diabetes</Title>
          <ISOAbbreviation>Diabetes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Profilin-1 haploinsufficiency protects against obesity-associated glucose intolerance and preserves adipose tissue immune homeostasis.</ArticleTitle>
        <Pagination>
          <MedlinePgn>3718-26</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-0050</ELocationID>
        <Abstract>
          <AbstractText>Metabolic inflammation may contribute to the pathogenesis of obesity and its comorbidities, including type 2 diabetes and cardiovascular disease. Previously, we showed that the actin-binding protein profilin-1 (pfn) plays a role in atherogenesis because pfn heterozygote mice (PfnHet) exhibited a significant reduction in atherosclerotic lesion burden and vascular inflammation. In the current study, we tested whether pfn haploinsufficiency would also limit diet-induced adipose tissue inflammation and insulin resistance (IR). First, we found that a high-fat diet (HFD) upregulated pfn expression in epididymal and subcutaneous white adipose tissue (WAT) but not in the liver or muscle of C57BL/6 mice compared with normal chow. Pfn expression in WAT correlated with F4/80, an established marker for mature macrophages. Of note, HFD elevated pfn protein levels in both stromal vascular cells and adipocytes of WAT. We also found that PfnHet were significantly protected from HFD-induced glucose intolerance observed in pfn wild-type mice. With HFD, PfnHet displayed blunted expression of systemic and WAT proinflammatory cytokines and decreased accumulation of adipose tissue macrophages, which were also preferentially biased toward an M2-like phenotype; this correlated with preserved frequency of regulatory T cells. Taken together, the findings indicate that pfn haploinsufficiency protects against diet-induced IR and inflammation by modulating WAT immune homeostasis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Romeo</LastName>
            <ForeName>Giulio R</ForeName>
            <Initials>GR</Initials>
            <Affiliation>Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pae</LastName>
            <ForeName>Munkyong</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eberl&#xE9;</LastName>
            <ForeName>Delphine</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jongsoon</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shoelson</LastName>
            <ForeName>Steven E</ForeName>
            <Initials>SE</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01-DK-036836</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01-DK-51729</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Diabetes</MedlineTA>
        <NlmUniqueID>0372763</NlmUniqueID>
        <ISSNLinking>0012-1797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Antigens, Differentiation</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Profilins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>STAT3 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Stat3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>monocyte-macrophage differentiation antigen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>AIM</CitationSubset>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Adipose Tissue, White</DescriptorName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Antigens, Differentiation</DescriptorName>
          <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glucose Intolerance</DescriptorName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="Y">Haploinsufficiency</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Insulin Resistance</DescriptorName>
          <QualifierName MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Profilins</DescriptorName>
          <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Subcutaneous Fat</DescriptorName>
          <QualifierName MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherID Source="NLM">PMC3806603 [Available on 11/01/14]</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="aheadofprint">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">db13-0050</ArticleId>
        <ArticleId IdType="doi">10.2337/db13-0050</ArticleId>
        <ArticleId IdType="pubmed">23884883</ArticleId>
        <ArticleId IdType="pmc">PMC3806603</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">23881149</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>7</Month>
        <Day>24</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-4881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Jul</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of preventive cardiology</Title>
          <ISOAbbreviation>Eur J Prev Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alarming rise in prevalence of atherogenic dyslipidaemia in the black population of Cape Town: the Cardiovascular Risk in Black South Africans (CRIBSA) study.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the prevalence, determinants, and management of dyslipidaemia in the 25-74-year-old urban black population of Cape Town and examine the changes between 1990 and 2008/09 in the 25-64-year-old sample.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In 2008/09, a representative cross-sectional sample, stratified for age and sex, was randomly selected from the same townships sampled in 1990. Cardiovascular disease (CVD) risk factors were determined by questionnaires, clinical measurements, and fasting biochemical analyses. Survey logistic regression analysis assessed the determinants of raised low-density lipoprotein cholesterol (LDL-C).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1099 participants in 2008/09 (392 men and 707 women; response rate 86%). The prevalence of raised total cholesterol (TC), raised LDL-C, and reduced high-density lipoprotein cholesterol (HDL-C) were 25.2% (95% confidence interval, CI, 20.0-31.3), 37.8% (95% CI 32.5-43.4), and 55.2% (95% CI 49.9-60.4) in men and 23.1% (95% CI 20.0-26.5), 47.0% (95% CI 43.1-50.9), and 66.8% (95% CI 62.9-70.5) in women, respectively. Between 1990 and 2008/09, raised LDL-C and reduced HDL-C prevalence increased significantly with no change for raised TC. Among participants with raised LDL-C, only 2.6% were aware of their diagnosis, 2.7% were on treatment, and 1.5% had LDL-C &lt;3?mmol/l. In the logistic model, increasing age (odds ratio, OR, 1.04, 95% CI 1.03-1.05; p?&lt;?0.001), rising body mass index (OR 1.03, 95% CI 1.01-1.05; p?=?0.003), and fat intake =30% of diet (OR 1.37, 95% CI 1.02-1.85; p?=?0.035) were significantly associated with LDL-C =3?mmol/l but not sex, physical activity, or urbanization.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The dyslipidaemia pattern in this population requires full lipogram screening in high-risk individuals and demands improved management using a total CVD risk approach.</AbstractText>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Peer</LastName>
            <ForeName>Nasheeta</ForeName>
            <Initials>N</Initials>
            <Affiliation>Medical Research Council, Durban and Cape Town, South Africa.</Affiliation>
          </Author>
          <Author>
            <LastName>Steyn</LastName>
            <ForeName>Krisela</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author>
            <LastName>Lombard</LastName>
            <ForeName>Carl</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author>
            <LastName>Gaziano</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author>
            <LastName>Levitt</LastName>
            <ForeName>Naomi</ForeName>
            <Initials>N</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eur J Prev Cardiol</MedlineTA>
        <NlmUniqueID>101564430</NlmUniqueID>
        <ISSNLinking>2047-4873</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Black</Keyword>
        <Keyword MajorTopicYN="N">South Africa</Keyword>
        <Keyword MajorTopicYN="N">cholesterol</Keyword>
        <Keyword MajorTopicYN="N">epidemiology</Keyword>
        <Keyword MajorTopicYN="N">high-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">lipid management</Keyword>
        <Keyword MajorTopicYN="N">lipids</Keyword>
        <Keyword MajorTopicYN="N">low-density lipoprotein cholesterol</Keyword>
        <Keyword MajorTopicYN="N">triglycerides</Keyword>
        <Keyword MajorTopicYN="N">urban</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">2047487313497865</ArticleId>
        <ArticleId IdType="doi">10.1177/2047487313497865</ArticleId>
        <ArticleId IdType="pubmed">23881149</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">23876511</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>7</Month>
        <Day>23</Day>
      </DateCreated>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-6809</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2013</Year>
              <Month>Jul</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of vascular surgery</Title>
          <ISOAbbreviation>J. Vasc. Surg.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Diet-induced obesity drives negative mouse vein graft wall remodeling.</ArticleTitle>
        <Pagination>
          <MedlinePgn/>
        </Pagination>
        <ELocationID EIdType="pii">S0741-5214(13)01012-4</ELocationID>
        <ELocationID EIdType="doi">10.1016/j.jvs.2013.05.033</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The heightened inflammatory phenotype associated with obesity has been linked to the development of cardiovascular diseases. Short-term high-fat feeding induces a proinflammatory state that may impact the blood vessel wall. CD11c, a significantly increased dendritic cell biomarker during diet-induced obesity (DIO), may have a mechanistic role in this high-fat feeding effect. We hypothesized that the proinflammatory effect of short-term DIO accelerates vein bypass graft failure via CD11c-dependent mechanisms.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Male 9-week-old DIO mice (n&#xA0;= 13, C57BL/6J recipients; n&#xA0;= 6, CD11c(-/-) recipients) and normal chow controls (n&#xA0;= 15, C57BL/6J recipients; n&#xA0;= 6, CD11c(-/-) recipients) underwent unilateral carotid interposition vein isografting (inferior vena cava from the same diet and genetic background donor), with a midgraft or outflow focal stenosis. Vein grafts were harvested at either 1&#xA0;week (immunohistochemical staining for early CD11c expression) or 4&#xA0;weeks later (morphometric analyses and CD11c evaluation).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Despite a 40% larger body size, C57BL/6J DIO mice had 44% smaller poststenosis vein graft lumens (P&#xA0;= .03) than their controls via an acceleration of overall negative vein graft wall remodeling in the day-28 midgraft focal stenosis model but not in the outflow stenosis model. Higher CD11c expression occurred in DIO midgraft-stenosis vein graft walls, both at postoperative days 7 and 28. In contrast, with in&#xA0;vivo CD11c deficiency, DIO did not elicit this poststenotic negative remodeling but attenuated intimal hyperplasia.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings highlight negative wall remodeling as a potential factor leading to vein graft failure and provide direct evidence that short-term dietary alterations in the mammalian metabolic milieu can have lasting implications related to acute vascular interventions. DIO induces negative mouse vein graft wall remodeling via CD11c-depedent pathways.</AbstractText>
          <CopyrightInformation>Copyright &#xA9; 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList>
          <Author>
            <LastName>Yu</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <Affiliation>Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, Mass.</Affiliation>
          </Author>
          <Author>
            <LastName>Nguyen</LastName>
            <ForeName>Binh T</ForeName>
            <Initials>BT</Initials>
          </Author>
          <Author>
            <LastName>Tao</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author>
            <LastName>Jiang</LastName>
            <ForeName>Tianyu</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author>
            <LastName>Ozaki</LastName>
            <ForeName>C Keith</ForeName>
            <Initials>CK</Initials>
          </Author>
        </AuthorList>
        <Language>ENG</Language>
        <GrantList>
          <Grant>
            <GrantID>R01 HL079135</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 HL007734</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType>JOURNAL ARTICLE</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Vasc Surg</MedlineTA>
        <NlmUniqueID>8407742</NlmUniqueID>
        <ISSNLinking>0741-5214</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">S0741-5214(13)01012-4</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jvs.2013.05.033</ArticleId>
        <ArticleId IdType="pubmed">23876511</ArticleId>
        <ArticleId IdType="pmc">PMC3823755</ArticleId>
        <ArticleId IdType="mid">NIHMS484579</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
      <PMID Version="1">23875703</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCreated>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1470-8736</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>126</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical science (London, England : 1979)</Title>
          <ISOAbbreviation>Clin. Sci.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Involvement of the HIF-1a and Wnt/&#xDF;-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury.</ArticleTitle>
        <Pagination>
          <MedlinePgn>163-74</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1042/CS20130025</ELocationID>
        <Abstract>
          <AbstractText>Besides cardioprotective effects, the AT1R (angiotensin-II type 1 receptor) antagonist losartan protects the liver from IRI [IR (ischaemia/reperfusion) injury], but the mechanism has not been fully determined. The HIF (hypoxia inducible factor)-1a and Wnt/&#xDF;-catenin signalling pathways have been reported to be involved in the mechanism of liver IRI. Therefore the aim of the present study was to determine whether the Wnt/HIF axis is part of the mechanism of the positive effect of AngII inhibition by losartan in liver IRI in rats. Various measurements were made in MCD/HF-NASH (methionine- and choline-deficient-diet/high-fat-diet-induced non-alcoholic steatohepatitis) rats with liver IRI. Acute losartan pre-administration markedly reversed the IR-suppressed levels of the hepatic-protective factors IL (interleukin)-6, IFN (interferon)-?, Wnt3a, &#xDF;-catenin and HIF-1a, and decreased hepatic blood flow and IR-elevated serum ALT (alanine aminotransferase), hepatic TNF (tumour necrosis factor)-a, IL-1a, hepatic congestion, vacuolization and necrosis, hepatic Suzuki IRI scores, necrotic index and levels of TBARS (thiobarbituric acid-reacting substances) in MCD/HF-NASH rats. Furthermore, acute Wnt3a pre-treatment significantly inhibited IR-elevated serum ALT, hepatic Suzuki IRI scores and TBARS, and restored the IR-depleted &#xDF;-catenin/HIF-1a activity in MCD/HF-NASH rats. Simultaneous acute sFRP2 (secreted frizzled-related protein 2; a Wnt3a inhibitor) pre-treatment eliminated the losartan-related beneficial effects in MCD/HF-NASH rats with liver IRI, which was accompanied by a decrease in hepatic HIF-1a/&#xDF;-catenin activity. Losartan-induced up-regulation of HIF-1a and Wnt/&#xDF;-catenin signalling was associated with the recovery of IR-inhibited hepatic Bcl-2, Mn-SOD (manganese superoxide), Cu/Zn-SOD (copper/zinc superoxide) and GSH levels, and the suppression of IR-increased hepatic catalase and caspase 3/caspase 8 levels in MCD/HF-NASH rats. In conclusion, up-regulation of the HIF-1a and Wnt/&#xDF;-catenin signalling pathways are part of the mechanism of the positive effects of losartan-related AngII inhibition in MCD/HF-NASH rats with liver IRI. Our study highlights the potential of the dual-organ protective agent losartan in NASH patients with steatotic livers and cardiovascular risk.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Ying-Ying</ForeName>
            <Initials>YY</Initials>
            <Affiliation>?Graduate Institute of Traditional Chinese Medicine, Chang Gung University, Taipei, Taiwan.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Pei-Chang</ForeName>
            <Initials>PC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yi-Tsau</ForeName>
            <Initials>YT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Wei-Ping</ForeName>
            <Initials>WP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuo</LastName>
            <ForeName>Ying-Ju</ForeName>
            <Initials>YJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kuei-Chuan</ForeName>
            <Initials>KC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsieh</LastName>
            <ForeName>Yun-Cheng</ForeName>
            <Initials>YC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Tzung-Yan</ForeName>
            <Initials>TY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Han-Chieh</ForeName>
            <Initials>HC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Sci (Lond)</MedlineTA>
        <NlmUniqueID>7905731</NlmUniqueID>
        <ISSNLinking>0143-5221</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>FRZB protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Thiobarbituric Acid Reactive Substances</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Wnt3A Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>Wnt3a protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance>beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JMS50MPO89</RegistryNumber>
          <NameOfSubstance>Losartan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease">Non-alcoholic Fatty Liver Disease</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Fatty Liver</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Glycoproteins</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Losartan</DescriptorName>
          <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Reperfusion Injury</DescriptorName>
          <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Thiobarbituric Acid Reactive Substances</DescriptorName>
          <QualifierName MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">Wnt3A Protein</DescriptorName>
          <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pii">CS20130025</ArticleId>
        <ArticleId IdType="doi">10.1042/CS20130025</ArticleId>
        <ArticleId IdType="pubmed">23875703</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
      <PMID Version="1">23874490</PMID>
      <DateCreated>
        <Year>2013</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCreated>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice.</ArticleTitle>
        <Pagination>
          <MedlinePgn>e68039</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0068039</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">New strategies to overcome complications of cardiovascular diseases are needed. Since it has been demonstrated that atherosclerosis is an inflammatory disease, modulation of the immune system may be a promising approach. Previously, it was suggested that antibodies may confer protective effects on the development of atherosclerosis. In this study, we hypothesised that passive immunization with anti-oxLDL IgM antibodies specific for hypochlorite (HOCl) may be athero-protective in mice.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Monoclonal mouse IgM antibodies were produced and the antibody with specificity for hypochlorite-oxLDL (HOCl-oxLDL) (Moab A7S8) was selected. VH sequence determination revealed that Moab A7S8 is a natural IgM antibody. Atherosclerosis in LDLr(-/-) mice was induced by a perivascular collar placement around the right carotid artery in combination with feeding a high-fat diet. Subsequently, the mice were treated every six days with 500 &#xB5;g Moab A7S8, non-relevant IgM or with PBS and the carotid arteries and aortic roots were studied for atherosclerosis. Passive immunization with this Moab A7S8 resulted in a significant reduced plaque volume formation in LDLr(-/-) mice when compared with PBS treatment (P = 0.002 and P = 0.035). Cholesterol levels decreased by 20% when mice were treated with Moab A7S8 compared to PBS. Furthermore, anti-oxLDL specific IgM and IgG antibody production increased significantly in the Moab A7S8 treated mice in comparison with PBS treated mice.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data show that passive immunization with a natural IgM antibody, directed to HOCl-oxLDL, can reduce atherosclerotic plaque development. We postulate that specific antibody therapy may be developed for use in human cardiovascular diseases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Leeuwen</LastName>
            <ForeName>Marcella</ForeName>
            <Initials>M</Initials>
            <Affiliation>Internal Medicine, Clinical and Experimental Immunology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kemna</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Winther</LastName>
            <ForeName>Menno P J</ForeName>
            <Initials>MP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boon</LastName>
            <ForeName>Louis</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duijvestijn</LastName>
            <ForeName>Adriaan M</ForeName>
            <Initials>AM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henatsch</LastName>
            <ForeName>Darius</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bos</LastName>
            <ForeName>Nico A</ForeName>
            <Initials>NA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gijbels</LastName>
            <ForeName>Marion J J</ForeName>
            <Initials>MJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tervaert</LastName>
            <ForeName>Jan Willem Cohen</ForeName>
            <Initials>JW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType>Journal Article</PublicationType>
          <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2001 Feb 27;103(8):1164-70</RefSource>
          <PMID Version="1">11222482</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Int J Cardiol. 2013 Jul 31;167(2):464-9</RefSource>
          <PMID Version="1">22305633</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>JAMA. 2001 Nov 7;286(17):2136-42</RefSource>
          <PMID Version="1">11694155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Med. 2003 Jun;9(6):736-43</RefSource>
          <PMID Version="1">12740573</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2003 Oct;112(8):1176-85</RefSource>
          <PMID Version="1">14561702</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>N Engl J Med. 2003 Oct 23;349(17):1595-604</RefSource>
          <PMID Version="1">14573731</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Circulation. 2003 Oct 28;108(17):2107-12</RefSource>
          <PMID Version="1">14530200</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Am J Med. 2004 Mar 15;116(6):429-30</RefSource>
          <PMID Version="1">15006595</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40</RefSource>
          <PMID Version="1">15215425</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2004 Aug;114(3):427-37</RefSource>
          <PMID Version="1">15286809</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nature. 1970 Aug 15;227(5259):680-5</RefSource>
          <PMID Version="1">5432063</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1989 May;86(10):3833-7</RefSource>
          <PMID Version="1">2726754</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1994 Jul;94(1):437-44</RefSource>
          <PMID Version="1">8040285</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1997 Dec 15;100(12):2995-3004</RefSource>
          <PMID Version="1">9399945</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10089-93</RefSource>
          <PMID Version="1">9707605</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 1999 Jun;103(11):1547-60</RefSource>
          <PMID Version="1">10359564</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Immunol. 2005 Jan 15;174(2):1046-54</RefSource>
          <PMID Version="1">15634929</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1102-11</RefSource>
          <PMID Version="1">15790935</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Lipid Res. 2005 Jul;46(7):1353-63</RefSource>
          <PMID Version="1">15897601</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Immunol. 2006 Jul;6(7):508-19</RefSource>
          <PMID Version="1">16778830</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2006 Sep;188(1):160-6</RefSource>
          <PMID Version="1">16307748</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2006 Nov;189(1):83-90</RefSource>
          <PMID Version="1">16386745</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Opin Mol Ther. 2007 Apr;9(2):176-82</RefSource>
          <PMID Version="1">17458172</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2007 Jul 10;50(2):159-65</RefSource>
          <PMID Version="1">17616301</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Exp Immunol. 2007 Aug;149(2):257-64</RefSource>
          <PMID Version="1">17521320</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Am Coll Cardiol. 2007 Aug 7;50(6):540-6</RefSource>
          <PMID Version="1">17678738</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):84-9</RefSource>
          <PMID Version="1">17991873</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Curr Drug Targets. 2008 Mar;9(3):190-5</RefSource>
          <PMID Version="1">18336236</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell. 2008 Apr 18;133(2):235-49</RefSource>
          <PMID Version="1">18423196</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Exp Immunol. 2008 Nov;154(2):264-9</RefSource>
          <PMID Version="1">18778362</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Clin Invest. 2009 May;119(5):1335-49</RefSource>
          <PMID Version="1">19363291</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Autoimmun Rev. 2009 Sep;9(1):53-7</RefSource>
          <PMID Version="1">19285155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Ann N Y Acad Sci. 2009 Sep;1173:274-9</RefSource>
          <PMID Version="1">19758162</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cardiovasc Res. 2010 Feb 1;85(3):622-30</RefSource>
          <PMID Version="1">19819882</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Clin Immunol. 2010 Jan;134(1):47-54</RefSource>
          <PMID Version="1">19748321</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>J Autoimmun. 2010 Mar;34(2):73-9</RefSource>
          <PMID Version="1">19726160</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Cell Metab. 2010 Aug 4;12(2):142-53</RefSource>
          <PMID Version="1">20674859</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Stroke. 2010 Nov;41(11):2687-9</RefSource>
          <PMID Version="1">20947847</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Nat Rev Drug Discov. 2011 May;10(5):365-76</RefSource>
          <PMID Version="1">21532566</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Atherosclerosis. 2012 Jan;220(1):59-65</RefSource>
          <PMID Version="1">22062590</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="Cites">
          <RefSource>Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1333-9</RefSource>
          <PMID Version="1">11498462</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <OtherID Source="NLM">PMC3713002</OtherID>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="ppublish">
          <Year>2013</Year>
          <Month/>
          <Day/>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="epublish">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="doi">10.1371/journal.pone.0068039</ArticleId>
        <ArticleId IdType="pii">PONE-D-12-13250</ArticleId>
        <ArticleId IdType="pubmed">23874490</ArticleId>
        <ArticleId IdType="pmc">PMC3713002</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
